



HTA Austria

Austrian Institute for
Health Technology Assessment
GmbH

Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia

EUnetHTA OTCA27 assessment



eunethta
EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT



HTA Austria
Austrian Institute for
Health Technology Assessment
GmbH

Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia

Executive summary of the
EUnetHTA OTCA27 assessment



eunethta
EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT

This decision support document provides a synthesis of the EUnetHTA OTCA27 report 'Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)' including adaptations to the Austrian context.

Project Team EUnetHTA assessment (OTCA27)

Project leader: European Network for Health Technology Assessment (EUnetHTA)

Authors: 1. Regione Emilia-Romagna (RER), Italy
2. Austrian Institute for Health Technology Assessment GmbH (AIHTA), Austria

Project Support EUnetHTA assessment (OTCA27)

External Review: Dr. Franco Bergamaschi, Italy

Dr. Alfio Capizzi, Italy

Internal Review: Azienda Zero, Italy

Swiss Network for Health Technology Assessment (SNHTA), Switzerland

State Health Care Accreditation Agency (VASPVT), Lithuania

German summary and adaptation to the Austrian context: Judit Erdös, MA

Internal review of the adaptation for the Austrian context: Melanie Walter, PhD Eu-MSc

Correspondence: Judit.erdos@aihta.at

This report should be referenced as follows:

Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia: German summary of the EUnetHTA OTCA27 assessment. AIHTA Decision Support Documents No. 129; 2021. Vienna: Austrian Institute for Health Technology Assessment GmbH.

Conflict of interest

All authors and the reviewers involved in the production of this report have declared they have no conflicts of interest in relation to the technology assessed according to the Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org).

Disclaimer

The final version of the Adaptation to the Austrian context and the policy recommendations are under the full responsibility of the AIHTA.

IMPRINT

Publisher:

HTA Austria – Austrian Institute for Health Technology Assessment GmbH

Garnisongasse 7/Top 20 | 1090 Vienna – Austria

<https://www.aihta.at/>

Responsible for content:

Priv.-Doz. Dr. phil. Claudia Wild, managing director

AIHTA Decision Support Documents do not appear on a regular basis and serve to publicize the research results of the Austrian Institute for Health Technology Assessment.

AIHTA Decision Support Documents are only available to the public via the Internet at

http://eprints.aihta.at/view/types/hta_report.html.

AIHTA Decision Support Documents No.: 129

ISSN online 1998-0469

© 2021 AIHTA – All rights reserved

Content

| | |
|----------------------------|----|
| Content..... | 5 |
| 1 Executive Summary..... | 7 |
| 2 Zusammenfassung..... | 13 |
| 3 References..... | 22 |
| EUnetHTA OTCA27 assessment | |

List of abbreviations

| | |
|----------|--|
| BPH | Benigne Prostatahyperplasie/ Benign prostatic hyperplasia |
| BPHII | Benign Prostatic Hyperplasia International Index |
| B-TUEP | Enucleation with bipolar energy |
| B-TUERP | Bipolar transurethral enucleoresection |
| B-TUVP | Transurethral electrovaporization |
| B-VEP | Bipolar vapoenucleation |
| CE | Conformité Européenne |
| CI | Confidence interval |
| DioLEP | Diode laser enucleation |
| DioLVP | Diode laser vaporization |
| EAU | European Association of Urology |
| EUnetHTA | European network for Health Technology Assessment |
| FDA | Food and Drug Administration |
| HoLEP | Holmium Laser Enucleation |
| IIEF | International Index of Erectile Function |
| IPSS | International Prostate Symptom Score |
| IPSS | International Prostate Symptom Score |
| LUTS | Lower urinary tract symptoms |
| MCID | Minimal clinically important difference |
| M-TUERP | Monopolar transurethral enucleoresection |
| OP | Open prostatectomy / Offene Prostatektomie |
| OTCA27 | Other Technologies Collaborative Assessment 27 |
| PUL | Prostatic urethral lift |
| PVEP | Photoselective vapoenucleation |
| PVP | Photoselektive Vaporization der Prostata |
| PVR | Postvoid residual volume |
| QoL | Quality of life |
| RCT | Randomised controlled trial |
| ThuLEP | Thulium laser enucleation |
| ThuVAP | Thulium laser vaporesection |
| ThuVEP | Thulium laser vapoenucleation |
| TmLRP | Thulium laser resection |
| TUIP | Transurethral incision |
| TUMT | Transurethral microwave therapy |
| TURP | Transurethral prostate resection / Transurethrale Resektion der Prostata |
| TUVRP | Transurethral vaporesection |
| WAVE | Water vapour thermal therapy |

1 Executive Summary

Introduction

Health Problem

Benign prostatic hyperplasia (BPH) is a common non-malignant urological condition that involves the progressive proliferation of glandular epithelium, smooth muscle, and connective tissue in the transition zone of the prostate. In a large proportion of BPH patients, prostate enlargement causes bladder outflow obstruction which has an adverse impact on the lower urinary tract function, resulting in lower urinary tract symptoms (LUTS). The worldwide prevalence of BPH among men aged 51-60 is estimated to be 42%, between the age of 71-80 it is 82%. However, only 30% of those affected require treatment. The spectrum of therapy options ranges from watchful waiting through medication to numerous surgical procedures. The most common indication for surgical intervention is moderate-to-severe voiding symptoms attributed to BPH that are refractory to conservative or medical therapy (relative operation indications).

Description of Technologies

Transurethral resection of the prostate (**TURP**) has remained the cornerstone of BPH surgical treatment for decades. Despite its high rate of success, TURP has a perioperative morbidity rate of around 20% and long-term complications including frequent ejaculatory dysfunction, erectile dysfunction, urethral strictures, urinary tract infection, urinary incontinence. **Open prostatectomy** is infrequently used in case of large prostates, as for the complications above.

The development of different minimally invasive technologies provides alternatives which are expected to have similar effectiveness but better safety profile compared to TURP.

Different ablative technologies have been developed, which determine the removal of excess prostatic tissue in different ways using:

- resection through holmium or thulium lasers (**TmLRP**) in alternative to classical TURP;
- enucleation, using either a holmium (**HoLEP**), thulium (**ThuLEP**) or diode (**DioLEP**) laser, or different electrodes delivering bipolar energy (**B-TUEP**);
- vaporization through a bipolar electrode (**B-TUVP**) or a laser system (**PVP** or with diode laser – **DioLVP**) removing excessive prostate tissue by heating and evaporating it;
- hybrid techniques like vapoenucleation (with a thulium laser – **ThuVEP** – or with bipolar energy – **B-VEP**), vaporessection (using resection with the help of electric current or laser and vaporization with the use of a vaporization electrode – **TUVRP** and **ThuVARP**) or enucleo-resection (using monopolar **M-TUERP** - or bipolar energy – **B-TUERP**);
- **aquablation**, using high-speed jet of saline (waterjet);
- transurethral microwave therapy (**TUMT**), using electromagnetic waves to thermoablate prostatic tissue;

benign prostatic hyperplasia (BPH) can cause lower urinary tract symptoms (LUTS)

indication for surgery: moderate to severe LUTS refractory to conservative therapy or medication

standard surgical interventions: transurethral prostate resection (TURP) and open prostatectomy

several new minimally invasive technologies as alternatives

ablative methods: TmLRP, HoLEP, ThuLEP, DioLEP, B-TUEP, B-TUVP, PVP, DioLVP, ThuVEP, V-VEP, TUVRP, ThuVARP, M-TUERP, B-TUERP, aquablation, TUMT, WAVE

**non-ablative methods:
TUIP, PAE, PVA, PUL,
TIND**

- water vapor thermal therapy (**WAVE**), using convective water vapor generated through radiofrequency current and injected into the prostate.

Also non ablative techniques have been developed, specifically:

- **TUIP**, incising the bladder neck to reduce the gland's pressure on the urethra;
- prostate artery embolization (**PAE**), using polyvinyl alcohol (**PVA**) and other newer synthetic biocompatible materials to reduce the blood flow in the prostate, causing it to undergo ischemic necrosis;
- prostatic urethral lift (**PUL**), using small permanent implants: one end is anchored in the urethra and the other is attached to the firm outer surface of the prostatic capsule, so pulling the prostatic lobe away from the urethra;
- temporary implantable nitinol device (**TIND**), creating new channels in the urethra to increase urine flow.

Methods

**based on the
EUnetHTA Assessment
OTCA27, adapted
for the Austrian
context**

The present summary is based on the EUnetHTA Assessment OTCA27, which evaluates clinical effectiveness and safety of a total of 21 surgical technologies in comparison to TURP, open prostatectomy, or between each other.

A systematic literature search was carried out in March 2020 and an update search in January 2021. Only RCTs were considered for the assessment of clinical efficacy and safety. Sham-controlled studies were only considered if RCTs with direct comparisons could not be identified. The risk of bias at study level was assessed with the Cochrane Risk of Bias 2.0 tool. The data of the decision-relevant endpoints was rated according to the GRADE scheme. Whenever possible, quantitative analysis methods with meta-analysis were carried out.

Domain clinical effectiveness

**critical endpoints for
clinical effectiveness**

The following endpoints were defined as critical: international prostate symptom score (IPSS), quality of life score (QoL), international index of erectile function score (IIEF), BPH impact index score (BPHII), maximum urinary flow (Qmax), post-void residual (PVR), catheterization time, re-intervention rate, hospital stay, and operation time.

Domain safety

**critical endpoints for
safety**

The following endpoints were defined as critical: intra- and postoperative serious adverse events (SAEs) and non-serious adverse events (AEs).

Results

Available evidence

**84 RCTs over all
interventions, average
group-size of 63 pts**

Eighty-four RCTs (in 94 publications) were eventually selected; all but three of these RCTs were two-arm trials. Sixty-six RCTs (three multi-arm) compared newer technologies vs TURP, 18 (three multi-arm) compared two newer technologies vs each other, one (multi-arm) compared newer technologies vs open prostatectomy and one vs sham. All trials were relatively small-sized: the highest number of patients per study arm was 205, with an average size of 63. The vast majority of studies included heterogeneous populations in terms of prostate size and it was not possible to assess effectiveness and safety of the different technologies in subgroups according to prostate size.

Clinical effectiveness

New technologies vs TURP: IPSS and Qmax

Some of the available RCTs and pooled data showed:

- statistically significant improvements vs TURP for IPSS in favour of HoLEP, B-TUEP, TUVRP and ThuLEP (from pooled data), and in favour of B-TUERP (from single RCTs);
- for the latter outcome, statistically significant improvements in favour of TURP vs TUMT, PVP (from pooled data), PAE, PUL and DioLVP (from single RCTs);
- statistically significant improvements vs TURP for Qmax in favour of HoLEP, B-TUEP, TUVRP (from pooled data), in favour of TUIP + TURP and B-TUERP (from single RCTs);
- for the latter outcome, statistically significant improvements in favour of TURP vs TUMT, PVP and TUIP (from pooled data), PAE, PUL, DioLVP and ThuVARP (from single RCTs).

Nevertheless, the clinical relevance of the observed differences is either low or difficult to establish: pooled estimates of the mean difference are most of the times below the Minimal Clinically Important Differences (MCIDs) reported in the scientific literature.

New technologies vs TURP: PVR and quality of life

Few RCTs showed statistically significant improvements in favour of HoLEP and B-TUERP vs TURP (pooled data) and in favour of TURP vs PVP and TUMT (for PVR), ThuLEP (for QoL), PAE and PUL (the latter from single RCTs). However, it is not possible to establish the clinical relevance of the observed differences since MCID has not been established for PVR and QoL.

New technologies vs open prostatectomy

Open prostatectomy was used as comparator only in one of the selected RCTs, showing quite longer hospital time (more than 4 days more) compared to B-TUEP and B-TUVP.

Comparisons between new technologies

As for comparisons among newer technologies, few studies are available showing statistically significant differences in favour of:

- B-TUEP vs HoLEP for Qmax
- ThuLEP vs HoLEP for Qmax, IPSS, PVR, and QoL
- ThuVEP vs HoLEP for QoL (from a single RCT)
- PVP vs HoLEP for QoL
- HoLEP vs PVP for IPSS, Qmax, PVR and reintervention rate
- PVP vs B-TUVP for PVR
- DioLEP vs B-TUEP and vs B-TUERP for irritative symptoms (the latter from a single RCT)

Safety

The available comparisons did not show differences for bladder perforation, bladder and ureteral injury, erectile dysfunction, TUR syndrome, urethral stricture and bladder neck contracture.

IPSS and Qmax: some sat. sign. improvements in favour of new technologies

clinical relevance low or difficult to establish

PVR and QoL: sat. sign. improvements in favour of new technologies; clinical relevance not established

longer hospitalization for open prostatectomy vs. B-TUEP and B-TUVP

some stat. sign. differences for comparisons between new technologies

safety: some stat. sign. improvements for new technologies compared to TURP

Comparisons of new technologies vs TURP

Some of the available RCTs and pooled data showed statistically significant improvements in favour of newer technologies compared to TURP for some of the critical and important outcomes considered in this REA, specifically:

- a rate ratio of 0.4 for **retrograde ejaculation** for TUIP, an absolute reduction of 16% for aquablation and an absolute reduction (from 34% to 0%) of anejaculation for PUL (the latter two from single RCTs);
- a rate ratio for **transfusion requirement** in the order of 0.1-0.3 for HoLEP, ThuLEP, B-TUVP and PVP and a reduction of 9% for M-TUERP (the latter from a single RCT);
- a rate ratio for **urinary tract infection** between 0.2 and 0.4 for HoLEP and PAE;
- a reduction of **urinary incontinence** of 15% for PUL (from a single RCT);
- but also reductions in favour of TURP vs new technologies
- a 7% reduction of **re-catheterization** and 11% reduction of retention for M-TUERP (from a single RCT)

Viceversa, when compared to newer technologies TURP reduces **incontinence** compared to HoLEP, B-TUEP (rate ratio 1.9) and PVP (rate ratio 2.6) as well as **urinary tract infection** compared to PVP (rate ratio 1.8).

Comparisons among newer technologies

Few data from single RCTs are available, showing statistically significant differences in favour of ThuLEP vs HoLEP for incontinence (rate ratio 3.4) and of ThuVEP vs HoLEP for urinary retention (13% absolute difference from a single RCT).

Upcoming evidence

13 ongoing RCTs for several interventions

Thirteen ongoing RCTs on minimally invasive interventions for BPH were identified, some of which are already overdue or have a planned primary completion date in 2027 at the latest. Of these, HoLEP is being investigated in six studies, the interventions TUIP, B-TUEP, B-TURP, PUL, PVP, PVEP, and DioVAP in one study each.

Reimbursement

only PVP, TURP, and prostatectomy are reimbursed

Currently, only the interventions PVP, TURP, as well as open and laparoscopic (radical) prostatectomy are reimbursed by the Austrian health care system.

Discussion

quality of evidence mostly low to very low, rarely moderate

Quality of evidence for all outcomes has been judged low to very low, rarely as moderate, considering internal and external validity. As for internal validity, several studies provided limited information in terms of random allocation, allocation concealment and losses to follow-up; study protocols or trial registrations were rarely available to check for selective reporting; and, since surgery trials could be blinded to patients and to assessors (although rarely declared) but not to surgeons (although their optimal performance cannot be in doubt), biases in assessment of outcomes cannot be ruled out, especially in assessing subjective outcomes. Then, some inconsistency in results and relevant uncertainties (due to low precision of estimates) also contributed to lower quality judgements, as well as statistical heterogeneity and

the uncertain external validity due to limited information about prostate size of the included patients or the inclusion of heterogeneous populations especially in this regard.

Conclusion

Minimally invasive technologies are expected to reduce short and long-term side effects of standard surgical treatments for BPH (in particular of TURP) while preserving effectiveness on functional outcomes.

As for functional outcomes, statistically significant differences are shown in few comparisons and results are, most of the times, below the threshold for minimal clinically important difference. Quality of the related evidence has been graded low to very low, suggesting limited confidence in the estimates and that further research may be likely to change these estimates.

As for impact on sexual activity, ThuLEP, TUIP, aquablation, and PUL may provide some advantage over TURP, with quality of evidence from moderate (reduced impact on retrograde ejaculation in case of patients with small prostates undertaking TUIP) to low/very low.

Regarding other possible safety concerns and side effects, some newer technologies may offer some advantage over TURP reducing transfusion requirement; mixed results (improvement or worsening), in limited to very few technologies, are available for urinary tract infection and incontinence.

Small sample sizes, biases in study design, heterogeneous populations, and (most of the times) undefined primary hypothesis indicate the need for more and better research, so that advantages and disadvantages of all these technologies could be more clearly defined.

**functional endpoints:
only few comparisons
show clinically
relevant differences
with stat. sign., limited
quality of evidence**

**possible benefit of
single interventions
with regard to sexual
activity**

**safety: partially
reduced risk of need
for blood transfusions,
also opposite effects**

**limitations of the
available studies
indicate a need for
further research**

2 Zusammenfassung

Einleitung

Indikation und therapeutisches Ziel

Die benigne Prostatahyperplasie (BPH) ist eine gutartige Vergrößerung der männlichen Vorsteherdrüse (Prostata) welche, aufgrund der Raumforderung, eine Verengung der Harnröhre verursachen kann. Dies geht mit massiven Problemen beim Wasserlassen einher, welche unter Symptome des unteren Harntraktes (engl. lower urinary tract symptoms; LUTS) zusammengefasst werden. Dazu gehören u. a. ein verzögertes Einsetzen der Blasenentleerung trotz starken Harndrangs, Pressmiktion, Restharnempfinden, ein schwacher Harnstrahl, nachtröpfelnder Urin, lange Dauer der Blasenentleerung und schon kurze Zeit nach dem Urinieren einsetzender erneuter Harndrang [1, 2].

Die weltweite Prävalenz der BPH unter Männer im Alter zwischen 51 und 60 Jahren wird auf 42% geschätzt, in der Altersgruppe 71 bis 80 Jahre bereits auf 82% [2]. Allerdings weisen nur 30% dieser Betroffenen Symptome auf und bedürfen einer medizinischen Behandlung [1]. Laut einer Umfrage unter österreichischen Männern im Alter von 15 bis 89 Jahren wird die Prävalenz von mäßiger bis schwerer LUTS auf 9,1% geschätzt. Allerdings bleibt unklar, wie viele der betroffenen unter einer BPH leiden [2].

Da Störungen beim Wasserlassen mit zunehmendem Alter relativ häufig sind und aufgrund der Symptomvielfalt der BPH, folgen die Therapieempfehlungen einem abgestuften diagnostischen Vorgehen.

Für die Behandlung der BPH steht eine Vielzahl von Therapieoptionen zur Verfügung, wobei alle als Therapieziel die Linderung der LUTS Symptome haben. Das Spektrum reicht von anfänglichem Beobachten, über Medikamente bis hin zu zahlreichen Operationsverfahren. Die häufigsten Indikationen für chirurgische Eingriffe sind mittelschwere bis schwere LUTS, die auf eine konservative oder medizinische Therapie nicht ansprechen (relative Operationsindikationen). Eine chirurgische Behandlung ist auch erforderlich, wenn bei Patienten eine wiederkehrende oder refraktäre Harnretention, Überlaufinkontinenz, wiederkehrende Harnwegsinfekte, Blasensteine oder Divertikel, eine behandlungsresistente makroskopische Hämaturie oder eine Erweiterung der oberen Harnwege (mit oder ohne Niereninsuffizienz) aufgrund von BPH aufgetreten sind (absolute Operationsindikationen) [1].

Die Wahl der geeigneten Operationstechnik hängt von zahlreichen Faktoren ab, u.a. der Prostatagröße, möglichen Komorbiditäten, der Anästhesiefähigkeit, den Präferenzen des Patienten, der Bereitschaft zu einem chirurgischen Eingriff, sowie der generellen Verfügbarkeit der jeweiligen chirurgischen Methoden und der Erfahrung des Chirurgen mit diesen Operationstechniken. Die Europäische Gesellschaft für Urologie (European Association of Urology/EAU) stellt mit ihrer aktuellen klinischen Leitlinie einen detaillierten Behandlungsalgorithmus für das Management und die Wahl der optimalen Behandlungsmethode von BPH-assoziiierter LUTS zur Verfügung [3].

gutartige Prostatahyperplasie (BPH)

Vergrößerung der Prostata verursacht mäßige bis schwere Harntrakt-Beschwerden (LUTS)

weltweite Prävalenz: 42% Männer 51-60 J, 82% 71-80 J; nicht alle symptomatisch

österr. Umfrage zu LUTS: 9,1% aller Männer jeglichen Alters

Vielzahl an Therapieoptionen: Beobachten, Medikamente, zahlreichen Operationsverfahren

relative vs. absolute Indikationen für chirurgischen Eingriff

Faktoren, die die Wahl der Operationstechnik beeinflussen

Behandlungsalgorithmus der EAU Leitlinie

Beschreibung der Technologien

TURP und offene Prostatektomie als Standardmethoden

Die transurethrale Resektion der Prostata (TURP) gilt als die Standardmethode zur Behandlung der BPH aller Prostatavergrößerungen, aber vor allem bei einer Prostatagröße von 30 bis 80 cm³. Für eine Prostatagröße über 80 cm³ ist die wesentlich invasivere offene Prostatektomie empfohlen.

hohes Risiko für sexuelle Dysfunktion und Inkontinenz bei Standardmethoden

Zwar ermöglichen TURP und offene Prostatektomie eine maximale Entfernung des betroffenen Prostatagewebes, mit ausgezeichnetem symptomatischem Nutzen, allerdings geht mit ihnen auch ein nicht unerhebliches Risiko für sexuelle Dysfunktionen und Inkontinenz einher.

LKF-Abrechnung 2015

Im Jahr 2015 wurde die TURP 5.983 mal und die offene Prostatektomie 150 mal in österreichischen Spitälern abgerechnet [2].

Minimal-invasive Interventionen:

Verschiedene minimal-invasive Technologien bieten Alternativen, welche ähnliche Wirksamkeit, aber ein besseres Sicherheitsprofil im Vergleich zu den Standardtherapien aufweisen sollen.

ablative Methoden: TmLRP, HoLEP, ThuLEP, DioLEP, B-TUEP, B-TUVP, PVP, DioLVP, ThuVEP, V-VEP, TUVRP, ThuVARP, M-TUERP, B-TUERP, aquablation, TUMT, WAVE

Dazu gehören unterschiedliche ablative Methoden zur Entfernung von überschüssigem Prostatagewebe:

- Resektion durch einen Holmium- oder Thulium-Laser (**TmLRP**) als Alternative zur klassischen TURP;
- Enukleation, bei der die vergrößerte Prostata aus der Prostata kapsel herausgelöst wird, ohne in sie hineinzuschneiden oder sie zu zerteilen, entweder mit einem Holmium- (**HoLEP**), Thulium- (**ThuLEP**) oder Diodenlaser (**DioLEP**) oder mit verschiedenen Elektroden, die bipolare Energie liefern (**B-TUEP**);
- Vaporisation durch eine bipolare Elektrode (**B-TUVP**) oder ein Lasersystem (z.B. mit Greenlight Laser - **PVP** oder mit Diodenlaser - **DioLVP**) zur Entfernung von überschüssigem Prostatagewebe durch Erhitzen und Verdampfen;
- Hybridtechniken wie Vapoenukleation (z.B. mit einem Thulium-Laser - **ThuVEP** - oder mit bipolarer Energie - **B-VEP**), Vaporesektion (unter Verwendung von Resektion mit Hilfe von elektrischem Strom oder Laser und Vaporisation mit Hilfe einer Vaporisationselektrode - **TUVRP** und **ThuVARP**) oder Enukleoresektion (unter Verwendung von monopolarer - **M-TUERP** - oder bipolarer Energie - **B-TUERP**);
- **Aquablation**, unter der Verwendung eines Hochgeschwindigkeitsstrahls aus Kochsalzlösung;
- transurethrale Mikrowellentherapie (**TUMT**), bei der elektromagnetische Wellen zur Thermoablation des Prostatagewebes eingesetzt werden;
- Wasserdampfthermotherapie (**WAVE**), bei der konvektiver Wasserdampf durch Hochfrequenzstrom erzeugt und in die Prostata injiziert wird.

nicht-ablative Methoden: TUIP, PAE, PVA, PUL, TIND

Auch nicht-ablative Methoden stehen zur Verfügung:

- **TUIP**, Inzision des Blasenhalses, um den Druck der Prostata auf die Harnröhre zu reduzieren; dieses Verfahren ist eine Option vor allem für Männer mit kleinerer Prostata, welches einen Kompromiss zwischen geringerer Wirksamkeit und höherer Sicherheit oder geringerer Beeinträchtigung der Sexualfunktion ermöglicht;
- Prostata-Arterien-Embolisation (**PAE**), bei der Polyvinylalkohol (PVA) und andere neuere synthetische biokompatible Materialien

verwendet werden, um den Blutfluss in der Prostata zu reduzieren, wodurch diese eine ischämische Nekrose erleidet;

- Prostatic urethral lift (**PUL**): Dabei werden kleine permanente Implantate zum einen in der Harnröhre verankert und das andere Ende an der festen Außenfläche der Prostatakapsel befestigt, wodurch der Prostatalappen von der Harnröhre weggezogen wird;
- Ein temporäres implantierbares Nitinol-Gerät (**TIND**), das neue Kanäle in der Harnröhre schafft, um den Urinfluss zu erhöhen. Es wird in der prostatistischen Harnröhre platziert, wo es sich ausdehnt und somit das obstruktive Gewebe komprimiert. In den folgenden Tagen erzeugt der von den Streben des Geräts ausgeübte Druck ischämische Bereiche in der prostatistischen Harnröhre und im Blasenhal, wodurch neue Längskanäle, durch die der Urin fließen kann, entstehen.

Laut der American Urologic Association sind einige Techniken (z.B. HoLEP und ThuLEP) Prostatagrößen-unabhängig, während andere Techniken (z.B. PVP, Aquablation, WAVE, TUMT, TUVP, PUL) speziell für kleine bis mittelgroße Prostata und TUIP nur für kleine Prostata geeignet sind.

Technologien für unterschiedliche Prostatagrößen geeignet

Methoden

Die vorliegende Zusammenfassung basiert auf dem EUnetHTA OTCA27 Assessment [1]. Dieser umfassende Bericht bewertet die klinische Wirksamkeit und Sicherheit von insgesamt 21 chirurgischen Technologien bei Patienten mit BPH mit chirurgischer Indikation im Vergleich zu den Standardverfahren TURP und offener Prostatektomie, oder zueinander selbst.

EUnetHTA Assessment zu 21 chirurgischen Therapien (inkl. WAVE)

Für die Beurteilung der klinischen Wirksamkeit und Sicherheit wurden nur Ergebnisse aus randomisierten kontrollierten Studien (RCTs) eingeschlossen. RCTs, welche die untersuchten Technologien mit Scheinverfahren verglichen, wurden nur dann berücksichtigt, wenn für die jeweiligen Technologien keine vergleichenden Head-to-Head-RCTs gefunden werden konnten.

Scheinkontrollierte Studien eingeschlossen, wenn keine direkten Vergleiche möglich

Eine systematische Literaturrecherche in mehreren Datenbanken (Cochrane Library, Embase, Medline) wurde im März 2020 durchgeführt, im Januar 2021 folgte hierzu eine Update-Recherche. Zusätzliche Informationen wurden durch eine Internetsuche, Handsuche nach potentiell relevanten HTA-Berichten sowie einer Suche nach laufenden Studien (Clinical Trials Registry Platform und Clinicaltrials.gov) gewonnen.

systematische Literatursuche in 3 Datenbanken, Handsuche, Suche nach laufenden Studien

Fünf Review-Autor*innen extrahierten unabhängig voneinander unter Verwendung eines für eigens für den Review entwickelten Datenextraktionsformulars. Das Risiko einer Verzerrung (engl. risk of bias; RoB) auf Studienebene wurde anhand des Cochrane Risk of Bias 2.0 Tools bewertet. Anschließend folgte eine Bewertung der Qualität der Evidenz mit dem Grading of Recommendations Assessment, Development and Evaluation (GRADE) Schema. Wann immer möglich, wurden quantitative Analysemethoden mit Meta-Analysen für Wirksamkeit und Sicherheits-Endpunkte unter der Verwendung von RevMan 5.3 durchgeführt.

RoB- und GRADE-Bewertung

Klinische Wirksamkeit

**Endpunkte
Wirksamkeit: IPSS,
QoL, IIEF, BPHII,
Qmax, PVR, Dauer der
Katheterisierung,
Reinterventionsrate,
Spitallaufenthalt,
Operationsdauer**

Die folgenden Endpunkte wurden als entscheidend für eine Bewertung der klinischen Wirksamkeit definiert:

- International Prostate Symptom Score (IPSS)
- Lebensqualität (engl. quality of life; QoL)
- Erektile Dysfunktion (International Index of Erectile Function; IIEF)
- BPH Impact Index (BPHII)
- maximaler Harnfluss (Qmax)
- Restharn (engl. post-void residual; PVR)
- Katheterisierungsdauer
- Krankenhausaufenthalt
- Reinterventionsrate

**Patient Reported
Outcomes:
IPSS, QoL, BPHII und
IIEF**

IPSS, QoL, BPHII und IIEF wurden mittels validierten Patienten-Fragebögen erhoben (Patient Reported Outcomes – PRO). Der IPSS score gibt den Schweregrad der LUTS an, wobei eine Punktzahl von 1-7 milde, 8-19 mäßige und 20-35 schwere Symptome anzeigt. Der QoL-Score erstreckt sich von 0 bis 6, wobei ein niedrigerer Wert eine bessere QoL anzeigt. BPHII misst Auswirkungen von Harnbeschwerden auf die Lebensqualität, wobei niedrigere Werte auf weniger Symptome hinweisen und IIEF misst Erektionsstörungen, wobei niedrigere Werte eine schlechtere sexuelle Funktion bedeuten.

**objektive
Messinstrumente:
Qmax und PVR**

Qmax und PVR können objektiv mittels Uroflowmetrie gemessen werden, wobei niedrigere Qmax-Werte auf eine mögliche Verstopfung des Blasenauslasses hinweisen und PVR die Harnretention nach der Entleerung der Blase misst. Dieser Endpunkt ist aber nicht geeignet, den Schweregrad der LUTS zuverlässig zu bestimmen, da eine hohe Inter-Beobachter sowie Inter-Equipment Variabilität bei der Messung vorliegen kann.

Sicherheit

**Endpunkte Sicherheit:
intra- und
postoperative
Komplikationen**

Die folgenden gruppierten Endpunkte wurden als entscheidend für eine Bewertung der Sicherheit definiert:

- intraoperative Komplikationen (Blutverlust, Verletzung der Blase)
- postoperative Komplikationen (erektile Dysfunktion, Harn-inkontinenz, Harnröhrenstriktur, Blasenhaliskontraktur, akuter Harnverhalt, retrograde Ejakulation, und Harnwegsinfektion)

Ergebnisse

Verfügbare Evidenz

**insgesamt 84 RCTs
eingeschlossen über
alle Vergleiche**

Anhand der Literatursuche konnten insgesamt 84 RCTs (in 94 Publikationen) identifiziert werden, von denen alle bis auf drei ein zweiarmiges Studiendesign aufwiesen. Sechszwanzig RCTs (drei davon mehrarmig) verglichen neuere Technologien mit TURP, 18 (drei davon mehrarmig) zwei neue Technologien miteinander, eine mehrarmige Studie verglich neuere Technologien mit der offenen Prostatektomie und eine weitere gegen eine Scheinbehandlung.

Die maximale Anzahl an Patienten pro Studienarm lag bei 205, im Mittel aber nur bei 63. Die am häufigsten untersuchte Technologie in den eingeschlossenen Studien war HoLEP (23 Studien), gefolgt von B-TUVP (13 Studien), B-TUEP (12 Studien), ThuLEP (9 Studien), DioLEP und PVP (6 Studien), TUIP (5 Studien), TUMT und TUVRP (4 Studien), DioLVP und PAE (3 Studien), B-TUERP, ThuVEP, TmLRP und TUIP+TURP (2 Studien), Aquablation, B-VEP, M-TUERP, PUL, ThuVARP und WAVE (1 Studie). WAVE wurde nur in einem RCT gegen Scheinbehandlung untersucht, womit keine Vergleiche zu alternativen Technologien bewertet werden konnten. Zur Bewertung der Technologie TIND wurde kein RCT identifiziert.

Die überwiegende Mehrheit der Studien schloss heterogene Populationen in Bezug auf die Prostatagröße der Patienten ein. Eine Bewertung der klinischen Wirksamkeit und Sicherheit der verschiedenen Technologien unterteilt in vordefinierte Prostatagrößen-Untergruppen war daher nicht möglich. Studien mit relativ homogenen Populationen gab es für TUIP im Vergleich mit TURP, welche Patienten mit kleinerer Prostata (weniger als 30-40 cm³) einschlossen. Studien zu DioLEP (in zwei RCTs), WAVE und Aquablation (in einem RCT) schlossen Patienten mit einer Prostatagröße zwischen 30 und 80 cm³ ein; einzelne Studien zu HoLEP, B-VEP (jeweils in zwei RCTs), PVP, B-TUEP und M-TUERP (jeweils in einem RCT), hingegen nur Patienten mit einer Prostatagröße >80 cm³.

Klinische Wirksamkeit

Ein umfassender Überblick über alle Interventionsvergleiche wird für die Wirksamkeits-Endpunkte IPSS und Qmax, je nach sechs und zwölf Monaten, sowie benötigte Reinterventionen im EUnetHTA bereitgestellt.

Neue Technologien vs. TURP: IPSS und Qmax (mit Follow-up >6 Monate)

Es konnten statistisch signifikante Unterschiede gegenüber TURP bei IPSS und Qmax sowohl zugunsten neuer Technologien als auch zugunsten der TURP gezeigt werden. Die Verbesserungen lagen jedoch meist nur wenig über dem in der Literatur beschriebenen minimalen klinisch relevanten Unterschied.

Die eingeschlossenen RCTs bzw. deren gepoolte Daten zeigten:

- IPSS: statistisch signifikante Verbesserungen gegenüber TURP zugunsten von HoLEP, B-TUEP, B-TUVP und ThuLEP (gepoolte Daten) und zugunsten von B-TUERP (einzelne RCTs)
- IPSS: statistisch signifikante Verbesserungen zugunsten von TURP vs. TUMT, PVP (gepoolte Daten), PUL, PAE und DioLVP (einzelne RCTs)
- Qmax: statistisch signifikante Verbesserungen gegenüber TURP zugunsten von HoLEP, B-TUEP und B-TUVP (gepoolte Daten) und zugunsten von TUIP + TURP und B-TUERP (einzelne RCTs)
- Qmax: statistisch signifikante Verbesserungen zugunsten von TURP vs. TUMT, und TUIP (gepoolte Daten), PAE, PUL, DioLVP und ThuVARP (einzelne RCTs).

kleine Studienpopulationen, im Schnitt nur 63 Pat. pro Studienarm, häufigste Interventionen: HoLEP (23), B-TUVP (13), B-TUEP (12), ThuLEP (9)

meist heterogene Studienpopulationen über alle Prostatagrößen hinweg

umfangreicher Überblick aller Ergebnisse in Appendix

stat. sign. Verbesserungen bei IPSS und Qmax zugunsten neuer Technologien vs. TURP, aber auch gegenseitliche Evidenz zugunsten TURP vs. neue Technologien vorhanden

**stat. sign.
Verbesserungen bei
PVR und QoL
zugunsten HoLEP und
B-TUERP vs. TURP,
aber auch zugunsten
TURP vs. 5 andere
neue Technologien**

Neue Technologien vs. TURP: PVR und Lebensqualität

Nur vereinzelte RCTs zeigten statistisch signifikante Verbesserungen bezüglich PVR und QoL: Einerseits bei gepoolten Daten zugunsten zweier neuer Technologien, HoLEP und B-TUERP und andererseits zugunsten der TURP gegenüber fünf neuen Technologien (PVP und TUMT bei PVR; ThuLEP bei QoL; PAE und PUL aus einzelnen RCTs). Da für PVR und QoL keine minimalen klinisch relevanten Unterschiede in der Literatur angegeben wurde, konnte keine Aussage über die klinische Relevanz dieser Unterschiede getroffen werden.

**Reinterventionen
seltener bei HoLEP
(vs. TURP)**

Neue Technologien vs. TURP: Reintervention

Für den Endpunkt Reintervention standen nur begrenzt Informationen zur Verfügung. Nur für die Technologie HoLEP zeigte sich eine geringere Zahl an benötigten Reinterventionen im Vergleich zur TURP und auch zur PVP, bei niedriger bis sehr niedriger Qualität der Evidenz.

Im Gegensatz dazu war das Risiko für Reinterventionen bei TUIP, eine Behandlungsmethode für Patienten mit geringer Prostatavergrößerung, im Vergleich zur TURP erhöht, bei niedriger Qualität der Evidenz.

**reduzierter
Krankenhausauf-
enthalt bei neuen
Technologien vs.
TURP, dennoch
längere Dauer bei den
Operationen bei neuen
Technologien**

Neue Technologien vs. TURP: Krankenhausaufenthalt und Operationszeit

Im Vergleich zur TURP zeigte sich bei den neueren Technologien eine reduzierte Dauer des Krankenhausaufenthalts, welche weniger als einen Tag bis zu 1-2 Tage ausmachte. Bezüglich der Dauer der Operation selbst, werden für neuere Technologien im Vergleich zur TURP im Allgemeinen mehr Zeit benötigt (mit Ausnahme der TUIP, die eine kürzere Operationszeit als die TURP ermöglicht). Die Unterschiede liegen jedoch in der Größenordnung von Minuten. Bei beiden Endpunkten war aufgrund der statistische Heterogenität, welche möglicherweise auf unterschiedliche Vorgehensweisen in verschiedenen klinischen Zentren zurückzuführen ist, eine Zusammenführung der Daten und eine gepoolte Analyse nicht möglich.

**längerer Krankhaus-
aufenthalt bei offener
Prostatektomie (vs. B-
TUEP, B-TUVP)**

Neue Technologien vs. offene Prostatektomie

Die offene Prostatektomie wurde nur in einer der ausgewählten RCTs als Komparator verwendet, es zeigte sich hier eine deutlich längere Krankenhaus-Aufenthaltsdauer (>4 zusätzliche Tage) im Vergleich zu B-TUEP und B-TUVP.

**einzelne direkte
Vergleiche zwischen
zwei minimal-
invasiven
Technologien**

Vergleiche zwischen neuen Technologien

Bezüglich direkter Vergleiche zwischen neueren Technologien berichteten die eingeschlossenen Studien statistisch signifikante Unterschiede zugunsten von:

- B-TUEP vs. HoLEP und vs. B-TUVP für Qmax
- ThuLEP vs. HoLEP für IPSS, PVR und QoL
- Thuvep vs HoLEP für QoL (1 RCT)
- PVP vs. HoLEP für QoL
- HoLEP vs. PVP für IPSS, Qmax, PVR und Reinterventionsrate
- PVP vs. B-TUVP für PVR
- DioLEP vs B-TUEP und vs B-TUERP für irritative Symptome (1 RCT)

Sicherheit

Ein umfassender Überblick über alle Interventionsvergleiche wird für die Sicherheits-Endpunkte erektile Dysfunktion, retrograde Ejakulation, Transfusionsbedarf, Harnwegsinfektion, Harnröhrenstriktur sowie Harninkontinenz im EUnetHTA bereitgestellt.

Die eingeschlossenen Interventions-Vergleiche zeigten keine Unterschiede für Blasenperforationen, Blasen- und Ureterverletzungen, TUR-Syndrom, Harnröhrenstrikturen und Blasenhalskontrakturen.

Neue Technologien vs. TURP

Bei einigen der eingeschlossenen RCTs konnten statistisch signifikante Verbesserungen hinsichtlich der Sicherheitsendpunkte zugunsten der neueren Technologien im Vergleich zur TURP nachgewiesen werden, insbesondere für:

- retrograde Ejakulation: Ratenverhältnis von 0,4 zugunsten TUIP, eine absolute Reduktion um 16% zugunsten Aquablation und eine absolute Reduktion der Anejakulation (von 34% auf 0%) zugunsten PUL (die letzteren aus einzelnen RCTs);
- erektile Dysfunktion: eine um 27% geringere Inzidenz in der ThuLEP-Gruppe (1 RCT);
- Bedarf an Bluttransfusionen: Ratenverhältnisse zwischen 0,1-0,3 zugunsten HoLEP, ThuLEP, B-TUVP und PVP und eine Reduktion um 9% bei M-TUERP (letzteres aus 1 RCT);
- Harnwegsinfektionen: Ratenverhältnisse zwischen 0,2 und 0,4 zugunsten HoLEP und PAE;
- Harninkontinenz: Reduktion um 15% in der PUL-Gruppe (1 RCT);
- Re-Katheterisierungen: Reduktion um 7% in der M-TUERP-Gruppe (1 RCT)
- Harnretentionen: Reduktion um 11% in der M-TUERP-Gruppe (1 RCT)

Im Gegensatz dazu konnte eine statistisch signifikante Reduktion zugunsten der TURP im Vergleich zu neueren Technologien für die folgenden Endpunkte nachgewiesen werden:

- Inkontinenz im Vergleich zu HoLEP, B-TUEP (Ratenverhältnis 1,9) und PVP (Ratenverhältnis 2,6)
- Harnwegsinfektionen im Vergleich zu PVP (Ratenverhältnis 1,8)

Vergleiche zwischen neuen Technologien

Für Vergleiche zwischen zwei neueren minimal-invasiven Technologien stehen nur wenige Daten aus vereinzelt RCTs zur Verfügung: Statistisch signifikante Unterschiede konnten für den Endpunkt Inkontinenz zugunsten von ThuLEP vs. HoLEP (Ratenverhältnis 3,4) und für den Endpunkt Harnverhalt zugunsten ThuVEP vs. HoLEP (13% absolute Differenz) nachgewiesen werden.

Laufende Studien

Es konnten 13 derzeit laufende RCTs zu minimal-invasiven Intervention bei BPH identifiziert werden, deren geplantes Ende teilweise schon überfällig bzw. mit spätestens 2027 angegeben ist. Davon wird HoLEP in sechs Studien

umfangreicher Überblick aller Ergebnisse in Appendix

teilweise stat. sign. Reduktion der Sicherheitsendpunkte zugunsten neuer Technologien im Vergleich zu TURP: u.a. bei retrograde Ejakulation, erektile Dysfunktion, Bedarf an Transfusionen, ...

im Gegensatz auch: stat. sign. Reduktion von Inkontinenz zugunsten TURP (vs. zu HoLEP, B-TUEP, PVP) und Harnwegsinfektionen (vs. PVP)

nur einzelne Studien mit Evidenz für Sicherheit im Vergleich zwischen zwei neuen Technologien

13 laufende RCT zu minimal-invasiven Interventionen bei BPH

untersucht und die Methoden TUIP, B-TUEP, B-TURP, PUL, PVP, PVEP und DioVAP jeweils in einer Studie.

Kostenerstattung

derzeit nur PVP, TURP und Prostatektomie erstattet

Derzeit sind nur die Interventionen PVP, TURP, sowie die offene und laparoskopische (radikale) Prostatektomie im österreichischen stationären Leistungskatalog abgebildet.

Diskussion

Qualität der Evidenz: meist niedrig bis sehr niedrig, selten moderat

Die Qualität der Evidenz für die Wirksamkeits- und Sicherheitsendpunkte wurde unter Berücksichtigung der internen und externen Validität meist als niedrig bis sehr niedrig, in seltenen Fällen als moderat, eingestuft.

RoB: teilweise fehlende Information zu Randomisierung und loss to follow-up, Verblindung nicht immer gegeben, fehlende Studienprotokolle, subjektiv erhobene Endpunkte

In Bezug auf die interne Validität (RoB), gaben mehrere Studien nur begrenzt Informationen zu Randomisierung und der verdeckten Zuordnung der Studienteilnehmer; auch der Verlust an Patienten bis zum Zeitpunkt der Nachbeobachtung (engl. loss to follow-up) wurde nicht durchgehend berichtet. Ebenso waren Studienprotokolle bzw. Registrierungen der Studien, welche zur Einschätzung selektiver Berichterstattung nötig sind, nur selten verfügbar. Meist können bei Studien zu chirurgischen Interventionen nur die Patienten und Begutachter verblindet werden (wenn auch in den hier eingeschlossenen Studien selten deklariert), nicht aber für die durchführenden Chirurg*innen selbst. Dies kann, vor allem bei subjektiv-gemessenen Endpunkten, das Risiko möglicher Verzerrungen bei der Bewertung der Ergebnisse erhöhen.

inkonsistente Effektschätzungen und niedrige Präzision

Des Weiteren wurde die Qualität der Evidenz teilweise auch aufgrund von Inkonsistenzen durch entgegengesetzte Effektschätzungen, sowie Unsicherheiten durch niedrige Präzision dieser, niedriger bewertet.

insbesondere keine Power-Analysen für Sicherheitsendpunkte

Trotz des angenommenen Sicherheits-Vorteils der neuen weniger invasiven Technologien, wurde bei keiner der eingeschlossenen Studien eine Power-Analyse hinsichtlich dieser Endpunkte berechnet: nur 5 Studien wurden hinsichtlich der Katheterisierungsdauer statistisch gepowert, diese hängt allerdings nur indirekt mit der Sicherheit der Interventionen zusammen.

limitierte externe Validität

Eine externe Validität der vorliegenden Studien und Evidenz ist aufgrund begrenzter Informationen zu Prostatagrößen der eingeschlossenen Patienten und der Einbeziehung heterogener Populationen nicht durchgehend vorhanden.

Annahme: minimal-invasive Methoden sollen gleich effektiv aber sicherer sein → heterogene Evidenzlage

Schlussfolgerung

Die Anwendung von minimal-invasiven Technologien soll die kurz- und langfristigen Nebenwirkungen der chirurgischen Standardbehandlungen für BPH (insbesondere der TURP) reduzieren und gleichzeitig die gute klinische Wirksamkeit erhalten.

funktionelle Endpunkte: nur wenig Vergleiche zeigen klinisch relevante Unterschiede mit stat. Signifikanz

Dennoch zeigen sich, bezüglich der funktionellen Endpunkte der klinischen Wirksamkeit, nur in wenigen Interventions-Vergleichen statistisch signifikante Unterschiede. Zusätzlich liegen diese meist unterhalb der Schwelle für einen minimalen, klinisch bedeutsamen Unterschied. Die Qualität dieser Evidenz wurde

als niedrig bis sehr niedrig eingestuft, was auf eine begrenzte Vertrauenswürdigkeit dieser hindeutet und, dass weitere Forschung die Effektschätzungen wahrscheinlich beeinflussen wird.

Bezüglich der Auswirkungen auf die sexuelle Aktivität, könnten ThuLEP, TUIP, Aquablation und PUL einen gewissen Vorteil gegenüber der TURP bieten, wobei auch hier die Qualität der Evidenz nur auf moderat bis niedrig/sehr niedrig eingestuft wurde.

Hinsichtlich der Sicherheit und Nebenwirkungen bieten einige neuere Technologien möglicherweise einen gewissen Vorteil gegenüber der TURP, z.B. durch einen reduzierten Bedarf an Bluttransfusionen. Das Auftreten von Harnwegsinfektionen und neuerlicher Inkontinenz wurde nur für eine geringe Zahl an Interventionen untersucht. Zusätzlich zeigten sich dabei gegensätzliche Effekte, die sowohl auf ein verringertes als auch vermehrtes Vorkommen dieser hindeutet.

Die überwiegend kleinen Stichproben, Verzerrungen im Studiendesign, heterogene Populationen und (meist) nicht vordefinierten primäre Untersuchungshypothesen verweisen ebenfalls auf eine Notwendigkeit weiterer und robusterer Forschung, welche die Vor- und Nachteile der einzelnen Technologien klarer definieren könnte.

Der vorliegende EUnethTA OTCA27 Bericht ermöglicht, aufgrund der Vielzahl der bewerteten Technologien und Vergleiche, einen umfassenden und aktuellen Überblick über die verfügbare Evidenz zu minimal-invasiven chirurgischen Technologien zur Behandlung von BPH. Es wird dennoch angemerkt, dass in diesem Bericht die ethischen, organisatorischen und ökonomischen Aspekte der verschiedenen Technologien nicht bewertet wurden.

möglicher Vorteil einzelner Interventionen bzgl. sexueller Aktivität

Sicherheit: teilweise geringeres Risiko für Bedarf an Bluttransfusionen, teilweise gegensätzliche Effekte

Limitationen der vorhandenen Studien weisen auf weiteren Forschungsbedarf hin

umfassender und aktueller Überblick über minimal-invasive Interventionen bei BPH

ethische, organisatorische und ökonom. Aspekte nicht untersucht

3 References

- [1] EUnetHTA OTCA27 Authoring Team. Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH). Draft Report of Collaborative Assessment. 2021.
- [2] Vreugdenburg TD and Wild C. Prostate artery embolisation for benign prostatic hyperplasia. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; 2017.
- [3] European Association of Urology (EAU). EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2018; [cited 11.12.2020]. Available from: <https://uroweb.org/guidelines/>.



eunethta

EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT

EUnetHTA Joint Action 3

**EUnetHTA Core HTA of other technologies
using the HTA Core Model[®]**

**COMPARATIVE EFFECTIVENESS OF SURGICAL TECHNIQUES AND
DEVICES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA**

Project ID: OTCA27

Version 1.0, 30 April 2021



This report is part of the project / joint action '724130 / EUnetHTA JA3' which has received funding from the European Union's Health Programme (2014-2020)

DOCUMENT HISTORY AND CONTRIBUTORS

| Version | Date | Description |
|---------|----------|---|
| V0.1 | 31/12/21 | First draft. |
| V0.2 | 08/01/21 | Input from co-author has been processed. |
| V0.3 | 12/03/21 | Input from dedicated reviewers has been processed. |
| V0.4 | 12/04/21 | Input from external experts and manufacturer(s) has been processed. |
| V0.5 | 23/04/21 | Input from medical editor has been processed. |
| V1.0 | 30/04/21 | Final report |

Disclaimer

The content of this assessment represents a consolidated view based on the consensus within the Authoring Team. It cannot be considered to reflect the views of the European Network for Health Technology Assessment (EUnetHTA), the EUnetHTA participating institutions, the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

EUnetHTA Joint Action 3 is supported by a grant from the European Commission. The sole responsibility for the content of this document lies with the authors and neither the European Commission nor EUnetHTA are responsible for any use that may be made of the information contained herein.

The HTA Core Model for Rapid Relative Effectiveness Assessments developed within EUnetHTA has been utilised when producing the contents and structure of this assessment report. The assessment elements, specified in the Core Model for Rapid Relative Effectiveness Assessments Version 4.2, are indicated in the footnotes of the respective domain in order to provide further orienting support. The HTA Core Model Version 4.2 is available here:

https://eunetha.eu/wp-content/uploads/2018/06/HTACoreModel_ForRapidREAs4.2-3.pdf.

Assessment Team

| ASSESSMENT TEAM | | |
|-----------------------|--------------------|---|
| Authoring Team | Author | Giulio Formoso, Olivera Djuric, Laura Bonvicini, Annamaria Pezzarossi, Luciana Ballini (Regione Emilia-Romagna, Italy) |
| | Co-Author | Judit Erdos (HTA Austria – Austrian Institute for Health Technology Assessment GmbH, Austria) |
| | Statistical expert | Ana Jeroncic (Department of Research in Biomedicine and Health, University of Split School of Medicine, Croatia) |
| Dedicated Reviewer(s) | | Heike Raatz, Felix Gurthner (Swiss Network for HTA, Switzerland) |
| | | Anna Cavazzana, Erica Ceresola, Sara Nocera, Valentina Montresor, Chiara Marchioro (Azienda Zero-Veneto, Italy) |
| | | Vitalija Mazgelė, Kristina Grigaitė (State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania, Lithuania) |
| Project Manager | | Judit Erdos (HTA Austria – Austrian Institute for Health Technology Assessment GmbH, Austria) |

Acknowledgements

| | Name, affiliation | Description of tasks |
|--------------------|--|---|
| External Expert(s) | Dr Franco Bergamaschi, Chief of Urology (IRCCS – Arcispedale Santa Maria Nuova-Reggio Emilia, Italy) Dr Alfio Capizzi, Medical Manager and HTA expert (Azienda Ospedale – Università di Padova, Italy) Dr Iain Robertson, Consultant Interventional Radiologists (Glasgow, Scotland) | Clinical advisory activity, review of text sections with clinically relevant content, GRADEpro voting |
| Manufacturer(s) | Neotract Inc. | Factual accuracy check |
| Medical Editor(s) | Compuscript Ltd., Ireland | Medical editing |

Conflict of interest

All authors, co-authors, dedicated reviewers, observers and external experts (health care professionals, patients or patient representatives) involved in the production of this assessment have declared they have no conflicts of interest in relation to the technology and comparator(s) assessed according to the EUnetHTA declaration of interest (DOI) form, which was evaluated following the EUnetHTA Procedure Guidance for handling DOI form (<https://eunetha.eu/doi>).

Copyright:

EUnetHTA assessments are published under a “cc/by/nc” Creative Commons Licence

<https://creativecommons.org/licenses/by-nc/2.0/es/deed.en>



How to cite this assessment

Please, cite this assessment as follows:

EUnetHTA OTCA27 Authoring Team. Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. Collaborative Assessment. Diemen (The Netherlands): EUnetHTA; 2021. Report No.: OTCA27. Available from: <https://www.eunetha.eu>.

Contact the EUnetHTA Secretariat EUnetHTA@zinl.nl with inquiries about this assessment.

TABLE OF CONTENTS

| | |
|--|-----------|
| LIST OF ABBREVIATIONS..... | 8 |
| EXECUTIVE SUMMARY OF THE ASSESSMENT OF SURGICAL TECHNIQUES AND DEVICES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA..... | 11 |
| SCOPE..... | 11 |
| HEALTH PROBLEM..... | 11 |
| DESCRIPTION OF THE TECHNOLOGIES AND COMPARATORS | 11 |
| METHODS | 12 |
| RESULTS..... | 13 |
| Clinical effectiveness: direct comparisons | 13 |
| Safety: direct comparisons..... | 14 |
| QUALITY OF EVIDENCE | 15 |
| CONCLUDING SUMMARY | 15 |
| 1 BACKGROUND..... | 16 |
| 1.1 OVERVIEW OF THE DISEASE, HEALTH CONDITION AND TARGET POPULATION | 16 |
| 1.2 CURRENT CLINICAL PRACTICE | 18 |
| 1.3 FEATURES OF THE INTERVENTION..... | 19 |
| 2 OBJECTIVES AND SCOPE..... | 28 |
| 3 METHODS | 31 |
| 3.1 CLINICAL EFFECTIVENESS AND SAFETY | 31 |
| 3.1.1 Information retrieval..... | 31 |
| 3.1.2 Selection of relevant studies and documents..... | 32 |
| 3.1.3 Data extraction..... | 32 |
| 3.1.4 Quality rating and RoB assessment | 33 |
| 3.1.5 Data analyses and synthesis..... | 34 |
| 3.1.5.1 Certainty of the evidence (if applicable)..... | 36 |
| 3.1.6 Patient involvement | 36 |
| 3.1.7 External expert involvement | 36 |
| 4 RESULTS: CLINICAL EFFECTIVENESS AND SAFETY | 37 |
| 4.1 INFORMATION RETRIEVAL | 37 |
| 4.2 STUDIES INCLUDED IN THE ASSESSMENT..... | 38 |
| 4.3 DESCRIPTION OF THE EVIDENCE USED | 40 |
| 4.4 RESULTS FOR CLINICAL EFFECTIVENESS AND SAFETY | 57 |
| 4.4.1 Clinical effectiveness | 57 |
| 4.4.1.1 Resection techniques..... | 57 |
| 4.4.1.2 Enucleation techniques | 58 |
| 4.4.1.3 Vaporization techniques..... | 100 |
| 4.4.1.4 Hybrid techniques: Vapoenucleation..... | 117 |
| 4.4.1.5 Hybrid techniques: Vaporesection | 119 |
| 4.4.1.6 Hybrid techniques: Enucleoresection..... | 123 |
| 4.4.1.7 Aquablation | 125 |
| 4.4.1.8 TUMT..... | 127 |
| 4.4.1.9 WAVE | 131 |
| 4.4.1.10 Nonablative techniques..... | 132 |
| 4.4.2 Safety..... | 141 |
| 4.4.2.1 Resection techniques..... | 141 |
| 4.4.2.2 Enucleation techniques | 143 |
| 4.4.2.3 Vaporisation techniques..... | 162 |
| 4.4.2.4 Hybrid techniques: Vapoenucleation..... | 172 |

| | |
|---|------------|
| 4.4.2.5 Hybrid techniques: Vaporessection | 173 |
| 4.4.2.6 Hybrid techniques: Enucleoresection..... | 175 |
| 4.4.2.7 Aquablation | 177 |
| 4.4.2.8 TUMT..... | 177 |
| 4.4.2.9 WAVE..... | 179 |
| 4.4.2.10 Nonablative techniques..... | 180 |
| 5 OVERVIEW OF EFFECTIVENESS OUTCOMES | 186 |
| 6 OVERVIEW OF SAFETY OUTCOMES..... | 194 |
| 7 DISCUSSION..... | 204 |
| Clinical effectiveness: direct comparisons..... | 206 |
| Safety: direct comparisons | 207 |
| 8 CONCLUDING SUMMARY | 209 |
| 9 REFERENCES..... | 210 |
| APPENDIX 1 | 225 |
| APPENDIX 2 | 226 |
| APPENDIX 3 | 227 |
| APPENDIX 4 | 231 |
| APPENDIX 5 | 376 |
| APPENDIX 6 | 387 |

LIST OF TABLES AND FIGURES

Tables

| | |
|--|----|
| Table 1-1: Synonyms, abbreviations, full name, energy sources and the name used in this assessment for technologies used for the treatment of benign prostatic hyperplasia | 26 |
| Table 2-1: Scope of the assessment..... | 28 |
| Table 3-1: Definition of the quality of the evidence | 36 |
| Table 4-1: Number of studies addressing each comparison between technologies of interest and comparators, in descending order..... | 38 |
| Table 4-2: RCTs presenting a formal power calculation and the hypothesis tested among the RCTs included in the assessment..... | 39 |
| Table 4-3: Characteristics of the studies included in the assessment | 40 |
| Table 4-4: Summary of the applicability of the body of studies..... | 55 |
| Table 4-5: Effectiveness outcomes assessed in RCTs comparing TmLRP versus TURP | 57 |
| Table 4-6: Effectiveness outcomes assessed in RCTs comparing HoLEP versus TURP..... | 58 |
| Table 4-7: Effectiveness outcomes assessed in RCTs comparing HoLEP versus B-TUEP | 67 |
| Table 4-8: Effectiveness outcomes assessed in RCTs comparing HoLEP versus ThuLEP | 70 |
| Table 4-9: Effectiveness outcomes assessed in RCTs comparing HoLEP versus PVP | 75 |
| Table 4-10: Effectiveness outcomes assessed in RCTs comparing ThuLEP versus TURP..... | 80 |
| Table 4-11: Effectiveness outcomes assessed in RCTs comparing DioLEP versus TURP | 85 |
| Table 4-12: Effectiveness outcomes assessed in RCTs comparing B-TUEP versus TURP | 87 |
| Table 4-13: Effectiveness outcomes assessed in RCTs comparing B-TUEP versus DioLEP | 96 |

| | |
|---|-----|
| Table 4-14: Effectiveness outcomes for B-TUEP versus B-TUVP assessed in Geavlete 2015 (n=160; high RoB) | 99 |
| Table 4-15: Effectiveness outcomes assessed in RCTs comparing B-TUVP versus TURP..... | 100 |
| Table 4-16: Effectiveness outcomes assessed in RCTs comparing DioLVP versus TURP | 108 |
| Table 4-17: Differences in IPSS for DioLVP versus TURP in Cetinkaya 2015 and Razzaghi 2014 | 109 |
| Table 4-18: Differences in Qmax for DioLVP versus TURP in Cetinkaya 2015 and Razzaghi 2014 | 110 |
| Table 4-19: Effectiveness outcomes assessed in RCTs comparing PVP versus TURP | 110 |
| Table 4-20: Effectiveness outcomes assessed in RCTs comparing PVP versus B-TUVP | 114 |
| Table 4-21: Effectiveness outcomes assessed in RCTs comparing B-VEP versus TURP | 117 |
| Table 4-22: Effectiveness outcomes assessed in RCTs comparing TUVRP versus TURP..... | 119 |
| Table 4-23: Effectiveness outcomes assessed in Hashim 2020 comparing TUVRP versus TURP..... | 123 |
| Table 4-24: Effectiveness outcomes assessed in Samir 2019 comparing B-TUERP versus TURP | 124 |
| Table 4-25: Effectiveness outcomes assessed in Xu 2013 (n=80; uncertain RoB) comparing B-TUERP versus DioLEP..... | 124 |
| Table 4-26: Effectiveness outcomes assessed in RCTs comparing Aquablation versus TURP.... | 125 |
| Table 4-27: Main effectiveness results from the WATER study..... | 126 |
| Table 4-28: Effectiveness outcomes assessed in RCTs comparing TUMT versus TURP | 127 |
| Table 4-29: Effectiveness outcomes assessed in McVary 2016b comparing WAVE versus sham | 131 |
| Table 4-30: Effectiveness outcomes assessed in RCTs comparing WAVE versus sham | 132 |
| Table 4-31: Effectiveness outcomes assessed in RCTs comparing TUIP versus TURP | 133 |
| Table 4-32: Effectiveness outcomes assessed in RCTs comparing TUIP + TURP versus TURP..... | 136 |
| Table 4-33: Effectiveness outcomes assessed in RCTs comparing PAE versus TURP..... | 137 |
| Table 4-34: Effectiveness outcomes assessed in RCTs comparing PUL versus TURP | 139 |
| Table 4-35: Effectiveness results from the RCT comparing PUL versus TURP | 140 |
| Table 4-36: Safety outcomes assessed in RCTs comparing TmLRP versus TURP | 141 |
| Table 4-37: Safety outcomes assessed in RCTs comparing HoLEP versus TURP..... | 144 |
| Table 4-38: Safety outcomes assessed in RCTs comparing HoLEP versus B-TUEP..... | 148 |
| Table 4-39: Safety outcomes assessed in RCTs comparing HoLEP versus ThuLEP..... | 149 |
| Table 4-40: Safety outcomes assessed in RCTs comparing HoLEP versus PVP..... | 151 |
| Table 4-41: Safety outcomes assessed in RCTs comparing ThuLEP versus TURP | 153 |
| Table 4-42: Safety outcomes assessed in RCTs comparing DioLEP versus TURP | 156 |
| Table 4-43: Safety outcomes assessed in RCTs comparing B-TUEP versus TURP | 157 |
| Table 4-44: Safety outcomes assessed in RCTs comparing B-TUEP versus DioLEP..... | 160 |
| Table 4-45: Safety outcomes assessed in RCTs comparing B-TUVP versus TURP | 162 |
| Table 4-46: Safety outcomes assessed in RCTs comparing DioLVP versus TURP | 166 |
| Table 4-47: Safety outcomes assessed in RCTs comparing PVP versus TURP | 168 |
| Table 4-48: Safety outcomes assessed in RCTs comparing PVP versus B-TUVP..... | 170 |
| Table 4-49: Safety outcome results in the RCT comparing ThuVEP versus TURP | 172 |
| Table 4-50: Safety outcomes assessed in RCTs comparing B-VEP versus TURP..... | 172 |

| | |
|---|-----|
| Table 4-51: Safety outcome results in Zhang 2015 comparing B-VEP versus TURP | 173 |
| Table 4-52: Safety outcomes assessed in RCTs comparing TUVRP versus TURP | 173 |
| Table 4-53: Safety outcome results in Samir 2019 comparing B-TUERP versus TURP | 175 |
| Table 4-54: Safety outcome results in Xu 2013 comparing B-TUERP versus DioLEP | 176 |
| Table 4-55: Safety outcome results in Li 2018 comparing M-TUERP versus TURP | 176 |
| Table 4-56: Safety outcomes assessed in publications comparing Aquablation versus TURP | 177 |
| Table 4-57: Safety outcomes assessed in RCTs comparing TUMT versus TURP | 178 |
| Table 4-58: Safety outcomes assessed in publications comparing WAVE versus sham | 179 |
| Table 4-59: Safety outcomes assessed in RCTs comparing TUIP versus TURP | 180 |
| Table 4-60: Safety outcomes assessed in RCTs comparing TUIP + TURP versus TURP | 182 |
| Table 4-61: Safety outcomes assessed in RCTs comparing PAE versus TURP | 183 |
| Table 4-62: Safety outcomes assessed in publications comparing PUL versus TURP | 185 |
| Table 4-63: Results for safety outcomes in RCTs comparing PUL versus TURP | 185 |
| Table 5-1: IPSS at 6 months: comparisons available, results and quality of evidence | 186 |
| Table 5-2: IPSS at 12 months: comparisons available, results and quality of evidence | 188 |
| Table 5-3: Qmax at 6 months: comparisons available, results and quality of evidence | 189 |
| Table 5-4: Qmax at 12 months: comparisons available, results and quality of evidence | 191 |
| Table 5-5: Reintervention: comparisons available, results and quality of evidence | 193 |
| Table 6-1: Erectile dysfunction: comparisons available, results and quality of evidence | 194 |
| Table 6-2: Retrograde ejaculation: comparisons available, results and quality of evidence | 195 |
| Table 6-3: Transfusion requirement: comparisons available, results and quality of evidence | 197 |
| Table 6-4: Urinary tract infection: comparisons available, results and quality of evidence | 199 |
| Table 6-5: Urethral stricture: comparisons available, results and quality of evidence | 200 |
| Table 6-6: Urinary incontinence: comparisons available, results and quality of evidence..... | 202 |
| | |
| Table A1: List of excluded studies (full text level) with reasons for exclusion) | 226 |
| Table A2: Overview of guidelines..... | 227 |
| Table A3: Studies included in the assessment: data extraction and risk of bias assessment..... | 231 |
| Table A4: Regulatory status | 376 |
| Table A5: Summary of (reimbursement) recommendations in European countries for the assessed technologies..... | 382 |
| Table A6: List of planned, ongoing, withdrawn and completed studies without results on the assessed technologies | 387 |

Figures

| | |
|--|----|
| Figure 4-1: Flow chart of information retrieval for clinical effectiveness and safety..... | 37 |
| Figure 4-2: Risk of bias in the studies included in the assessment. | 56 |

LIST OF ABBREVIATIONS

| | |
|---------------|---|
| AUA | American Urological Association |
| AUR | Acute urinary retention |
| BEEP | Bipolar endoscopic enucleation |
| BPE | Benign prostate enlargement |
| BPEP | Bipolar plasmakinetic enucleation of the prostate |
| BPH | Benign prostatic hyperplasia |
| BPHII | Benign Prostatic Hyperplasia Impact Index |
| BOO | Bladder outlet obstruction |
| BPVP | Bipolar button plasma vaporisation of the prostate |
| B-TUEP | Bipolar transurethral enucleation of the prostate |
| B-TUERP | Bipolar transurethral enucleation and resection (enucleoresection) of the prostate |
| B-TURP | Bipolar transurethral resection of the prostate |
| B-TUVP | Bipolar transurethral vaporisation of the prostate |
| B-VEP | Bipolar vapoenucleation of the prostate |
| C-BPVP | Continuous bipolar plasma vaporisation of the prostate |
| CI | Confidence interval |
| DALY | Disability-adjusted life year |
| DioLEP | Diode laser enucleation of the prostate |
| DioLVP/DioVAP | Diode laser vaporisation of the prostate |
| DOICU | Declaration of interest and confidentiality undertaking |
| ELEP | Eraser laser enucleation of the prostate |
| GRADE | Grading of Recommendations, Assessment, Development and Evaluation |
| H | High (quality of evidence) |
| HoLEP | Holmium laser enucleation of the prostate |
| HoVAP | Holmium laser vaporisation of the prostate |
| HRQoL | Health-related quality of life |
| ICD | International Classification of Diseases |
| ICIQ-MLUTS | International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms module |
| IIEF | International Index of Erectile Function |
| IPSS | International Prostate Symptom Score |
| ISI | Incontinence Severity Index |
| ITT | Intention to treat |
| KTP | Potassium titanyl phosphate |
| L | Low (quality of evidence) |
| LBO | Lithium triborate |
| LUTS | Lower urinary tract symptoms |

| | |
|----------|--|
| M | Moderate (quality of evidence) |
| MCID | Minimal clinically important difference |
| MD | Mean difference |
| MeSH | Medical subject headings |
| MSHQ-EJD | Male Sexual Health Questionnaire for Ejaculatory Dysfunction |
| MIST | Minimally invasive surgical treatment |
| M-TUERP | Monopolar transurethral enucleoresection of the prostate |
| M-TURP | Monopolar transurethral resection of the prostate |
| n.a. | Not available |
| n.r. | Not reported |
| OAB-SF | Overactive bladder questionnaire-short form |
| OP | Open prostatectomy |
| PAE | Prostate artery embolisation |
| PKEP | Plasmakinetic enucleation of the prostate |
| PKRP | Plasmakinetic resection of the prostate |
| PKVP | Plasmakinetic vaporisation |
| PP | Per protocol |
| PSA | Prostate-specific antigen |
| PUL | Prostatic urethral lift |
| PVA | Poly(vinyl alcohol) |
| PVEP | Plasmakinetic vapoenucleation of the prostate |
| PVP | Photoselective vaporisation of the prostate |
| PVR | Postvoid residual |
| Qmax | Peak/maximum flow rate |
| Qmed | Average flow rate |
| QoL | Quality of life |
| RCT | Randomised controlled trial |
| REA | Relative effectiveness assessment |
| RR | Risk ratio |
| S-BPVP | Standard bipolar plasma vaporisation of the prostate |
| SD | Standard deviation |
| SMD | Standardised mean difference |
| STURP | Selective transurethral resection of the prostate |
| ThuLEP | Thulium laser enucleation of the prostate |
| ThuVAP | Thulium laser vaporisation of the prostate |
| ThuVARP | Thulium laser vaporesection of the prostate |
| ThuVEP | Thulium laser vapoenucleation of the prostate |
| TIND | Temporary implantable nitinol device |
| TmLRP | Thulium laser resection of the prostate |

| | |
|--------------|---|
| TUEB | Transurethral enucleation with bipolar energy |
| TUIBN | Transurethral incision of the bladder neck |
| TUIP | Transurethral incision of the prostate |
| TUMT | Transurethral microwave therapy |
| TUR syndrome | Transurethral resection syndrome |
| TURiS | Transurethral resection in saline |
| TURP | Transurethral resection of the prostate |
| TUViS | Transurethral vaporisation in saline |
| TUVRP | Transurethral vaporesection of the prostate |
| UTI | Urinary tract infection |
| VL | Very low (quality of evidence) |
| WAVE | Water vapour energy |

EXECUTIVE SUMMARY OF THE ASSESSMENT OF SURGICAL TECHNIQUES AND DEVICES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Scope

The aim of this rapid assessment is to provide comparisons among different minimally invasive surgical treatments for benign prostatic hyperplasia (BPH) to assess their relative effectiveness and safety in patients with an indication for surgical treatment.

Health problem

BPH is a common nonmalignant urological condition that involves progressive proliferation of the glandular epithelium, smooth muscle and connective tissue in the transition zone of the prostate. In a large proportion of BPH patients, prostate enlargement causes bladder outlet obstruction (BOO), which has an adverse impact on lower urinary tract function, resulting in lower urinary tract symptoms (LUTS). On average, approximately one in four men are likely to develop BPH over their lifetime. Bothersome LUTS occur in up to 30% of men older than 65 years, of whom one-quarter will develop severe LUTS. As many as 30% of those who develop BPH receive treatment for the condition.

The most common indication for surgical intervention is moderate to severe BOO attributed to BPH that is refractory to conservative or medical therapy (relative indications for surgery).

Description of the technologies and comparators

Transurethral resection of the prostate (TURP) has remained the cornerstone of BPH surgical treatment for decades. Despite its high rate of success, TURP has a perioperative morbidity rate of approximately 20% and long-term complications that include ejaculatory dysfunction, erectile dysfunction, urethral strictures, urinary tract infection (UTI) and urinary incontinence. Open prostatectomy (OP) is infrequently used, mainly for large prostates, because of the complications outlined above.

The development of different minimally invasive technologies has provided alternatives that are expected to have similar effectiveness, or else lower effectiveness but with a more favourable impact on patient quality of life (QoL) and better safety profile, compared to TURP. Therefore, patients are (or should be) involved in therapeutic decisions in light of their personal trade-off between expected effectiveness and QoL.

Different ablative technologies have been developed that remove excess prostatic tissue in different ways. These include the following:

- Resection with holmium or thulium lasers (e.g., thulium laser resection of the prostate [TmLRP]) as an alternative to classical TURP;
- Enucleation using a holmium (HoLEP), thulium (ThuLEP) or diode (DioLEP) laser, or different electrodes delivering bipolar energy (bipolar transurethral enucleation of the prostate [B-TUEP]) to peel the enlarged prostate from the prostatic capsule without cutting into it or dissecting the gland;

- Vaporisation with a bipolar electrode (B-TUVP) or a laser system (e.g., potassium titanyl phosphate [KTP] or lithium triborate [LBO] photoselective vaporisation [PVP] or with a diode laser [DiLVLP]) to remove excess prostate tissue by heating and evaporating it;
- Hybrid techniques such as vapoenucleation of the prostate (e.g., with a thulium laser [Thu-VEP] or with bipolar energy [B-VEP]), vaporessection of the prostate (resection with an electric current or laser and vaporisation with a vaporisation electrode [TUVRP and ThuVARP]) and transurethral enucleoresection of the prostate (using monopolar [M-TUERP] or bipolar [B-TUERP] energy);
- Aquablation, which uses a high-speed jet of saline (waterjet) to remove excess prostate tissue;
- Transurethral microwave therapy (TUMT), which uses electromagnetic waves to thermoablate prostatic tissue; and
- Water vapour thermal therapy (WAVE), in which convective water vapour generated with a radiofrequency current is injected into the prostate to destroy excess tissue.

Nonablative techniques have also been developed. These include the following:

- Transurethral incision of the prostate (TUIP), which involves cutting into the bladder neck to reduce the pressure of the gland on the urethra;
- Prostate artery embolisation (PAE), which uses poly(vinyl alcohol) (PVA) and other newer synthetic biocompatible materials to reduce blood flow in the prostate, causing the gland to undergo ischaemic necrosis;
- Prostatic urethral lift (PUL), which involves the insertion of small, adjustable, permanent implants that create an open channel to increase urinary flow; and
- Temporary implantable nitinol devices (TINDs), which create new channels in the urethra to increase urinary flow.

In this relative effectiveness assessment (REA) we assessed the effectiveness and safety of 21 of these technologies as compared to TURP.

Methods

We included randomised controlled trials (RCTs) comparing each of the technologies of interest to comparators (TURP and/or OP). RCTs comparing each of the technologies of interest to sham procedures were considered only if head-to-head comparative RCTs were not found for those technologies.

A systematic review of the literature was performed according to the Cochrane methodology. As one high-quality systematic review was published in November 2019, the systematic search was performed with January 2019 as the start date for technologies included in that review. For all of the other technologies, no time limits were considered.

Five review authors independently extracted data using a data extraction form developed for this review. The study quality of the RCTs included was rated using the Cochrane risk of bias (RoB) tool. The level of confidence/certainty in the body of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) scheme. Whenever possible, quantitative analysis methods for meta-analysis were applied for the SAF and EFF domains using RevMan 5.3.

Results

Eighty-four RCTs (described in 94 publications) were eventually selected; all but three of these RCTs were two-arm trials. Sixty-six RCTs (3 multiarm trials) compared newer technologies versus TURP, 18 (3 multiarm trials) compared two newer technologies to each other; one (multiarm) compared newer technologies to OP and one to a sham procedure. All trials were relatively small in size: the highest number of patients per study arm was 205, with an average size of 63. The vast majority of studies included heterogeneous populations in terms of prostate size and it was not possible to assess the effectiveness and safety of the different technologies in subgroups according to prostate size.

Clinical effectiveness: direct comparisons

New technologies versus TURP: IPSS and Qmax

Pooled data, and some of the available RCTs when pooling was not possible, showed the following results:

- Statistically significant improvements versus TURP for the International Prostate Symptom Score (IPSS) in favour of HoLEP, B-TUEP, TUVRP and ThuLEP from pooled data, and in favour of B-TUERP from single RCTs.
- For IPSS, statistically significant improvements in favour of TURP versus TUMT, PVP and PAE from pooled data, and versus PUL and DioLVP from single RCTs.
- Statistically significant improvements versus TURP for the maximum flow rate (Qmax) in favour of HoLEP, B-TUEP and TUVRP from pooled data, and in favour of TUIP + TURP and B-TUERP from single RCTs.
- Statistically significant improvements in Qmax in favour of TURP versus TUMT, PVP and TUIP from pooled data, and versus PAE, PUL, DioLVP and ThuVARP from single RCTs.

Nevertheless, the clinical relevance of the differences observed is either low or difficult to establish: pooled estimates of the mean difference (MD) are in most cases below the minimal clinically important difference (MCID) values reported in the literature. While this suggests that choosing one specific technology often may not make any difference for the majority of patients, we cannot exclude the possibility that some patients may experience a relevant benefit by choosing one technology instead of another one.

New technologies versus TURP: PVR and QoL

A few RCTs showed statistically significant improvements for both postvoid residual (PVR) and QoL in favour of HoLEP (pooled data) and B-TUERP (single RCT) versus TURP. Conversely, TURP showed better PVR versus PVP and TUMT from pooled data, and versus PUL and PAE from single RCTs. TURP also showed better QoL data versus ThuLEP from pooled data. However, it is not possible to establish the clinical relevance of the differences observed since MCID has not been established for PVR and QoL. In addition, these differences were numerically small and therefore, even though the range of the score is unknown, it seems unlikely that these differences were clinically relevant.

New technologies versus OP

OP was used as comparator in only one of the RCTs selected, and showed quite longer hospitalisation time (>4 days more) compared to B-TUEP and B-TUVP.

Comparisons between new technologies

Regarding comparisons among newer technologies, a few of the studies available show statistically significant differences in favour of the following:

- B-TUEP versus HoLEP for Qmax;
- ThuLEP versus HoLEP for Qmax, IPSS, PVR and QoL;
- ThuVEP versus HoLEP for QoL (from a single RCT);
- PVP versus HoLEP for QoL;
- HoLEP versus PVP for IPSS, Qmax, PVR and the reintervention rate;
- PVP versus B-TUVP for PVR; and
- DioLEP versus B-TUEP and versus B-TUERP for irritative symptoms (the latter from a single RCT).

Safety: direct comparisons

The available comparisons did not show differences for bladder perforation, bladder or ureteral injury, erectile dysfunction, TUR syndrome, urethral stricture or bladder neck contracture.

Comparisons of new technologies versus TURP

Some of the RCTs and pooled data showed statistically significant improvements in favour of newer technologies compared to TURP for some of the critical outcomes considered in this REA (plus recatheterisation, graded as important). The specific details are as follows:

- A rate ratio of 0.4 for retrograde ejaculation for TUIP, an absolute reduction of 16% for Aquablation and an absolute reduction (from 34% to 0%) for anejaculation for PUL (the latter 2 from single RCTs);
- A rate ratio for transfusion requirement of the order of 0.1–0.3 for HoLEP, ThuLEP, B-TUVP and PVP, and a reduction of 9% for M-TUERP (the latter from a single RCT);
- A rate ratio for UTI between 0.2 and 0.5 for HoLEP and PAE;
- A rate ratio for urinary incontinence of 0.1 for PAE and a reduction of 15% for PUL (the latter from a single RCT); and
- A 7% reduction in recatheterisation and an 11% reduction in urinary retention for M-TUERP (from a single RCT).

Outcomes that are worse for some technologies in comparison to TURP are as follows:

- Urinary incontinence for HoLEP, B-TUEP (rate ratio 1.9) and PVP (rate ratio 2.6);
- UTI for PVP (rate ratio 1.8); and
- Acute urinary retention (AUR) for PAE (rate ratio 2.2).

RCTs generally showed a shorter catheterisation time for the newer technologies, but the wide statistical heterogeneity, probably explained by different policies in different centres, precluded data pooling.

Comparisons among newer technologies

Some data from single RCTs are available and show statistically significant differences in favour of ThuLEP versus HoLEP for incontinence (rate ratio 3.4) and in favour of ThuVEP versus HoLEP for urinary retention (13% absolute difference from a single RCT).

Quality of evidence

The quality of the evidence for all these outcomes has been judged low to very low in most cases because of internal and external validity, inconsistency in results, low precision of the estimates and the heterogeneity of the study populations.

Concluding summary

Minimally invasive technologies are expected to reduce the short- and long-term side effects of standard surgical treatments for BPH (in particular in comparison to TURP) while preserving the effectiveness for functional outcomes.

For functional outcomes, a few comparisons revealed statistically significant differences, although the results in most cases are below the MCID threshold. The quality of the related evidence has been graded as low to very low, suggesting limited confidence in the estimates and that further research is likely to change these estimates.

Regarding the impact on sexual activity, ThuLEP, TUIP, Aquablation and PUL may provide some advantage over TURP, for which the quality of the evidence ranges from moderate (reduced impact on retrograde ejaculation for patients with small prostates undergoing TUIP) to low or very low.

For other possible safety concerns and side effects, some newer technologies may offer some advantage over TURP by reducing the transfusion requirement; a few technologies showed evidence of a positive or negative effect on UTI and incontinence.

Small sample sizes, biases in study design, heterogeneous populations and (in most cases) an undefined primary hypothesis indicate the need for more and better research so that the advantages and disadvantages of all these technologies can be more clearly defined.

1 BACKGROUND

1.1 Overview of the disease, health condition and target population

HTA CORE MODEL DOMAIN: CUR¹

BPH, also known as benign prostate enlargement (BPE), is a common nonmalignant urological condition that involves progressive proliferation of the glandular epithelium, smooth muscle and connective tissue in the transition zone of the prostate (the area around the urethra). In a large proportion of BPH patients, prostate enlargement causes BOO, which has an adverse impact on lower urinary tract function, resulting in LUTS.

LUTS attributed to BPH can be divided into storage (irritative), voiding and postmicturition symptoms. Storage symptoms include urgency, frequency, urgency incontinence and nocturia. Voiding symptoms comprise slow urinary stream, straining to void, urinary intermittency (stream starting and stopping during micturition) or hesitancy, splitting of the voiding stream and terminal dribbling [1]. Postmicturition symptoms include a feeling of incomplete emptying and postmicturition dribble. Storage symptoms are often more bothersome than voiding symptoms and BPH becomes clinically significant when it starts contributing to bothersome LUTS [2]. If left untreated, BPH leads to a reduction in Qmax and an increase in the risk of AUR, which is a medical emergency [3].

Aging and androgens are the two clearly established determinants for the development of BPH. In addition, race, obesity, metabolic syndrome, family history of BPH and genetic factors probably contribute to higher risk of BPH [4, 5]. The prostate normally undergoes two growth phases during a man's life. The first, in which the prostate doubles in size (rapid growth phase), starts as early as age 10 years and lasts until age 30 years. The second phase of growth begins around the age of 30 years and continues at a slower pace during most of a man's life (slow growth phase) [6]. BPH often occurs during the second growth phase.

Although the transition zone of the prostate (the part of the gland surrounding the urethra as it passes through the prostate) accounts for only 10% of prostate glandular tissue in young men, with aging it undergoes significant glandular proliferation (static component) and increases in smooth muscle tone and resistance (dynamic component), which can further lead to BOO and LUTS [4]. This process begins with the development of stromal nodules in the transition zone. The pathogenesis underlying these changes is still not well understood; however, several processes, such as age-related hormonal changes (androgen-induced increases in dihydrotestosterone levels) and systemic and localised inflammation, cause an increase in the rate of cell proliferation, a decrease in the rate of apoptosis (cell death) or both [7].

BPH represents a significant burden for patients since it leads to deterioration in their QoL. Disability-adjusted life year (DALY) is a term for the equivalent years of healthy life lost because of poor health or disability, with 1 DALY equating to 1 year of healthy life lost. According to the latest World Health Organization estimates for the European region (data from 2016), BPH was responsible for ~751,000 DALYs, accounting for 0.25% of the total DALYs caused by all conditions. By contrast, the proportion of DALYs attributable to prostate cancer and hypertensive heart disease is 0.71% and 0.87%, respectively [8].

¹ This section addresses the following assessment elements: A0002, A0003, A0004, A0005, A0006, A0007, A0011 and A0023.

LUTS/BPH is associated with high personal and societal burdens, both directly through increased medical costs and indirectly through loss of daily functioning and a negative impact on QoL for patients and their partners. A recent Spanish study of 610 patients reported and estimated median annual cost of €1070 per patient, including diagnostic tests and/or monitoring (54.6%), medical visits (20.5%) and treatment (29.6%), highlighting that the overall cost was higher for patients with a higher symptom score (€1127 vs. €920; $p < 0.001$) [9].

Overall, the global lifetime prevalence of BPH is 26.2% (95% confidence interval [CI] 22.8–29.6%) meaning that nearly one in four men will suffer from BPH over their lifetime [10]. Bothersome LUTS occur in up to 30% of men older than 65 years, of whom one-quarter develop severe LUTS over a period of 6 years [11]. The global prevalence of BPH was estimated in a recent meta-analysis that included 30 epidemiological studies from 25 countries [10]. Pooled global prevalence estimates increased with age, from 14.8% in the group aged 40–49 years to 20% in the group aged 50–59 years, 29.1% in the group aged 60–69 years, 36.8% in the group aged 70–79 years and 38.4% in the group aged 80 years and older. However, the level of heterogeneity was high. The authors concluded that some heterogeneity could probably be attributed to methodological differences across the different studies and different definitions of BPH.

Some 30% of men who develop BPH receive treatment for the condition. Decreasing mortality and increasing life expectancy mean that the elderly population is rapidly growing, so the prevalence of BPH and its associated burden are expected to increase.

According to the latest European guidelines [12] and advice received from external clinical experts involved in the assessment, the target population for this REA is adult men (>18 years of age) with LUTS attributed to BPH of non-neurological cause who do not find adequate relief with conservative or medical treatment or find side effects of medical treatment bothersome, and who may benefit from surgical treatment. Three subpopulations often identified in guidelines (prostate size <30 ml, 30–80 ml and >80 ml, or the same intervals for prostate weight measured in grammes) were considered as relevant patient subgroups.

The only available real-life study in Europe, conducted in France in 2013, showed that of 2,620,269 patients who required treatment for LUTS/BPO, 301,834 (11.5%) received surgical treatment over the period from 2004 to 2008 [13]. The average number of surgical procedures related to BPH management performed annually was estimated as approximately 60,000–70,000 [13, 14].

Regarding data outside of Europe, 44,000 men underwent surgical treatment in Korea during the period 2004–2008 [15]. In the USA, 54,399 TURP and 29,457 laser prostatectomy procedures were performed from 2001 to 2009 [16]. In Japan the total number of procedures decreased by 30%, from 20,413 in 2009 to 14,152 in 2014 [17], while in Australia a 39% increase in the rate of total procedures for BPH was reported from 2000 to 2018 (92/100,000 in 2000 and 133/100,000 in 2018) [18].

1.2 *Current clinical practice*

HTA CORE MODEL DOMAIN: CUR²

BPH is typically diagnosed clinically according to the presence of LUTS. Prostatic enlargement can be detected via manual rectal examination or transrectal ultrasonography. According to the latest European guidelines, primary diagnostic evaluation of patients with LUTS involves medical history, symptom score questionnaires (such as IPSS), urinalysis (dipstick and sediment), physical examination and measurement of prostate-specific antigen (PSA) and postvoid residual urine volume (PVR) urine [12]. A high baseline PVR indicates a higher likelihood of symptomatic deterioration over time, while increasing PVR over time may indicate treatment failure or provide indication for surgical intervention [1]. In the case of bothersome symptoms or significant PVR, the assessment should also include frequency volume charts and bladder diaries, together with ultrasound assessment and uroflowmetry. If the symptoms are not significantly bothersome or not impacting the patient's health, no further evaluation is needed [12, 19]. For men with suspected neurological disease or bladder hypocontractility in cases of very small prostate (high PVR even in the absence of BPH) urodynamic examination can be useful to assess whether the functionality of the bladder is preserved. Prostate imaging may also help in choosing the optimal treatment technique for patients.

While BPH alone does not need to be treated, BPH associated with LUTS may require treatment. Conservative treatment (watchful waiting and behavioural and dietary modifications) or medical treatments are usually the first choice of therapy for men with mild or moderate symptoms who are minimally bothered by their symptoms. According to the latest European guideline [12], the choice of treatment depends on the findings from patient evaluations, the ability of the treatment to change these findings, the treatment preferences of the individual patient and expectations to be met in terms of the speed of onset, efficacy, side effects, health-related QoL (HRQoL) and disease progression.

The most common indication for surgical intervention is moderate to severe voiding symptoms attributed to BPH that are refractory to conservative or medical therapy (relative indications for surgery). Surgical treatment is also required when patients have experienced recurrent or refractory urinary retention, overflow incontinence, recurrent UTIs, bladder stones or diverticula, treatment-resistant macroscopic haematuria because of BPH and/or BPE, or dilatation of the upper urinary tract because of BPH, with or without renal insufficiency (absolute indications for surgery).

The choice of surgical technique depends on several factors. These include prostate size, patient comorbidities, ability to undergo anaesthesia, patient preferences, willingness to accept surgery-associated specific side effects, the availability of surgical techniques in a particular centre and the experience of the surgeon with these techniques. The experience and preference of the treating surgeon, as well as the organisational and economic impact of different technologies in different countries, often have an important role in the choice of surgical treatment for BPH. Detailed treatment algorithms (that include the current standard or first choice and the alternative treatments) for bothersome LUTS refractory to conservative or medical treatment or in cases with absolute indications for intervention, stratified by the patient's ability to undergo anaesthesia and their cardiovascular risk and prostate size, are provided in the European Association of Urology guidelines for management of non-neurogenic male LUTS including BPH [12].

² This section addresses the following assessment elements: A0024 and A0025.

1.3 Features of the intervention

HTA CORE MODEL DOMAIN: TEC³

Most surgical procedures for BPH are performed via the urethra using a cystoscope. The majority of these therapies require hospitalisation. Potential complications of surgical procedures include TUR syndrome (a potentially life-threatening complication of TURP caused by excessive absorption of electrolyte-free irrigation fluids), bleeding, infection, urethral strictures, incontinence and sexual dysfunction. Hence, it is important that the treating surgeon informs the patient about the potential side effects so that an informed decision can be made considering these and the surgeon's preference and experience with the various methods.

According to the treatment principle (i.e., the mechanism of action), treatment strategies can be divided into ablative and nonablative technologies. Ablative therapies consist of treatments in which prostatic tissue is resected (removed) or ablated (destroyed) using a variety of energy sources, such as electrocautery (electrodes with monopolar or bipolar energy), lasers (holmium, thulium, diode, KTP or LBO), convective steam, high-pressure saline and microwaves [20]. There has been a shift from monopolar to bipolar electrodes and to laser treatments in the last couple of decades. The various lasers differ mainly in their absorption properties, penetration depth and wavelength mode (pulsed or continuous). All of the lasers use normal saline instead of distilled water to avoid TUR syndrome [21]. The general properties of the four types of lasers, regardless in which technology they are used, are as follows.

- Holmium (Ho:YAG) lasers have been commercially available since 1994. Ho:YAG is a type of solid-state, pulsed laser that is ideal for endoscopic use because of its fibre optic delivery and ability to treat tissue in a liquid-filled environment (e.g., saline or blood) [22]. The laser has a wavelength of 2140 nm [12, 23].
- Thulium (Tm:YAG) lasers, which have a wavelength between 1940 and 2013 nm, are also solid-state lasers that emit waves in continuous mode. A thulium laser has water and tissue absorption characteristics comparable to those of a holmium laser, but the continuous-wave output allows better tissue vaporisation [23, 24].
- Diode lasers are available with several different wavelengths (940, 980, 1064, 1318 and 1470 nm) [12]. The wavelength depends on the semiconductor used. A diode generates the laser light. Diode lasers can be applied continuously or in pulsed mode and their energy is absorbed by haemoglobin and water. Diode lasers use side-firing techniques to ensure better direct visual control by the surgeon. The tissue ablative property of a diode laser is twice that of a KTP laser, but less than in TURP [25]. Diode laser light can also be conveyed through optical fibres introduced transperineally or perineally into the prostate. The approach using this modification is called interstitial diode laser coagulation.
- A KTP or LBO laser produces light of the same wavelength of 532 nm within the visible green region of the electromagnetic spectrum. The energy is selectively absorbed by haemoglobin within prostatic tissue. The coagulation zone of a KTP laser is more than twice as deep as that of the diode laser owing to its affinity for haemoglobin [25].

In the nonablative therapy options the prostatic tissue is compressed. The various techniques use contrasting mechanisms of action (mechanical decompression vs. angiographic embolisation) to decrease the stress on the urethra [20].

³ This section addresses the following assessment elements: B0001, B0002, B0004, B0009, and A0020 (Appendix 5).

A) Ablative therapies

1) **Transurethral resection of the prostate.** TURP is considered the gold standard for surgical treatment of BPH. However, TURP is associated with some morbidity and long-term complications, including haematuria, urethral stricture, UTI, incontinence, and ejaculatory and erectile dysfunction. In TURP, prostate tissue is removed from the transition zone of the gland piece by piece and extracted at the end of the procedure using irrigation under general or spinal anaesthesia. TURP procedures require the use of a resectoscope, camera system and irrigation fluid. TURP can be divided into electrosurgical and laser resection sub-categories according to the energy used to resect tissue.

a) *Electrocautery:* For monopolar (M-TURP) or bipolar (B-TURP) TURP, the system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterise blood vessels.

- In M-TURP, energy travels through the body to reach a skin pad. The procedure requires the use of sterile water or a sorbitol or glycine solution.
- In B-TURP, bipolar circuitry is completed locally; the energy travels between an active and a passive pole situated on the resectoscope tip and requires less energy than M-TURP. B-TURP overcomes the limitation of M-TURP by allowing energy transmission in iso-osmolar solution (rather than hypo-osmolar solution), which results in excitation of sodium ions to form plasma and reduces the risk of TUR syndrome. Several device types are available that mostly differ in the way in which the electric current flow is delivered, the passive electrodes (two loops, single loop, resectoscope sheath), the shape of the active electrodes and the specialised electrosurgical generators. Operating frequencies differ between the generator units [12, 20, 23, 26]. The most common bipolar resection systems are the plasmakinetic system (plasmakinetic resection of the prostate [PKRP]), TURiS system (transurethral resection in saline) and the controlled tissue resection system [27].

b) *Laser resection with the so-called cutting lasers:*

- Thulium laser resection (TmLRP) was first reported in 2005. In TmLRP, a wavelength of approximately 2000 nm is emitted in continuous-wave mode, which is a wavelength that matches the water absorption peak in tissue, allowing very precise incision [28].
- Holmium laser resection (HoLRP) is performed with a modified continuous-flow resectoscope. An end-firing laser fibre is used as a cutting instrument to resect large pieces of prostate. The laser is then used to cut the resected tissue into smaller pieces before their removal. It is suitable for large prostates of up to 100 g. The coagulative ability of the holmium laser effectively seals tissue planes, which makes HoLRP a relatively bloodless operation and hence reduces possible transfusion requirements and avoids the dangers of TUR syndrome [29].

2) **Transurethral enucleation of the prostate.** TUEP involves peeling the enlarged prostate from the prostate capsule without cutting into or dissecting the gland. The transition zone of the prostate is removed along its surgical capsule under general or spinal anaesthesia. The resultant tissue is morcellated (removal of large masses of tissue) using a separate device called a morcellator. In some new-generation systems the morcellator is built into the enucleation device. The energy used for tissue enucleation is generated either via a laser, which is used to destruct prostatic tissue with minimal deep-tissue penetration, or via a bipolar system using different electrodes [21].

- a) *Transurethral enucleation with bipolar energy*: TUEB is also called bipolar transurethral enucleation (B-TUEP) or plasmakinetic enucleation (PKEP) or bipolar plasma enucleation (BPEP). This procedure allows enucleation of whole lobes of the prostate [30]. In this technique a plasma electrode and an enucleation loop, designed specifically for transurethral enucleation, are used [31].
- b) *Transurethral enucleation with laser*: There are several laser systems available for transurethral enucleation, all comprising a power unit and laser fibres. The differences, as outlined in the general laser descriptions, lie in the penetration depth, wave mode and absorption properties:
- Holmium laser enucleation of the prostate: In HoLEP the tissue penetration is 0.4 mm [23]. The laser creates bubbles of steam that separate tissue layers by tearing the tissue apart. The tissue effect is rapid and results in excellent haemostasis. HoLEP was an important technical improvement. The entire lobes of the gland are enucleated, moved into the bladder and morcellated [24].
 - Thulium laser enucleation of the prostate: In ThuLEP the tissue penetration is 0.2 mm [23].
 - Diode laser enucleation of the prostate: The penetration levels with DioLEP are deeper than with Ho:YAG or Tm:YAG lasers [23, 24]. Eraser laser is a type of diode laser and therefore this procedure is also referred to as eraser laser enucleation (ELEP) [32].
- 3) **Transurethral vaporisation**. TUVP involves removing excess prostate tissue by heating and evaporating it under general or spinal anaesthesia. Laser vaporisation and vaporessection (which is the combination of vaporisation and resection) are more widely used owing to the relatively short learning curve compared to enucleation [33]. The energy can be delivered via various systems. The following subcategories are introduced according to the energy source used.
- a) *Transurethral (electro-)vaporisation with bipolar energy*: B-TUVP was introduced in the late 1990s and as it was derived from (plasmakinetic) B-TURP, it is also called bipolar plasma vaporisation of the prostate (BPVP) or transurethral plasma vaporisation. The procedure is performed using a bipolar electrode and a high-frequency generator to create a plasma effect that can vaporise prostatic tissue. Energy can be delivered through a spherical rolling electrode (rollerball), a grooved roller electrode (Vaportrode) or a hemispherical mushroom electrode (button). Saline is typically used for irrigation [23]. Direct tissue contact and heat production are minimised. The bipolar electrode produces a constant plasma field that allows the electrode to glide over the tissue and vaporise a thin layer of the prostate without affecting the underlying tissue. Some sources call this transurethral vaporisation in saline (TUViS) [23, 34]. An indwelling urethral catheter is left in place at the end of the procedure [35].
- b) *Laser-based systems*
- Holmium laser vaporisation: HoVAP/HoLVP was first reported in 1994. A side-firing fibre is moved across the surface of the prostatic lobes to immediately vaporise or ablate prostatic tissue and obtain a prostatic cavity similar to that obtained with traditional TURP [36].
 - Thulium laser vaporisation: ThuVAP/ThuLVP is a purely vaporising technique. The beam is fully absorbed by water and therefore there is no need for side-firing delivery, as with Ho:YAG, KTP and LBO lasers [24].

- Diode laser vaporisation: In DioVAP/DioLVP, a large amount of energy is absorbed on the surface, resulting in vaporisation of the tissue [25].
- KTP (GreenLight laser) and LBO (GreenLight High Performance System) lasers for photoselective vaporisation (PVP): KTP and LBO energies are selectively absorbed by haemoglobin within prostatic tissue, which facilitates photoselective vaporisation and removal of prostatic tissue via rapid photothermal vaporisation of heated intracellular water. The penetration depth is 0.8 mm because of the shorter wavelength and absorption by haemoglobin, and the resulting coagulation zone is 1–2 mm. The procedure is usually performed with saline irrigation to prevent TUR syndrome. During the procedure, the prostate adenoma is vaporised sequentially outwards until the surgical capsule is exposed and a defect is created within the prostate parenchyma through which voiding becomes possible [23]. The GreenLight system was introduced in 2005 with power output of 80 W. This was upgraded to 120 W in 2010, after which a second upgrade resulted in the current GreenLight XPS with power output of 180 W. The 180-W GreenLight XPS system represents the current standard of generators for PVP [12]. The procedure can be performed either as day-case or inpatient treatment and is appropriate for vaporisation of larger prostates in a shorter time and for patients taking anticoagulants [37].

There are hybrid techniques that combine the three basic resection, enucleation and vaporisation approaches. The hybrid techniques most commonly performed are as follows.

4) Vapoenucleation

- a) *Bipolar vapoenucleation of the prostate*: In B-VEP, the vapoenucleation electrode for mechanical anatomical enucleation of the prostate is a combination of a vaporisation electrode and a mechanical dissection probe [38].
- b) *Thulium laser vapoenucleation*: ThuVEP was introduced in 2008 for patients with larger prostates [24].
- c) *Photoselective vapoenucleation*: PVEP starts with initial vaporisation of the anterior zone of the prostate to simplify the subsequent enucleation procedure. The PVEP technique involves a gradual learning path. As a start, localising the capsule for anatomic vaporisation can be achieved, followed by performing partial enucleations; then, when the necessary skills are developed, the whole en bloc enucleation procedure can be performed [39].

5) Vaporesection

- a) *Transurethral (electro-)vaporesection*: TUVRP with bipolar energy combines resection with the help of electric current and vaporisation with a vaporisation electrode. The term plasmakinetic vaporesection (PKVP) is often used as a synonym as it is a type of TUVRP in which a plasmakinetic system serves as the resection device [40]. With advances in bipolar technology, the popularity of TUVRP has increased and new developments have arisen, such as transurethral resection in saline with plasma vaporisation (TURiS-PVP). The plasma vaporisation electrode vaporises the tissue in a similar way to a laser, but without developing excessive heat. TURiS-PVP is performed with an Olympus Surg-Master UES-40 bipolar generator, a special ‘mushroom’ type or plasma button vaporesection electrode with continuous-flow saline irrigation. The spherical shape of the electrode with a plasma corona on its surface is gradually moved into direct contact with the tissue (the ‘hovering’ technique) and thus yields virtually bloodless vaporisation at 280–320 W [41].

- b) *Holmium laser vaporesection*: HoVARP utilises both vaporisation and laser resection techniques. This is a new application of the holmium laser and the procedure does not require the use of a morcellator [42].
- c) *Thulium laser vaporesection*: ThuVARP is a laser procedure that vaporises and resects the prostate using a technique similar to TURP. ThuVARP uses a Tm:YAG fibre to deliver light of 2000 nm in wavelength to vaporise and resect the prostate. Unlike other laser technologies, ThuVARP uses a surgical technique similar to TURP, involving visual resection of prostatic tissue using a working element and resecting in so-called chips. The similarity in technique to TURP allows a short learning curve for surgeons [43]. Although Tm:YAG is similar to Ho:YAG regarding its shallow tissue and water penetration and haemostasis, the vaporisation capacity is significantly increased by the continuous wave-emitting mode. Therefore, tissue ablation is achieved not only via resection but also via simultaneous vaporisation [24].
- d) *Diode laser vaporesection* is a recent development in diode laser applications. Procedures executed with diode lasers use side-firing techniques to ensure better direct visual control by the surgeon of the point of impact of the laser beam on the tissue [24].

6) **Enucleoresection**

- a) *Monopolar transurethral enucleoresection*: M-TUERP is a hybrid procedure combining enucleation and resection applied to larger prostates [44].
 - b) *Bipolar transurethral enucleoresection*: in B-TUERP (or bipolar PKEP) the prostate is transurethrally enucleated and resected using a bipolar plasmakinetic resectoscope [45]. In this procedure the wire loop of the electrode is used to locate the layers and coagulate bleeding. Once the right layers have been located, the prostate lobes are peeled off as a whole piece. The lobes are then pushed into the bladder, where they are cut and eventually removed; therefore, this method combines enucleation and resection [46].
- 7) **Aquablation**: Aquablation, also called transurethral waterjet ablation, uses a specialised system that combines image guidance (transrectal ultrasound) and a robotic handpiece for targeted heat-free removal of prostate tissue. The procedure is usually performed with the patient under general or spinal anaesthesia. The device consists of a robotic handpiece, a console and a planning unit. The robotic handpiece with an integrated cystoscope and ablation probe is inserted transurethrally into the bladder. Transrectal ultrasound is used before surgery to map the region that needs to be resected, as well as during the treatment to monitor the tissue resection in real time. After mapping, a high-speed jet of saline (waterjet) is delivered from the robotic handpiece to the prostate at various flow rates according to the depth of penetration required. The prostate is ablated, while major blood vessels and prostatic capsule are spared. The ablated tissue is aspirated through ports in the handpiece and can be used for histological analysis. Haemostasis can be achieved via cautery or by inflating a Foley balloon catheter inside the prostatic cavity. The average resection time is typically approximately 3–5 min. After the procedure, electrocautery via a cystoscope or resectoscope or traction from a three-way catheter balloon is used to achieve haemostasis, and continuous bladder irrigation is then started. Traction is removed a few hours after the procedure and irrigation is progressively decreased. The catheter is removed before the patient is discharged from hospital, usually the day after the procedure. The procedure is heat-free, which removes the risk of complications arising from thermal injury [20, 23, 47].
- 8) **Water vapour thermal therapy**: WAVE involves transurethral thermal therapy using convective water-vapour energy to destroy excess prostate tissue to achieve LUTS symptom relief. Radiofrequency current is used to generate wet thermal energy in the form of steam

[48, 49]. This method should not be confused with vaporisation of the prostate, in which (as described earlier) prostate tissue is heated and hence evaporates; in WAVE the water vapour is injected into the prostate through a device attached to a urological endoscope. This device is only for single use. The process is intended to disrupt cell membranes, leading to cell death and shrinkage of the prostate. The aim is to relieve obstructive symptoms without interfering with surrounding tissues that might impair sexual function. The vapour is injected for 9 s during treatment. The number of times this has to be performed in each lobe of the gland depends on the length of the prostatic urethra. The treatment can be customised to the configuration of the gland. Each device can deliver a maximum of 15 full injections, although fewer injections are needed for most treatments. The procedure is usually carried out under general anaesthesia or local anaesthesia with sedation, and lasts for up to 20 min [50]. WAVE is performed in the office or at an outpatient surgical centre with minimal anaesthesia [51]. There is currently just one device, called the Rezūm System, available on the market, which received US Food and Drug Administration approval in 2015 [52]. Rezūm is intended for treatment of prostates of $>30 \text{ cm}^3$ in volume (equivalent to 30 g) and is contraindicated for patients with a urinary sphincter implant or a penile prosthesis [50].

- 9) **Simple prostatectomy:** This involves surgical removal of the inner core of the prostate gland. Various techniques can be used for prostate removal, including OP and laparoscopic robot-assisted prostatectomy. Open surgery can use a suprapubic or retropubic approach. Laparoscopic prostatectomy is performed with the patient under general anaesthesia, using either a transperitoneal or an extraperitoneal approach with or without robotic assistance. Incisions are made in the lower abdomen to provide access for the laparoscope and surgical instruments. A transverse incision is made in the anterior wall of the prostate capsule. If a transvesical approach is used, an incision is made in the bladder neck to expose the prostate. The glandular tissue of the prostate is freed from the prostate capsule and removed through an umbilical-port incision. A catheter is inserted and the prostate capsule is closed with sutures [53].
- 10) **Transurethral microwave therapy:** In TUMT a specialised urethral catheter with an antenna that emits electromagnetic waves at a frequency of 915–1296 MHz is used to induce changes with localised heat. With this technique, prostate tissue can be locally thermoablated while normal temperatures in the surrounding tissue can be maintained [20]. TUMT is generally performed on an outpatient basis. Cooling fluid is circulated around the microwave antenna to prevent heat from damaging the urethra. To prevent the temperature outside the prostate from getting too high, a temperature sensor is inserted into the rectum during the procedure. If the temperature in the rectum increases too much, the treatment is turned off automatically until the temperature goes back down. General or spinal anaesthetic is needed during the procedure. A catheter is placed in the bladder after the procedure to help with urination [54].

B) Nonablative techniques

- 1) **Prostatic urethral lift:** In PUL, small permanent implants in the form of sutures are placed transurethally through a cystoscope via a hand-held device. The implants mechanically open the urethra and relieve obstruction. PUL is performed using the Urolift device, which was developed in 2004 [20, 23]. The PUL implants consist of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless steel urethral endpiece [55]. PUL can be performed under local anaesthesia with oral or intravenous sedation. PUL is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral- and median-lobe hyperplasia, in men aged 45 years or older. The upper limit for prostate size for PUL is 100 cm^3 [56].

- 2) **Prostate artery embolisation:** PAE is an emerging technology according to the latest guidelines [12, 20, 23]. This procedure is usually carried out under local anaesthesia, with access through the left or right femoral or radial artery. The arterial anatomy is displayed via digital subtraction angiography and the appropriate prostatic arterial supply is selectively embolised. Superselective catheterisation of the small prostatic arteries is performed using fine microcatheters through the pelvic arteries. Embolisation involves the introduction of microparticles to completely block the prostatic vessels. Embolisation agents include PVA and other newer synthetic biocompatible materials. The aim of the procedure is to reduce the blood flow in the prostate, causing it to undergo ischaemic necrosis and subsequent volume reduction, which relieves LUTS. PAE targets the whole prostate, and not just the critical areas, like the other technologies [12, 20]. It is common for patients to experience pelvic pain during and after the procedure but this does not usually last for more than 1–3 days. PAE is a technically demanding procedure and must be performed by an interventional radiologist with specific training. The procedure is usually carried out as a day surgery [57].
- 3) **Temporary implantable nitinol device:** The aim of TIND is to relieve the symptoms of BPH by creating new channels in the urethra to increase urine flow. The device is made of nitinol and consists of struts and an anchoring leaflet. Under local anaesthesia or light sedation, the device is placed in the prostatic urethra via a cystoscope under direct visualisation. The device expands in the prostatic urethra and hence compresses obstructive tissue. Over the following days, the pressure applied by struts in the device creates areas of ischaemia in the prostatic urethra and bladder neck. This creates new longitudinal channels through which urine can flow. TIND is left in position for 5 days, until the nitinol wires reach their complete expansion. After 5–7 days the device is removed in an outpatient procedure via a standard urethroscope. Insertion and removal of the device are both conducted as day-case procedures and take approximately 5 min [12, 58]. A second-generation implant was recently introduced; the iTIND comprises three nitinol elongated struts and an anchoring leaflet [59].
- 4) **Transurethral incision of the prostate:** TUIP involves cutting into the bladder outlet without tissue removal. Incising the bladder neck may reduce the pressure of the gland on the urethra, making urination easier. This procedure is an option for some men, such as those with smaller prostates. Usually, two deep incisions that go down to the capsule of the prostate are made. Bleeding is controlled with electrocautery [20].

TURP has remained the cornerstone of LUTS/BPO surgical treatment despite the development of the new minimally invasive surgical treatments (MISTs) described above and alternative surgical treatments. They are considered minimally invasive because they can be performed either in an office or outpatient setting with minimal recovery time and morbidity for the patient. Despite its high rate of success, TURP has a perioperative morbidity rate of approximately 20% and long-term complications including ejaculatory dysfunction (65%), erectile dysfunction (10%), urethral strictures (7%), UTI (4%), urinary incontinence (2%), and bleeding requiring transfusion (2%) [60]. MISTs may have lower effectiveness than TURP but a better safety profile, so the trade-off between effectiveness and complications might be important in some cases, as some patients might opt for lower effectiveness to avoid adverse effects.

Table 1-1: Synonyms, abbreviations, full name, energy sources and the name used in this assessment for technologies used for the treatment of benign prostatic hyperplasia

| Abbreviation | Full name | Category and abbreviation applied in the report | Energy source |
|--|--|---|------------------|
| Resection | | | |
| M-TURP | Monopolar transurethral resection | TURP | Monopolar |
| B-TURP | Bipolar transurethral resection | TURP | Bipolar |
| PKRP | Plasmakinetic resection | TURP | Bipolar |
| TURIS | Transurethral resection in saline | TURP | Bipolar |
| TmLRP | Thulium laser resection | TmLRP | Thulium laser |
| HoLRP | Holmium laser resection | HoLRP | Holmium laser |
| Enucleation | | | |
| HoLEP | Holmium laser enucleation | HoLEP | Holmium laser |
| ThuLEP | Thulium laser enucleation | ThuLEP | Thulium laser |
| DioLEP | Diode laser enucleation | DioLEP | Diode laser |
| ELEP | Eraser laser enucleation | DioLEP | Diode laser |
| B-TUEP | Bipolar transurethral enucleation | B-TUEP | Bipolar |
| B-PEP | Bipolar plasma enucleation | B-TUEP | Bipolar |
| BEEP | Bipolar endoscopic enucleation | B-TUEP | Bipolar |
| PKEP | Plasmakinetic enucleation | B-TUEP | Bipolar |
| TUEB | Transurethral enucleation with bipolar energy | B-TUEP | Bipolar |
| Vaporisation | | | |
| HoVAP | Holmium laser vaporisation | HoVAP | Holmium laser |
| ThuVAP | Thulium laser vaporisation | ThuVAP | Thulium laser |
| DioVAP | Diode laser vaporisation | DioLVP | Diode laser |
| B-TUVP | Bipolar transurethral vaporisation | B-TUVP | Bipolar |
| BPVP | Bipolar plasma vaporisation | B-TUVP | Bipolar |
| PKVP | Plasmakinetic vaporisation | B-TUVP | Bipolar |
| TUVIS | Transurethral vaporisation in saline | B-TUVP | Bipolar |
| PVP | Photoselective vaporisation/potassium titanyl phosphate laser vaporisation | PVP | GreenLight laser |
| Enucleoresection | | | |
| M-TUERP | Monopolar transurethral enucleoresection | M-TUERP | Monopolar |
| B-TUERP | Bipolar transurethral enucleoresection | B-TUERP | Bipolar |
| B-ERP | Bipolar enucleoresection | B-TUERP | Bipolar |
| PKERP | Plasmakinetic enucleoresection | B-TUERP | Bipolar |
| Enucleovaporisation/vapoenucleation | | | |
| ThuVEP | Thulium laser vapoenucleation | ThuVEP | Thulium laser |
| PVEP | Photoselective vapoenucleation | PVEP | GreenLight laser |
| B-VEP | Bipolar vapoenucleation | B-VEP | Bipolar |
| B-PKVEP | Bipolar plasmakinetic vapoenucleation | B-VEP | Bipolar |

| Abbreviation | Full name | Category and abbreviation applied in the report | Energy source |
|----------------------|---|---|-----------------------|
| Vaporesection | | | |
| TURIS-PVP | Transurethral resection in saline plasma vaporisation | TUVRP | Bipolar |
| TUVRP | Transurethral vaporesection | TUVRP | Bipolar |
| PKVP | Plasmakinetic vaporesection | TUVRP | Bipolar |
| ThuVARP | Thulium laser vaporesection | ThuVARP | Thulium laser |
| Incision | | | |
| TUIP | Transurethral incision | TUIP | - |
| Other | | | |
| Aquablation | Aquablation | - | Waterjet |
| PAE | Prostate artery embolisation | PAE | - |
| WAVE | Water vapour thermal therapy | WAVE | Water vapour |
| TUMT | Transurethral microwave therapy | TUMT | Electromagnetic waves |
| TIND | Temporary implantable nitinol device | TIND | - |
| PUL | Prostatic urethral lift | PUL | - |
| OP | Open prostatectomy | OP | - |

[Appendix 4](#) in the appendix presents a non-exhaustive list of products for the included technologies, their intended use and their regulatory status.

2 OBJECTIVES AND SCOPE

The rationale for this multitechnology assessment was to collaboratively produce structured (rapid) core HTA information on MISTs for BPH. In particular, the aim was to perform multiple comparisons between different interventions, either comparing minimally invasive treatments to each other or to a standard surgical treatment such as TURP or OP. An additional aim was to apply this collaboratively produced assessment in the national and/or regional context.

The aim of this rapid assessment is to provide comparisons among different MISTs for BPH to assess their relative effectiveness and safety for patients with an indication for surgical treatment and for different subpopulations according to prostate size.

This topic was chosen on the basis of a request from local decision-makers who commissioned the agency to carry out a HTA to assess the relative effectiveness and safety of MISTs compared to available alternatives. A specific interest was expressed for technologies included or recommended in guidelines from the European Association of Urology [12] and the American Urological Association [61]. In addition, the EUnetHTA Prioritisation List for Other Technologies contains other innovative interventions, such as water vaporisation and PAE, which are also proposed for the treatment of BPH. The topic was relevant to other partnering agencies that joined in a collaborative Assessment Team and decided to extend the scope for multiple technologies intended for BPH treatment.

The relevance of the topic lies in the fact that new technologies are intensely marketed in both public and private institutions but have not yet been widely introduced in the public sector and could have relevant organisational and economic impacts on services for patients needing surgery for BPH.

The project scope was discussed during the scoping e-meeting attended by the Assessment Team and external experts. During the meeting, it was agreed to adopt the GRADE approach to finalise the list of outcomes and rate the importance of each outcome (see [Section 3](#)).

Table 2-1: Scope of the assessment

| Description | Project scope |
|-------------------|---|
| Population | <ul style="list-style-type: none"> • The target condition is lower urinary tract symptoms (LUTS) attributed to non-neurological benign prostatic hyperplasia (BPH) (ICD-9 600.0; ICD-10 N40; MeSH term “Prostatic Hyperplasia”) • The target population is adult men (>18 years of age) with LUTS attributed to BPH of non-neurological cause. • Either prostate weight or size will be used to define three relevant subpopulations often identified in guidelines (prostate size <30 ml, 30–80 ml and >80 ml, or the same intervals measured as prostate weight in grammes) which will be addressed by subgroup analyses. <p><i>Rationale:</i> According to the American Urological Association guidelines [61], men with clinically significant LUTS attributable to BPH who do not find adequate relief with medical treatment or find the side effects of medical treatment bothersome may benefit from surgical treatment. Surgical treatment should be chosen for patients who:</p> <ul style="list-style-type: none"> - Did not improve after medical therapy; - Do not want medical therapy but request active treatment (patient preference); or - Present with a strong indication for therapy (refractory urinary retention, renal insufficiency due to BPH, bladder stones, recurrent urinary tract infection, recurrent haematuria refractory to 5α-reductase-inhibitors). |

| Description | Project scope | |
|--|---|--------------------------|
| Interventions^a | <ul style="list-style-type: none"> • Resection: bipolar (plasmakinetic), holmium laser, thulium laser • Enucleation: bipolar (plasmakinetic), holmium laser, thulium laser, diode laser • Vaporisation: bipolar (plasmakinetic, electrovaporisation), holmium laser, thulium laser, diode laser, KTP laser (photoselective vaporisation with 180 W) • Enucleoresection • Enucleovaporisation/vapoenucleation • Vaporesection • Aquablation • Photoselective vaporisation with enucleation • Prostate artery embolisation (PAE) • Prostatic urethral lift (PUL) • Transurethral incision (TUIP) • Transurethral microwave therapy (TUMT) • Water vapour therapy (WAVE) • Temporary implantable nitinol device (TIND) | |
| Comparisons (standards)^a | <ul style="list-style-type: none"> • Transurethral resection of the prostate (TURP. monopolar or bipolar) • Open prostatectomy or adenomectomy (OP) | |
| Outcomes | Effectiveness | |
| | | Importance rating |
| | IPSS | 9 (6–9), critical |
| | Qmax | 8.5 (2–9), critical |
| | PVR | 8 (2–9), critical |
| | Reintervention | 7.5 (6–9), critical |
| | BPH Impact Index | 7 (1–9), critical |
| | Quality of life measures (generic) | 6.5 (2–9), critical |
| | Qmed | 4.5 (1–8), important |
| | Persistent irritative symptoms | 6.5 (1–9), critical |
| | Postoperative LUTS | 5.5 (1–9), important |
| | Safety | |
| | Intraoperative complications | Importance rating |
| | Procedural blood loss and transfusion requirement | 7 (5–9), critical |
| | Bladder perforation | 7 (4–9), critical |
| | Bladder or ureteral injury | 6 (4–9), important |
| | Capsular perforation | 6 (5–9), important |
| | Intraoperative mortality | 6 (3–9), important |
| | Decrease in serum sodium | 4 (2–7), important |
| | Haemoglobin alteration | 3 (2–8), not important |
| | Intraoperative complications (technology-specific) | Importance rating |
| | Bowel injury (OP) | 7 (2–8), critical |
| | Rectal injury (OP) | 7 (2–8), critical |
| | Injury to adjacent structures (OP) | 6.5 (2–8), important |

| Description | Project scope | |
|---------------------|---|--------------------------|
| | Inadvertent embolisation of other sites (PAE) | 6 (2–8), important |
| | Vascular thrombosis (PAE) | 6 (2–9), important |
| | Incisional hernia (OP) | 6 (2–9), important |
| | Pseudoaneurysms (PAE) | 5 (2–7), important |
| | Dissection | 5 (2–9), important |
| | Damage to perivascular, neural or muscular structures (PAE) | 5 (2–8), important |
| | Vesicocutaneous fistula (OP) | 5 (2–8), important |
| | Epididymo-orchitis (OP) | 4.5 (2–8), important |
| | Haematomas (PAE) | 4 (2–6), important |
| | Vascular access (PAE) | 3 (2–6), not important |
| | Postoperative complications | Importance rating |
| | Erectile dysfunction | 8.5 (7–9), critical |
| | Urinary incontinence | 8 (7–9), critical |
| | Catheterisation time | 7 (1–9), critical |
| | TUR syndrome | 7 (5–9), critical |
| | Urethral stricture | 7 (4–9), critical |
| | Bladder neck contracture | 7 (5–9), critical |
| | Acute urinary retention | 7 (5–9), critical |
| | Urinary tract infection | 7 (3–9), critical |
| | Retrograde ejaculation | 7 (5–9), critical |
| | Recatheterisation | 6.5 (3–9), important |
| | Long-term mortality | 3.5 (1–9), not important |
| | Postoperative complications (technology-specific) | Importance rating |
| | Implant encrustation (PUL) | 6 (2–7), important |
| | Migration rate of the implant (PUL) | 6 (2–8), important |
| | Radiodermatitis (PAE) | 4 (2–6), important |
| | Other outcomes | Importance rating |
| | Hospitalisation time | 8 (5–9), critical |
| | Procedure time | 6 (3–9), important |
| Study design | Randomised controlled trials | |

^a The aim was to perform multiple comparisons and therefore the distinction between interventions and comparisons is merely indicative.

3 METHODS

The EUnethTA Guidelines, available at <https://eunetha.eu/methodology-guidelines/>, were consulted throughout the assessment process. To provide transparency regarding the development of the scope questions, the Assessment Team agreed to form a panel and to apply the GRADE method (<https://gdt.gradepro.org/app/handbook/handbook.html>) during the scoping phase to structure the process for the selection of outcomes and the rating of their importance. This process was developed as follows:

- An initial draft of the project plan, developed and agreed on by the authors and the co-authors, was circulated to dedicated reviewers and external experts.
- A scoping e-meeting was arranged with the Assessment Team and external experts to discuss the project plan and to agree on a preliminary list of outcomes of interest. During the scoping meeting it was also agreed to use GRADE and GRADEpro (an electronic tool that facilitates participation by panel members in the process; <https://gradepro.org/>) to conduct and finalise the scoping phase. For this purpose, a GRADE panel was established, comprising authors, co-authors, dedicated reviewers and external experts (organisations and not single individuals counted as panel members). Participation by patient representatives was actively sought, but without success.
- The research question (target population, intervention and comparator) and the list of outcomes were uploaded by the authors on GRADEpro and all members were registered for participation.
- Each member received an e-mail with access details for the GRADEpro system to check and approve the research question and the list of outcomes.
- Following approval by the panel, each member received an e-mail with an invitation to rate the importance of each of the listed outcomes using a predefined scale. The scale provided a choice between three categories of outcomes according to their importance for decision-making: “critical” (score between 7 and 9); “important” (score between 4 and 6); and “not important” (score between 1 and 3).
- Using the scores applied by all panel members, the median scores were calculated by the authors and a final overall rating of importance was assigned to each outcome. If median values could not be an integer, the mean was considered.

In the PICO table, ratings of importance are reported for each outcome. Summary-of-findings tables were completed only for outcomes rated as critical.

3.1 Clinical effectiveness and safety

3.1.1 Information retrieval

We included RCTs that compared the technologies of interest (see the PICO table) to each other and/or to comparators (TURP and/or OP). RCTs comparing each of the technologies of interest versus sham procedures were considered only if head-to-head comparative RCTs were not found for those technologies.

A systematic review of the literature was performed according to the Cochrane Handbook methodology (2019 version). The RevMan 5 tool for systematic reviews was also used for data extraction, RoB representation and summary-of-findings tables. As one high-quality systematic review was published in November 2019 [21] the systematic search was performed with January 2019 as

the starting date for technologies included in that review (HoLEP, ThuLEP, DioLEP, B-TUEP, DioLVP, M-TURP, B-TURP, B-TUVP and PVP). For all the other technologies, no time limits were considered.

The following sources of information and search techniques were considered.

Main information sources

- Bibliographic databases
 - MEDLINE
 - Embase
 - Cochrane Central Register of Controlled Trials

Further information sources and search techniques

A search of international guidelines, systematic and narrative reviews was performed in UpToDate to fulfil information required for the CUR domain (health problem and current use). Publicly available information on the technologies identified as relevant for the assessment was used for the TEC domain (description and technical characteristics) for the technologies being assessed.

3.1.2 Selection of relevant studies and documents

Assessment elements were selected in accordance with the HTA Core Model for Rapid Relative Effectiveness Assessment Version 4.2. EndNote was used for citation management. Details for the search strategy are available in [Appendix 1](#).

RCTs were checked for inclusion for the assessment of clinical effectiveness and safety. All RCTs included in the systematic review published in 2019 were retrieved and assessed for inclusion.

3.1.3 Data extraction

Five review authors (LB, OD, JE, GF and AP) independently extracted data using a data extraction form developed for this review ([Appendix 4](#)). For each study included, we recorded the following information: study design, length of follow-up, number of participants in the intervention and control groups, average age, sex, country, inclusion and exclusion criteria, data collection period, number of participants, description of the intervention and control, and outcomes. Data available from figures were extracted using PlotDigitizer version 2.6.9 for Windows. When values for the standard deviation or mean and standard deviation were missing, they were calculated according to the Cochrane recommendations [62], which were also used when combining data from two arms of the same study dealing with the same technology. When the median and range were available, mean and standard deviation values were calculated according to McGrath et al. [63]. Arms related to the same technology in the same multiarm study were combined according to the Cochrane recommendations [62]. Disagreements were discussed and resolved between reviewers.

The clinical relevance of results observed can be better discussed if MCID values are available and validated. MCIDs could be found only for IPSS (Barry et al. [64] reported an MCID of 3 points) and Qmax (the UK National Institute for Health and Care Excellence [11] reported an MCID of 2 ml/s). These MICDs are referred to when discussing the relevance of the IPSS and Qmax outcomes.

Some of the outcomes listed in the scope could overlap or need to be specifically defined. The working group agreed on the following specifications.

- Persistent irritative symptoms should include everything that refers to these symptoms, including early irritative symptoms. Dysuria was included among irritative symptoms. Whenever “urge incontinence” or “urgency” (or “micturition urgency”) was reported, these were classified as a “persistent irritative symptom”. Data for “mixed incontinence” were reported for both the persistent irritative symptoms and urinary incontinence outcomes.
- Urinary incontinence refers to symptoms specified simply as “urinary incontinence” or “stress incontinence” or “transient incontinence”. Data for “mixed incontinence” were reported for both the persistent irritative symptoms and urinary incontinence outcomes.
- For operative versus enucleation/vaporisation/resection time, only the overall operative time was considered.
- For blood loss during the procedure and the transfusion requirement, only data on blood loss leading to transfusion (discrete data) were considered.
- Erectile dysfunction was considered both as a discrete outcome and when measured using the International Index of Erectile Function (IIEF) questionnaire.
- For bladder neck contracture, data on infravesical obstruction, bladder neck stenosis and bladder neck sclerosis were aggregated under this outcome.
- For retrograde ejaculation, data on anejaculation were also considered under this outcome, since these are strictly related from a clinical perspective. Regarding the denominator for this outcome, either all patients or just sexually active patients were considered.

3.1.4 Quality rating and RoB assessment

For the TEC and CUR domains, no quality assessment tool was used, but multiple sources were used to validate and cross-check individual sources.

For the EFF (clinical effectiveness) and SAF (safety) domains, study quality for the RCTs included was rated using the Cochrane RoB tool [65].

Five review authors (LB, OD, JE, GF and AP) independently assessed RoB in the studies using the aforementioned methodology according to the following seven criteria:

- Random sequence generation, which influences the likelihood that allocation to treatments is randomised.
- Allocation concealment, which influences the unpredictability of treatment allocation and the possibility that selection bias occurs.
- Performance bias, which may influence surgery and approaches to patient care during follow-up. It should be noted that all the trials selected had an open-label design. Blinding of surgeons was not possible given the interventions being assessed. Patients and the clinicians in charge (not the surgeon) may have been blinded or not; in the latter case, they may have been somewhat “influenced” in the postoperative period by knowing the surgery technique.
- Detection bias, which is related to blinding of outcome assessors. A distinction has been made between subjective outcomes (those self-assessed by patients) and objective outcomes (assessed by external assessors). In the case of a difference in blinding between patients and assessors (e.g., if just patients or just assessors were blinded), detection bias was considered separately for subjective and objective outcomes.

- Incomplete outcome data, leading to attrition bias. Besides situations for which no attrition was declared and apparent, we considered studies to be at low risk of attrition bias when loss to follow-up was <5% and at high risk to attrition bias if the loss was $\geq 20\%$ (overall or in any group) [66] or if there was a difference of >15% in attrition between groups.
- Selective outcome reporting. Study protocols and trial registries were searched to assess whether data were reported for all of the prespecified primary outcomes and whether they were reported in the prespecified way. Unclear risk was assigned for cases for which a protocol or trial registry was not available. High risk was assigned in the case of a difference between reported outcomes and the protocol/registry or methods section, or if at least two outcomes had incomplete data (e.g., data shown as a figure and without statistical comparison between groups).
- In cases for which other possible sources of bias were deemed important (e.g., presence of conflicts of interest), these were recorded.

RCTs were judged at high RoB if there was at least one high-risk item among these categories (except for conflicts of interest); at low RoB if there were at least four low-risk items (except for conflicts of interest) and no high-risk items; and at uncertain RoB in all other cases.

3.1.5 Data analyses and synthesis

Measures of the treatment effect

For meta-analysis, we used the risk ratio (RR) with 95% CI for binary outcomes and the MD with 95% CI for continuous outcomes.

Data synthesis

Whenever possible, quantitative analysis methods were used in a meta-analysis for the SAF and EFF domains using RevMan 5.3. We pooled data using a fixed-effects model, or a random-effects model only when pooling data from more than five RCTs (to better control for heterogeneity). We avoided pooling of data when two studies showed results in different directions. We also avoided pooling of data for hospitalisation time, catheterisation time and procedure time, considering the possibility of high heterogeneity due to different policies in different centres.

We expressed dichotomous outcomes as the RR with 95% CI and we used the MD and 95% CI when outcomes were continuous. When urological symptom scores different from the IPSS were used, data were combined using the standardised mean difference (SMD).

A descriptive analysis of information is provided for other domains and whenever meta-analysis was not possible or was inappropriate. In some instances (i.e., in the case of wide statistical heterogeneity), even though pooled estimates could not be calculated, forest plots are presented to provide a visual representation of results from each study.

Assessment of heterogeneity

Heterogeneity was evaluated through visual inspection of forest plots (evaluating the amount of overlap of CIs) and through the I^2 statistic. According to the I^2 statistic, heterogeneity was judged as follows [67]:

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity;
- 50% to 90%: may represent substantial heterogeneity; and
- 75% to 100%: considerable heterogeneity.

These results were interpreted carefully, with consideration of the number of studies involved and their characteristics.

Sensitivity and subgroup analyses

To explore heterogeneity, in particular when statistical significance could be affected, we performed sensitivity analyses excluding studies considering their RoB and baseline characteristics (in terms of prostate size and age). Subgroup analyses were also performed if sufficient studies were available with subgroup data by patient age and prostate size.

Unit of analysis issues

Patients were the unit of analysis. When composite outcomes (e.g., irritative symptoms) were assessed, the number of events was counted instead.

Dealing with missing data

Given the high number of studies available, we did not contact principal investigators to retrieve possible unreported data.

We used only the number of patients with follow-up available as the denominator [68, 69]. When no loss to follow-up was specified, we used baseline denominators.

We evaluated methodological and statistical heterogeneity of included studies by considering their RoB, characteristics of study populations, by examining forest plots of their results and the I^2 statistic to assess inconsistency between studies.

Deviations from project plan

The heterogeneity of the study populations, which often encompassed wide and different ranges for prostate size, precluded subgroup analyses for the specific subpopulations initially considered according to prostate size (<30 ml, 30–80 ml and >80 ml, or <30 g, 30–80 g and >80 g) and network meta-analyses, as the transitivity assumption would have been violated. A prerequisite for network meta-analysis is that the transitivity assumption is warranted: all studies should be similar on average for all important effect modifiers. Analysis of baseline characteristics revealed quite wide heterogeneity, in particular regarding age and prostate size. However, visualisation of networks of parallel comparisons is provided for relevant functional and safety outcomes, together with information on the statistical significance, clinical relevance (for IPSS and Qmax) and the quality of the evidence.

3.1.5.1 Certainty of the evidence (if applicable)

The level of confidence/certainty in the body of evidence was assessed using the GRADE approach [70]. Judgements were based on study limitations (RoB), inconsistency of results, imprecision, indirectness of evidence and publication bias. Indirectness was considered in cases with pooling of heterogeneous RCTs in terms of prostate size. Outcomes assessed through single small RCTs were downgraded by two levels for imprecision. In addition, imprecision associated with rare events led to downgrading by two levels. The quality of the evidence was eventually assessed according to one of four grades (high, moderate, low and very low) as described in [Table 3-1](#).

Table 3-1: Definition of the quality of the evidence

| Quality | Definition |
|----------|--|
| High | “We are very confident that the true effect lies close to that of the estimate of the effect” |
| Moderate | “We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different” |
| Low | “Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect” |
| Very low | “We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect” |

3.1.6 Patient involvement

Participation by patient organisations/patient representatives was actively sought. An Open Call for Patient Input was published on the EUnetHTA website and was open for 1 month with a time extension of 2 weeks. Selected patient organisations were contacted via e-mail to inform them about the open call. However, the efforts made were unsuccessful and there was no response to the open call from any of the patient organisations contacted or from any individual patients.

3.1.7 External expert involvement

To guarantee quality assurance throughout the whole assessment process, external experts in the field of urology and radiology were involved in reviewing the project plan and the assessment draft. The external experts also participated in the scoping e-meeting and in rating the importance of outcomes using the GRADEpro software. They were also consulted during the assessment process if questions arose.

4 RESULTS: CLINICAL EFFECTIVENESS AND SAFETY

4.1 Information retrieval

Figure 4-1 shows the result of the information retrieval process for the main and further information sources according to the predefined inclusion criteria. References for the documents that were excluded after full-text checking are presented in [Appendix 2](#) with the reason for exclusion.




Figure 4-1: Flow chart of information retrieval for clinical effectiveness and safety.

The electronic search yielded 2491 references. To these we added all RCTs included in the aforementioned systematic review. Four reviewers (LB, OD, JE and GF) carried out the study selection process independently, in accordance with the previously defined PICO question. Disagreements were discussed and resolved between reviewers. After removing 812 duplicate records, we screened the remaining 1751 manuscripts. We excluded 1647 records after reading the abstract, and obtained the full-text report for 104 references for further assessment. Eight studies were excluded ([Figure 4-1](#)); the 96 records that met the inclusion criteria were finally included for qualitative analyses, corresponding to 86 RCTs.

The first search was carried out on 28 February 2020 and the last search on 18 January 2021.

4.2 Studies included in the assessment

Besides the technologies in the 2019 systematic review [21], the search identified 16 other technologies (TUIP, TUVRP, TUMT, PAE, TmLRP, TURP + TUIP, B-VEP, PVEP, Aquablation, WAVE, OP, PUL, M-TUERP, B-TUERP, ThuVARP and ThuVEP). [Table 4-1](#) shows the number of studies addressing each comparison.

Table 4-1: Number of studies addressing each comparison between technologies of interest and comparators, in descending order

| Comparison | Number of RCTs | Study IDs (in alphabetical order) ^a |
|----------------------|----------------|---|
| HoLEP vs. TURP | 14 | Bai 2019, Basic 2013, Chen 2013, Elshal 2020, Eltabey 2010, Fayad 2015, Gupta 2006, Hamouda 2014, Jhanwar 2017, Kuntz 2004, Mavuduru 2009 Montorsi 2004, Sun 2014, Tan 2003 |
| B-TUVP vs. TURP | 10 | Elsakka 2016, Geavlete 2011, Geavlete 2014, Geavlete 2015, Hon 2006, Karadag 2014, Kaya 2007, Nuhoglu 2011, Tefekli 2005, Zhang S 2012 |
| TUIP vs. TURP | 5 | Abd-El Kader 2012, Dørflinger 1992, Jahnsen 1998, Riehmman 1995, Tkocz 2002 |
| B-TUEP vs. TURP | 5 | Geavlete 2015, Luo 2014, Ran 2013, Zhao 2010, Zhu 2013 |
| ThuLEP vs. TURP | 5 | Bozzini 2017, Enikeev 2019, Shoji 2020, Swiniarski 2012, Yang 2013 |
| TUVRP vs. TURP | 5 | Dunsmuir 2003, Geavlete 2010, Gupta 2006, Tefekli 2005, Yee 2015, Yip 2011 |
| PAE vs. TURP | 5 | Abt 2018, Carnevale 2016, Gao 2014, Insausti 2020, Radwan 2020 |
| TUMT vs. TURP | 4 | Dahlstrandt 1995, D'Ancona 1998, Floratos 2001, Wagrell 2002 |
| PVP vs. TURP | 3 | Elshal 2020, Goliath study (Bachmann 2014, 2015, Thomas 2016), Jovanovic 2014 |
| HoLEP vs. B-TUEP | 3 | Habib 2020, Higazy 2020, Neill 2006 |
| HoLEP vs. ThuLEP | 3 | Bozzini 2020, Zhang F 2012, Zhang 2020 |
| DioLEP vs. TURP | 2 | Lusuardi 2011, Zhang 2019 |
| TmLRP vs. TURP | 2 | Xia 2008, Yan 2013 |
| TURP + TUIP vs. TURP | 2 | Li 2013, Yeni 2002 |
| DioLEP vs. B-TUEP | 2 | Wu 2016, Zou 2018 |
| PVP vs. B-TUVP | 2 | Ghobrial 2020, Kini 2020 |
| DioLVP vs. TURP | 2 | Cetinkaya 2015, Razzaghi 2014 |
| B-VEP vs. TURP | 1 | Wang 2020 |
| PVEP vs. TURP | 1 | Zhang 2015 |
| PVEP vs. HoLEP | 1 | Elshal 2015 |
| Aquablation vs. TURP | 1 | WATER study (Gilling 2018, 2019a, 2019b, 2020) |
| ThuLEP vs. B-TUEP | 1 | Feng 2016 |
| B-TUERP vs. TURP | 1 | Samir 2019 |
| DioLEP vs. B-TUERP | 1 | Xu 2013 |
| DioLEP vs. HoLEP | 1 | He 2019 |
| DioLVP vs. B-TUVP | 1 | Skinner 2017 |
| HoLEP vs. ThuVEP | 1 | Netsch 2017 |
| B-TUEP vs. B-TUVP | 1 | Geavlete 2015 |

| Comparison | Number of RCTs | Study IDs (in alphabetical order) ^a |
|------------------|----------------|--|
| ThuVARP vs. TURP | 1 | Hashim 2020 |
| M-TUERP vs. TURP | 1 | Li 2018 |
| PUL vs. TURP | 1 | BPH6 study (Sonksen 2015, Gratzke 2017) |
| HoLEP vs. PVP | 1 | Elshal 2020 |
| HoLEP vs. TUVRP | 1 | Gupta 2006 |
| ThuVEP vs. TURP | 1 | Chang 2015 |
| B-TUEP vs. OP | 1 | Geavlete 2015 |
| B-TUVP vs. OP | 1 | Geavlete 2015 |
| WAVE vs. sham | 1 | Rezüm II study (McVary 2016a, 2016b, 2018, 2019, Roehrborn 2017) |

^a Reference list numbers for all the studies are included in [Table 4-3](#).

[Table 4-2](#) lists the RCTs that included a formal power calculation and stated the hypothesis being tested.

Table 4-2: RCTs presenting a formal power calculation and the hypothesis tested among the RCTs included in the assessment

| Study | Technologies assessed | Primary outcome(s) | Hypothesis | Sample size |
|---------------------------------|-----------------------|--|----------------|-------------|
| Abt 2018 [71] | PAE vs. TURP | IPSS | Noninferiority | 103 |
| Cetinkaya 2015 [72] | DioLVP vs. TURP | IPSS | Superiority | 72 |
| Chen 2013 [73] | HoLEP vs. TURP | Operative time | Superiority | 280 |
| Elshal 2015 [74] | PVP vs. HoLEP | IPSS | Noninferiority | 103 |
| Elshal 2020 [75] | PVP, TURP vs. HoLEP | Retreatment | Noninferiority | 182 |
| Ghobrial 2020 [76] | PVP vs. B-TUVP | IPSS | Noninferiority | 119 |
| GOLIATH study [77-79] | PVP vs. TURP | IPSS | Noninferiority | 281 |
| Hashim 2020 [80] | ThuVARP vs. TURP | IPSS, Qmax | Noninferiority | 410 |
| Insausti 2020 [81] | PAE vs. TURP | Qmax | Noninferiority | 45 |
| Kuntz 2004 [82] | HoLEP vs. TURP | Qmax | Superiority | 200 |
| Lusuardi 2011 [83] | DioLEP vs. TURP | Hospitalisation time, catheterisation time | Superiority | 60 |
| Neill 2006 [84] | HoLEP vs. B-TUEP | Catheterisation time | Superiority | 40 |
| Tan 2003 [85] | HoLEP vs. TURP | Hospitalisation time, catheterisation time | Superiority | 61 |
| WATER study [86-90] | Aquablation vs. TURP | IPSS | Noninferiority | 181 |
| WAVE study [48, 49, 51, 52, 91] | WAVE vs. sham | IPSS | Superiority | 197 |
| Xia 2008 [92] | TmLRP vs. TURP | IPSS, Qmax | Superiority | 100 |
| Yee 2015 [93] | TUVRP vs. TURP | Hospitalisation time | Superiority | 168 |
| Yip 2011 [94] | TUVRP vs. TURP | Catheterisation time | Superiority | 86 |
| Zhang 2020 [95] | ThuLEP vs. HoLEP | Qmax | Superiority | 116 |
| Zhu 2013 [96] | B-TUEP vs. TURP | Catheterisation time | Superiority | 80 |
| Zou 2018 [97] | DioLEP vs. B-TUEP | IPSS, Qmax | Superiority | 114 |

4.3 Description of the evidence used

Appendix 4 provides a full description of the evidence used. Table 4-3 lists the characteristics of all the studies included in the assessment.

Table 4-3: Characteristics of the studies included in the assessment

The abbreviation for the technology as used in each publication is displayed in the table, with the abbreviation used in the assessment for consistency included in parentheses.

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|------------------------|---|------------|---|--|---|--|
| Abd-El Kader 2012 [98] | Egypt, 2005–10 | RCT | TUIP (n=40) | TURP (n=40) | Prostate weight ≤30 g (mean: 28) | IPSS, Qmed, Qmax, PVR, blood transfusion, catheterisation time, hospitalisation time, retrograde ejaculation, erectile dysfunction, bladder neck contracture, urethral stricture, reoperation |
| Abt 2018 [71] | Switzerland, 2014–17 | RCT | PAE (n=51) | TURP (n=52) | Prostate volume 25–80 ml (mean: 52) | IPSS, Qmax, PVR, ejaculatory dysfunction, catheterisation time, hospitalisation time, IIEF, persistent irritative symptoms, urinary retention, urinary incontinence, UTI, urethral stricture |
| Bai 2019 [99] | China, 2015–17 | RCT | HoLEP (n=33) | TURP (n=32) | Mean prostate volume: 82 ml | Qmax, PVR, IPSS, QoL, catheterisation time, hospitalisation time |
| Basic 2013 [100] | Serbia, 2011–12 | RCT | HoLEP (n=20) | TURP (n=20) | Prostate weight ≤50 g (mean: 46) | IPSS, QoL, PVR, blood transfusion, catheterisation time, hospitalisation time, bladder mucosal injury, urinary incontinence, AUR, persistent irritative symptoms, bladder neck stricture, reintervention |
| Bozzini 2017 [101] | Italy, 2014–15 | RCT | ThuLEP (n=102) | TURiS (n=106) (TURP) | Mean prostate volume: 86 ml | IPSS, Qmax, PVR, QoL, catheterisation time, hospitalisation time, blood transfusion, urinary retention, stress incontinence, urge incontinence, urethral stricture, bladder injury |
| Bozzini 2020 [102] | Italy, France, 2015–18 | RCT | HoLEP (n=121) | ThuLEP (n=115) | Mean prostate volume (SD): HoLEP: 86.3 ml (46.7) ThuLEP: 90.2 ml (42.7) | Hospital stay, operative time, catheterisation time, IPSS, Qmax, PVR, QoL, urinary retention, blood transfusion, bladder injury, stress incontinence, urge incontinence, urethral stricture |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|---|---|------------|---|--|--|--|
| BPH6 study: Gratzke 2017 [103] Sonksen 2015 [104] | Germany, Denmark, UK, 2012–13 | RCT | PUL (n=44) | TURP (n=35) | Mean prostate volume (SD), range: PUL: 38 ml (12), 16–59 TURP: 41 ml (13), 17–68 | <i>Gratzke 2017</i> : IPSS, MSHQ-EjD, ISI, adverse events, QoL <i>Sonksen 2015</i> : IPSS, MSHQ-EjD, ISI, adverse events, QoL, BPH II, Qmax, PVR, reintervention at ≤30 d and >30 – 365 d (due to bleeding, urethral stricture, return of LUTS) |
| Carnevale 2016 [105] | Brazil, 2010–11 | RCT | PAE (n=15) | TURP (n=15) | Mean prostate volume (SD), range: PAE: 63.0 ml (17.8), 34–97 TURP: 56.6 ml (21.5), 32–89 | IPSS, QoL, IIEF-5, PVR, Qmax, procedure time, hospital stay, blood transfusion requirement, capsular perforation, retrograde ejaculation, urinary incontinence, postoperative LUTS, recatheterisation, radiodermatitis |
| Cetinkaya 2015 [72] | Turkey, 2010–11 | RCT | PVP (n=36) | TURP (n=36) | Prostate volume <80 ml (mean: 53) | IPSS, Qmax, catheterisation time, hospitalisation time, urinary retention, retreatment, blood transfusion, capsule perforation, TUR syndrome, UTI, urethral stricture |
| Chang 2015 [106] | Taiwan, 2010–12 | RCT | ThuVEP (n=29) | TURP (n=30) | Mean prostate weight: 61 g | Qmed, QoL, IIEF-5, IPSS, Qmax, PVR, catheterisation time, hospitalisation time, AUR, recatheterisation, UTI, haemorrhage/haematuria requiring transfusion, TUR syndrome |
| Chen 2013 [73] | China, 2008–10 | RCT | PKRP (n=140) (TURP) | HoLEP (n=140) | Mean prostate size: 59 ml | Catheterisation time, hospitalisation time, IPSS, QoL, Qmax, PVR, IIEF-5, TUR syndrome, recatheterisation, blood transfusion, urinary incontinence, reoperation, retrograde ejaculation, urethral stricture, bladder neck contracture |
| D'Ancona 1998 [107] | The Netherlands, 1994–95 | RCT | TUMT (n=31) | TURP (n=21) | Prostate volume 30–100 ml, (mean: 44) | IPSS, Qmax, PVR, catheterisation time, UTI, hospitalisation time, irritative symptoms, retreatment |
| Dahlstrandt 1995 [108] | Sweden, n.r. | RCT | TUMT (n=37) | TURP (n=32) | Prostate length 35–50 mm (size not available) | Qmax, PVR, reintervention, urinary retention, urethral stricture, UTI, erectile dysfunction, blood loss, hospitalisation time |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|-----------------------|---|------------|---|--|--|--|
| Dørflinger 1992 [109] | Denmark, n.r. | RCT | TUIP (n=29) | TURP (n=31) | Prostate weight <20 g | Persistent irritative symptoms, LUTS, Qmax, blood transfusion, urethral stricture, bladder neck contracture, catheterisation time, reoperation, recatheterisation, retrograde ejaculation |
| Dunsmuir 2003 [110] | Australia, n.r. | RCT | B-TUVP(n=30) | TURP (n=21) | Mean prostate volume: 39 ml | Qmax, PVR, AUA symptom score, catheter removal, time to discharge, recatheterisation |
| Elsakka 2016 [111] | Egypt, 2020–12 | RCT | B-TUVP (n=40) | TURP (n=42) | Prostate volume <80 ml (mean:52) | IPSS, Qmax, PVR, catheterisation time, bladder perforation, recatheterisation, UTI, stress urinary incontinence, bladder neck obstruction, bleeding necessitating transfusion, TUR syndrome, urethral stricture, reintervention |
| Eishal 2015 [74] | Canada, 2012–13 | RCT | PVEP (n=53) | HoLEP (n=50) | Prostate volume 40–150 ml (mean: 85) | Qmax, PVR, IPSS, QoL, IIEF-15, catheterisation time, hospitalisation time, dysuria, urge incontinence, stress incontinence, capsular violation, bladder injury, anaemia requiring transfusion, UTI, bladder neck contracture, urethral stricture |
| Eishal 2020 [75] | Egypt, 2014–16 | RCT | PVP (n=60) HoLEP (n=60) | TURiS (n=60) (TURP) | Mean prostate volume (SD): PVP: 103 ml (25) HoLEP: 107 ml (21) TURiS: 106 ml (23) | Retreatment, hospital stay, operative time, time to catheter removal, dysuria, IIEF, IPSS, Qmax, PVR, QoL, capsular perforation, blood transfusion, bladder wall injury, UTI |
| Eltabey 2010 [112] | Saudi Arabia, 2008–09 | RCT | HoLEP (n=40) | TURP (n=40) | Prostate volume 30–100 ml (mean: 60) | Qmax, PVR, AUA symptom score, catheterisation time, hospitalisation time, irritative voiding symptoms, urge incontinence, stress incontinence, mixed incontinence, blood transfusion, urethral stricture |
| Enikeev 2019 [113] | Russia, n.r. | RCT | ThuLEP (n=51) | TURP (n=52) | Prostate volume <80 cm ³ (mean: 62) | PVR, IPSS, Qmax, QoL, catheterisation time, hospitalisation time, urinary incontinence, UTI, AUR, urethral stricture, bladder neck contracture, retrograde ejaculation |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|---------------------|---|------------|--|--|--|---|
| Fayad 2015 [114] | Egypt, 2008–13 | RCT | HoLEP (n=60) | TURP (n=60) | Mean prostate volume: 68 ml | IPSS, Qmax, PVR, blood loss, intraoperative and postoperative complications, catheterisation time, hospitalisation time |
| Feng 2016 [115] | China, 2011–13 | RCT | ThuLEP (n=61) | PKEP (n=66) (B-TUEP) | Mean prostate volume: 68 ml | IPSS, QoL, Qmax, PVR, catheterisation time, hospitalisation time, complications |
| Floratos 2001 [116] | The Netherlands, 1996–97 | RCT | TUMT (n=78) | TURP (n=66) | Prostate volume \geq 30 ml (mean: 45) | PVR, IPSS, Qmax, QoL, retreatment, urethral stricture, bladder neck contracture |
| Gao 2014 [117] | China, 2007–12 | RCT | PAE (n=57) | TURP (n=57) | Mean prostate volume (SD): PAE: 64.7 ml (19.7) TURP: 63.5 ml (8.6) | IPSS, QoL, PVR, Qmax, operative time, decrease in serum sodium levels within 24 hours after the procedure, transfusion requirement, hospital stay, catheter requirements, reintervention, TUR syndrome, AUR, UTI, urethral stricture, bladder neck contracture |
| Geavlete 2010 [41] | Romania, n.r. | RCT | TURiS-PVP (n=75) (TUVRP) | TURP (n=80) | Prostate volume 30–80 ml (mean: 56) | IPSS, HRQoL, Qmax, PVR, catheterisation time, capsular perforation, intraoperative bleeding, blood transfusion, UTI, AUR, dysuria, urinary urgency |
| Geavlete 2011 [118] | Romania, n.r. | RCT | BPVP (n=170) (B-TUVP) | Total TURP (n=340) TURiS (n=170) M-TURP (n=170) | Mean prostate volume: 54 ml (range 30–80) | IPSS, QoL, Qmax, PVR, catheterisation time, hospitalisation time, intraoperative bleeding, blood transfusion, capsular perforation, TUR syndrome, early irritative symptoms, dysuria, bladder neck sclerosis, urinary stricture, urinary incontinence, UTI, retreatment |
| Geavlete 2014 [119] | Romania, n.r. | RCT | Total BPVP (n=120) C-BPVP (n=60) ⁴ S-BPVP (n=60) (B-TUVP) | TURP (n=60) | Mean prostate volume: 54 ml | IPSS, QoL, Qmax, PVR, capsular perforation, catheterisation time, hospitalisation time |

⁴ C-BPVP and S-BPVP are types of B-PVP

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--|---|------------|---|--|---|---|
| Geavlete 2015 [120] | Romania, 2009-13 | RCT | BPEP (n=80) (B-TUEP) TUViS (n=80) (B-TUVP) | TURiS (n=80) (TURP) Open prostatectomy (n=80) | Prostate volume \geq 80 ml (mean: 127) | IPSS, QoL, Qmax, PVR, catheterisation time, hospitalisation time, blood transfusion, recatheterisation, urinary stricture, urinary incontinence, UTI |
| Ghobrial 2020 [76] | Egypt, 2014–15 | RCT | PVP (n=58) | B-TUVP (n=61) | Prostate volume 30–80 ml (mean: 58) | Qmax, PVR, IPSS, QoL, IIEF-15, catheterisation time, hospitalisation time, UTI, postoperative LUTS, bladder neck contracture, urethral stricture, urinary incontinence, urinary retention, anaemia necessitating blood transfusion, bladder wall injury, capsular violation, retrograde ejaculation-anejaculation |
| Goliath study: Bachmann 2014 [77] Bachmann 2015 [78] Thomas 2016 [79] | Nine European countries, 2011–12 | RCT | PVP (n=136) | TURP (n=133) | Prostate volume \leq 100 ml (mean: 47) | IPSS, Qmax, PVR, IIEF-5, UTI, irritative symptoms, stricture (meatal, urethral, bladder neck), urinary incontinence, urinary retention, reoperation, catheterisation time, hospitalisation time, transfusion, retrograde ejaculation |
| Gupta 2006 [121] | India, 2002–03 | RCT | HoLEP (n=50) TUVRP (n=50) | TURP (n=50) | Prostate weight >40 g (mean: 60) | IPSS, Qmax, PVR, catheterisation time, blood transfusion, capsular perforation, bladder mucosal injury, transient dysuria, urethral stricture, incontinence |
| Habib 2020 [122] | Egypt, 2016–18 | RCT | HoLEP (n=33) | PKEP (n=31) (B-TUEP) | Prostate weight \geq 80 g (range: 80–270) | PVR, IPSS, Qmax, QoL, IIEF, catheterisation time, hospitalisation time, capsule perforation, urinary retention, transient urinary incontinence, irritative symptoms, UTI, blood transfusion, bladder neck contracture |
| Hamouda 2014 [123] | Egypt, 2009–10 | RCT | HoLEP (n=30) | TURP (n=30) | Prostate weight 20–80 g (mean: 56) | AUA symptom score (corresponding 7/8 to IPSS), Qmax, PVR, UTI, blood transfusion, urethral stricture, irritative symptoms, incontinence, catheterisation time, hospitalisation time |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--------------------|---|------------|---|--|---|---|
| Hashim 2020 [43] | UK, 2014–16 | RCT | ThuVARP (n=205) | TURP (n=205) | Median prostate weight (range): ThuVARP 35 g (25–50) TURP 40 g (20–50) | Qmax, IPSS, complications until 12-month follow-up, hospitalisation time, perioperative complications, postoperative catheterisation time, PVR, blood loss during surgery (change in haemoglobin and blood transfusion rate), absorption of irrigation fluid, LUTS (IPSS, ICIQ-MLUTS), sexual function (ICIQ-MLUTS sex, IIEF), quality of life (IPSS QoL subscore, ICIQ-LUTS QoL), patient satisfaction (ICIQ Satisfaction questionnaire) |
| He 2019 [124] | China, 2016–17 | RCT | DioLEP (n=63) | HoLEP (n=63) | Mean prostate volume (SD): DioLEP: 83.0 ml (34.8) HoLEP: 75.6 ml (28.9) | Qmax, PVR, IPSS, QoL, decrease in serum sodium, bladder injury, blood transfusion, capsule perforation, TUR syndrome, urinary retention, recatheterisation, retrograde ejaculation, urinary incontinence, UTI, urethral stricture, bladder neck contracture, operative time, catheterisation time, hospitalisation time |
| Higazy 2020 [125] | Egypt, 2018 | RCT | HoLEP (n=60) | B-PEP (n=60) (B-TUEP) | Mean prostate volume (SD), range: HoLEP: 135.19 ml (34.84), 90–200 B-PEP: 125.00 ml (26.93), 95–180 | Operative time (from initiation of the endoscopic procedure to catheter insertion), enucleation and morcellation time, volume of resected tissue, perioperative complications according to the Clavien–Dindo classification, catheterisation time, hospitalisation time, PSA, Qmax, PVR, IPSS, QoL (1-, 3- and 12-month follow-up) |
| Hon 2006 [126] | UK, n.r. | RCT | PKVP (n=81) (B-TUVP) | TURP (n=79) | Mean prostate volume: 39 ml | Intraoperative blood loss, postoperative hospitalisation time, transfusion, urethral stricture, reintervention, IPSS, Qmax, Qmed, PVR, QoL |
| Insausti 2020 [81] | Spain, 2014–17 | RCT | PAE (n=23) | TURP (n=22) | Prostate volume (SD): PAE: 60.0 cm ³ (21.6) TURP: 62.8 cm ³ (23.8) | Qmax, IPSS, QoL, prostate volume, PVR, IIEF-6, PSA, adverse events according to Clavien–Dindo classification, patient satisfaction, pain |
| Jahnsen 1998 [127] | Sweden, 1991 | RCT | TUIP (n=43) | TURP (n=42) | Prostate weight 20–40 g (mean: 26) | Qmax, PVR, blood loss, transfusion, catheterisation time, reinterventions |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|----------------------|---|------------|---|--|--|--|
| Jhanwar 2017 [128] | India, 2012–15 | RCT | HoLEP (n=72) | TURP (n=72) | Prostate weight >60 g (mean: 75) | IPSS, PVR, Qmax, blood transfusion, TUR syndrome, UTI, urinary incontinence, urethral stricture, recatheterisation, IIEF, hospitalisation time, catheterisation time |
| Jovanovic 2014 [129] | Serbia, 2011–13 | RCT | PVP (n=31) | TURP (n=31) | Prostate volume <100 ml (mean: 61) | IPSS, Qmax, PVR, operative time, catheterisation time, hospitalisation time, blood transfusion, capsule perforation, TUR syndrome, dysuria/urge, bladder neck contracture, urethral stricture, urinary incontinence |
| Karadag 2014 [130] | Turkey, 2008–12 | RCT | PKVP (n=96) (B-TUVP) | PKRP (n=87) (TURP) | Mean prostate volume: 51 ml | Qmax, PVR, IPSS, blood loss, catheterisation time, infravesical obstruction, incontinence, UTI |
| Kaya 2007 [131] | Turkey, 2001–13 | RCT | PKVP (n=25) (B-TUVP) | TURP (n=15) | Mean prostate volume (SD): PKVP: 50 ml (2) TURP: 51 ml (1) | IPSS, Qmax, urethral stricture, erectile dysfunction, retrograde ejaculation, overall satisfaction |
| Kini 2020 [132] | USA, 2016–18 | RCT | PVP (n=13) | BPVP (n=14) (B-TUVP) | Mean prostate volume ≤80 ml | Ejaculation preservation, erection preservation, IPSS, QoL, PVR, OAB-SF, free flow uroflowmetry, PSA |
| Kuntz 2004 [82] | n.r., 1999–2001 | RCT | HoLEP (n=100) | TURP (n=100) | Mean prostate volume (SD), range: HoLEP: 53.5 ml (20), 20–95 TURP: 49.9 ml (21.1), 20–99 | AUA symptom score (corresponding 7/8 to IPSS), Qmax, catheterisation time, post-operative hospitalisation time, operative time, decrease in serum sodium, PVR, sexual function, continence, intraoperative and postoperative complications |
| Li 2013 [133] | China, 2009–10 | RCT | TURP (n=61) | STURP + TUIBN (n=63) (TURP + TUIP) | Mean prostate volume (SD): TURP: 29.01 ml (4.96) STURP + TUIBN: 31.54 ml (6.93) | Operative time, intraoperative blood loss, hospitalisation time, changes in serum sodium, catheterisation time, TUR syndrome, perioperative complications, IPSS, Qmax, PVR, major adverse events (AUR, need for prostate biopsy, gross haematuria, acute UTI, urinary stricture, bladder contracture, prostate cancer, QoL |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|---------------------|---|------------|---|--|--|---|
| Li 2018 [134] | China, 2012–14 | RCT | B-TURP (n=44) (TURP) | M-TUERP (n=42) | Mean prostate volume (SD): B-TURP: 88.02 ml (9.38) M-TUERP: 87.5 ml (8.27) | PVR, QoL, IPSS, Qmax, change in serum sodium, change in haemoglobin, operative time, trocar cystostomy time, debris evacuation time, intraoperative intravesical pressure, catheterisation time, immediate or late post-operative complications, TUR syndrome, micturition parameters, duration of bladder irrigation, weight of resected tissue |
| Luo 2014 [135] | China, 2009–11 | RCT | PKEP (n=155) (B-TUEP) | PKRP (n=155) (TURP) | Mean prostate volume (SD): PKEP: 61.8 ml (18.7) PKRP: 61.7 ml (19) | IPSS, Qmax, QoL, PVR, TURS, UTIs, incontinence, recatheterisation, bladder neck contracture, urethral stricture, blood transfusion, hospitalisation time, catheterisation time, blood loss, operative time |
| Lusuardi 2011 [83] | Austria, 2010 | RCT | ELEP (n=30) (DioLEP) | B-TURP (n=30) (TURP) | Mean prostate volume (SD), range: ELEP: 59.5 ml (15.13), 34–89 B-TURP: 59.1 ml (14.2), 35–89 | Blood loss, operative time, catheterisation time, hospitalisation time, intraoperative irrigation, Qmax, IPSS, QoL, PVR |
| Mavuduru 2009 [136] | India, n.r. | RCT | HoLEP (n=15) | TURP (n=15) | Mean prostate weight (SD): HoLEP: 36.33 g (11.4) TURP: 36.53 g (12.33) | Operative time, intraoperative adverse events, blood transfusion, TUR syndrome, catheterisation time, complications after catheter removal, median time to discharge, IPSS, PVR, adverse events, urethral stricture |
| Montorsi 2004 [137] | Italy, 2002 | RCT | HoLEP (n=52) | TURP (n=48) | Mean prostate volume (SD): HoLEP: 70.3 ml (36.7) TURP: 56.2 ml (19.4) | Operative time, blood loss, catheterisation time, hospitalisation time, Qmax, Qmed, IPSS, QoL, IIEF, early and late adverse events |
| Neill 2006 [84] | New Zealand, 2001–03 | RCT | HoLEP (n=20) | PKEP (n=20) (B-TUEP) | Mean prostate volume (SD): HoLEP 57 cm ³ (5.1) PKEP 51 cm ³ (3.9) | Operative time, pathology specimen weight, energy requirement, amount of intraoperative and postoperative irrigant used, duration of indwelling catheter, time spent in the post-operative recovery room, hospitalisation time, adverse events, IPSS, sexual function, continence and dysuria, adverse events (only 12 months: bladder irrigation required, |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--------------------------------|---|------------|---|--|--|---|
| Neill 2006 [84] (continuation) | | | | | | UTI, urethral stricture, urinary incontinence, reoperation, transfusion), Qmax, urodynamic pressure flow, prostate volume |
| Netsch 2017 [138] | Germany, 2015–16 | RCT | ThuVEP (n=48) | HoLEP (n=46) | Median prostate volume (range): ThuVEP 82.5 ml (47.75–100.00) HoLEP 77.5 ml (45.75–110.25) | IPSS, QoL, Qmax, PVR, operative time, catheterisation time, hospitalisation time, complication rate |
| Nuhoglu 2011 [139] | Turkey, 2009–10 | RCT | B-TUVP (n=43) | TURP (n=47) | Mean prostate volume (SD): TUVP 51.7 ml (19.6) TURP 53.2 ml (21.4) | IPSS, PVR, Qmax, prostate volume, operative time, amount of bleeding, post-operative hyponatraemia, catheter retention time, blood transfusion, urethral stricture, recatheterisation, urinary retention, re-TURP, bladder neck incision, urethral stricture, reoperation, TUR syndrome, urinary incontinence |
| Radwan 2020 [140] | Egypt, 2016-2018 | RCT | PAE (n=20) | Total TURP (n=40) M-TURP (n=20) B-TURP (n=20) | Prostate volume (range): PAE: 31–95 g M-TURP: 25–99 g B-TURP: 30–99 g | IPSS, PVR, Qmed, AUR, catheter time, operative time, TUR syndrome. |
| Ran 2013 [141] | China, 2011 | RCT | PKEP (n=30) (B-TUEP) | PKRP (n=30) (TURP) | Mean prostate volume (SD): PKEP 71.6 ml (20.0) PKEP 67.2 ml (24.9) | Weight of resected prostate tissue, absorption of irrigation fluid, operative time, hospitalisation time, catheterisation time, intra-operative complications (capsular perforation, obturator nerve reflection, transfusion), reduction in haemoglobin, decrease in sodium, reduction in haematocrit, severe complications (TUR syndrome, myocardial arrhythmia) |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--|---|------------|---|--|--|---|
| Razzaghi 2014 [142] | Iran, 2010–12 | RCT | DioLVP (n=57) | TURP (n=58) | Mean prostate volume (SD): TURP 59.6 ml (14.1) DioLVP 61.1 ml (16.1) | IPSS, PVR, Qmax, prostate volume, PSA level, operative time, changes in haemoglobin, serum sodium, perioperative and post-operative complications, hospitalisation time, catheterisation time |
| Rezūm II study: McVary 2016a [48] McVary 2016b [91] McVary 2018 [52] McVary 2019 [49] Roehrborn 2017 [51] | USA, 2013-14 | RCT | WAVE (n=136) | Sham (n=61) | Mean prostate volume (SD): WAVE: 45.8 cm ³ (13) Sham: 44.5 cm ³ (13.3) | IPSS, QoL, Qmax, BPHII, IIEF-15 (erectile function), MSHQ-EjD (ejaculatory function) |
| Riehmman 1995 [143] | USA, 1985–90 | RCT | TURP (n=56) | TUIP (n=61) | n.r. | Obstructive and irritative symptom scores, Qmax |
| Samir 2019 [144] | Egypt, 2015–19 | RCT | B-TUERP (n=120) | B-TURP (n=120) (TURP) | Mean prostate volume (SD): B-TUERP 105.3 ml (20.26) B-TURP 112.7 ml (23.15) | Operative time, resected prostate tissue weight, catheterisation time, hospitalisation time, IPSS, QoL, residual prostate volume, Qmax, PVR, TUR syndrome, haemoglobin decrease, blood transfusion, urethral stricture, urinary incontinence |
| Shoji 2020 [145] | Japan, 2017–2019 | RCT | ThuLEP (n=70) | B-TURP (n=70) (TURP) | Median prostate size (range): ThuLEP 53 ml (40–143) B-TURP 53 ml (34–116) | IPSS, IPSS QoL, Qmax, PVR, IIEF-5, urinary incontinence, operative time, hospitalisation time, catheterisation time, UTI, capsule perforation, blood transfusion, recatheterisation, urethral stricture, bladder neck contracture, erectile dysfunction |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|-----------------------|---|------------|---|--|---|---|
| Skinner 2017 [146] | Canada, 2014–16 | RCT | DioLVP (n=25) | B-TUVP (n=30) | Mean prostate weight: DioLVP 46.6 g B-TUVP 47.8 g | IPSS, QoL, surgical team satisfaction, side effects and complications, costs |
| Sun 2014 [147] | China, 2010–11 | RCT | HoLEP (n=82) | TURP (n=82) | Mean prostate weight (SD) HoLEP 55.11 g (29.03) TURP 56.22 g (30.48) | Qmax, PVR, IPSS, QoL, operative time, bladder irrigation time, time of indwelling catheter, hospitalisation time, weight of resected prostate, haemoglobin level 1 day after surgery, blood sodium level 1 day after surgery, hyponatraemia, blood transfusion, urethral stricture |
| Swiniarski 2012 [148] | Poland, 2007–09 | RCT | ThuLEP (n=54) | TURP (n=52) | Mean prostate volume (SD): ThuLEP 62.03 cm ³ (23.7) TURP 66.5 cm ³ (22.0) | Laser use time, morcellation time, catheterisation time, hospitalisation time, energy used, haemoglobin loss, tissue weight removed, IPSS, QoL, Qmax, PVR, perioperative and postoperative complications |
| Tan 2003 [85] | New Zealand, 1997–2000 | RCT | HoLEP (n=31) | TURP (n=30) | Mean prostate volume: HoLEP 77.8 ml TURP 70.0 ml | Catheterisation time, hospitalisation time, blood transfusion, QoL, IPSS, Qmax, time that the resectoscope sheath was in place, time that the laser or electrocautery unit was in action, morcellation time in the HoLEP group, amount of tissue resected, total irrigation volume, continence and sexual function, PVR, adverse events, reoperation, recatheterisation, UTIs |
| Tefekli 2005 [149] | Turkey, 2001–02 | RCT | PKVP (n=51) (TUVRP) | TURP (n=50) | Mean prostate weight (SD): PKVP 50.1 g (17.3) TURP 54 g (15.2) | IPSS, uroflowmetry scores, operative time, catheterisation time, hospitalisation time, complications |
| Tkocz 2002 [150] | Poland, n.r. | RCT | TUIP (n=50) | TURP (n=50) | Prostate weight <30 g | Mean weight of the resected adenoma, mean weight of the incised adenoma, IPSS, QoL, daily and nocturnal micturition frequency, mean volume of a single urine portion, Qmax during free flowmetry and during pressure-flow study, PVR, urine retention, |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--|---|------------|---|--|--|--|
| Tkocz 2002 [150] (continuation) | | | | | | maximal cystometric capacity, detrusor pressure and detrusor pressure Qmax, compliance of the bladder, opening detrusor pressure, linearised passive urethral resistance relation, detrusor instability, transfusion, retrograde ejaculation, urine incontinence |
| Wagrell 2002 [151] | USA, Sweden Denmark, 1998–99 | RCT | TUMT (n=100) | TURP (n=46) | Mean prostate volume (SD): TUMT: 48.9 cm ³ (15.8) TURP: 52.7 cm ³ (17.3) | IPSS, Qmax, PVR, QoL, adverse events (serious adverse events defined separately), catheterisation time |
| Wang 2020 [152] | China, 2017–18 | RCT | PVEP (n=50) (B-VEP) | PKRP (n=51) (TURP) | Mean prostate volume (SD): PVEP: 119.51 ml (18.14) PKRP: 121.72 ml (18.78) | Qmax, IPSS, PVR, QoL, IIEF-5, erectile dysfunction, anejaculation |
| WATER study: Gilling 2018 [86] Gilling 2019a [87] Gilling 2019b [88] Gilling 2020 [90] | USA, UK, Australia, New Zealand, 2015–16 | RCT | Aquablation (n=116) | TURP (n=65) | Mean prostate volume (SD): Aquablation: 54.1 ml (16.2) TURP: 51.8 ml (13.8) | <i>Gilling 2018</i> : IPSS, adverse events, resection time, total operative time, hospitalisation time, reoperation or repeat intervention rate, proportion of sexually active subjects who reported worsening sexual function through 6 months on IIEF-5 (6-point decrease) or MSHQ-EjD (2-point decrease), serious device- or procedure-related adverse event <i>Gilling 2019a</i> : IPSS, QoL, Qmax, PVR, complications <i>Gilling 2019b</i> : Procedure-related complications occurring between months 12 and 24, IPSS, QoL, Qmax, MSHQ-EjD change and PVR at 24 months <i>Gilling 2020</i> : IPSS, IIEF, PVR, QoL, bladder neck contracture, dysuria, retrograde ejaculation, urethral stricture, urinary retention, UTI, urinary urgency, frequency, difficulty or leakage, dysuria, erectile dysfunction, reintervention |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--------------------|---|------------|---|--|--|--|
| Wu 2016 [153] | China, 2013–14 | RCT | DioLEP (n=40) | PKEP (n=40) (B-TUEP) | Mean prostate volume (SD): PKEP 93.3 ml (18.5) DioLEP 98.6 ml (21.6) | IIEF-5, perioperative or postoperative complications, IPSS, Qmax, PVR, QoL, operative time, resected prostate volume, catheterisation time, hospitalisation time, haemoglobin decrease |
| Xia 2008 [92] | China, 2004–05 | RCT | TmLRP (n=52) | TURP (n=48) | Prostate weight <100 g | IPSS, QoL, IIEF-5, PVR, Qmax, operative time, serum sodium decrease, catheterisation time, hospitalisation time, blood transfusion, TUR syndrome, UTI, recatheterisation, acute urinary incontinence, retrograde ejaculation, urethral stricture |
| Xu 2013 [154] | China, 2011 | RCT | PKERP (n=40) (B-TUERP) | DioLEP (n=40) | Mean prostate volume (SD): PKERP: 65.79 ml (24.63) DioLEP: 68.72 ml (22.28) | PVR, Qmax, IPSS, QoL, operative time, changes in serum sodium, blood transfusion, catheterisation time, hospitalisation time, mortality, TUR syndrome, bladder injury, transient incontinence, urethral stricture, irritative symptoms |
| Yan 2013 [155] | China, 2010–11 | RCT | TmLRP (n=40) | TURP (n=40) | Mean prostate volume (SD), range: TmLRP: 52.9 ml (12.3), 37–92 TURP: 54.3 ml (11.1), 39–90 | IPSS, Qmax, TUR syndrome, blood transfusion, recatheterisation, urinary incontinence, urethral stricture, retrograde ejaculation, reoperation, decrease in serum sodium, catheterisation time, operative time, mortality |
| Yang 2013 [156] | China, 2009–10 | RCT | ThuLEP (n=79) | PKRP (n=79) (TURP) | Prostate weight <100 g | IPSS, QoL, Qmax, PVR, blood transfusion, operative time, AUR, postoperative catheterisation time, hospitalisation time |
| Yee 2015 [93] | China, 2013 | RCT | TURiS-PVP (n=84) (TUVRP) | TURP (n=84) | Mean prostate volume (SD) TURiS-PVP: 57.2 ml (25.4) TURP: 66.1 ml (30.2) | IPSS, QoL, Qmax, PVR, operative time, catheterisation time, dysuria, hospitalisation time, TUR syndrome, blood transfusion |
| Yeni 2002 [157] | Turkey, n.r. | RCT | M-TURP + TUIP (n=20) (TURP + TUIP) | TURP (n=20) | Prostate volume ≤25 ml | IPSS, Qmax, operative time, length of hospital stay, bladder neck contracture, procedural blood loss and transfusion requirement, retrograde ejaculation, erectile dysfunction, TUR syndrome |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--------------------|---|------------|---|--|---|--|
| Yip 2011 [94] | China, n.r. | RCT | TURiS-PVP (n=46) (TUVRP) | B-TURP (n=40) (TURP) | Mean prostate volume (SD): TURiS-PVP: 61 cm ³ (23.8) B-TURP: 61.5 cm ³ (34.5) | IPSS, Qmax, catheter time, length of hospital stay, dysuria score, reintervention, blood transfusion |
| Zhang 2015 [158] | China, 2012–14 | RCT | PVEP (n=56) | PKRP (n=56) (TURP) | Prostate volume >90 ml | IPSS, QoL, Q max, PVR, operative time, serum sodium decrease, transfusion, catheterisation time, hospitalisation time, urinary incontinence and urethral stricture |
| Zhang 2019 [159] | China, 2016–17 | RCT | DioLEP (n=76) | PKRP (n=76) (TURP) | Prostate volume ≤80 ml | Qmax, PVR, IPSS, QoL, serum sodium decrease, operative time, catheterisation time, hospitalisation time, blood transfusion, TUR syndrome, urinary incontinence, capsular perforation, urethral stricture |
| Zhang 2020 [95] | China, 2016–2017 | RCT | HoLEP (n=58) | ThuLEP (n=58) | Mean prostate volume (SD): HoLEP 93.0 ml (7.2) ThuLEP 91.8 ml (6.9) | IPSS, QoL, Qmax, PVR, operative time, catheterisation time, hospitalisation time, urinary incontinence, urinary retention, bladder injury, UTI, urethral stricture, bladder-neck contracture, recatheterisation |
| Zhang F 2012 [160] | China, 2007–09 | RCT | ThuLEP (n=71) | HoLEP (n=62) | Prostate weight <80 g | IPSS, Qmax, PVR, bleeding, reoperation, urethral/bladder neck stricture, operative time, serum sodium decrease, postoperative catheterisation time |
| Zhang S 2012 [161] | China, 2009–12 | RCT | BPVP (n=15) (B-TUVP) | TURP (n=15) | Prostate volume 25–125 ml | IPSS, QoL, Qmax, catheterisation time, blood loss, hospitalisation time |
| Zhao 2010 [162] | China, 2004–06 | RCT | PKEP (n=102) (B-TUEP) | TURP (n=102) | Prostate weight >20 g | IPSS, QoL, IIEF-5, Qmax, PVR, sexual function, operative time, change in serum sodium, blood transfusion, TUR syndrome, UTI, transient incontinence, retrograde ejaculation, urethral stricture, bladder neck contracture, dysuria, catheterisation time, hospitalisation time, reintervention |

| Study reference/ID | Sites or regions, countries, study period | Study type | Intervention (number of randomised/enrolled patients) | Comparator(s) (number of randomised/enrolled patients) | Patient population (prostate size/volume) | Critical endpoints |
|--------------------|---|------------|---|--|--|---|
| Zhu 2013 [96] | China, 2004–06 | RCT | PKEP (n=40) (B-TUEP) | B-TURP (n=40) (TURP) | Prostate volume 70–200 ml | IPSS, Qmax, QoL, PVR, IIEF-5, operative time, catheterisation time, postoperative hospitalisation time, urinary retention, transient incontinence, UTI |
| Zou 2018 [97] | China, 2015 | RCT | DioLEP (n=57) | BEEP (n=57) (B-TUEP) | Prostate volume (SD) DioLEP: 59.5 ml (28.8) BEEP: 63.4 ml (36.4) | Operative time, enucleation time, morcellation time, enucleated prostate weight, decrease in haemoglobin, decrease in serum sodium, catheterisation time, hospitalisation time, Qmax, IPSS, PVR, IIEF-5, QoL, PSA, adverse events |

Abbreviations: AUA=American Urological Association; AUR=AUR; BPHI=Benign Prostatic Hyperplasia Impact Index; B-TUEP=bipolar transurethral enucleation of the prostate; B-TURP=bipolar transurethral resection of the prostate; B-TUERP=bipolar transurethral enucleoresection of the prostate; B-TUVP=bipolar transurethral vaporisation of the prostate; B-VEP=bipolar vapoenucleation of the prostate; BPVP=bipolar plasma vaporisation of the prostate; C-BPVP=continuous bipolar plasma vaporisation of the prostate; DioLEP=diode laser enucleation of the prostate; DioLVP=diode laser vaporisation of the prostate; ELEP=eraser laser enucleation of the prostate; HoLEP=holmium laser enucleation of the prostate; HRQoL=health-related quality of life; ICIQ-MLUTS=International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms module; IIEF=International Index of Erectile Function; IPSS=International Prostate Symptom Score; ISI=Incontinence Severity Index; LUTS=lower urinary tract symptoms; MSHQ-EjD=Male Sexual Health Questionnaire-Ejaculatory Dysfunction; M-TUERP=monopolar transurethral enucleoresection of the prostate; n=number of randomised (included) patients; n=relevant subpopulation; n.r.=not reported; OAB-SF=Overactive Bladder Questionnaire-Short Form; PAE=prostate artery embolisation; PKEP=plasmakinetic enucleation of the prostate; PKRP=plasmakinetic resection of the prostate; PSA=prostate-specific antigen; PVEP=photoselective vapoenucleation of the prostate; PVP=photoselective vaporisation of the prostate; PVR=postvoid residual; Qmax= peak/maximum flow rate; Qmed=average flow rate; QoL=quality of life; RCT=randomised controlled trial; S-BPVP=standard bipolar plasma vaporisation of the prostate; SD=standard deviation; STURP=selective transurethral resection of the prostate; ThuLEP=thulium laser enucleation of the prostate; TmLRP=thulium laser resection of the prostate; TUIP=transurethral incision of the prostate; TUMT=transurethral microwave therapy; TURP=transurethral resection of the prostate; TUR syndrome=transurethral resection syndrome; ThuVAP=thulium laser vaporisation of the prostate; ThuVARP=thulium laser vaporesection of the prostate; ThuVEP=thulium laser vapoenucleation of the prostate; TUIBN=transurethral incision of the bladder neck; TURiS=transurethral resection in saline; TUVRP=transurethral vaporesection of the prostate; TUViS=transurethral vaporisation in saline; UTI=urinary tract infection.

Table 4-4: Summary of the applicability of the body of studies

| Domain | Description of the applicability of the evidence |
|--------------|---|
| Population | Patient candidates for benign prostatic hyperplasia (BPH) surgery were included, with prostate size ranging from <20 ml to >150 ml. Few technologies were studied in relatively homogeneous patient populations in terms of prostate size. Most of the studies included patients with a wide prostate size range, precluding the possibility of performing subgroup analyses. |
| Intervention | Twenty-one technologies as an alternative to transurethral resection of the prostate (TURP) and open prostatectomy, using either ablative or nonablative methodologies. |
| Comparators | TURP, representing the standard of care for BPH surgery up to now, and open prostatectomy in the case of large prostates. |
| Outcomes | Functional outcomes were assessed in almost all randomised controlled trials (RCTs) at different/repeated follow-up times, ranging from 1 week to 48 months after surgery. Limited information on minimal clinically important differences may limit the relevance of related data for decision-making. Reintervention was assessed in a few studies, as well as irritative symptoms. Most studies reported data on hospitalisation and operative time. Data on different perioperative and postoperative complications were also available in most of the studies. Outcomes related to sexual function were available in some of the trials, whereas data on TUR syndrome were available in few studies. |
| Setting | The selected RCTs were conducted in centres in different countries and geographic areas, mostly in Europe, China and North America. |

Comparative effectiveness of surgical techniques and devices for the treatment of BPH

| | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias | | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias | | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|------------------|---|---|---|---|--|--------------------------------------|------------|---------------|---|---|---|---|--|--------------------------------------|------------|----------------|---|---|---|---|--|--------------------------------------|------------|
| Abd-El Kader2012 | ? | ? | ? | ? | ? | ? | ? | Gilling2019 | + | ? | ? | + | + | + | ? | Riehm1995 | ? | ? | ? | ? | ? | ? | ? |
| Abt 2018 | + | + | + | + | + | + | + | Gilling2019b | + | ? | ? | + | + | + | + | Samir2019 | ? | + | ? | ? | ? | ? | + |
| Bachmann2014 | + | + | + | ? | + | + | + | Gilling2020 | + | ? | ? | + | ? | + | + | Shoji2020 | + | ? | ? | ? | ? | ? | + |
| Bachmann2015 | + | + | + | ? | ? | ? | + | Gratzk2017 | + | + | + | ? | + | + | + | Skinner2017 | + | ? | ? | ? | ? | ? | + |
| Bai2019 | + | ? | ? | ? | ? | ? | + | Gupta2006 | ? | ? | ? | ? | ? | ? | ? | Sun2014 | ? | ? | ? | ? | ? | ? | + |
| Basic 2013 | ? | ? | ? | ? | + | ? | + | Habib2020 | ? | + | ? | ? | + | + | + | Swiniarski2012 | + | ? | ? | ? | ? | ? | + |
| Bozzini2017 | ? | ? | ? | ? | ? | ? | + | Hamouda2014 | ? | ? | ? | ? | + | ? | ? | Tan2003 | + | ? | ? | ? | ? | ? | + |
| Bozzini2020 | + | + | + | + | + | + | + | Hashim2020 | + | ? | ? | ? | + | + | + | Tefekly2005 | ? | ? | ? | ? | + | ? | ? |
| Carnevale2016 | ? | ? | ? | ? | ? | ? | + | He2019 | + | ? | ? | ? | + | + | + | Thomas2016 | + | + | + | ? | ? | ? | + |
| Cetinkaya2015 | + | + | + | ? | + | ? | ? | Higazy2020 | ? | + | + | + | + | + | + | Tkocz2002 | ? | ? | ? | ? | ? | ? | ? |
| Chang 2015 | ? | ? | + | + | + | + | + | Hon2006 | + | + | ? | ? | ? | ? | ? | Wagrell2002 | ? | ? | ? | ? | ? | ? | + |
| Chen2013 | + | + | ? | ? | ? | ? | + | Insausti2020 | + | ? | + | ? | + | + | + | Wang2020 | ? | ? | ? | ? | + | ? | ? |
| D'Ancona1998 | ? | ? | ? | ? | + | ? | ? | Jahson1998 | ? | ? | ? | ? | + | + | + | Wu2016 | + | + | ? | ? | ? | ? | + |
| Dahlstrand1995 | ? | ? | ? | ? | ? | ? | ? | Jhanwar2016 | ? | ? | ? | ? | ? | ? | ? | Xia2008 | ? | ? | ? | ? | + | ? | + |
| Dunsmuir2003 | + | ? | + | ? | + | + | ? | Jovanovic2014 | ? | ? | ? | ? | ? | ? | ? | Xu2013 | ? | ? | ? | ? | + | ? | + |
| Darflinger1992 | ? | ? | ? | ? | + | ? | ? | Karadag2014 | ? | ? | ? | ? | ? | ? | ? | Yan2013 | ? | ? | ? | ? | + | ? | + |
| Elsakka2016 | ? | ? | ? | ? | + | ? | ? | Kaya2007 | + | + | ? | ? | + | + | ? | Yang2013 | ? | ? | ? | ? | + | ? | + |
| Eishal2015 | + | ? | ? | ? | + | ? | + | Kini2020 | + | + | ? | ? | + | + | + | Yee2015 | + | ? | ? | ? | + | ? | + |
| Eishal2020 | + | + | ? | ? | ? | ? | + | Kuntz2004 | + | ? | ? | ? | + | + | + | Yeni2002 | ? | ? | ? | ? | ? | ? | ? |
| Eltabey2010 | + | ? | ? | ? | ? | ? | ? | Li2013 | ? | ? | ? | + | + | + | ? | Yip2011 | + | ? | ? | ? | + | + | + |
| Enikeev2019 | ? | + | ? | ? | ? | ? | ? | Luo2014 | ? | ? | ? | ? | ? | ? | ? | Zhang+F2012 | + | ? | ? | ? | + | ? | ? |
| Fayad2015 | + | + | ? | ? | ? | ? | + | Lusuardi2011 | + | ? | ? | ? | ? | ? | ? | Zhang+S2012 | + | + | ? | ? | + | ? | ? |
| Floratos2001 | ? | ? | ? | ? | ? | ? | + | Mavuduru2009 | + | + | ? | ? | ? | ? | ? | Zhang2015 | + | ? | ? | ? | + | ? | + |
| Gao2014 | + | ? | ? | ? | ? | ? | + | Montorsi2004 | ? | ? | ? | ? | + | + | ? | Zhang2019 | + | + | ? | ? | + | ? | + |
| Geavlete2010 | + | + | + | ? | ? | ? | + | Neill2006 | ? | ? | + | + | ? | ? | + | Zhang2020 | + | ? | ? | ? | + | ? | + |
| Geavlete2011 | ? | + | + | ? | ? | ? | + | Netsch2017 | + | ? | ? | ? | ? | ? | ? | Zhao2010 | + | + | ? | ? | + | + | + |
| Geavlete2014 | ? | + | ? | ? | ? | ? | + | Nuhoglu2011 | ? | ? | ? | ? | ? | ? | ? | Zhu2013 | + | + | ? | ? | + | ? | ? |
| Geavlete2015 | ? | + | ? | ? | ? | ? | + | Radwan2020 | + | + | ? | ? | ? | ? | ? | Zou2018 | + | + | ? | ? | ? | ? | + |
| Ghobrial2020 | + | ? | ? | ? | ? | ? | + | Ran2013 | ? | ? | ? | ? | ? | ? | ? | | | | | | | | |
| Gilling2018 | + | ? | ? | + | + | + | + | Razzaghi2014 | + | ? | ? | ? | ? | ? | ? | | | | | | | | |

Figure 4-2: Risk of bias in the studies included in the assessment.

4.4 Results for clinical effectiveness and safety

4.4.1 Clinical effectiveness

HTA CORE MODEL DOMAIN: EFF⁵

4.4.1.1 Resection techniques

TmLRP

TmLRP was assessed in two of the RCTs, with comparison to TURP (n=180).

TmLRP versus TURP

Two RCTs (Xia 2008, n=100; Yan 2013, n=80) compared TmLRP versus TURP for the outcomes listed in [Table 4-5](#). No data were available for Qmed, BPHII, irritative symptoms or postoperative LUTS (as a binary outcome).

Table 4-5: Effectiveness outcomes assessed in RCTs comparing TmLRP versus TURP

| Study ID | Xia 2008 | Yan 2013 |
|----------------------|----------|----------|
| IPSS at 1 month | x | |
| IPSS at 3 months | | x |
| IPSS at 6 months | x | |
| IPSS at 12 months | x | |
| Qmax at 1 month | x | |
| Qmax at 3 months | | x |
| Qmax at 6 months | x | |
| Qmax at 12 months | x | |
| PVR at 1 month | x | |
| PVR at 6 months | x | |
| PVR at 12 months | x | |
| QoL at 1 month | x | |
| QoL at 6 months | x | |
| QoL at 12 months | x | |
| Hospitalisation time | x | |
| Procedure time | x | x |
| Reintervention total | | x |

Patients included in the studies had a prostate size between 30 and 97 ml, mostly falling within the 30–80 ml subgroup.


⁵ This section addresses the following assessment elements: D0005, D0011, D0012 and D0013

Pooling of data was not possible for any of the available outcomes. Operative time is in favour of TmLRP in Xia 2008 and in favour of TURP in Yan 2013.

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Procedure time (min)



In Xia 2008 a shorter hospital stay was observed for TmLRP (115.1 vs. 161.1 h; $p < 0.001$, 95% CI not available, uncertain RoB).

4.4.1.2 Enucleation techniques

HoLEP

HoLEP was assessed in 23 of the RCTs, including a total of 2701 patients. Twenty-two were two-arm studies and one (Eishal 2020) was a three-arm RCT. Fourteen studies compared HoLEP versus TURP (n=1549), three compared HoLEP versus ThuLEP (n=485) and HoLEP versus B-TUEP (n=224), two compared HoLEP versus PVP (n=223), and one compared HoLEP versus DioLEP (n=126) and ThuVEP (n=94).

HoLEP versus TURP

Fourteen RCTs compared HoLEP versus TURP, providing data on the outcomes indicated in Table 4-6. No data were available for BPHII or postoperative LUTS (as a binary outcome).

Table 4-6: Effectiveness outcomes assessed in RCTs comparing HoLEP versus TURP

| Study ID | Sun 2014 | Tan 2003 | Bai 2019 | Basic 2013 | Chen 2013 | Eltabey 2010 | Fayad 2015 | Hamouda 2014 | Jhanwar 2017 | Gupta 2006 | Kuntz 2004 | Mavuduru 2009 | Montorsi 2004 | Eishal 2020 ^a |
|-------------------|----------|----------|----------|------------|-----------|--------------|------------|--------------|--------------|------------|------------|---------------|---------------|--------------------------|
| IPSS at 1 month | x | x | | x | x | x | x | x | x | | x | | x | x |
| IPSS at 3 months | | x | | x | | | | x | x | | | x | | x |
| IPSS at 6 months | | x | | x | x | x | | x | x | x | x | | x | |
| IPSS at 12 months | x | x | | x | x | x | x | x | x | x | x | | x | x |
| IPSS at 24 months | | | | | x | | | | x | | | | | x |
| IPSS at 36 months | | | | | | | | | | | | | | x |
| Qmax at 1 month | x | x | | | x | x | x | x | x | | x | | x | x |

| Study ID | Sun 2014 | Tan 2003 | Bai 2019 | Basic 2013 | Chen 2013 | Eltabey 2010 | Fayad 2015 | Hamouda 2014 | Jhanwar 2017 | Gupta 2006 | Kuntz 2004 | Mavuduru 2009 | Montorsi 2004 | Elishal 2020 ^a |
|--------------------------------|----------|----------|----------|------------|-----------|--------------|------------|--------------|--------------|------------|------------|---------------|---------------|---------------------------|
| Qmax at 3 months | | x | | | | | | x | x | | | x | | x |
| Qmax at 6 months | | x | | | x | x | | x | x | x | x | | x | |
| Qmax at 12 months | x | x | | | x | x | x | x | x | x | x | | x | x |
| Qmax at 24 months | | | | | x | | | | x | | | | | x |
| Qmax at 36 months | | | | | | | | | | | | | | x |
| PVR at 1 month | x | | | x | | x | | x | x | | x | | | x |
| PVR at 3 months | | | | x | | | | x | x | | | x | | x |
| PVR at 6 months | | x | | x | x | x | | x | x | x | x | | | |
| PVR at 12 months | x | | | x | | x | | x | x | x | x | | | x |
| PVR at 24 months | | | | | | | | | x | | | | | x |
| PVR at 36 months | | | | | | | | | | | | | | x |
| Reintervention total | | x | | x | | | | | | | x | | x | x |
| QoL at 1 month | x | x | | x | x | | | | | | | | x | x |
| QoL at 3 months | | x | | x | | | | | | | | | | x |
| QoL at 6 months | | x | | x | x | | | | | | | | x | |
| QoL at 12 months | x | x | | x | x | | | | | | | | x | x |
| QoL at 24 months | | | | | x | | | | | | | | | x |
| QoL at 36 months | | | | | | | | | | | | | | x |
| Qmed at 1 month | | | | | | | | | | | | | x | |
| Qmed at 6 months | | | | | | | | | | | | | x | |
| Qmed at 12 months | | | | | | | | | | | | | x | |
| Persistent irritative symptoms | | | | x | | x | | x | | x | | | | x |
| Postoperative LUTS | | | | | | | | | | | | | | x |
| Hospitalisation time | x | x | x | x | x | x | | x | x | | x | | x | x ^b |
| Procedure time | x | | x | x | x | x | | x | x | x | x | x | x | x |

^a Data for IPSS, Qmax, QoL and PVR were extrapolated from graphs.

^b Data were estimated according to McGrath et al. [63].

The patient cohorts in the studies were heterogeneous in terms of prostate size category. Average size was available in 13 of 14 the studies, whereas information on the range was available in only five studies (range from 20 to 156 ml). Prostate size was used as an inclusion criterion in only six studies. For our prespecified prostate size subgroups, none of the studies included patients that could be assigned exclusively to one of these. All but three studies included patients with prostate size in the range 30–80 ml.

Pooling of data was possible for IPSS, Qmax and PVR (at 1, 3, 6, 12 and 24 months), QoL (1, 3, 6 and 12 months), reintervention, persistent irritative symptoms, hospitalisation time and procedure time. Data from Basic 2013 were excluded from the analyses since this study appears to be an outlier in all the analyses and the patient cohort had a smaller prostate size and was younger than

in most of the other studies. Exclusion of this study helped to somewhat reduce the heterogeneity, although substantial heterogeneity remained in some analyses.


Differences in favour of HoLEP were found for IPSS at 1 month (mean -0.52, 95% CI -0.91 to -0.13; $I^2=49%$, high RoB); Qmax at 12 months (mean 0.63 ml/s, 95% CI 0.07-1.20; $I^2=28%$, high RoB) and 24 months (mean 0.92 ml/s, 95% CI 0.19-1.66; $I^2=63%$, uncertain RoB); PVR at 6 months (mean -4.98 ml, 95% CI -9.34 to -0.63; $I^2=83%$, uncertain RoB) and 12 months (mean -7.56 ml, 95% CI -14.30 to -0.81; $I^2=86%$, uncertain RoB); QoL at 12 months (mean -0.21, 95% CI -0.33 to -0.10; $I^2=74%$, uncertain RoB); and reintervention (RR 0.46, 95% CI 0.23-0.94; $I^2=64%$, high RoB). Hospitalisation time was shorter in all but one study (up to 2 days less), whereas procedure time was shorter for TURP in almost all studies (up to 26 min less). Pooled differences in favour of HoLEP for IPSS and Qmax (as well as their CIs) were below the MCID reported in the scientific literature. Pooled results do not show differences for persistent irritative symptoms. Subgroup analyses by age and baseline IPSS did not substantially reduce heterogeneity, whereas subgroup analyses by prostate size showed that response in larger prostates was more homogeneous. The quality of the evidence for all these outcomes was judged as low to very low because of indirectness, inconsistency and RoB.

No data were available for BPHII or postoperative LUTS (as a binary outcome). Qmed was assessed in one RCT, which showed differences in favour of HoLEP at 1 month (13.3 vs. 10.1 ml/s; $p=0.02$, 95% CI not available), 6 months (13.3 vs. 9.1 ml/s; $p=0.01$, 95% CI not available) and 12 months (15.5 vs. 12.1 ml/s; $p=0.01$, 95% CI not available). Postoperative LUTS were assessed in one RCT, which showed lower incidence with HoLEP (3.3%) than with TURP (17.7%; $p=0.01$, 95% CI not available). All these differences were judged to be associated with uncertain RoB.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 6 months




Notes: SD values for Gupta 2006 were estimated using the mean of SDs from Chen 2013, Eltabey 2010, Homouda 2014 and Kuntz2004, which are the studies with the most similar prostate size. Lower IPSS values are better.

IPSS at 12 months




Notes: SD values for Gupta 2006 were estimated using the mean of SDs from Chen 2013, Eltabey 2010, Homouda 2014 and Kuntz2004 which are the studies with the most similar prostate size. Lower IPSS values are better.

IPSS at 12 months with subgroups by prostate size




Note: lower IPSS scores are better.

IPSS at 24 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Notes: SD values for Gupta 2006 were estimated using the mean of SDs from Chen 2013, Eltabey 2010, Homouda 2014 and Kuntz 2004, which are the studies with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 12 months




Notes: SD values for Gupta 2006 were estimated using the mean of SDs from Chen 2013, Eltabey 2010, Homouda 2014 and Kuntz 2004, which are the studies with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 12 months with subgroups by prostate size




Notes: SD values for Gupta 2006 were estimated using the mean of SDs from Chen 2013, Eltabey 2010, Homouda 2014 and Kuntz 2004, which are the studies with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 24 months




Note: higher Qmax values are better.

PVR (ml) at 1 month




Note: lower PVR values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

PVR (ml) at 24 months




Note: lower PVR values are better.

QoL at 1 month




Note: lower QoL scores are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

QoL at 12 months




Note: lower QoL scores are better.


Reintervention




Persistent irritative symptoms



Hospitalisation time (days)



Procedure time (min)



HoLEP versus B-TUEP

Three RCTs (Neill 2006, n=40; Habib 2020, n=64; Higazy 2020, n=120) compared HoLEP versus B-TUEP. Patients included in Habib 2020 and Higazy 2020 had a prostate size >80 ml and can be classified in the large prostate subgroup, whereas patients in Neill 2006 were mostly in the 30–80 ml subgroup. These three studies provided data for the outcomes indicated in Table 4-7. No data were available for Qmed, BPHII or postoperative LUTS (as a binary outcome).

Table 4-7: Effectiveness outcomes assessed in RCTs comparing HoLEP versus B-TUEP

| Study ID | Neill 2006 | Habib 2020 ^a | Higazy 2020 |
|-------------------|------------|-------------------------|-------------|
| IPSS at 1 month | x | | x |
| IPSS at 3 months | x | | x |
| IPSS at 6 months | x | | |
| IPSS at 12 months | x | x | x |
| Qmax at 1 month | x | | x |
| Qmax at 3 months | x | | x |
| Qmax at 6 months | x | | |
| Qmax at 12 months | x | x | x |
| PVR at 1 month | | | x |
| PVR at 3 months | | | x |
| PVR at 6 months | x | | |
| PVR at 12 months | | x | x |

| Study ID | Neill 2006 | Habib 2020 ^a | Higazy 2020 |
|--------------------------------|------------|-------------------------|-------------|
| QoL at 12 months | | x | x |
| Reintervention | x | | |
| Procedure time | x | x | x |
| Hospitalisation time | x | x | x |
| Persistent irritative symptoms | | x | |


^a Only data on IPSS could be estimated according to the Cochrane Handbook method.

Pooling of data was possible for IPSS and Qmax at 1, 3 and 12 months and PVR at 12 months. Regarding functional outcomes, sensitivity analyses were performed with exclusion of Neill 2006 owing to its large SD and high RoB; the direction of the effect and the statistical significance did not change in these analyses. In particular, a difference in favour of B-TUEP was shown for Qmax at 1 month (1.5 ml/s, 95% CI 0.8–2.3; I²=26%, high RoB) and at 12 months (0.72 ml/s, 95% CI 0.06–1.38; I²=0%, high RoB); the quality of the evidence was judged as low because of indirectness and inconsistency. A shorter procedure time was observed for HoLEP in all three studies (up to 22 min less).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

Hospitalisation time (days)



Procedure time (min)



HoLEP versus DioLEP

One RCT (He 2019, n=126; low RoB) compared HoLEP versus DioLEP among patients with an average prostate size of 79.3 ml for the outcomes Qmax, PVR, IPSS and QoL at 3, 6 and 12 months, operative time and hospital stay. No differences between the groups were observed for any of these outcomes.

HoLEP versus ThuLEP

Three RCTs (Zhang F 2012, n=133; uncertain RoB; Bozzini 2020, n=236; high RoB; Zhang 2020, n=116; uncertain RoB) compared HoLEP versus ThuLEP for the outcomes presented in [Table 4-8](#).

Table 4-8: Effectiveness outcomes assessed in RCTs comparing HoLEP versus ThuLEP

| Study ID | Bozzini 2020 | Zhang F 2012 ^a | Zhang 2020 ^b |
|--------------------------------|--------------|---------------------------|-------------------------|
| IPSS at 1 month | | x | x |
| IPSS at 3 months | x | | x |
| IPSS at 6 months | | x | x |
| IPSS at 12 months | | x | x |
| IPSS at 18 months | | x | x |
| Qmax at 1 month | | x | x |
| Qmax at 3 months | x | | x |
| Qmax at 6 months | | x | x |
| Qmax at 12 months | | x | x |
| Qmax at 18 months | | x | x |
| PVR at 1 month | | x | x |
| PVR at 3 months | x | | x |
| PVR at 6 months | | x | x |
| PVR at 12 months | | x | x |
| PVR at 18 months | | x | x |
| QoL at 1 month | | x | x |
| QoL at 3 months | x | | x |
| QoL at 6 months | | x | x |
| QoL at 12 months | | x | x |
| QoL at 18 months | | x | x |
| Persistent irritative symptoms | | x | |
| Hospitalisation time | | x | x |
| Procedure time | x | x | x |

^a Data for IPSS, Qmax, QoL and PVR were extrapolated from graphs.

^b Data for IPSS, PVR, QoL and hospitalisation time were estimated according to the Cochrane Handbook method.

Patients included in these studies were heterogeneous in terms of prostate size category. In particular, in Zhang F 2012 the mean size was 45 ml, whereas in Bozzini 2020 and Zhang 2020 the mean size was 88 and 92 ml, respectively. Pooling of data was avoided in light of such population heterogeneity when statistical heterogeneity was also apparent.


Pooled analyses were possible for IPSS at 3 and 12 months, Qmax at 1 and 18 months, PVR at 1, 3, 6 and 18 months and QoL at 6 and 12 months.

Differences in favour of ThuLEP were found for IPSS at 3 months (mean 0.96, 95% CI 0.53–1.39; $I^2=0\%$, high RoB); PVR at 1 month (mean 3.86 ml, 95% CI 1.19–6.52; $I^2=3\%$, high RoB); and QoL at 6 months (mean 0.09, 95% CI 0.01–0.17; $I^2=0\%$, high RoB). Hospitalisation time was shorter in all but one study (up to 2 days less), whereas procedure time was shorter for TURP in almost all studies (up to 26 min less). The quality of the evidence for all these outcomes was judged as low to very low because of indirectness, inconsistency and RoB. No data were available for BPHII or postoperative LUTS (as a binary outcome). Qmed was assessed in one RCT, which showed differences in favour of HoLEP at 1 month (13.3 vs. 10.1 ml/s; $p=0.02$, 95% CI not available), 6 months (13.3 vs. 9.1 ml/s; $p=0.01$, 95% CI not available) and 12 months (15.5 vs. 12.1 ml/s; $p=0.01$, 95% CI not available). Postoperative LUTS were assessed in one RCT, which showed lower incidence with HoLEP (3.3%) than with TURP (17.7%; $p=0.01$, 95% CI not available).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 6 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

IPSS at 12 months in a sensitivity analysis without Zhang F 2012




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

Qmax (ml/s) at 18 months




Note: higher Qmax values are better.

PVR (ml) at 1 month




Note: lower PVR values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

PVR (ml) at 18 months




Note: lower PVR values are better.

QoL at 1 month




Note: lower QoL scores are better.

QoL 3 months




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

QoL at 12 months



Note: lower QoL scores are better.

QoL at 18 months



Note: lower QoL scores are better.

| Study ID | Elshal 2015 ^a | Elshal 2020 ^a |
|--------------------------------|--------------------------|--------------------------|
| QoL at 12 months | x | x |
| QoL at 24 months | | x |
| QoL at 36 months | | x |
| Reintervention total | | x |
| Persistent irritative symptoms | x | x |
| Postoperative LUTS | | x |
| Hospitalisation time | x | x ^b |
| Procedure time | x | x |

^a Data for IPSS, Qmax, QoL and PVR were extrapolated from graphs.


^b Data were estimated according to McGrath et al. [63].

Pooling of data was possible for IPSS, Qmax, PVR and QoL at 1, 3, and 12 months, for reintervention and for persistent irritative symptoms. Differences in favour of HoLEP were observed for IPSS at 3 months (mean -3.05, 95% CI -4.96 to -1.14; I²=50%, uncertain RoB) and 12 months (mean -2.61, 95% CI -3.94 to -1.28; I²=46%, uncertain RoB); Qmax at 3 months (mean 5.51, 95% CI 1.93-9.08; I²=0%, uncertain RoB) and 12 months (mean 11.77, 95% CI 8.39-15.16; I²=93%, uncertain RoB); PVR at 1 month (mean -14.96, 95% CI -25.41 to -4.51; I²=0%, uncertain RoB) and 12 months (mean -13.78, 95% CI -24.39 to -3.17; I²=19%, uncertain RoB); and reintervention (RR 0.26, 95% CI 0.10-0.67; I²=37%, uncertain RoB). A difference in favour of PVP was observed for QoL at 1 month (mean 0.50, 95% CI 0.10-0.90; I²=0%, uncertain RoB). The quality of the evidence was considered moderate to low for functional outcomes (owing to imprecision, and inconsistency when I²>40%) and moderate for reintervention (owing to inconsistency). These differences are higher than the 2 ml/s MCID threshold for Qmax and around the MCID for IPSS.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.


Reintervention




Persistent irritative symptoms



Hospitalisation time (days)



Procedure time (min)



ThuLEP

ThuLEP was assessed in nine of the RCTs, including a total of 1327 patients: five RCTs versus TURP (n=715), three RCTs versus HoLEP (n=485) and one RCT versus B-TUEP (n=127).

ThuLEP versus TURP

Five RCTs (Bozzini 2017, n=208; Yang 2013, n=158, Enikeev 2019, n=103; Swiniarski 2012, n=106; Shoji 2020, n=140), all with uncertain RoB, compared ThuLEP versus TURP. One study (Yang 2013) included patients with prostate volume <100 ml. The other four studies (Bozzini 2017, Swiniarski 2012, Enikeev 2019 and Shoji 2020) included patients on the basis of other inclusion criteria and regardless of prostate size. Consequently, mean/median prostate size differed between the studies (from 53 to 89.3 ml for ThuLEP and from 53 to 81.9 ml for TURP). Three studies reported prostate volume ranges that overall comprised prostates from 28 to 149 ml. Outcomes assessed in these studies are indicated in Table 4-10. There were no data for BPHII or reintervention.

Table 4-10: Effectiveness outcomes assessed in RCTs comparing ThuLEP versus TURP

| Study ID | Bozzini 2017 | Enikeev 2019 | Swiniarski 2012 | Yang 2013 | Shoji 2020 ^a |
|--------------------------------|--------------|--------------|-----------------|-----------|-------------------------|
| IPSS at 1 month | | | x | x | x |
| IPSS at 3 months | x | | x | x | x |
| IPSS at 6 months | | x | | x | x |
| IPSS at 12 months | | x | | x | x |
| IPSS at 18 months | | | | x | |
| Qmax at 1 month | | | x | x | x |
| Qmax at 3 months | x | | x | x | x |
| Qmax at 6 months | | x | | x | x |
| Qmax at 12 months | | x | | x | x |
| Qmax at 18 months | | | | x | |
| PVR at 1 month | | | x | x | |
| PVR at 3 months | x | | x | x | |
| PVR at 6 months | | x | | x | |
| PVR at 12 months | | x | | x | |
| PVR at 18 months | | | | x | |
| QoL at 1 month | | | x | x | x |
| QoL at 3 months | x | | x | x | x |
| QoL at 6 months | | x | | x | x |
| QoL at 12 months | | x | | x | x |
| QoL at 18 months | | | | x | |
| Persistent irritative symptoms | x | | x | | |
| Hospitalisation time | x | x | x | x | x ^b |
| Procedure time | x | x | x | x | x ^b |

^a Data for IPSS, Qmax and QoL were extrapolated from graphs.

^b Data estimated according to McGrath et al. [63].

Pooling of data was possible for IPSS, Qmax, PVR and QoL at 1, 3, 6 and 12 months, intervention, persistent irritative symptoms, procedure time and hospitalisation time. Differences in favour of ThuLEP were observed for IPSS at 1 month (mean -0.58, 95% CI -1.00 to -0.17; $I^2=68%$, uncertain RoB) and 6 months (mean -0.72, 95% CI -1.14 to -0.29; $I^2=0%$, uncertain RoB). PVR at 3 months was in favour of ThuLEP, although high heterogeneity observed in this analysis could be explained by Bozzini 2017 (higher prostate size than other studies) and exclusion of this study led to loss of statistical significance. Heterogeneity is not easy to explain for IPSS at 1 month. Hospitalisation time was shorter for ThuLEP in three of the four studies, with great heterogeneity of results. Differences in favour of TURP were observed for QoL at 1 month (mean 0.10, 95% CI 0.04-0.16; $I^2=0%$, uncertain RoB). Procedure time was shorter for TURP in three of the four studies, with great heterogeneity of results. The quality of the evidence for these outcomes was judged to be low for IPSS at 1 month and for QoL at 1 month because of inconsistency and imprecision (small sample size).


For the other outcomes, no significant differences were observed. It should be noted that Swiniarski 2012 considered only patients without an indwelling catheter for calculation of Qmax and PVR values.

Yang 2013 also reported results for IPSS, Qmax, PVR and QoL at 18 months for ThuLEP versus TURP, with no significant differences between the groups. Owing to the different scale used to calculate QoL, data from Bozzini 2017 could not be pooled; however, no significant difference was found for this outcome at 3 months.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better,

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 6 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

PVR (ml) at 1 month




Note: lower PVR values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 3 months in a sensitivity analysis excluding Bozzini 2017




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

QoL at 1 month




Note: lower QoL scores are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 3 months in a sensitivity analysis excluding Bozzini 2017




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

QoL at 12 months




Note: lower QoL scores are better.


Persistent irritative symptoms



Hospitalisation time (days)



Procedure time (min)



ThuLEP versus B-TUEP

See the section on B-TUEP.

ThuLEP versus HoLEP

See the section on HoLEP.

DioLEP

DioLEP was assessed in six of the RCTs, including a total of 612 patients: two RCTs versus TURP (212 patients), two RCTs versus B-TUEP (n=194) and one RCT versus each of HoLEP (n=126) and B-ERP (n=80).

DioLEP versus TURP

Two RCTs (Lusuardi 2011, n=60; uncertain RoB; Zhang 2019, n=152; low RoB) compared DioLEP versus TURP. Outcomes assessed in these studies are indicated in Table 4-11. There were no data for BPHII or reintervention.

Table 4-11: Effectiveness outcomes assessed in RCTs comparing DioLEP versus TURP

| Study ID | Lusuardi 2011 | Zhang 2019 |
|-------------------|---------------|------------|
| IPSS at 1 month | x | |
| IPSS at 3 months | | x |
| IPSS at 6 months | x | x |
| IPSS at 12 months | | x |
| Qmax at 1 month | x | |
| Qmax at 3 months | | x |
| Qmax at 6 months | x | x |
| Qmax at 12 months | | x |


| Study ID | Lusuardi 2011 | Zhang 2019 |
|--------------------------------|---------------|------------|
| PVR at 1 month | x | |
| PVR at 3 months | | x |
| PVR at 6 months | x | x |
| PVR at 12 months | | x |
| QoL at 1 month | x | |
| QoL at 3 months | | x |
| QoL at 6 months | x | x |
| QoL at 12 months | | x |
| Hospitalisation time | x | x |
| Procedure time | x | x |
| Persistent irritative symptoms | x | |

The patient cohorts in both studies had similar prostate volume ranges (32–80 ml and 34–89 ml in the DioLEP arms, and 34–80 ml and 35–89 ml in the TURP arms). Pooling of data was possible for IPSS, Qmax PVR and QoL at 6 months. No differences were observed for these outcomes. Hospitalisation time was in favour of DioLEP, although the mean hospital stay was very different in the two studies (DioLEP vs. TURP: 1.8 vs. 3.8 days in Lusuardi 2011, MD -2.0, 95% CI -2.3 to -1.7; and 7.9 vs. 9.5 days in Zhang 2019, MD -1.6, 95% CI -1.95 to -1.25). Results for procedure time were in opposite directions in the two studies: 8.6 min shorter for TURP in Lusuardi 2011 (95% CI 4.6–12.6) and 33.2 min shorter for DioLEP in Zhang 2019 (95% CI -41.5 to -24.9).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 6 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

PVR (ml) at 6 months



Note: lower PVR values are better.

QoL at 6 months



Note: lower QoL scores are better.

DioLEP versus B-TUEP

See the section on B-TUEP.

DioLEP versus HoLEP

See the section on HoLEP.

DioLEP versus B-ERP

See the section on B-TUERP.

B-TUEP

B-TUEP was assessed in twelve of the RCTs, in comparisons with TURP (5 RCTs; n=974), HoLEP (3 RCT; n=224), DioLEP (2 RCT; n=194), ThuLEP (1 RCT; n=127), B-TUVP and OP (1 RCT; n=320).

B-TUEP versus TURP

Five RCTs compared B-TUEP versus TURP, providing data for the outcomes listed in Table 4-12. No data were available for Qmed, BPHII, reintervention or postoperative LUTS (as a binary outcome).

Table 4-12: Effectiveness outcomes assessed in RCTs comparing B-TUEP versus TURP

| Study ID | Luo 2014 | Ran 2013 | Zhao 2010 | Zhu 2013 ^a | Geavlete 2015 |
|------------------|----------|----------|-----------|-----------------------|---------------|
| IPSS at 1 month | x | | x | x | x |
| IPSS at 3 months | x | | x | | x |
| IPSS at 6 months | x | | x | x | x |

| Study ID | Luo 2014 | Ran 2013 | Zhao 2010 | Zhu 2013 ^a | Geavlete 2015 |
|--------------------------------|----------|----------|-----------|-----------------------|---------------|
| IPSS at 12 months | x | | x | x | x |
| IPSS at 18 months | | | x | | |
| IPSS at 24 months | x | | x | x | |
| IPSS at 36 months | | | x | x | |
| Qmax at 1 month | x | | x | x | x |
| Qmax at 3 months | x | | x | | x |
| Qmax at 6 months | x | | x | x | x |
| Qmax at 12 months | x | | x | x | x |
| Qmax at 18 months | | | x | | |
| Qmax at 24 months | x | | x | x | |
| Qmax at 36 months | | | x | x | |
| PVR at 1 month | | | x | x | x |
| PVR at 3 months | | | x | | x |
| PVR at 6 months | | | x | x | x |
| PVR at 12 months | | | x | x | x |
| PVR at 18 months | | | x | | |
| PVR at 24 months | | | x | x | |
| PVR at 36 months | | | x | x | |
| QoL at 1 month | x | | x | x | x |
| QoL at 3 months | x | | x | | x |
| QoL at 6 months | x | | x | x | x |
| QoL at 12 months | x | | x | x | x |
| QoL at 18 months | | | x | | |
| QoL at 24 months | x | | x | x | |
| QoL at 36 months | | | x | x | |
| Persistent irritative symptoms | | | x | | |
| Hospitalisation time | x | x | x | x | x |
| Procedure time | x | x | x | x | x |

^a Data for QoL and PVR data were estimated according to the Cochrane Handbook method.

Patients included in the studies were heterogeneous in terms of prostate size category. Patients with prostate size >70 ml and >80 ml were included in Zhu 2013 and Geavlete 2015, respectively, whereas patients in the other three studies had an average prostate size between 62 and 69 ml (no range or inclusion criteria available).

Pooling of data was possible for IPSS (1, 3, 6, 12, 24 and 36 months), Qmax (1, 3, 6, 12, 24 and 36 months), PVR (1, 3, 6, 12, 24 and 36 months) QoL (1, 3, 6, 12, 24 and 36 months), hospitalisation time and procedure time.


Differences in favour of B-TUEP were found for IPSS at 6 months (mean -0.36, 95% CI -0.71 to 0.00; $I^2=0\%$, high RoB) and 24 months (mean -0.62, 95% CI -1.02 to -0.23; $I^2=93\%$, high RoB) and Qmax at 6 months (mean 0.95, 95% CI 0.33-1.58; $I^2=82\%$, high RoB). Hospitalisation time was shorter for B-TUEP in three of the four RCTs (MD was up to 1.5 days less). Considering the

statistical heterogeneity observed, sensitivity analyses were performed for Qmax at 6 months, IPSS at 12 months (showing borderline significance) and 24 months, and PVR 12 months after excluding Zhao 2010 (outlier and high RoB for random sequence generation). For PVR at 12 months, these sensitivity analyses did not reduce the statistical heterogeneity and no differences were observed, whereas the heterogeneity (as well as the significance or borderline significance) disappeared in the analyses of IPSS at 12 and 24 months and Qmax 6 months. The overall quality of the evidence for these outcomes was judged as very low (owing to indirectness, inconsistency and RoB in the studies).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 6 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

IPSS at 12 months in the sensitivity analysis excluding Zhao 2010




Note: lower IPSS scores are better.

IPSS at 24 months




Note: lower IPSS scores are better.

IPSS at 24 months in the sensitivity analysis excluding Zhao 2010




Note: lower IPSS scores are better.

IPSS at 36 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months in the sensitivity analysis excluding Zhao 2010)




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

Qmax (ml/s) at 24 months




Note: higher Qmax values are better.

Qmax (ml/s) at 36 months




Note: higher Qmax values are better.

PVR (ml) at 1 month




Note: lower PVR values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

PVR (ml) at 12 months in the sensitivity analysis excluding Zhao 2010




Note: lower PVR values are better.

PVR (ml) at 24 months




Note: lower PVR values are better.

PVR (ml) at 36 months




Note: lower PVR values are better.

QoL at 1 month




Note: lower QoL scores are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

QoL at 6 months in the sensitivity analysis excluding Zhao 2010




Note: lower QoL scores are better.

QoL at 12 months




Note: lower QoL scores are better.

QoL at 12 months in the sensitivity analysis excluding Zhao 2010




Note: lower QoL scores are better.

QoL at 24 months




Note: lower QoL scores are better.

QoL at 24 months in the sensitivity analysis excluding Zhao 2010




Note: lower QoL scores are better.

QoL at 36 months




Note: lower QoL scores are better.

Hospitalisation time (days)



Procedure time (min)



B-TUEP versus HoLEP

See the section on HoLEP.

B-TUEP versus DioLEP

Two RCTs (Wu 2016, n=80; uncertain RoB; Zou 2018, n=114; high RoB) compared B-TUEP versus DioLEP. Patients included in Wu 2016 had a prostate size >80 ml and can be classified in our large prostate subgroup, whereas patients in Zou 2018 had a prostate size between 20 and 160 ml (mean: 62 ml). These two studies provided data for the outcomes listed in Table 4-13. No data were available for Qmed, BPHII, reintervention or postoperative LUTS (as a binary outcome).

Table 4-13: Effectiveness outcomes assessed in RCTs comparing B-TUEP versus DioLEP

| Study ID | Wu 2016 | Zou 2018 ^a |
|--------------------------------|---------|-----------------------|
| IPSS at 3 months | x | x |
| IPSS at 6 months | x | x |
| IPSS at 12 months | x | x |
| Qmax at 3 months | x | x |
| Qmax at 6 months | x | x |
| Qmax at 12 months | x | x |
| PVR at 3 months | x | x |
| PVR at 6 months | x | |
| PVR at 12 months | x | x |
| QoL at 3 months | x | x |
| QoL at 6 months | x | x |
| QoL at 12 months | x | x |
| Hospitalisation time | x | x ^b |
| Procedure time | x | x |
| Persistent irritative symptoms | x | x |


^a Data for IPSS, Qmax and QoL were extrapolated from graphs; data for PVR could not be extrapolated.

^b Data estimated according to the Cochrane Handbook method.

Pooling of data was possible for IPSS, Qmax, QoL (at 3, 6 and 12 months) and persistent irritative symptoms. A difference was observed for persistent irritative symptoms in favour of DioLEP (RR 0.48, 95% CI 0.30–0.79; $I^2=43\%$, high RoB). The quality of the evidence was judged as low because of indirectness and RoB.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 3 months


Note: lower IPSS scores are better.

IPSS at 6 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

QoL at 12 months




Note: lower QoL scores are better.


Persistent irritative symptoms



Hospitalisation time (days)



Procedure time (min)



B-TUEP versus ThuLEP

One RCT with uncertain RoB (Feng 2016, n=127) compared B-TUEP versus ThuLEP among patients with an average prostate size of 68 ml, assessing IPSS, Qmax, PVR and QoL at 3, 6 and 12 months, as well as operative time and hospital stay. Analyses did not show any differences between the treatment groups.

B-TUEP versus B-TUVP

One RCT with high RoB (Geavlete 2015, n=160) compared B-TUEP versus B-TUVP among patients with a prostate size >80 ml, assessing the outcomes shown in Table 4-14. Differences were observed in favour of B-TUEP for Qmax (with possible borderline clinical relevance) and operative time. As 95% CIs were not available, it was not possible to assess the uncertainty associated with these estimates.

Table 4-14: Effectiveness outcomes for B-TUEP versus B-TUVP assessed in Geavlete 2015 (n=160; high RoB)

| Outcome | B-TUEP | B-TUVP | p value ^a |
|--------------------------|--------|--------|----------------------|
| IPSS at 1 month | 6.9 | 6.6 | Not significant |
| IPSS at 3 months | 5.4 | 5.3 | Not significant |
| IPSS at 6 months | 4.5 | 4.9 | Not significant |
| IPSS at 12 months | 4.2 | 4.5 | Not significant |
| Qmax at 1 month (ml/s) | 23.7 | 21.4 | Not significant |
| Qmax at 3 months (ml/s) | 24.6 | 21.9 | Significant |
| Qmax at 6 months (ml/s) | 25.2 | 22.3 | Significant |
| Qmax at 12 months (ml/s) | 25.6 | 22.8 | Significant |
| PVR at 1 month (ml) | 37.1 | 39.9 | Not significant |
| PVR at 3 months (ml) | 28.6 | 29.9 | Not significant |
| PVR at 6 months (ml) | 21.7 | 31.3 | Not significant |
| PVR at 12 months (ml) | 19.7 | 25.2 | Not significant |
| QoL at 1 month | 1.8 | 1.9 | Not significant |
| QoL at 3 months | 1.4 | 1.3 | Not significant |
| QoL at 6 months | 1.2 | 0.9 | Not significant |
| QoL at 12 months | 0.9 | 0.8 | Not significant |
| Operative time (min) | 87.4 | 118.1 | Significant |
| Hospital stay (days) | 2.5 | 2.1 | Not significant |

^a Confidence intervals and exact p values unavailable.

B-TUEP versus OP

One RCT with high RoB (Geavlete 2015, n=160) compared B-TUEP versus OP among patients with a prostate size >80 ml, assessing IPSS, Qmax, PVR and QoL at 1, 3, 6 and 12 months, as well as operative time and hospital stay. A shorter hospital stay (2.5 vs. 6.7 days; p<0.01, 95% CI not available) was observed in favour of B-TUEP. As the 95% CI was not available, it was not possible to assess the uncertainty associated with this estimate.

4.4.1.3 Vaporization techniques

B-TUVP

B-TUVP was assessed in 14 of the RCTs, including a total of 1866 patients: nine RCTs versus TURP (n=1371), two RCTs versus PVP (n=144), and one RCT versus each of DioLVP (n=55), B-TUEP (n=147) and OP (n=149).

B-TUVP versus TURP

B-TUVP was assessed in comparison to TURP in ten of the RCTs (Elsakka 2016, Geavlete 2011, Geavlete 2014, Geavlete 2015, Hon 2006, Karadag 2014, Kaya 2007, Nuhoglu 2011, Tefekli 2005, Zhang S 2012), including a total of 1371 patients. Outcomes assessed in these studies are indicated in [Table 4-15](#). No data were available for BPHII.

Table 4-15: Effectiveness outcomes assessed in RCTs comparing B-TUVP versus TURP

| Study ID | Elsakka 2016 | Geavlete 2011 ^{a,b} | Geavlete 2014 ^b | Geavlete 2015 | Hon 2006 | Karadag 2014 | Kaya 2007 | Nuhoglu 2011 | Tefekli 2005 | Zhang S 2012 |
|-------------------|--------------|------------------------------|----------------------------|---------------|----------|--------------|-----------|--------------|--------------|--------------|
| IPSS at 1 month | | x | x | x | | x | | x | | |
| IPSS at 3 months | x | x | x | x | | | | x | x | |
| IPSS at 6 months | x | x | x | x | | | | | x | |
| IPSS at 12 months | | x | | x | x | x | | x | x | |
| IPSS at 18 months | | x | | | | | | | | |
| IPSS at 24 months | | | | | | | x | | | |
| IPSS at 36 months | | | | | | | x | | | |
| IPSS at 48 months | | | | | | | | | | |
| Qmax at 1 month | | x | x | x | | x | | x | | |
| Qmax at 3 months | x | x | x | x | | | | x | x | |
| Qmax at 6 months | x | x | x | x | | | | | x | |
| Qmax at 12 months | | x | | x | x | x | | x | x | |
| Qmax at 18 months | | x | | | | | | | | |
| Qmax at 24 months | | | | | | | x | | | |
| Qmax at 36 months | | | | | | | x | | | |
| PVR at 1 month | | x | x | x | | x | | | | |
| PVR at 3 months | x | x | x | x | | | | | | |
| PVR at 6 months | x | x | x | x | | | | | | |
| PVR at 12 months | | x | | x | x | x | | x | | |
| PVR at 18 months | | x | | | | | | | | |
| QoL at 1 month | | x | x | x | | | | | | |
| QoL at 3 months | | x | x | x | | | | | | |

| Study ID | Elsakka 2016 | Geavlete 2011 ^{a,b} | Geavlete 2014 ^b | Geavlete 2015 | Hon 2006 | Karadag 2014 | Kaya 2007 | Nuhoglu 2011 | Tefekli 2005 | Zhang S 2012 |
|--------------------------------|--------------|------------------------------|----------------------------|---------------|----------|--------------|-----------|--------------|--------------|--------------|
| QoL at 6 months | | x | x | x | | | | | | |
| QoL at 12 months | | x | | x | x | | | | | |
| QoL at 18 months | | x | | | | | | | | |
| Qmed at 12 months | | | | | x | | | | | |
| Reintervention total | x | x | | | | | x | x | x | |
| Persistent irritative symptoms | | x | x | | | | | | x | |
| Postoperative LUTS | | x | | | | | | | | |
| Hospitalisation time | | x | x | x | x | | | | | x |
| Procedure time | x | x | x | x | x | x | | x | x | x |

^a Date for IPSS, Qmax, PVR and QoL were estimated using the quantile estimation method of McGrath et al. [63].

^b Data from arms with the same technology were combined according to the Cochrane method.


Prostate size was used as an inclusion criterion in seven of these ten studies. Patients included were heterogeneous in terms of prostate size category. While four studies included patients with a prostate volume of <80 ml, Kaya 2007 included patients with prostate volumes <60 ml, Zhang S 2012 with prostate size between 25 and 125 ml, and Geavlete 2015 with prostate size >80 ml. The latter is the only study providing information on the range for prostate volume (80–297 ml). Data could be pooled for IPSS, Qmax, PVR and QoL at 1, 3, 6 and 12 months; reintervention; and persistent irritative symptoms. For functional outcomes, B-TUVP showed more favourable effects than TURP, except for PVR at 3 and 6 months, for which B-TUVP and TURP, respectively, was more favourable. However, very high statistical heterogeneity was detected in analyses of IPSS, Qmax and PVR that could not be explained and that limits the reliability of the results. Sensitivity analyses were performed excluding Elsakka 2016 (the trial with the youngest population, more than 10 years younger in comparison to the other RCTs), but no impact on heterogeneity or statistical significance was observed, except for PVR at 3 months.

Pooled estimates showed significant differences, in particular for IPSS at 1 month (mean -2.41, 95% CI -2.70 to -2.12; $I^2=94%$, uncertain RoB), 3 months (without Elsakka 2016: mean -2.31, 95% CI -2.58 to -2.04; $I^2=95%$, uncertain RoB) and 6 months (without Elsakka 2016: mean -2.37, 95% CI -2.58 to -2.16; $I^2=98%$, uncertain RoB); Qmax at 1 month (mean 1.45, 95% CI 0.92–1.98; $I^2=94%$, uncertain RoB), 3 months (without Elsakka 2016: mean 1.59, 95% CI 1.03–2.14; $I^2=95%$, uncertain RoB) and 6 months (without Elsakka 2016: mean 1.74, 95% CI 1.19–2.30; $I^2=95%$, uncertain RoB); PVR at 3 months (without Elsakka 2016: mean -2.20, 95% CI -3.74 to -0.66; $I^2=0%$, uncertain RoB) and 6 months (without Elsakka 2016: mean 4.63, 95% CI 1.63–7.64; $I^2=67%$, uncertain RoB); and QoL at 1 month (mean -0.30, 95% CI -0.35 to -0.25; $I^2=0%$, uncertain RoB), 3 months (mean -0.29, 95% CI -0.36 to -0.22; $I^2=40%$, uncertain RoB), 6 months (mean -0.27, 95% CI -0.34 to -0.20; $I^2=32%$, uncertain RoB) and 12 months (mean -0.15, 95% CI -0.22 to -0.07; $I^2=62%$, uncertain RoB). The quality of the evidence for these estimates is low because of indirectness and inconsistency.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Notes: SD values for Geavlete 2014 are from Nuhoglu 2011, the study with the most similar prostate size. Lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 3 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from Nuhoglu 2011, the study with the most similar prostate size. Lower IPSS scores are better.

IPSS at 6 months




Notes: SD values for Geavlete 2014 are from Tefekli 2005, the study with the most similar prostate size. Lower IPSS scores are better.

IPSS at 6 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from Tefekli 2005, the study with the most similar prostate size. Lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Notes: SD values for Geavlete 2014 are from Nuhoglu 2011, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 3 months




Notes: SD values for Geavlete 2014 are from Nuhoglu 2011, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 3 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from Nuhoglu 2011, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 6 months




Notes: SD values for Geavlete 2014 are from Tefekli 2005, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 6 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from Tefekli 2005, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

PVR (ml) at 1 month




Notes: SD values for Geavlete 2014 are from Karadag 2014, the study with the most similar prostate size. Lower PVR values are better.

PVR (ml) at 3 months




Notes: SD values for Geavlete 2014 are from the data for PVR at 1 month in Karadag 2014, the study with the most similar prostate size. Lower PVR values are better.

PVR (ml) at 3 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from the data for PVR at 1 month in Karadag 2014, the study with the most similar prostate size. Lower PVR values are better.

PVR (ml) at 6 months




Notes: SD values for Geavlete 2014 are from the data for PVR at 1 month in Karadag 2014, the study with the most similar prostate size. Lower PVR values are better.

PVR (ml) at 6 months in the sensitivity analysis excluding Elsakka 2016 (younger patients)




Notes: SD values for Geavlete 2014 are from the data for PVR at 1 month in Karadag 2014, the study with the most similar prostate size. Lower PVR values are better.

PVR at 12 months




Note: Lower PVR values are better.

QoL at 1 month




Notes: SD values for Geavlete 2014 are from Geavlete 2011, the study with the most similar prostate size. Lower QoL scores are better.

QoL at 3 months




Notes: SD values for Geavlete 2014 are from Geavlete 2011, the study with the most similar prostate size. Lower QoL values are better.

QoL at 6 months




Notes: SD values for Geavlete 2014 are from Geavlete 2011, the study with the most similar prostate size. Lower QoL values are better.

QoL at 12 months




Note: lower QoL values are better.


Irritative symptoms




Reintervention



Hospitalisation time (days)



Procedure time (min)



B-TUVP versus PVP

See the section on PVP.

B-TUVP versus DioLVP

One study (Skinner 2017, n=55; unclear RoB) compared B-TUVP versus DioLVP for the outcomes IPSS and QoL (at 3 months) and operative time. The mean prostate size was 47 ml (no range or inclusion criteria available). A significant difference in operative time in favour of B-TUVP (24.3 vs. 33.5 min; p<0.05, 95% CI not available) was observed. No differences were found for IPSS or QoL (at 3 months).

B-TUVP versus B-TUEP

See the section on B-TUEP.

B-TUVP versus OP

One study (Geavlete 2015, n=160; high RoB) compared B-TUVP versus OP among patients with a prostate size >80 ml for the outcomes Qmax, PVR, IPSS and QoL at 1, 3, 6 and 12 months, as well as operative time and hospital stay. Significant differences in favour of OP were observed for operative time (118.1 vs. 79.4 min; p value and 95% CI not available) and in favour of B-TUVP for hospital stay (2.1 vs. 6.7 days; p value and 95% CI not available).

DioLVP

DioLVP was assessed in three of the RCTs, including a total of 242 patients: two RCTs versus TURP (n=187) and one RCT versus B-TUVP (n=55).

DioLVP versus TURP

Two RCTs (Cetinkaya 2015, n=72; high RoB; Razzaghi 2014, n=115; uncertain RoB) compared DioLVP versus TURP. Outcomes assessed in these studies are indicated in [Table 4-16](#). There were no data on BPHII.

Table 4-16: Effectiveness outcomes assessed in RCTs comparing DioLVP versus TURP


| Study ID | Razzaghi 2014 | Cetinkaya 2015 |
|----------------------|---------------|----------------|
| IPSS at 1 month | x | |
| IPSS at 3 months | | x |
| IPSS at 6 months | x | |
| IPSS at 12 months | x | |
| IPSS at 24 months | x | |
| Qmax at 1 month | x | |
| Qmax at 3 months | | x |
| Qmax at 6 months | x | |
| Qmax at 12 months | x | |
| Qmax at 24 months | x | |
| PVR at 6 months | x | |
| PVR at 12 months | x | |
| PVR at 24 months | x | |
| Reintervention | x | x |
| Hospitalisation time | x | x |
| Procedure time | x | x |

Prostate volume was an inclusion criterion in both studies, and differed between them: >100 ml for Razzaghi 2014 and <80 ml for Cetinkaya 2015. Neither of the studies reported the range for prostate volume. Pooling of data was possible for reintervention. Hospitalisation time was shorter for DioLVP in both studies (MD up to 1.4 days less). Meta-analysis was not possible for the other outcomes since the follow-up times were substantially different. Comparison results for IPSS and Qmax in each of the two studies are presented in [Table 4-17](#) and [Table 4-18](#). Razzaghi 2014 showed significant differences for both IPSS and Qmax at 12 and 24 months in favour of TURP that are close to the MCID thresholds of 3 points for IPSS and 2 ml/s for Qmax.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Reintervention



Hospitalisation time (days)



Procedure time (min)




Table 4-17: Differences in IPSS for DioLVP versus TURP in Cetinkaya 2015 and Razzaghi 2014

| Study | Risk of bias | DioLVP | TURP | Follow-up | Statistical significance |
|----------------|--------------|--------|------|-----------|--------------------------|
| Cetinkaya 2015 | High | 8.38 | 8.31 | 3 months | n.a. |
| Razzaghi 2014 | Uncertain | 10.6 | 11.4 | 1 month | p=0.26 |
| | | 8.5 | 7.8 | 6 month | p=0.1 |
| | | 8.7 | 7.4 | 12 months | p=0.01; 95% CI n.a. |
| | | 10.4 | 7.7 | 24 months | p=0.04; 95% CI n.a. |

Abbreviations: n.a.=not available.

Table 4-18: Differences in Qmax for DioLVP versus TURP in Cetinkaya 2015 and Razzaghi 2014

| Study | Risk of bias | DioLVP | TURP | Follow-up | Statistical significance |
|----------------|--------------|--------|------|-----------|--------------------------|
| Cetinkaya 2015 | High | 16.34 | 18.5 | 3 months | n.a. |
| Razzaghi 2014 | Uncertain | 15.6 | 15.7 | 1 month | p=0.85 |
| | | 20.6 | 19.8 | 6 month | p=0.24 |
| | | 19.8 | 21.7 | 12 months | p=0.004; 95% CI n.a. |
| | | 18.5 | 21.1 | 24 months | p=0.0001; 95% CI n.a. |

Abbreviations: n.a.=not available.

DioLVP versus B-TUVP

See the section on B-TUVP.

PVP

PVP was assessed in five of the RCTs, with comparisons to TURP (3 RCTs; n=465), B-TUVP (2 RCTs; n=146) and HoLEP (1 RCT; n=103).

PVP versus TURP

Three RCTs (Goliath study [Bachmann 2014, Bachmann 2015, Thomas 2016], n=281; Jovanovic 2014, n=62; Elshal 2020, n=122) compared PVP versus TURP for the outcomes listed in [Table 4-19](#). No data were available for Qmed, BPHII or postoperative LUTS (as a binary outcome).

Table 4-19: Effectiveness outcomes assessed in RCTs comparing PVP versus TURP

| Study ID | Jovanovic 2014 | Goliath study (Bachmann 2014, 2015; Thomas 2016) | Elshal 2020 ^a |
|-------------------|----------------|--|--------------------------|
| IPSS at 1 month | | | x |
| IPSS at 3 months | | x | x |
| IPSS at 6 months | | x | |
| IPSS at 12 months | | x | x |
| IPSS at 24 months | | x | x |
| IPSS at 36 months | | | x |
| Qmax at 1 month | | | x |
| Qmax at 3 months | | x | x |
| Qmax at 6 months | | x | |
| Qmax at 12 months | | x | x |
| Qmax at 24 months | | x | x |
| Qmax at 36 months | | | x |
| PVR at 1 month | | | x |
| PVR at 3 months | | x | x |
| PVR at 6 months | | x | |
| PVR at 12 months | | x | x |

| Study ID | Jovanovic 2014 | Goliath study (Bachmann 2014, 2015; Thomas 2016) | Elshal 2020 ^a |
|--------------------------------|----------------|--|--------------------------|
| PVR at 24 months | | X | X |
| PVR at 36 months | | | X |
| PVR at 48 months | | | |
| Reintervention total | | X | X |
| QoL at 1 month | | | X |
| QoL at 3 months | | X | X |
| QoL at 6 months | | X | |
| QoL at 12 months | | X | X |
| QoL at 24 months | | X | X |
| Persistent irritative symptoms | | X | X |
| Hospitalisation time | X | X | X ^b |
| Procedure time | X | X | X |

^a Data for IPSS, Qmax, QoL and PVR were extrapolated from graphs.

^b Data estimated according to McGrath et al. [63].

Patient populations were heterogeneous in terms of prostate size: in the Goliath study and Jovanovic 2014 the prostate size was <100 ml (mean 47 ml in the Goliath study and 61 ml in Jovanovic 2014; no ranges were available); Elshal 2020 enrolled patients with prostate size between 80 and 150 ml (mean 106 ml).


Pooling of data was possible for IPSS (3 and 12 months), Qmax (3 and 12 months), PVR (3, 12 and 24 months), QoL (3,12 and 24 months) and reintervention. Differences were found in favour of TURP for IPSS at 12 months (mean 1.20, 95% CI 0.00–2.40; I²=0%, high RoB) and PVR at 12 months (mean 11.23 ml, 95% CI 2.98–19.48; I²=0%, high RoB). The quality of the evidence for these outcomes was judged as low because of RoB and indirectness. Hospitalisation time was shorter for PVP (up to 2.5 days less) and procedure time was shorter for TURP (~10 min less).

No differences were found between the two technologies for Qmax, QoL, reintervention or irritative symptoms.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 3 months




Note: lower IPSS scores are better.

PVR at 12 months




Note: lower PVR values are better.

PVR at 24 months




Note: lower PVR values are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 12 months




Note: lower QoL scores are better.

QoL at 24 months




Note: lower QoL scores are better.


Reintervention




Persistent irritative symptoms



Hospitalisation time



Procedure time



PVP versus B-TUVP

Two RCTs (Ghobrial 2020, n=119; Kini 2020, n=27) compared PVP versus B-TUVP for the outcomes listed in Table 4-20. No data were available for Qmed, BPHII, reintervention or persistent irritative symptoms.

Table 4-20: Effectiveness outcomes assessed in RCTs comparing PVP versus B-TUVP

| Study ID | Ghobrial 2020 ^a | Kini 2020 |
|-------------------|----------------------------|-----------|
| IPSS at 1 month | x | x |
| IPSS at 3 months | x (at 4 months) | x |
| IPSS at 6 months | | x |
| IPSS at 12 months | x | |
| IPSS at 24 months | x | |
| Qmax at 1 month | | x |
| Qmax at 3 months | x (at 4 months) | x |
| Qmax at 6 months | | x |

| Study ID | Ghobrial 2020 ^a | Kini 2020 |
|----------------------|----------------------------|-----------|
| Qmax at 12 months | x | |
| Qmax at 24 months | x | |
| PVR at 3 months | x (at 4 months) | |
| PVR at 12 months | x | |
| PVR at 24 months | x | |
| QoL at 1 month | | x |
| QoL at 3 months | x (4 months) | x |
| QoL at 6 months | | x |
| QoL at 12 months | x | |
| QoL at 24 months | x | |
| Hospitalisation time | x | |
| Procedure time | x | |

^a Data for IPSS, Qmax and PVR were extrapolated from graphs.


Prostate size was between 30 and 80 ml in Ghobrial 2020 and <80 ml in Kini 2020.

Pooling of data was possible for IPSS at 3 months, Qmax at 1 and 3 months and QoL at 1 month. A difference in favour of PVP was found for IPSS at 3 months (mean -2.20, 95% CI -4.03 to -0.38; I²=63%, high RoB). The quality of the evidence was judged as low because of RoB and inconsistency.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

QoL at 1 month



Note: lower QoL scores are better.

QoL at 3 months



Note: lower QoL scores are better.

PVP versus HoLEP

See the section on HoLEP.

4.4.1.4 Hybrid techniques: Vapoenucleation

ThuVEP

ThuVEP was assessed in two of the RCTs, including a total of 153 patients: one RCT versus TURP (n=59) and one RCT versus HoLEP (n=94).

ThuVEP versus TURP

One study (Chang 2015, n=59; uncertain RoB) compared ThuVEP versus TURP. Prostate volume was not considered as an inclusion criterion; the mean prostate weight was 57.2 g in the ThuVEP group and 64.7 g in the TURP group. Only PVR and hospital stay data could be retrieved from this study, with no significant differences between the technologies. There were no data on IPSS, Qmax, QoL, BPHII, reintervention or operative time.

ThuVEP versus HoLEP

See the section on HoLEP.

B-VEP

B-VEP versus TURP

Two RCTs (Wang 2020, n=101; uncertain RoB; Zhang 2015, n=112; uncertain RoB) including 213 patients compared B-VEP versus TURP. Outcomes assessed in these studies are indicated in [Table 4-21](#). There were no data for BPHII or reintervention.

Table 4-21: Effectiveness outcomes assessed in RCTs comparing B-VEP versus TURP


| Study ID | Zhang 2015 | Wang 2020 |
|----------------------|------------|-----------|
| IPSS at 3 months | x | x |
| IPSS at 6 months | | x |
| Qmax at 3 months | x | x |
| Qmax at 6 months | | x |
| PVR at 3 months | x | x |
| PVR at 6 months | | x |
| QoL at 3 months | x | x |
| QoL at 6 months | | x |
| Hospitalisation time | x | |
| Procedure time | x | |

Both studies included patients with prostate volume >90 ml. Pooling of data was possible for IPSS, Qmax, PVR and QoL at 3 months, for which no significant differences were observed. In the study by Zhang 2015, both procedure time (63.9 vs. 78.1 min; p<0.001, 95% CI not available) and hospitalisation time (100.2 vs. 116.0 h; p=0.004, 95% CI not available) were significantly shorter in the B-VEP group compared to TURP.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 3 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

PVR (ml) at 3 months



Note: lower PVR values are better.

QoL at 3 months



Note: lower QoL scores are better.

4.4.1.5 Hybrid techniques: Vaporessection

TUVRP

TUVRP was assessed in comparison to TURP in four of the RCTs, including a total of 560 patients.

TUVRP versus TURP

Five RCTs (Dunsmuir 2003, n=51; Geavlete 2010, n=155; Gupta 2006, n=100; Yip 2011, n=86; Yee 2015, n=168) compared TUVRP versus TURP for the outcomes listed in [Table 4-22](#). No data were available for Qmed, BPHII or postoperative LUTS (as a binary outcome).

Table 4-22: Effectiveness outcomes assessed in RCTs comparing TUVRP versus TURP

| Study ID | Dunsmuir 2003 ^a | Geavlete 2010 | Yee 2015 | Yip 2011 | Gupta 2006 |
|--------------------------------|----------------------------|---------------|----------|----------------|----------------|
| IPSS at 1 month | | x | | x | |
| IPSS at 3 months | x | x | x | | |
| IPSS at 6 months | x | x | x | | x |
| IPSS at 12 months | x | | | | x |
| Qmax at 1 month | | x | | x ^b | |
| Qmax at 3 months | x | x | x | | |
| Qmax at 6 months | x | x | x | | x |
| Qmax at 12 months | x | | | | x |
| PVR at 1 month | | x | | | |
| PVR at 3 months | x | x | x | | |
| PVR at 6 months | x | x | x | | x ^c |
| PVR at 12 months | x | | | | x ^c |
| QoL at 1 month | | x | | | |
| QoL at 3 months | | x | x | | |
| QoL at 6 months | | x | x | | |
| Reintervention at 1 month | | | | x | |
| Persistent irritative symptoms | | | x | x | |
| Hospitalisation time | x | x | x | x | |
| Procedure time | x | x | x | x | x |

^a Data for IPSS, Qmax, QoL and PVR were extrapolated from graphs.

^b Data for IPSS at 1 month were extrapolated from a graph.

^c Data not available.

Patients included in one study (Geavlete 2010) had prostate size falling entirely within the 30–80 ml subgroup, whereas two studies (Yip 2011 and Yee 2015) included patients with an average prostate size of 61 ml and one study (Dunsmuir 2003) included patients with a prostate size between 16 and 60 ml.


Pooling of data was possible for IPSS (at 3, 6 and 12 months), Qmax (at 1, 3, 6 and 12 months) and PVR and QoL (at 3 and 6 months). Differences were found in favour of TUVRP for IPSS at 3 months (mean -1.45 , 95% CI -2.55 to -0.34 ; $I^2=88\%$, high RoB), but high heterogeneity, possibly

due to RoB (random sequence generation in Geavlete 2010) and differences in the homogeneity of the populations studied, may limit the value of the pooled result (sensitivity analyses without Geavlete 2010 do not show significant differences); and for Qmax at 1 month (mean 2.12, 95% CI 0.39–3.85; $I^2=0\%$, high RoB). The quality of the evidence was judged as low for IPSS at 3 months (owing to inconsistency and RoB) and for Qmax at 1 month (downgraded for imprecision and RoB).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 1 month




Note: lower IPSS scores are better.

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 6 months




Notes: SD values for Gupta 2006 are from Yee 2015, the study with the most similar prostate size. Lower IPSS scores are better.

IPSS at 12 months




Notes: SD values for Gupta 2006 are from the data for IPSS at 6 months in Yee 2015 since prostate size in the two studies is similar and IPSS SDs are stable. Lower IPSS scores are better.

Qmax (ml/s) at 1 month




Note: higher Qmax values are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Notes: SD values for Gupta 2006 are from Yee 2015, the study with the most similar prostate size. Higher Qmax values are better.

Qmax (ml/s) at 12 months




Notes: SD values for Gupta 2006 are from the data for Qmax at 6 months in Yee 2015 since prostate size in the two studies is similar and the Qmax SDs are stable. Higher Qmax values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

QoL at 3 months




Note: lower QoL scores are better.

QoL at 6 months




Note: lower QoL scores are better.

Hospitalisation time (h)



Procedure time



ThuVARP

ThuVARP was assessed in one RCT (Hashim 2020, uncertain RoB), comparing ThuVARP versus TURP and including a total of 410 patients with prostate size between 20 and 50 ml.

A noninferiority hypothesis was postulated for IPSS and Qmax at 12 months (co-primary endpoints) for a difference of <2.5 points and <4 ml/s, respectively. In the intention-to-treat analysis, ThuVARP was noninferior to TURP for IPSS, while TURP was superior to ThuVARP for Qmax (MD 3 ml/s, 95% CI –5.8 to –0.5). The latter result is around the MCID, although it should be considered that 26% of patients allocated to ThuVARP were eventually switched to TURP for several reasons (e.g., equipment issues, large prostate, bleeding, poor visibility) and 2% did not undergo TURP. A complete list of reasons for failure to undergo the randomised treatment is available in the supplementary appendix of the RCT [43]. No data are available for PVR, QoL, procedure time or postoperative LUTS (as a binary outcome). [Table 4-23](#) shows the available results.

Table 4-23: Effectiveness outcomes assessed in Hashim 2020 comparing TUVRP versus TURP

| Outcome | ThuVARP | TURP | p value (95% CI) |
|----------------------------|---------|------|------------------|
| IPSS at 12 months | 6.4 | 6.3 | (–0.9 to 1.5) |
| IPSS quality of life | 1.7 | 1.5 | 0.29 |
| Qmax at 12 months (ml/s) | 20.2 | 23.2 | (–5.8 to –0.5) |
| Reintervention (%) | 2.0 | 1.0 | – |
| Frequency >8 times/day (%) | 12 | 10 | 0.60 |
| Nocturia (%) | 44 | 37 | 0.10 |
| Frequency >8 times/day (%) | 12 | 10 | 0.60 |
| Hospital stay (h) | 48 | 48 | 0.31 |

4.4.1.6 Hybrid techniques: Enucleoresection**B-TUERP**

B-TUERP was assessed in two RCTs, including a total of 320 patients.

B-TUERP versus TURP

One RCT (Samir 2019, n=240; uncertain RoB) compared B-TUERP versus TURP among patients with a prostate size >80 ml for the outcomes listed in [Table 4-24](#). The authors reported significant differences in favour of B-TUERP versus TURP for functional outcomes (except Qmax at 6 months and QoL at 24 months) and hospital stay; operative time was longer with B-TUERP. Since 95% CIs were not available, it was not possible to assess imprecision associated with the reported estimates.

No data were available for Qmed, BPHII, reintervention, irritative symptoms or postoperative LUTS (as a binary outcome).

Table 4-24: Effectiveness outcomes assessed in Samir 2019 comparing B-TUERP versus TURP

| Outcome | B-TUERP | TURP | p value |
|--------------------------|---------|------|---------|
| IPSS at 1 month | 15 | 19 | <0.01 |
| IPSS at 6 months | 12 | 13 | 0.002 |
| IPSS at 24 months | 6 | 7 | 0.009 |
| Qmax at 1 month (ml/s) | 19.0 | 15.4 | <0.001 |
| Qmax at 6 months (ml/s) | 22.0 | 19.0 | 0.76 |
| Qmax at 24 months (ml/s) | 24.9 | 20.1 | 0.03 |
| PVR at 1 month (ml) | 22.1 | 32.6 | <0.001 |
| PVR at 6 months (ml) | 19.4 | 22.7 | 0.02 |
| PVR at 24 months (ml) | 18.6 | 24.7 | 0.001 |
| QoL at 1 month | 2.5 | 3 | 0.01 |
| QoL at 6 months | 2 | 2.5 | <0.001 |
| QoL at 24 months | 1 | 2 | 0.24 |
| Operative time (min) | 105.1 | 61.1 | <0.001 |
| Hospital stay (h) | 52.5 | 60.4 | <0.001 |

B-TUERP versus DioLEP

One RCT (Xu 2013, n=80, uncertain risk of bias) compared these two technologies in patients with average prostate size of 67 ml (no range or inclusion criteria available), assessing the outcomes listed in Table 4-25. Compared to DioLEP, B-TUERP needed a longer operative time and was associated with higher incidence of irritative symptoms. Since 95% CIs were not available, it was not possible to assess uncertainty associated with the reported estimates.

No data are available for Qmed, BPHII, reintervention or postoperative LUTS (as a binary outcome).

Table 4-25: Effectiveness outcomes assessed in Xu 2013 (n=80; uncertain RoB) comparing B-TUERP versus DioLEP

| Outcome | B-TUERP | DioLEP | p value |
|--------------------------|---------|--------|---------|
| IPSS at 3 months | 7.5 | 7.0 | 0.24 |
| IPSS at 6 months | 6.3 | 6.1 | 0.51 |
| IPSS at 12 months | 5.3 | 4.9 | 0.17 |
| Qmax at 3 months (ml/s) | 22.9 | 23.1 | 0.82 |
| Qmax at 6 months (ml/s) | 23.1 | 23.3 | 0.81 |
| Qmax at 12 months (ml/s) | 23.3 | 23.5 | 0.87 |
| PVR at 3 months (ml) | 20.3 | 16.0 | 0.55 |
| PVR at 6 months (ml) | 4.8 | 4.1 | 0.80 |
| PVR at 12 months (ml) | 2.2 | 1.3 | 0.34 |
| QoL at 3 months | 1.9 | 1.7 | 0.25 |
| QoL at 6 months | 1.6 | 1.5 | 0.56 |
| QoL at 12 months | 1.2 | 1.2 | 0.63 |
| Operative time (min) | 50.3 | 33.7 | <0.001 |

| Outcome | B-TUERP | DioLEP | p value |
|-------------------------|---------|--------|---------|
| Hospital stay (days) | 5.3 | 5.0 | 0.10 |
| Irritative symptoms (%) | 35.0 | 12.5 | 0.02 |

M-TUERP

M-TUERP was assessed in one RCT (Li 2018, n=86; high RoB) in comparison to TURP for 86 patients. The study included patients with prostate volume >80 ml. Operative time was the only effectiveness outcome retrievable and it did not significantly differ between the groups. There were no data on IPSS, Qmax, PVR, QoL, hospitalisation time or BPHII.

4.4.1.7 Aquablation

Aquablation was assessed in one RCT (WATER study), with four publications presenting results at different follow-up times for comparison to TURP among 181 patients (Gilling 2018, 2019a, 2019b, 2020; uncertain RoB). The outcomes assessed in these papers are listed in [Table 4-26](#). No data were available for BPHII.

Table 4-26: Effectiveness outcomes assessed in RCTs comparing Aquablation versus TURP

| Study ID | Gilling 2018 | Gilling 2019a | Gilling 2019b | Gilling 2020 |
|-----------------------------|--------------|---------------|---------------|--------------|
| IPSS at 1 month | | | x | x |
| IPSS at 3 months | | | x | x |
| IPSS at 6 months | x | x | x | x |
| IPSS at 12 months | | | x | x |
| IPSS at 24 months | | | x | x |
| IPSS at 36 months | | | | x |
| Qmax at 1 month | | | x | x |
| Qmax at 3 months | | | x | x |
| Qmax at 6 months | x | x | x | x |
| Qmax at 12 months | | | x | x |
| Qmax at 24 months | | | x | x |
| Qmax at 36 months | | | | x |
| PVR at 1 month | | | x | x |
| PVR at 3 months | | | x | x |
| PVR at 6 months | x | x | x | x |
| PVR at 12 months | | | x | x |
| PVR at 24 months | | | x | x |
| PVR at 36 months | | | | x |
| Reintervention at baseline | x | | | |
| Reintervention at 12 months | | x | | |
| Reintervention at 24 months | | | x | |
| Reintervention at 36 months | | | | x |

| Study ID | Gilling 2018 | Gilling 2019a | Gilling 2019b | Gilling 2020 |
|----------------------|--------------|---------------|---------------|--------------|
| QoL at 1 month | | | | x |
| QoL at 3 months | | | | x |
| QoL at 6 months | | | | x |
| QoL at 12 months | | | | x |
| QoL at 24 months | | | | x |
| QoL at 36 months | | | | x |
| Hospitalisation time | x | | | |
| Procedure time | x | | | |

The WATER study presented data for 6, 12, 24 and 36 months of follow-up and included patients with prostate size in the range 30–80 ml. Mean prostate size was 54.1 ml in the Aquablation group and 51.8 ml in the TURP group. At 6 months, the primary efficacy endpoint was the change in IPSS from baseline, with noninferiority declared if the lower bound for the two-sided 95% CI for the difference in score change at 6 months exceeded -4.7 points. The MD in score change at 6 months was 1.8 points greater for Aquablation (16.9 points for Aquablation vs. 15.1 points for TURP) showing noninferiority of Aquablation versus TURP ($p < 0.0001$), whereas superiority was not shown for this or for the other outcomes (results presented in [Table 4-27](#)). The quality of the evidence was rated as low owing to uncertain RoB for allocation, performance and attrition bias and considering the imprecision of the estimates.

Table 4-27: Main effectiveness results from the WATER study

| Aquablation vs. TURP (Gilling 2018, 2019a, 2019b, 2020, n=181; uncertain risk of bias) | | | | |
|--|-------------------|-------------------|-----------|---|
| Outcome | Aquablation | TURP | Follow-up | Statistical significance |
| Qmax (ml/s) | 20.3 | 18 | 6 months | 0.14 |
| | 10.3 ^a | 10.6 ^a | 12 months | 0.863 |
| | 11.2 ^a | 8.6 ^a | 24 months | 0.188 |
| | 11.6 ^a | 8.2 ^a | 36 months | 0.084 |
| PVR (ml) | 42 | 48 | 6 months | – |
| | 52 ^a | 63 ^a | 12 months | 0.462 |
| | 57 ^a | 70 ^a | 24 months | 0.389 |
| | 52 ^a | 53 ^a | 36 months | 0.980 |
| IPSS | 5.9 | 6.8 | 6 months | Noninferiority $p < 0.0001$ Superiority $p = 0.1347$ |
| | 15.1 ^a | 15.1 ^a | 12 months | 0.989 |
| | 14.7 ^a | 14.9 ^a | 24 months | 0.830 |
| | 14.4 ^a | 13.9 ^a | 36 months | 0.684 |
| QoL | 1.3 | 1.5 | 6 months | 0.458 |
| | 3.2 ^a | 3.5 ^a | 12 months | 0.317 |
| | 3.2 ^a | 3.3 ^a | 24 months | 0.700 |
| | 3.2 ^a | 3.2 ^a | 36 months | 0.784 |
| Operative time (min) | 33 | 36 | | 0.27 |
| Postoperative stay (days) | 1.4 | 1.4 | | 0.34 |

^a Mean improvement.

4.4.1.8 TUMT

TUMT was assessed in four RCTs, all of which were comparisons versus TURP (n=419).

TUMT versus TURP

Four studies including 419 patients (D'Ancona 1989, n=52; uncertain RoB; Dahlstrandt 1995, n=69; uncertain RoB; Wagrell 2002, n=154; high RoB, Floratos 2001, n=144; uncertain RoB) compared TUMT versus TURP. Outcomes assessed in these studies are indicated in [Table 4-28](#). There were no data on BPHII, hospitalisation time or procedure time.

Table 4-28: Effectiveness outcomes assessed in RCTs comparing TUMT versus TURP

| Study ID | Dahlstrandt 1995 | Floratos 2001 ^a | D'Ancona 1998 | Wagrell 2002 |
|-------------------|------------------|----------------------------|---------------|--------------|
| IPSS at 3 months | x | | x | x |
| IPSS at 6 months | x | | x | x |
| IPSS at 12 months | x | x | x | x |
| IPSS at 24 months | x | x | | |
| IPSS at 30 months | | | x | |
| IPSS at 36 months | | x | | |
| Qmax at 3 months | x | | x | x |
| Qmax at 6 months | x | | x | x |
| Qmax at 12 months | x | x | x | x |
| Qmax at 24 months | x | x | | |
| Qmax at 30 months | | | x | |
| Qmax at 36 months | | x | | |
| PVR at 3 months | x | | x | |
| PVR at 6 months | x | | x | |
| PVR at 12 months | x | x | x | x |
| PVR at 24 months | x | x | | |
| PVR at 30 months | | | x | |
| PVR at 36 months | | x | | |
| Reintervention | x | x | | |
| QoL at 3 months | | | | x |
| QoL at 6 months | | | | x |
| QoL at 12 months | | x | | x |
| QoL at 24 months | | x | | |
| QoL at 36 months | | x | | |

^a Data for IPSS and Qmax were extracted from graphs; data for PVR and QoL were not extracted.


Two studies used prostate volume (>30 ml Floratos 2001; 30–100 ml Wagrell 2002) as an inclusion criterion. One study (Dahlstrandt 1995) used prostate length as an inclusion criterion (35–50 mm), while another (D'Ancona 1998) used both prostate length (25–50 mm) and prostate volume (30–100 ml) to select patients. Mean prostate volume was similar in the three studies that reported it (42–48.9 ml for TUMT and 44–52.7 ml for TURP). Only one study reported a prostate volume range (30–82 for ml TUMT and 31–86 ml for TURP).

Dahlstrandt 1995 used the Madsen Symptom Score, so in pooling of data this was considered together with IPSS for symptom score as an outcome (using SMD) at 3, 6, 12 and 24 months; pooling of data was also possible for Qmax (same timing), PVR at 3, 6 and 12 months, and re-intervention. Significant differences were observed in favour of TURP for symptom score at 3 months (mean 0.36, 95% CI 0.07–0.66; $I^2=0\%$, uncertain RoB), 6 months (mean 0.44, 95% CI 0.18–0.70; $I^2=2\%$, high RoB), 12 months (mean 0.63, 95% CI 0.40–0.85; $I^2=85\%$, high RoB) and 24 months (mean 2.04, 95% CI 0.96–3.12; $I^2=88\%$, high RoB); Qmax at 3 months (mean –4.31 ml/s, 95% CI –6.25 to –2.37; $I^2=59\%$, high RoB), 6 months (mean –2.94 ml/s, 95% CI –4.43 to –1.44; $I^2=91\%$, high RoB), 12 months (mean –5.52 ml/s, 95% CI –7.18 to –3.87; $I^2=79\%$, high RoB) and 24 months (mean –5.52 ml/s, 95% CI –7.72 to –3.33; $I^2=0\%$, high RoB); and PVR at 12 months (mean 22.56 ml, 95% CI 6.82–38.31; $I^2=66\%$, high RoB). The latter analysis lacks statistical significance when data from Dahlstrandt 1995 (showing very high values) are excluded. High heterogeneity could be explained by attrition bias in one study (D’Ancona 1998, for longer follow-up), a possible impact of unequal randomisation on study power in two studies (D’Ancona 1998 and Wagrell 2002), and data reliability in Floratos 2001 (data extracted from figures). The differences were below the MCID for IPSS and higher than the MCID for Qmax. The quality of the evidence was judged moderate for symptom score at 3 months (owing to imprecision) and 6 months (owing to RoB); low for symptom score and Qmax at 12 months (owing to inconsistency and RoB) and Qmax at 24 months (owing to imprecision and RoB); and very low for symptom score at 24 months and for Qmax at 3 and 6 months (owing to imprecision, inconsistency and RoB).

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Symptom intensity score at 3 months (Dahlstrandt 1995 reported the Madsen Symptom Score; SMDs used)




Note: lower scores are better.

Symptom intensity score at 3 months in the sensitivity analysis excluding D’Ancona 1998 (imbalanced randomisation, possibly underpowered)




Note: lower scores are better.

Symptom intensity score at 6 months (Dahlstrandt 1995 reported the Madsen Symptom Score; SMDs used)




Note: lower scores are better.

Symptom intensity score at 12 months (Dahlstrandt 1995 reported the Madsen Symptom Score; SMDs used)




Note: lower scores are better.

Symptom intensity score at 24 months




Note: lower scores are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 6 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

Qmax (ml/s) at 24 months




Note: higher Qmax values are better.

PVR (ml) at 3 months




Note: lower PVR values are better.

PVR (ml) at 6 months




Note: lower PVR values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

PVR (ml) at 12 months in the sensitivity analysis excluding Dahlstrandt 1995 (very high values)



Note: lower PVR values are better.

Reintervention



4.4.1.9 WAVE

WAVE was assessed in one RCT versus sham, including 197 patients (136 WAVE vs. 61 sham) with a prostate size of 30–80 ml, with the possibility for patients in the sham arm to cross over after 3 months. Multiple publications are available with different follow-up periods. Only 3-month data (before crossover) were extracted (McVary 2016b; low RoB). Outcomes assessed in the RCT are indicated in Table 4-29. No data for reintervention, hospitalisation time or procedure time were reported.

Table 4-29: Effectiveness outcomes assessed in McVary 2016b comparing WAVE versus sham

| Study ID | McVary 2016b |
|--------------------|--------------|
| IPSS at 1 month | x |
| IPSS at 3 months | x |
| IPSS at 6 months | x |
| IPSS at 12 months | x |
| Qmax at 1 month | x |
| Qmax at 3 months | x |
| Qmax at 6 months | x |
| Qmax at 12 months | x |
| BPH II at 3 months | x |
| QoL at 1 month | x |
| QoL at 3 months | x |
| QoL at 6 months | x |
| QoL at 12 months | x |
| PVR at 3 month | x |

IPSS, Qmax, QoL and PBHII at 3 months significantly differed between the groups, in favour of WAVE (Table 4-30). Lack of CIs for these estimates precluded assessment of their variability. The mean change in IPSS at 3 months was -11.2 (95% CI -12.5 to -9.9) in the WAVE arm and -4.3 (95% CI -6.1 to -2.5) in the sham arm, which was a significant difference in favour of WAVE ($p < 0.0001$). The reduction in both arms was above the MCID of 3 points, but whether the difference between the two technologies is above the MCID is unclear. For Qmax the mean change at 3 months was 6.2 ml/s in the WAVE arm and 0.5 ml/s in the sham arm, a significant difference in favour of WAVE ($p < 0.0001$). The mean change in the WAVE arm was above the MCID of 2 ml/s. At 3 months, the decrease in mean BPHII score was -3.4 (95% CI -4.0 to -2.4) in the WAVE arm and -0.9 (95% CI -1.3 to -0.5) in the sham arm, a significant difference in favour of WAVE ($p = 0.0003$). The mean reduction in QoL score at 3 months (a lower score indicates a patient benefit) was -2.1 (95% CI -2.4 to -1.8) in the WAVE arm and -0.9 (95% CI -1.3 to -0.5) in the sham arm, a significant difference in favour of WAVE ($p < 0.0001$).

It was not possible to assess how WAVE compares to other technologies because of the lack of head-to-head comparisons.

Table 4-30: Effectiveness outcomes assessed in RCTs comparing WAVE versus sham

| WAVE vs. sham (McVary 2016a, McVary 2016b, Roehrborn 2017, McVary 2018, McVary 2019; n=135; high risk of bias) | | | |
|---|-------------|-------------|--------------------|
| Outcome | WAVE | Sham | p value |
| Qmax at 3 months (ml/s) | 16.1 | 10.8 | <0.01; 95% CI n.a. |
| BPHI at 3 months | 2.9 | 4.7 | <0.01; 95% CI n.a. |
| IPSS at 3 months | 10.8 | 17.5 | <0.01; 95% CI n.a. |
| QoL at 3 months | 2.3 | 3.5 | <0.01; 95% CI n.a. |

Abbreviations: n.a.=not available.

4.4.1.10 Nonablative techniques

TUIP

TUIP versus TURP

TUIP was assessed in five RCTs in comparison to TURP (Abd-El Kader 2012, Dørflinger 1992, Jahnsen 1998, Riehmman 1995, Tkocz 2002), including a total of 451 patients with prostate size of <30 ml (except Jahnsen 1998, in which patients with prostate size between 20 and 40 ml were included; the mean size was 26 ml). Outcomes assessed in these studies are listed in Table 4-31; it should be noted that Dørflinger 1992 and Jahnsen 1998 used the Madsen-Iversen Symptom Score instead of IPSS, and Riehmman 1995 used the Nedsen BPH questionnaire; all have been used as symptom intensity scores). No data were available for BPHII.

Table 4-31: Effectiveness outcomes assessed in RCTs comparing TUIP versus TURP

| Study ID | Abd-El Kader 2012 | Dørflinger 1992 | Jahnsen 1998 | Rihmann 1995 | Tkocz 2002 |
|--------------------------------|-------------------|-----------------|--------------|--------------|------------|
| IPSS at 3 months | | | | | |
| IPSS at 12 months | | | | | |
| IPSS at 24 months | | | | x | x |
| IPSS at 48 months | x | | | x | |
| Qmax at 3 months | | x | | | |
| Qmax at 12 months | | x | | | |
| Qmax at 24 months | | | | x | x |
| Qmax at 48 months | x | | | x | |
| Qmed at 48 months | x | | | | |
| PVR at 48 months | x | | | | |
| QoL at 24 months | | | | | x |
| Reintervention total | | | x | | |
| Reintervention at 12 months | | x | | | |
| Reintervention at 48 months | x | | | x | |
| Persistent irritative symptoms | | x | | | |
| Postoperative LUTS | | x | | | |
| Hospitalisation time | x | | | x | |
| Procedure time | x | x | x | x | |


Pooling of data was possible for symptom intensity scores (at 3, 12 and 24 months), Qmax (at 3, 12, 24 and 48 months) and reintervention. Significant differences were observed in favour of TURP for Qmax at 3 months (mean -4.87 ml/s, 95% CI -7.32 to -2.42 ; $I^2=0\%$, high RoB), 12 months (mean -4.71 ml/s, 95% CI -7.54 to -1.88 ; $I^2=0\%$, high RoB), 24 months (mean -1.12 ml/s, 95% CI -1.80 to -0.44 ; $I^2=89\%$, high RoB) and 48 months (mean -1.80 ml/s, 95% CI -2.20 to -1.40 ; $I^2=0\%$, high RoB) and reintervention (RR 1.80, 95% CI 1.08–3.00; $I^2=0\%$, high RoB). Hospitalisation time was shorter for TUIP (~ 1 day less) as well as procedure time (up to 40 min less). No differences were observed for symptom score (from pooled data), PVR, QoL, Qmed, persistent irritative symptoms or postoperative LUTS (from single RCTs). No data were retrieved for BPHII.

Three of the five studies included for direct comparison of TUIP versus TURP (Jahnsen 1998, Rihmann 1995, Dørflinger 1992) were judged at high RoB and two at uncertain RoB. Results for functional outcomes seem to indicate that for patients with a small prostate (<30 – 40 ml) TURP performs better for Qmax at all time points. The MD values are higher than the MCID up to 1 year (decreasing thereafter), with low quality of evidence at 3, 12 and 48 months (RoB and imprecision) and very low quality of evidence at 24 months (with additional inconsistency, which was not easy to explain given the quite homogeneous populations in the studies, except for the slightly older population in Jahnsen 1998). There was also 80% higher relative risk of reintervention with TUIP, for which the quality of the evidence was judged as low owing to RoB and imprecision. It should be noted that three of the five studies were carried out in the 1990s and the technology might have undergone some technical changes since then.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Symptom intensity score at 3 months (different questionnaires; SMDs used)




Note: lower scores are better.

Symptom intensity score at 12 months (different questionnaires; SMDs used)




Note: lower scores are better.

Symptom intensity score at 24 months (different questionnaires; SMDs used)




Note: lower scores are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

Qmax (ml/s) at 24 months




Note: higher Qmax values are better.

Qmax (ml/s) at 48 months




Note: higher Qmax values are better.


Reintervention within 48–60 months



Hospitalisation time (days)



Procedure time (min)



TUIP + TURP versus TURP

TUIP was also tested in association with TURP in two RCTs, including a total of 164 patients, with TURP alone as the comparator. Yeni 2002 (n=40) and Li 2013 (n=124) included patients with a small prostate (<25 ml in Yeni 2002 and 20–40 ml in Li 2013), assessing the outcomes listed in [Table 4-32](#). Yeni 2002 reported changes from baseline for IPSS and Qmax and these data could

not be pooled. Li 2013 reported higher Qmax at 6 months for TUIP + TURP (mean 6.69, 95% CI 4.29–9.09; high RoB). Data for procedure time showed high heterogeneity (favouring TURP in Li 2013 and TURP + TUIP in Yeni 2002). No data are available for PVR, Qmed, BPHII, reintervention, irritative symptoms or postoperative LUTS (as a binary outcome).

Table 4-32: Effectiveness outcomes assessed in RCTs comparing TUIP + TURP versus TURP


| Study ID | Li 2013 | Yeni 2002 |
|----------------------|---------|----------------|
| IPSS at 6 months | x | x ^a |
| Qmax at 6 months | x | x ^a |
| QoL at 6 months | x | |
| Hospitalisation time | x | x |
| Procedure time | x | x |

^a Data could not be extrapolated.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Procedure time (min)



Hospitalisation time (days)



PAE

PAE was assessed in five RCTs: Abt 2018 (n=103; prostate size 25–80 ml), Carnevale 2016 (n=30; prostate size 32–97 ml), Gao (n=114; prostate size 20–100 ml), Insausti 2020 (n=45; average prostate size 60 ml) and Radwan 2020 (n=60; prostate size <100 ml), comparing PAE to TURP for the outcomes listed in Table 4-33 and including a total of 352 patients. Two of these RCTs postulated a noninferiority hypothesis for PAE versus TURP: Abt 2018 for IPSS at 3 months (primary endpoint) for a difference of <3 points, which was rejected as an adjusted analysis showed an estimated difference of 2.9, with the CI including differences up to 5.2 that may be clinically relevant. Insausti 2020 hypothesised a difference for noninferiority < -0.5 ml/s for Qmax at 1 year, that was also rejected.

Pooling of data was only possible for IPSS at 3 months (MD 3.48, 95% CI 2.86–4.11; $I^2=0\%$, uncertain RoB, moderate quality of evidence owing to imprecision) and persistent irritative symptoms (RR 0.59, 95% CI 0.28–1.21; $I^2=20\%$, high RoB, low quality of evidence owing to imprecision and RoB). Pooling was not performed for other outcomes because of statistical heterogeneity (unexplained) and lack of SD values in Insausti 2020 and Radwan 2020. Insausti 2020 reported within-group differences for QoL that favoured TURP (MD 0.69, 95% CI not available). Radwan 2020 presented data for two TURP groups (M-TURP and B-TURP) that could not be combined, and also reported within-group differences favouring TURP for IPSS at 6 months (MD 4; p value and 95% CI not available) and Qmed (MD 5; $p>0.001$, 95% CI not available),

Table 4-33: Effectiveness outcomes assessed in RCTs comparing PAE versus TURP

| Study ID | Abt 2018 ^a | Insausti 2020 ^b | Radwan 2020 ^b | Carnevale 2016 | Gau 2014 ^a |
|--------------------------------|-----------------------|----------------------------|--------------------------|----------------|-----------------------|
| IPSS at 1 month | | | x | | x |
| IPSS at 3 months | x | x | | | x |
| IPSS at 6 months | | x | x | | x |
| IPSS at 12 months | | x | | x | x |
| IPSS at 24 months | | | | | x |
| Qmax at 1 month | | | | | x |
| Qmax at 3 months | x | x | | | x |
| Qmax at 6 months | | x | x | | x |
| Qmax at 12 months | | x | | x | x |
| Qmax at 24 months | | | | | x |
| PVR at 1 month | | | | | x |
| PVR at 3 months | x | x | | | x |
| PVR at 6 months | | x | | | x |
| PVR at 12 months | | x | | x | x |
| PVR at 24 months | | | | | x |
| QoL at 1 month | | | | | x |
| QoL at 3 months | x | x | | | x |
| QoL at 6 months | | x | | | x |
| QoL at 12 months | | x | | x | x |
| QoL at 24 months | | | | | x |
| Qmed at 1 month | | | x | | |
| Persistent irritative symptoms | x | x | | | |
| Postoperative LUTS | | | | x | |
| Hospitalisation time | x | x ^c | | x ^c | x |
| Procedure time | x | | x | x | x |

^a Data for IPSS, Qmax, PVR and QoL were extracted from graphs.


^b SD values for IPSS, Qmax, PVR and QoL data in Insausti 2020 and IPSS and Qmax data in Radwan 2020 were not extrapolated.

^c It was not possible to use these data.

Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

IPSS at 3 months




Note: lower IPSS scores are better.

IPSS at 12 months




Note: lower IPSS scores are better.

Qmax (ml/s) at 3 months




Note: higher Qmax values are better.

Qmax (ml/s) at 12 months




Note: higher Qmax values are better.

PVR (ml) at 12 months




Note: lower PVR values are better.

QoL at 12 months




Note: lower QoL scores are better.


Persistent irritative symptoms



Hospitalisation time (days)



Procedure time (min)



Prostatic urethral lift

PUL was assessed in two publications (Sonksen 2015, n=79; Gratzke 2017, n=80; high RoB) presenting data at different follow-up times for the same RCT in comparison to TURP. The outcomes assessed are listed in Table 4-34. There were no unassessed functional outcomes.

Table 4-34: Effectiveness outcomes assessed in RCTs comparing PUL versus TURP

| Study ID | Gratzke 2017 | Sonksen 2015 |
|-------------------|--------------|--------------|
| IPSS at 1 month | x | x |
| IPSS at 3 months | x | x |
| IPSS at 6 months | x | x |
| IPSS at 12 months | x | x |
| IPSS at 24 months | x | |
| Qmax at 3 months | x | x |
| Qmax at 6 months | x | x |

| Study ID | Gratzke 2017 | Sonksen 2015 |
|-----------------------------|--------------|--------------|
| Qmax at 12 months | x | x |
| Qmax at 24 months | x | |
| PVR at 3 months | x | x |
| PVR at 6 months | x | x |
| PVR at 12 months | x | x |
| PVR at 24 months | x | |
| Reintervention at 1 month | | x |
| Reintervention at 12 months | | x |
| Reintervention at 24 months | x | |
| BPHII at 1 month | x | x |
| BPHII at 3 months | x | x |
| BPHII at 6 months | x | x |
| BPHII at 12 months | x | x |
| BPHII at 24 months | x | |
| QoL at 1 month | x | x |
| QoL at 3 months | x | x |
| QoL at 6 months | x | x |
| QoL at 12 months | x | x |
| QoL at 24 months | x | |
| Hospitalisation time | | x |
| Procedure time | | x |

This RCT included patients with a prostate volume ≤ 60 ml. Prostate volume ranged from 16 ml to 59 ml in the PUL group, and from 17 ml to 68 ml in the TURP group. Qmax at 3, 6, 12 and 24 months, PVR at 3, 6 and 12 months, and IPSS at 12 and 24 months after surgery showed significant differences between the groups in favour of TURP (Table 4-35). Differences were also above the MCID for both IPSS reduction (-11.4 PUL vs. -15.4 TURP at 12 months, and -9.2 PUL vs. -15.3 TURP at 24 months) and Qmax improvement (4.0 ml/s PUL vs. 13.7 ml/s TURP at 12 months and 5.0 ml/s PUL vs. 15.5 ml/s TURP at 24 months). There were no significant differences in QoL or BPHII.

Table 4-35. Effectiveness results from the RCT comparing PUL versus TURP

| PUL vs. TURP (Sonksen 2015, n=79; Gratzke 2017, n=80; high risk of bias) | | | |
|--|------|------|---------------------|
| Outcome | PUL | TURP | p value |
| Qmax at 3 months (ml/s) | 13.6 | 21.7 | <0.001; 95% CI n.a. |
| Qmax at 6 months (ml/s) | 13.5 | 19.0 | 0.003; 95% CI n.a. |
| Qmax at 12 months (ml/s) | 13.6 | 23.2 | <0.001; 95% CI n.a. |
| Qmax at 24 months (ml/s) | 14.3 | 25.5 | 0.002; 95% CI n.a. |
| PVR at 3 months (ml) | 77.3 | 47.6 | 0.01; 95% CI n.a. |
| PVR at 6 months (ml) | 80.7 | 46.2 | 0.01; 95% CI n.a. |
| PVR at 12 months (ml) | 93.7 | 33.6 | 0.002; 95% CI n.a. |

| PUL vs. TURP (Sonksen 2015, n=79; Gratzke 2017, n=80; high risk of bias) | | | |
|---|------------|-------------|--------------------|
| Outcome | PUL | TURP | p value |
| PVR at 24 months (ml) | 69.9 | 56.4 | 0.09 |
| IPSS at 1 month | 10.5 | 12.9 | 0.42 |
| IPSS at 3 months | 10.5 | 10.8 | 0.98 |
| IPSS at 6 months | 9.2 | 8.0 | 0.42 |
| IPSS at 12 months | 10.9 | 7.3 | 0.01; 95% CI n.a. |
| IPSS at 24 months | 12.2 | 7.4 | 0.004; 95% CI n.a. |
| QoL at 1 month | 2.2 | 3.0 | 0.14 |
| QoL at 3 months | 2.1 | 2.4 | 0.55 |
| QoL at 6 months | 1.9 | 1.8 | 0.79 |
| QoL at 12 months | 1.9 | 1.5 | 0.44 |
| QoL at 24 months | 2.1 | 1.3 | 0.07 |
| BPHII at 1 month | 4.0 | 5.3 | 0.14 |
| BPHII at 3 months | 2.6 | 3.8 | 0.10 |
| BPHII at 6 months | 2.3 | 2.2 | 0.79 |
| BPHII at 12 months | 2.3 | 1.8 | 0.84 |
| BPHII at 24 months | 3.0 | 1.5 | 0.13 |

Abbreviations: n.a.=not available.

4.4.2 Safety

HTA CORE MODEL DOMAIN: SAF⁶

4.4.2.1 Resection techniques

TmLRP

TmLRP versus TURP

TmLRP was assessed in two of the RCTs (Xia 2008, n=100; Yan 2013, n=80) against TURP as the comparator for the outcomes listed in [Table 4-36](#).

Table 4-36: Safety outcomes assessed in RCTs comparing TmLRP versus TURP

| Study ID | Xia 2008 | Yan 2013 |
|--|-----------------|-----------------|
| <i>Intraoperative complications</i> | | |
| Transfusion requirement | x | x (0 events) |
| Decrease in serum sodium | x | x |

⁶ This section addresses the following assessment element: C0002, C0005, C0007, C0008.

| Study ID | Xia 2008 | Yan 2013 |
|--|--------------|--------------|
| Postoperative complications | | |
| IIEF (erectile dysfunction score) at 6 months | x | |
| IIEF (erectile dysfunction score) at 12 months | x | |
| Urinary incontinence | x | x |
| Catheterisation time | x | x |
| TUR syndrome | x | x (0 events) |
| Urethral stricture | x | x |
| Acute urinary retention | x | |
| Urinary tract infection | x | |
| Retrograde ejaculation | x | x |
| Recatheterisation | x (0 events) | x |


Patients included in these studies had prostate size between 30 and 97 ml, mostly falling within 30–80 ml.

Pooling of data was possible for decrease in serum sodium, urinary incontinence, urethral stricture and retrograde ejaculation. Decrease in serum sodium was the only outcome showing a difference, which was in favour of TmLRP (mean -3.73 mmol/l, 95% CI -4.41 to -3.05 ; $I^2=0\%$, uncertain RoB). The quality of the evidence for this outcome was moderate owing to uncertain RoB for several domains.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Decrease in serum sodium (mmol/l)




Urinary incontinence




Urethral stricture




Retrograde ejaculation for all patients



Retrograde ejaculation for sexually active patients



Catheterisation time (h)



4.4.2.2 Enucleation techniques

HoLEP

HoLEP was assessed in 23 of the selected RCTs (see Table 4-3), including a total of 2688 patients. Twenty-two RCTs were two-arm studies and one (Elshal 2020) was a three-arm RCT. Fourteen studies compared HoLEP versus TURP (n=1549), three compared HoLEP versus ThuLEP (n=485) and versus B-TUEP (n=211), two compared HoLEP versus PVP (n=223), and one compared HoLEP versus DioLEP (n=126) and versus ThuVEP (n=94).

HoLEP versus TURP

Fourteen RCTs compared HoLEP versus TURP for the outcomes indicated in Table 4-37. No study provided data on bladder perforation.

Table 4-37: Safety outcomes assessed in RCTs comparing HoLEP versus TURP

| Study ID | Sun 2014 | Tan 2003 | Bai 2019 | Basic 2013 | Chen 2013 | Eltabey 2010 | Fayad 2015 | Hamouda 2014 | Jhanwar 2017 | Gupta 2006 | Kuntz 2004 | Mavuduru 2009 | Montorsi 2004 | Elishal 2020 |
|----------------------------|----------|----------|----------|------------|----------------|--------------|------------|--------------|----------------|------------|----------------|---------------|---------------|----------------|
| Transfusion requirement | x | x | | x | x | x | x | x | x | x | x | x | x | x |
| Bladder or ureteral injury | | | | x | | | | | | x | | | | x ^c |
| Capsular perforation | | | | | | | | | | x | | x | | x |
| Decrease in serum sodium | x | | | | x | | x | | x | x | x | | | |
| Erectile dysfunction | | | | | | | | | x | | | | | |
| Urinary incontinence | | x | | x | x | x | x | x | x | x | x | x | x | x |
| Catheterisation time | x | x | x | x | x | x | x | x | x | x | x | x | x | x ^b |
| TUR syndrome | | | | | x ^c | | | | x ^c | | | | x | |
| Urethral stricture | x | x | | | x ^a | x | x | x | x | x | x | x | x | |
| Bladder neck contracture | | | | x | x ^a | | | | | | x | | | X |
| Acute urinary retention | | | | x | | | x | | | | | | x | |
| Urinary tract infection | | x | | | | | | x | x | | | | | x ^c |
| Retrograde ejaculation | | | | | x | | | | | | x ^a | | | |
| Recatheterisation | | x | | | x | | | | x ^c | x | x | x | | x |

^a Could not be extrapolated since only the percentage of sexually active patients with this complication is reported and there is no indication of the number of sexually active patients.

^b Data estimated according to McGrath et al. [63].

^c Zero events.

Patients included in the selected studies were heterogeneous in terms of prostate size category. The average size was available in 13 of the 14 studies, whereas information on prostate size range was available in only five studies (range: from 20 to 156 ml). Prostate size was used as an inclusion criterion in only six studies. Regarding our prespecified prostate size subgroups, none of the studies included patients that could be assigned exclusively to one of these. All but three studies included patients in the 30–80 ml range.

Pooling of data was possible for all of the outcomes above, except for erectile dysfunction (but IIEF-5 was available) and retrograde ejaculation, for which no differences were found. Data from Montorsi 2004 were excluded from analyses because of a relevant baseline imbalance in mean prostate size. Data from Basic 2013 were excluded since this study appears to be an outlier among all the analyses and the patient cohort had a smaller prostate size and was younger than in most of the other studies.


Differences in favour of HoLEP were found for transfusion requirement (RR 0.19, 95% CI 0.08–0.45; $I^2=0\%$, high RoB), decrease in serum sodium (–0.86 mmol/l, 95% CI –1.47 to –0.26; $I^2=72\%$, high RoB), catheterisation time (–15.72 h, 95% CI –17.88 to –13.56; $I^2=62\%$) and UTI (RR 0.19, 95% CI 0.07–0.50; $I^2=0\%$, uncertain RoB). Differences in favour of TURP were found for urinary incontinence (RR 1.89, 95% CI 1.09–3.27; $I^2=3\%$, high RoB). Pooled results do not show differences for bladder or ureteral injury, capsular perforation, IIEF-5, urethral stricture, bladder neck contracture, AUR or recatheterisation. No study provided data on bladder perforation.

Heterogeneity does not seem to be associated with prostate size. The quality of the evidence was judged as moderate for transfusion requirement and urinary incontinence (owing to high to uncertain RoB in the studies included) and UTI (owing to imprecision) and low for decrease in serum sodium (owing to RoB and inconsistency).


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement




Capsular perforation




Decrease in serum sodium (mmol/l)




IIEF-5 at 6 months




Urinary incontinence




Catheterisation time (h)




Urethral stricture




Bladder neck contracture




Acute urinary retention



Urinary tract infection



Recatheterisation



HoLEP versus B-TUEP

Three RCTs compared HoLEP versus B-TUEP. Patients included in Habib 2020 and Higazy 2020 had a prostate size >80 ml and can be classified in the large prostate subgroup, whereas patients in Neill 2006 mostly had prostate size within the 30–80 ml subgroup. These three studies provided data for the outcomes listed in Table 4-38. No data were available for bladder perforation, bladder or ureteral injury, erectile dysfunction, TUR syndrome or retrograde ejaculation.

Table 4-38: Safety outcomes assessed in RCTs comparing HoLEP versus B-TUEP


| Study ID | Neill 2006 | Habib 2020 | Higazy 2020 |
|-------------------------------------|--------------|------------|-------------|
| Intraoperative complications | | | |
| Transfusion requirement | x (0 events) | x | |
| Bladder or ureteral injury | | | x |
| Capsular perforation | | x | x |
| Intraoperative mortality | | | x |
| Decrease in serum sodium | | x | |
| Postoperative complications | | | |
| Urinary incontinence | x | x | x |
| Catheterisation time | x | x | x |
| Urethral stricture | x (0 events) | | x |
| Bladder neck contracture | | x | x |
| Acute urinary retention | | x | |
| Urinary tract infection | x | x | x |
| Recatheterisation | x | | |

Pooling of data was possible for capsular perforation, urinary incontinence, bladder neck contracture and UTI. Catheterisation time was shorter for HoLEP in two out of the three RCTs (pooling was not carried out owing to heterogeneity). No differences were found for other outcomes.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Capsular perforation




Urinary incontinence




Catheterisation time (h)



Bladder neck contracture



Urinary tract infection



HoLEP versus DioLEP

One RCT (He 2019; n=126; low RoB) compared HoLEP versus DioLEP among patients with an average prostate size of 79.3 ml, assessing catheterisation time, decrease in serum sodium, dysuria/urinary retention, recatheterisation, retrograde ejaculation, urinary incontinence, UTI, urethral stricture, bladder neck contracture, bladder injury, blood transfusion, capsule perforation and TUR syndrome. No differences for any outcome were observed between the groups.

HoLEP versus ThuLEP

Three RCTs (Zhang F 2012, n=133; uncertain RoB; Zhang 2020, n=116; uncertain RoB; Bozzini 2020, n=236; high RoB) compared HoLEP versus ThuLEP for the outcomes listed in Table 4-39. The three studies enrolled different populations in terms of prostate size (mean 45 ml in Zhang F 2012, 88 ml in Bozzini 2020 and 92 ml in Zhang 2020). Data could be pooled for bladder or ureteral injury, urinary incontinence, urethral stricture, bladder neck contracture and AUR. A difference in favour of ThuLEP was found for urinary incontinence (RR 3.40, 95% CI 1.14–10.14; I²=0%, high RoB). The quality of the evidence was judged as moderate because of RoB.

Table 4-39: Safety outcomes assessed in RCTs comparing HoLEP versus ThuLEP


| Study ID | Zhang F 2012 | Bozzini 2020 | Zhang 2020 |
|----------------------------|--------------|--------------|------------|
| Transfusion requirement | x (0 events) | x | |
| Bladder or ureteral injury | | x | x |
| Capsular perforation | x | | |

| Study ID | Zhang F 2012 | Bozzini 2020 | Zhang 2020 |
|--------------------------|--------------|--------------|------------|
| Urinary incontinence | | x | x |
| Catheterisation time | x | x | x |
| Urethral stricture | | x | x |
| Bladder neck contracture | x | | x |
| Acute urinary retention | | x | x |
| Urinary tract infection | | | x |
| Recatheterisation | | | x |


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Bladder or ureteral injury




Urinary incontinence





Catheterisation time (days)



Urethral stricture



Bladder neck contracture*Acute urinary retention***HoLEP versus ThuVEP**

One RCT (Netsch 2017; n=94; uncertain RoB) compared HoLEP versus ThuVEP among patients with prostate size ranging from 46 to 110 ml, assessing AUR, bladder injury, UTI and urinary incontinence. A difference in favour of ThuVEP was shown for AUR (15.2% vs. 2.1%; p=0.02, 95% CI not available).

HoLEP versus PVP

Two RCTs (Elshal 2015, n=103; uncertain RoB; Elshal 2020, n=120; uncertain RoB) compared HoLEP versus PVP among patients with prostate size ranging from 40 to 150 ml for the outcomes listed in Table 4-40. Pooling of data was possible for bladder or ureteral injury, capsular perforation, bladder neck contracture, UTI and recatheterisation. No differences for any of the outcomes assessed were observed between the groups.

Table 4-40: Safety outcomes assessed in RCTs comparing HoLEP versus PVP

| Study ID | Elshal 2015 | Elshal 2020 |
|-----------------------------------|--------------|----------------|
| Transfusion requirement | x | x (0 events) |
| Bladder or ureteral injury | x | x |
| Capsular perforation | x | x |
| Decrease in serum sodium | x | |
| IIEF (erectile dysfunction score) | | x |
| Urinary incontinence | x (0 events) | x |
| Catheterisation time | x | x ^a |
| Urethral stricture | x | |
| Bladder neck contracture | x | x |
| Acute urinary retention | | x |
| Urinary tract infection | x | x |
| Retrograde ejaculation | | x |
| Recatheterisation | x | x |


^a Data estimated according to McGrath et al. [63].

Pooling of data was possible for the majority of the safety outcomes. Data were in favour of ThuLEP for transfusion requirement (RR 0.24, 95% CI 0.06–0.94; $I^2=0\%$, uncertain RoB). The quality of the evidence was judged as moderate (owing to imprecision). Catheterisation time was shorter for ThuLEP in three of the four RCTs, with highly heterogeneous results. There were no statistically significant differences between the groups for the other outcomes.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement




Urinary incontinence




Catheterisation time (days)




Urethral stricture




Bladder neck contracture




Acute urinary retention



Urinary tract infection



Retrograde ejaculation



ThuLEP versus B-TUEP

See the section on B-TUEP.

ThuLEP versus HoLEP

See the section on HoLEP.

DioLEP

DioLEP was assessed in six of the RCTs, including a total of 506 patients: two RCTs versus TURP (n=212), two RCTs versus B-TUEP (n=194), and one RCT versus each of HoLEP (n=126) and B-ERP (n=80).

DioLEP versus TURP

Two RCTs (Lusuardi 2011, n=60; uncertain RoB; Zhang 2019, n=152; low RoB) compared DioLEP versus TURP. The prostate volume range was similar in both studies (32–80 ml and 34–89 ml for DioLEP and 34–80 ml and 35–89 ml for TURP). Outcomes assessed in these studies are indicated in Table 4-42. There were no data on bladder perforation, intraoperative mortality, erectile dysfunction, retrograde ejaculation or long-term mortality.

Table 4-42: Safety outcomes assessed in RCTs comparing DioLEP versus TURP


| Study ID | Lusuardi 2011 | Zhang 2019 |
|-------------------------------------|---------------|--------------|
| Intraoperative complications | | |
| Transfusion requirement | x (0 events) | x (0 events) |
| Bladder or ureteral injury | | x |
| Capsular perforation | | x |
| Decrease in serum sodium | | x |
| Postoperative complications | | |
| Urinary incontinence | x | x |
| Catheterisation time | x | x |
| TUR syndrome | | x |
| Urethral stricture | x (0 events) | x |
| Bladder neck contracture | x | |
| Urinary tract infection | x | |
| Recatheterisation | | x |

Pooling of data was only possible for urinary incontinence and catheterisation time. The latter was shorter for DioLEP (up to 2.4 days less). In both studies there was no need for blood transfusion. No differences between the groups were reported for any of the other outcomes of interest assessed in each study.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Urinary incontinence



Catheterisation time (days)



DioLEP versus B-TUEP

See the section on B-TUEP.

DioLEP versus HoLEP

See the section on HoLEP.

DioLEP versus B-TUERP

See the section on B-TUERP.

B-TUEP

B-TUEP was assessed in ten of the RCTs, with comparisons to TURP (4 RCTs; n=911), DioLEP (2 RCTs; n=194), HoLEP (2 RCTs; n=104), ThuLEP (1 RCTs; n=127) and B-TUVP and OP (1 RCT; n=320), for a total of 1656 patients.

B-TUEP versus TURP

Five RCTs compared B-TUEP versus TURP, providing data for the outcomes listed in [Table 4-43](#). No data were available for bladder perforation or bladder or ureteral injury.

Table 4-43: Safety outcomes assessed in RCTs comparing B-TUEP versus TURP

| Study ID | Luo 2014 | Ran 2013 | Zhao 2010 | Zhu 2013 | Geavlete 2015 |
|--|--------------|--------------|-----------|----------|---------------|
| Intraoperative complications | | | | | |
| Transfusion requirement | x (0 events) | x (0 events) | x | | x |
| Capsular perforation | | x | | | |
| Decrease in serum sodium | | x | | | |
| <i>Postoperative complications</i> | | | | | |
| IIEF (erectile dysfunction score) at baseline | | | x | x | |
| IIEF (erectile dysfunction score) at 6 months | | | x | x | |
| IIEF (erectile dysfunction score) at 12 months | | | x | x | |
| IIEF (erectile dysfunction score) at 24 months | | | x | x | |
| IIEF (erectile dysfunction score) at 36 months | | | x | x | |
| Urinary incontinence | x | | x | x | x |
| Catheterisation time | x | x | x | x | x |
| TUR syndrome | x (0 events) | x (0 events) | x | | |
| Urethral stricture | x | | x | | x |
| Bladder neck contracture | x | | x | | x |
| Acute urinary retention | | | | x | |
| Urinary tract infection | x | | x | x | x |
| Retrograde ejaculation | | | x | | |
| Recatheterisation | x | | | | x |


Patients included in the studies were heterogeneous in terms of prostate size category. Patients with prostate size >70 ml and >80 ml were included in Zhu 2013 and Geavlete 2015, respectively, whereas patients in the other three studies had an average prostate size between 62 and 69 ml (no range or inclusion criteria available). Pooling of data was possible for all of the outcomes assessed by (or with data in) more than one study.

Catheterisation time was shorter for B-TUEP in four of the five RCTs (MD up to 29 h less). The risk of urinary incontinence was higher for B-TUEP (RR 1.88, 95% CI 1.14–3.10; I²=22%, high RoB), with the quality of evidence judged as very low because of indirectness, inconsistency and high RoB.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement




Urinary tract infection




IIEF at 6 months




IIEF at 12 months




IIEF at 24 months




IIEF at 36 months




Urinary incontinence





Catheterisation time (h)



Urethral stricture



Bladder neck contracture*Recatheterisation***B-TUEP versus HoLEP**

See the section on HoLEP.

B-TUEP versus DioLEP

Two RCTs with uncertain RoB (Wu 2016; Zou 2018) compared B-TUEP versus DioLEP. Patients included in Wu 2016 had a prostate size >80 ml and can be classified in the large prostate subgroup, whereas patients in Zou 2018 had prostate size between 20 and 160 ml (mean: 62 ml). These two studies provided data for the outcomes listed in Table 4-44. No data were available for bladder perforation, bladder or ureteral injury, decrease in serum sodium or AUR.

Table 4-44: Safety outcomes assessed in RCTs comparing B-TUEP versus DioLEP

| Study ID | Wu 2016 | Zou 2018 |
|--|---------|----------------|
| <i>Intraoperative complications</i> | | |
| Transfusion requirement | x | |
| Capsular perforation | x | |
| <i>Postoperative complications</i> | | |
| IIEF (erectile dysfunction score) at 3 months | x | |
| IIEF (erectile dysfunction score) at 6 months | x | x |
| IIEF (erectile dysfunction score) at 12 months | x | x ^a |
| Urinary incontinence | x | x |
| Catheterisation time | x | x ^a |
| TUR syndrome | x | |
| Urethral stricture | x | |
| Bladder neck contracture | | x |
| Urinary tract infection | | x |
| Retrograde ejaculation | x | x |
| Recatheterisation | x | x |


^a Data calculated according to the Cochrane Handbook method.

Pooling of data was possible for urinary incontinence, retrograde ejaculation, recatheterisation, IIEF at 6 months and irritative symptoms. No differences between the groups were found for any of these outcomes.

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Urinary incontinence




Retrograde ejaculation



Catheterisation time (days)



Recatheterisation



IIEF at 6 months



B-TUEP versus ThuLEP

One RCT with uncertain RoB (Feng 2016; n=127) compared B-TUEP versus ThuLEP among patients with an average prostate size of 68 ml, assessing catheterisation time, TUR syndrome, urinary incontinence, decrease in serum sodium, capsule perforation, urethral stricture, bladder mucosal damage, blood transfusion requirement, UTI, recatheterisation and bladder neck contracture. A shorter catheterisation time was observed in favour of ThuLEP (1.9 vs. 2.3 days; p=0.04, 95% CI not available).

B-TUEP versus B-TUVP

One RCT with high RoB (Geavlete 2015; n=160) compared B-TUEP versus B-TUVP among patients with a prostate size >80 ml, assessing catheterisation time and blood transfusion requirement. No differences between the groups were observed.

B-TUEP versus OP

One RCT with high RoB (Geavlete 2015; n=160) compared B-TUEP versus OP among patients with a prostate size >80 ml, assessing catheterisation time and blood transfusion requirement. A shorter catheterisation time was observed in favour of B-TUEP (1.6 vs. 5.4 days; p value and 95% CI not available).

4.4.2.3 Vaporisation techniques**B-TUVP**

B-TUVP was assessed in 15 RCTs including a total of 2170 patients: ten RCTs versus TURP (n=1691), two RCTs versus PVP (n=117) and one RCT each versus DioLVP (n=55), B-TUEP (n=147) and OP (n=160).

B-TUVP versus TURP

B-TUVP was assessed in comparison to TURP in ten RCTs (Elsakka 2016, Geavlete 2011, Geavlete 2014, Geavlete 2015, Hon 2016, Karadag 2014, Kaya 2007, Nuhoglu 2011, Tefekli 2005, Zhang S. 2012) that included a total of 1691 patients. Outcomes assessed in these studies are listed in [Table 4-45](#).

Table 4-45: Safety outcomes assessed in RCTs comparing B-TUVP versus TURP

| Study ID | Elsakka 2016 | Geavlete 2011 | Geavlete 2014 | Geavlete 2015 | Hon 2006 | Karadag 2014 | Kaya 2007 | Nuhoglu 2011 | Tefekli 2005 | Zhang S 2012 |
|--|--------------|---------------|---------------|---------------|----------|--------------|-----------|--------------|--------------|--------------|
| <i>Intraoperative complications</i> | | | | | | | | | | |
| Transfusion requirement | x | x | | x | x | x | | x | x | x |
| Bladder perforation | x | | | | | | | | | |
| Bladder or ureteral injury | | | x | | | | | | | |
| Capsular perforation | | x | | | | | | | | |
| Intraoperative mortality | x | | | | | | | | | |
| Decrease in serum sodium | x | | | | x | | | | | |

| Study ID | Elsakka 2016 | Geavlete 2011 | Geavlete 2014 | Geavlete 2015 | Hon 2006 | Karadag 2014 | Kaya 2007 | Nuhoglu 2011 | Tefekli 2005 | Zhang S 2012 |
|------------------------------------|--------------|---------------|---------------|---------------|----------|----------------|----------------|----------------|----------------|--------------|
| Postoperative complications | | | | | | | | | | |
| Erectile dysfunction | | | | | | | X | | X ^a | |
| Urinary incontinence | X | X | | X | | X | X ^a | X ^a | X | |
| Catheterisation time | X | X | X | X | | X | | X | X | X |
| TUR syndrome | X | X | | | | | | X ^a | | |
| Urethral stricture | X | X | | X | X | | X | X | X | |
| Bladder neck contracture | X | X | | X | | X | | | | |
| Acute urinary retention | | | | | | | | X | X | |
| Urinary tract infection | X | X | | X | | X ^a | | | | |
| Retrograde ejaculation | | | | | | | X | | X | |
| Recatheterisation | X | X | X | X | | | | X | X | |

^a Zero events.


Prostate size was used as an inclusion criterion in seven of these ten studies. Patients included were heterogeneous in terms of the prostate size category. While four studies included patients with prostate volume of <80 ml, Kaya 2007 included patients with prostate volume of <60 ml, Zhang S 2012 with prostate size between 25 and 125 ml and Geavlete 2015 with prostate size >80 ml. The latter is the only study providing information on the range for prostate volume (80–297 ml).

Pooling of the data was possible for all outcomes in Table 4-45 except for bladder perforation, bladder or ureteral injury, capsular perforation, erectile dysfunction. Data on decrease of serum sodium were not pooled for high heterogeneity of the two available studies. A significant difference in favour of B-TUVP was found for blood transfusion requirement (RR 0.30, 95% CI 0.11–0.81; I²=0%, uncertain RoB); the quality of the evidence was rated as moderate (owing to uncertain RoB).


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement




Decrease in serum sodium (mmol/l)




Urinary incontinence




Catheterisation time (h)




TUR syndrome




Urethral stricture




Bladder neck contracture




Acute urinary retention




Urinary tract infection



Retrograde ejaculation



Recatheterisation



B-TUVP versus PVP

See the section on PVP.

B-TUVP versus DioLVP

One study (Skinner 2017, n=55; unclear RoB) compared B-TUVP versus DioLVP for the outcomes catheterisation time, stricture and bladder injury. The mean prostate size was 47 ml (no range or inclusion criteria available). No statistically significant differences between the groups were observed for any of the outcomes reported.

B-TUVP versus B-TUEP

See the section on B-TUEP.

B-TUVP versus OP

One study (Geavlete 2015, n=160; high RoB) compared B-TUVP versus OP in a cohort of patients with a prostate size >80 ml. Only data for catheterisation time and blood transfusion requirement were reported, with no significant differences observed between the groups.

DioLVP

DioLVP was assessed in three of the RCTs, including a total of 242 patients: two trials versus TURP (n=204) and one versus B-TUVP (n=55).

DioLVP versus TURP

Two RCTs (Cetinkaya 2015, n=72; high RoB; Razzaghi 2014, n=115; uncertain RoB) compared DioLVP versus TURP. Outcomes assessed in these studies are listed in [Table 4-46](#). No data for bladder perforation, bladder or ureteral injury, intraoperative mortality, retrograde ejaculation or long-term mortality were reported.

Table 4-46: Safety outcomes assessed in RCTs comparing DioLVP versus TURP

| Study ID | Razzaghi 2014 | Cetinkaya 2015 |
|--|---------------|----------------|
| <i>Intraoperative complications</i> | | |
| Transfusion requirement | x | x |
| Capsular perforation | x | x |
| Decrease in serum sodium | x | |
| <i>Postoperative complications</i> | | |
| Erectile dysfunction | x | |
| Urinary incontinence | x | |
| Catheterisation time | x | x |
| TUR syndrome | x | x ^a |
| Urethral stricture | x | x (0 events) |
| Bladder neck contracture | x | |

| Study ID | Razzaghi 2014 | Cetinkaya 2015 |
|-------------------------|---------------|----------------|
| Acute urinary retention | | x |
| Urinary tract infection | x | x (0 events) |
| Recatheterisation | x | |

^a Incomplete data.


Inclusion criteria for prostate volume varied substantially. Razzaghi 2014 excluded patients with a prostate volume >100 ml, while Cetinkaya 2015 considered prostate volumes of <80 ml. Neither of the studies reported the range for prostate volume; mean values were only slightly higher in the first study (61.1 and 50.6 ml in the DioLVP group and 59.6 and 54.8 ml in the TURP group).

Pooling of data was possible for transfusion requirement and capsular perforation. Catheterisation time was shorter for DioLVP in both studies, with very heterogeneous results. Other safety outcomes were not significantly different between the groups. Outcomes reported only in Razzaghi 2014 (decrease in serum sodium, erectile dysfunction, urinary incontinence, bladder neck contracture and recatheterisation) or only in Cetinkaya 2015 (AUR) showed no significant differences between the groups. TUR syndrome was reported in both studies, but only Razzaghi 2014 tested the difference between the DioLVP and TURP groups, which was not statistically significant.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement



Capsular perforation



Catheterisation time (days)



DioLVP versus B-TUVP

See the section on B-TUVP.

PVP

PVP was assessed in six of the RCTs, with comparisons to TURP (3 RCTs; n=465), B-TUVP (2 RCTs; n=146) and HoLEP (1 RCT; n=103).

PVP versus TURP

Three RCTs (Goliath study, with 3 publications: Bachmann 2014, Bachmann 2015, Thomas 2016, n=281; Jovanovic 2014, n=62; Elshal 2020, n=122) compared PVP versus TURP for the outcomes listed in Table 4-47. Patients in the Goliath study and Jovanovic 2014 had a prostate size <100 ml (mean: 47 ml in the Goliath study and 61 ml in Jovanovic 2014; no ranges available); Elshal 2020 enrolled patients with a prostate size between 80 and 150 ml.

No data were available for bladder perforation or decrease in serum sodium

Table 4-47: Safety outcomes assessed in RCTs comparing PVP versus TURP

| Study ID | Jovanovic 2014 | Goliath study | Elshal 2020 |
|----------------------------|----------------|---------------|----------------|
| Transfusion requirement | x | x | x |
| Bladder or ureteral injury | | | x |
| Capsular perforation | x | | x |
| IIEF at 3 months | | | x |
| IIEF at 12 months | | x | x |
| IIEF at 24 months | | x | x |
| IIEF at 36 months | | | x |
| Urinary incontinence | | x | x |
| Catheterisation time | x | x | x ^a |
| TUR syndrome | x | | |
| Urethral stricture | | x | |
| Bladder neck contracture | x | | x (0 events) |
| Acute urinary retention | | x | x |
| Urinary tract infection | | x | x |
| Retrograde ejaculation | | x | x ^b |
| Recatheterisation | | | x |

^a Data estimated according to McGrath et al. [63].

^b Data not extractable.


Pooling of data was possible for blood transfusion, capsular perforation, urinary incontinence, bladder neck contracture, AUR, UTI, and IIEF at 12 and 24 months. Differences were found in favour of PVP for transfusion requirement (RR 0.11, 95% CI 0.02–0.59; $I^2=0\%$, high RoB) and capsular perforation (RR 0.15, 95% CI 0.03–0.78; $I^2=0\%$, high RoB). Catheterisation time was shorter for PVP in both studies, with very heterogeneous results. Differences were found in favour of TURP for urinary incontinence (RR 2.60, 95% CI 1.18–5.72; $I^2=0\%$, high RoB) and UTI (RR 1.75, 95%

CI 1.01–3.04; $I^2=0\%$, high RoB). The quality of the evidence was judged as low because of indirectness and RoB for all these outcomes.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement




Capsular perforation




Urinary incontinence




Catheterisation time (days)



Acute urinary retention




Urinary tract infection



IIEF-5 at 12 months



IIEF-5 at 24 months




PVP versus B-TUVP

Two RCTs (Ghobrial 2020, n=119; Kini 2020, n=27) compared PVP versus B-TUVP for the outcomes listed in Table 4-48. No data were available for bladder perforation or TUR syndrome. Prostate size was between 30 and 80 ml in Ghobrial 2020 and <80 ml in Kini 2020. Pooling of data was not possible for any outcome. No differences were observed between the PVP and B-TUVP groups in either of the studies for the outcomes assessed.

Table 4-48: Safety outcomes assessed in RCTs comparing PVP versus B-TUVP

| Study ID | Ghobrial 2020 | Kini 2020 |
|-------------------------------------|---------------|-----------|
| Intraoperative complications | | |
| Transfusion requirement | x | |
| Bladder or ureteral injury | x | |
| Capsular perforation | x | |
| Decrease in serum sodium | x | |
| Postoperative complications | | |
| Erectile dysfunction | | x |
| Urinary incontinence | x | |
| Catheterisation time | x | |
| Urethral stricture | x | |

| Study ID | Ghobrial 2020 | Kini 2020 |
|--------------------------|---------------|-----------|
| Bladder neck contracture | x | |
| Acute urinary retention | x | |
| Urinary tract infection | x | |
| Retrograde ejaculation | x | |
| Recatheterisation | x | |



PVP versus HoLEP

See the section on HoLEP.

4.4.2.4 Hybrid techniques: Vapoenucleation

ThuVEP

ThuVEP was assessed in two RCTs, including a total of 153 patients: one RCT versus TURP (n=59) and one RCT versus HoLEP (n=94).

ThuVEP versus TURP

One study (Chang 2015; n=59; uncertain RoB) compared ThuVEP versus TURP. Of the four safety outcomes assessed (Table 4-49), only catheter time was significantly shorter in the ThuVEP group (1.8 vs. 2.3 days; p=0.001, 95% CI not available). The lack of CIs for these estimates precluded assessment of their variability. There were no data for transfusion requirement, bladder perforation, bladder or ureteral injury, capsular perforation, intraoperative mortality, erectile dysfunction, urinary incontinence, urethral stricture, bladder neck contracture, AUR, retrograde ejaculation, recatheterisation, persistent irritative symptoms or long-term mortality.

Table 4-49: Safety outcome results in the RCT comparing ThuVEP versus TURP

| ThuVEP vs. TURP (Chang 2015; n=59; uncertain risk of bias) | | | |
|---|--------------------|------------------|------------------------|
| Outcome | ThuVEP n=29 | TURP n=30 | p value; 95% CI |
| Catheterisation time (days) | 1.8 | 2.3 | 0.001; 95% CI n.a. |
| Decrease in serum sodium (mmol/l) | 0.3 | 1.6 | 0.47; 95% CI n.a. |
| Urinary tract infection (%) | 0 | 0 | – |
| TUR syndrome (%) | 0 | 0 | – |

Abbreviations: n.a.=not available.

ThuVEP versus HoLEP

See the section on HoLEP.

B-VEP

B-VEP was assessed in two RCTs (n=213) with TURP as the comparator in both.

B-VEP versus TURP

Two RCTs (Wang 2020 n=101; uncertain RoB; Zhang 2015, n=112; uncertain RoB) compared B-VEP versus TURP. Outcomes assessed in these studies are listed in Table 4-50. There were no data reported for bladder perforation, bladder or ureteral injury, capsular perforation, intraoperative mortality, TUR syndrome, bladder neck contracture, AUR, UTI, retrograde ejaculation, recatheterisation, persistent irritative symptoms or long-term mortality.

Table 4-50: Safety outcomes assessed in RCTs comparing B-VEP versus TURP

| Study ID | Zhang 2015 | Wang 2020 |
|--|-------------------|------------------|
| <i>Intraoperative complications</i> | | |
| Transfusion requirement | x | |
| Decrease in serum sodium | x | |

| Study ID | Zhang 2015 | Wang 2020 |
|--|------------|-----------|
| Postoperative complications | | |
| Erectile dysfunction | | x |
| IIEF (erectile dysfunction score) 3 months | | x |
| IIEF (erectile dysfunction score) 6 months | | x |
| Urinary incontinence | x | |
| Catheterisation time | x | |
| Urethral stricture | x | |

Pooling of data was not possible for any of the outcomes. In Zhang 2015, decrease in serum sodium, catheterisation time, incontinence and urethral stricture at 3 months were reported (Table 4-51). Of these, catheterisation time was significantly shorter in the B-VEP group (49.3 vs. 78.1 h; $p < 0.001$). There were no 95% CIs reported, which precluded assessment of the variability of the estimate.

Table 4-51: Safety outcome results in Zhang 2015 comparing B-VEP versus TURP

| Outcome | B-VEP | TURP | p value; 95% CI |
|--------------------------|-------|-------|---------------------|
| Catheterisation time (h) | 49.3 | 78.1 | <0.001; 95% CI n.a. |
| Urethral stricture | 3.6% | 8.9% | 0.27; 95% CI n.a. |
| Urinary incontinence | 5.4% | 12.5% | 0.18; 95% CI n.a. |

Abbreviations: n.a.=not available.

4.4.2.5 Hybrid techniques: Vaporessection

TUVRP

TUVRP was assessed in five RCTs, comparing it to TURP for a total of 560 patients.

TUVRP versus TURP

Five RCTs (Dunsmuir 2003, n=51; Geavlete 2010, n=155; Gupta 2006, n=100; Yip 2011, n=86; Yee 2015, n=168) compared these two technologies for the outcomes listed in the Table 4-52. No data were available for bladder perforation, erectile dysfunction, bladder neck contracture or retrograde ejaculation.

Table 4-52: Safety outcomes assessed in RCTs comparing TUVRP versus TURP

| Study ID | Dunsmuir 2003 | Yee 2015 | Yip 2011 | Geavlete 2010 | Gupta 2006 |
|-------------------------------------|----------------|----------|----------|---------------|--------------|
| Intraoperative complications | | | | | |
| Transfusion requirement | x (0 events) | x | x | x | x |
| Capsular perforation | | | | x | x (0 events) |
| Decrease in serum sodium | x ^a | | x | | |
| Postoperative complications | | | | | |
| Urinary incontinence | | | | | x |

| Study ID | Dunsmuir 2003 | Yee 2015 | Yip 2011 | Geavlete 2010 | Gupta 2006 |
|-------------------------|---------------|----------|----------|---------------|------------|
| Catheterisation time | x | x | x | x | x |
| TUR syndrome | | x | | | |
| Acute urinary retention | | | | x | |
| Urinary tract infection | | | | x | x |
| Recatheterisation | x | | x | | |
| Urethral stricture | | | | | x |

^a Data could not be extrapolated.


Patients included in Geavlete 2010 had a prostate size in the 30–80 ml subgroup, whereas Yip 2011 and Yee 2015 included patients with an average prostate size of 61 ml (no inclusion criteria or range available), Dunsmuir 2003 included patients with a prostate size between 16 and 60 ml and Gupta 2006 included patients with a prostate size between 40 and 133 ml.

Pooling of data was possible for transfusion requirement, UTI and recatheterisation. No differences between the groups were found for these outcomes.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Transfusion requirement



Urinary tract infection



Recatheterisation



B-TUERP versus DioLEP

One RCT (Xu 2013, n=80; uncertain RoB) compared B-TUERP versus DioLEP among patients with an average prostate size of 67 ml (no range or inclusion criteria available), assessing the outcomes listed in [Table 4-54](#). Catheterisation time was longer with B-TUERP than with DioLEP. Since 95% CIs were not available, it was not possible to assess the imprecision associated with the estimates reported.

No data were available for bladder perforation, bladder neck contracture, AUR, UTI, retrograde ejaculation, erectile dysfunction or recatheterisation.

Table 4-54: Safety outcome results in Xu 2013 comparing B-TUERP versus DioLEP

| Outcome | B-TUERP | DioLEP | p-value |
|-----------------------------------|---------|--------|---------|
| Catheterisation time (days) | 46.7 | 27.5 | <0.001 |
| TUR syndrome (%) | 0 | 0 | – |
| Urinary incontinence (%) | 10 | 7.5 | 0.69 |
| Decrease in serum sodium (mmol/l) | 4.3 | 3.0 | 0.12 |
| Blood transfusion (%) | 0 | 0 | – |
| Urethral stricture (%) | 0 | 0 | – |
| Bladder injury (%) | 0 | 0 | – |
| Capsule perforation (%) | 2.5 | 5.0 | 0.56 |

M-TUERP

M-TUERP was assessed in one RCT (Li 2018, n=86; high RoB) in a comparison versus TURP among 86 patients. Data were retrieved for blood transfusion requirement, decrease in serum sodium, urethral stricture, catheterisation time, urinary retention, recatheterisation and urinary incontinence. There were no data for bladder perforation, bladder or ureteral injury, capsular perforation, intraoperative mortality, erectile dysfunction, TUR syndrome, bladder neck contracture, AUR, UTI, retrograde ejaculation, persistent irritative symptoms or long-term mortality. The M-TUERP group had a significantly shorter catheterisation time and significantly lower rates of urinary retention, recatheterisation and blood transfusion requirement ([Table 4-55](#)). Lack of CIs precluded assessment of the variability of the estimates.

Table 4-55: Safety outcome results in Li 2018 comparing M-TUERP versus TURP

| Outcome | M-TUERP | TURP | p value; 95% CI |
|-----------------------------------|---------|-------|---------------------|
| Catheterisation time (h) | 41.57 | 48.77 | 0.01; 95% CI n.a. |
| Decrease in serum sodium (mmol/l) | 1.41 | 1.42 | 0.69; 95% CI n.a. |
| Dysuria/urinary retention | 0% | 11.4% | <0.001; 95% CI n.a. |
| Recatheterisation | 0% | 6.8% | <0.001; 95% CI n.a. |
| Urinary incontinence | 0% | 0% | – |
| Urethral stricture | 2.4% | 2.3% | 0.95; 95% CI n.a. |
| Blood transfusion | 0% | 9.1% | <0.001; 95% CI n.a. |

Abbreviations: n.a.=not available.

4.4.2.7 Aquablation

Aquablation was assessed in one RCT (WATER study), with four publications presenting results at different follow-up times for comparison to TURP among a total of 181 patients (Gilling 2018, 2019a, 2019b, 2020; uncertain RoB). Outcomes reported in these publications are listed in [Table 4-56](#). No data were available for procedural blood loss, bladder or ureteral injury, capsular perforation, urinary incontinence, intraoperative mortality, decrease in serum sodium, recatheterisation, TUR syndrome and long-term mortality.

Table 4-56: Safety outcomes assessed in publications comparing Aquablation versus TURP

| Study ID | Gilling 2018 | Gilling 2019a | Gilling 2019b | Gilling 2020 |
|--|--------------|---------------|---------------|--------------|
| <i>Intraoperative complications</i> | | | | |
| Transfusion requirement | x | | | |
| Bladder perforation | | | | x |
| <i>Postoperative complications</i> | | | | |
| Erectile dysfunction | | x | | x |
| Urethral stricture | x | | | x |
| Bladder neck contracture | | x | x | x |
| Acute urinary retention | x | | x | x |
| Urinary tract infection | x | x | x | x |
| Retrograde ejaculation | x | | x | x |
| Persistent irritative symptoms | x | x | x | x |

Retrograde ejaculation was the only outcome for which there was a significant difference. This difference was observed at 100-day follow-up (7.1% vs. 23.1%; $p=0.005$, 95% CI not available) in favour of Aquablation; there was no statistical comparison of the cumulative data at 3 years (11.3% vs. 31.1%).

4.4.2.8 TUMT

TUMT was assessed in four RCTs, all of which were comparisons versus TURP (n=419).

TUMT versus TURP

Four studies including 419 patients (D'Ancona 1989, n=52; uncertain RoB; Dahlstrandt 1995, n=69; uncertain RoB; Wagrell 2002, n=154; high RoB, Floratos 2001, n=144; uncertain RoB) compared TUMT versus TURP. Only postoperative outcomes were assessed in these studies ([Table 4-57](#)). There were no data for intraoperative complications (transfusion requirement, procedural blood loss, bladder perforation, bladder or ureteral injury, capsular perforation, intraoperative mortality, decrease in serum sodium), retrograde ejaculation, recatheterisation or long-term mortality.

Table 4-57: Safety outcomes assessed in RCTs comparing TUMT versus TURP

| Study ID | Dahlstrandt 1995 | Floratos 2001 | D'Ancona 1998 | Wagrell 2002 |
|------------------------------------|------------------|---------------|----------------|--------------|
| Postoperative complications | | | | |
| Erectile dysfunction | x (0 events) | | | x |
| Urinary incontinence | | | | x |
| Catheterisation time | | | x ^a | x |
| TUR syndrome | | | | x |
| Urethral stricture | x | x | | |
| Bladder neck contracture | | x | | |
| Acute urinary retention | x | | | x |
| Urinary tract infection | x | | x | x |
| Persistent irritative symptoms | | | | x |

^a Data could not be extrapolated.


Two studies used prostate volume of >30 ml (Floratos 2001) or 30–100 ml (Wagrell 2002) as an inclusion criterion. One study used prostate length as an inclusion criterion (Dahlstrandt 1995; 35–50 mm), while another study (D'Ancona 1998) used both prostate length (25–50 mm) and prostate volume (30–100 ml) to select patients. The mean prostate volume was similar in the three studies that reported this parameter (from 42 to 48.9 ml for TUMT and from 44 to 52.7 ml for TURP). Only one study reported the range for prostate volume (30–82 ml for TUMT and 31–86 ml for TURP).

Pooling of data was possible for urethral stricture, AUR and UTI evaluated at 1 month in Dahlstrandt 1995 and at 36 months in Floratos 2001. No differences between the groups were observed for any outcome.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Urethral stricture



Acute urinary retention



Urinary tract infection



4.4.2.9 WAVE

WAVE was assessed in one RCT versus sham, including 197 patients with a prostate size of 30–80 ml, with the possibility for patients in the sham arm to cross over after 3 months. Multiple publications are available with results for follow-up at 3 months (before crossover), 12 months, and 2, 3 and 4 years (McVary 2016a, low RoB for the 3-month follow-up data, high RoB for the 12-month data; McVary 2016b low RoB for the 3-month data; Roehrborn 2017, high RoB; McVary 2018, high RoB; McVary 2019, high RoB). Outcomes assessed in these publications are listed in Table 4-58. The authors did not provide statistical comparisons. Data for intraoperative complications (transfusion requirement, procedural blood loss, bladder perforation, bladder or ureteral injury, capsular perforation, decrease in serum sodium), urethral stricture, bladder neck contracture, recatheterisation or long-term mortality were not reported. Three serious adverse events in two patients were reported: de novo urinary retention and nausea with vomiting due to sedative medication. Other nonserious procedural side effects were observed in 52 patients (38.2%). The most common side effects were dysuria (16.9%), haematuria (11.8%), haemospermia (7.4%), urinary frequency (5.9%), urgency (5.9%), urinary retention (3.7%), UTI (3.7%) and anejaculation (2.9%). These mild to moderate side effects were mostly resolved within 3 weeks. No late-occurring adverse events were reported at the 1-, 2-, 3-, and 4-year follow-up points. In the WAVE arm, 90.4% (122/135) of patients were catheterised for an average of 3.4±3.2 days. In the sham arm, 19.7% (12/61) of patients were catheterised for a mean of 0.9±0.8 days. Among patients treated with WAVE, there was an IIEF change of 0.1±7.4 points after 3 months, compared to -0.3±5.6 in the sham arm. This difference was not significant (p=0.795). Of the sexually active patients in the WAVE arm, 32% (29/90) achieved a clinically relevant difference after 3 months (difference of 2 points for patients with mild, 5 points for patients with moderate and 7 points for patients with severe erectile dysfunction).

Table 4-58: Safety outcomes assessed in publications comparing WAVE versus sham

| Study ID | McVary 2016a, 2016b |
|---|---------------------|
| Postoperative complications | |
| Erectile dysfunction | x |
| Urinary incontinence (frequency, urgency) | x |
| Acute urinary retention | x |
| Urinary tract infection | x |
| Retrograde ejaculation (anejaculation) | x |
| IIEF total score | x |
| Catheterisation time | x |

4.4.2.10 Nonablative techniques

TUIP

TUIP was assessed in five RCTs in comparison to TURP (Abd-El Kader 2012, Dørflinger 1992, Jahnson 1998, Riehmman 1995, Tkocz 2002), including a total of 451 patients with a prostate size of <30 ml (except Jahnson 1998, which included patients with prostate size between 20 and 40 ml; the mean size was 26 ml). Outcomes assessed in these studies are listed in Table 4-59. No data were available for bladder perforation, bladder or ureteral injury, capsular perforation, decrease in serum sodium, TUR syndrome, AUR or UTI.

Table 4-59: Safety outcomes assessed in RCTs comparing TUIP versus TURP

| Study ID | Abd-El Kader 2012 | Dørflinger 1992 | Jahnson 1998 | Riehmman 1995 | Tkocz 2002 |
|--|-------------------|-----------------|--------------|---------------|--------------|
| <i>Intraoperative complications</i> | | | | | |
| Transfusion requirement | x | x | x | | x (0 events) |
| <i>Postoperative complications</i> | | | | | |
| Erectile dysfunction | x | x | | | |
| Urinary incontinence | | | | | x |
| Catheterisation time | x | x ^a | x | x | |
| Urethral stricture | x | x | | | |
| Bladder neck contracture | x | x (0 events) | | | |
| Retrograde ejaculation | x | x | | x | x |
| Recatheterisation | | x | | | |

^a Data could not be extrapolated.


Data could be pooled for retrograde ejaculation, transfusion requirement, urethral stricture and erectile dysfunction. A differences was found in favour of TUIP for retrograde ejaculation (RR 0.38, 95% CI 0.25–0.57; $I^2=0\%$; high RoB); the quality of the evidence was judged as moderate (downgraded because of selective reporting in two studies). A difference with borderline significance was found for transfusion requirement (RR 0.18, 95% CI 0.03–1.01; $I^2=0\%$; high RoB), whereas no differences were found between the groups for urethral stricture or erectile dysfunction. Catheterisation time was shorter for the TUIP group in both studies (MD of ~1 day).

No data were available for bladder perforation, bladder or ureteral injury, capsular perforation, decrease in serum sodium, TUR syndrome, AUR or UTI.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Retrograde ejaculation




Transfusion requirement




Urethral stricture



Erectile dysfunction



Catheterisation time (days)



TUIP + TURP

TUIP was also tested in association with TURP in two RCTs including a total of 164 patients, with TURP alone as the comparator.

TUIP + TURP versus TURP

TUIP + TURP were compared to TURP alone in Yeni 2002 (n=40) and Li 2013 (n=124) among patients with a small prostate (<25 ml in Yeni 2002 and between 20 and 40 ml in Li 2013), assessing the outcomes listed in Table 4-60. No data were available for bladder perforation, bladder or ureteral injury, capsular perforation, decrease in serum sodium, urinary incontinence, catheterisation time, AUR or recatheterisation.

Table 4-60: Safety outcomes assessed in RCTs comparing TUIP + TURP versus TURP


| Study ID | Li 2013 | Yeni 2002 |
|-------------------------------------|---------|-----------|
| Intraoperative complications | | |
| Transfusion requirement | | x |
| Postoperative complications | | |
| Erectile dysfunction | | x |
| TUR syndrome | | x |
| Urethral stricture | x | |
| Bladder neck contracture | x | x |
| Urinary tract infection | x | |
| Retrograde ejaculation | | x |

Among the outcomes assessed, only data for bladder neck contracture could be pooled, with five cases among 81 patients in the TURP arms and zero cases among 83 patients in the TUIP + TURP arms. This difference in incidence was not statistically significant. For the other outcomes, no differences were observed between the groups in either of the two studies.

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Bladder neck contracture



PAE

PAE was assessed in five RCTs: Abt 2018 (n=103; prostate size 25–80 ml), Carnevale 2016 (n=30; prostate size 32–97 ml), Gao (n=114; prostate size 20–100 ml), Insausti 2020 (n=45; average prostate size 60 ml) and Radwan 2020 (n=60; prostate size <100 ml). The five studies compared PAE versus TURP for the outcomes listed in Table 4-61 and included a total of 352 patients.

Table 4-61: Safety outcomes assessed in RCTs comparing PAE versus TURP

| Study ID | Abt 2018 | Insausti 2020 | Radwan 2020 | Carnevale 2016 | Gau 2014 |
|-------------------------------------|----------|---------------|----------------|----------------|----------|
| Intraoperative complications | | | | | |
| Transfusion requirement | | | | x (0 events) | x |
| Postoperative complications | | | | | |
| Erectile dysfunction | | x | | | |
| Urinary incontinence | x | | | x | |
| Catheterisation time | x | | x ^a | | |
| TUR syndrome | | | x (0 events) | | x |
| Urethral stricture | x | x | | | x |
| Bladder neck contracture | | | | | x |
| Acute urinary retention | x | x | x | | x |
| Urinary tract infection | x | x | | | x |
| Retrograde ejaculation | x | x | | x | |
| Recatheterisation | | | | x | |

^a Data could not be extrapolated.

Pooling of data was possible for urinary incontinence, urethral stricture, AUR and UTI. A difference in favour of PAE was found for urinary incontinence (RR 0.13, 95% CI 0.02–0.98; $I^2=0\%$, high RoB) and UTI (RR 0.49, 95% CI 0.26–0.91; $I^2=0\%$, high RoB). A difference in favour of TURP was found for AUR (RR 2.23, 95% CI 1.12–4.41; $I^2=50\%$, high RoB). The quality of the evidence for these outcomes was judged a low because of RoB and imprecision.


Abt 2018 observed a shorter catheterisation time (by 2 days) and a trend towards lower incidence of ejaculatory dysfunction (56% vs. 84%; $p=0.06$) in the PAE group, although more than half of the patients in the PAE group suffered from this condition (highlighted by the study authors as an unexpected finding).

No data were available for inadvertent embolisation of other sites, vascular thrombosis, pseudoaneurysms, dissection, damage to perivascular, neural or muscular structures, radiodermatitis, transfusion requirement, bladder perforation, bladder or ureteral injury, capsular perforation, decrease in serum sodium, TUR syndrome, bladder neck contracture or recatheterisation.


Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Urinary incontinence




Urethral stricture




Acute urinary retention



Urinary tract infection



Retrograde ejaculation*



*Notes: Abt2018: only sexually active: PAE 14/25=56%, TURP 21/25=84%; Carnevale2016: no mention of sexually active patients; Insausti2020: few patients had sexual relationships. All patients were asked about ejaculatory volume before and after interventions

PUL

PUL was assessed in two publications (Sonksen 2015, n=79; Gratzke 2017, n=80; high RoB) presenting results for different follow-up times for the same RCT comparing PUL versus TURP. The outcomes assessed are listed in Table 4-62. There were no data for bladder perforation, bladder or ureteral injury, capsular perforation, intraoperative mortality, decrease in serum sodium, catheterisation time, TUR syndrome, bladder neck contracture, recatheterisation or long-term mortality.

Table 4-62: Safety outcomes assessed in publications comparing PUL versus TURP

| Study ID | Gratzke 2017 | Sonksen 2015 |
|-------------------------------------|--------------|--------------|
| Intraoperative complications | | |
| Transfusion requirement | | x |
| Postoperative complications | | |
| Erectile dysfunction | x | x |
| Urinary incontinence | x | x |
| Urethral stricture | | x |
| Acute urinary retention | | x |
| Urinary tract infection | | x |
| Retrograde ejaculation | x | x |
| Persistent irritative symptoms | | x |

This RCT included patients with prostate volume ≤ 60 ml. Only urinary incontinence (2% vs. 17%; $p=0.04$) and retrograde ejaculation (0% vs. 20%; $p=0.002$) significantly differed between the groups, in favour of PUL (Table 4-63). Since CIs were not available, it was not possible to assess the imprecision associated with these estimates.

Table 4-63: Results for safety outcomes in RCTs comparing PUL versus TURP

| PUL vs. TURP (Sonksen 2015, n=79; Gratzke 2017, n=80; high risk of bias) | | | |
|---|-----|------|--------------------|
| Outcome | PUL | TURP | p value; 95% CI |
| Persistent irritative symptoms (%) | 52 | 60 | 0.5; 95% CI n.a. |
| Urinary incontinence (%) | 2 | 17 | 0.04; 95% CI n.a. |
| Acute urinary retention (%) | 9 | 0 | 0.1; 95% CI n.a. |
| Retrograde ejaculation (%) | 0 | 20 | 0.002; 95% CI n.a. |
| Erectile dysfunction (%) | 0 | 9 | 0.08; 95% CI n.a. |
| Urethral stricture (%) | 0 | 3 | 0.4; 95% CI n.a. |
| Urinary tract infection (%) | 7 | 6 | 0.9; 95% CI n.a. |

Abbreviations: n.a.=not available.

5 OVERVIEW OF EFFECTIVENESS OUTCOMES

This section presents results for effectiveness outcomes by technology, with a synthesis of results for IPSS and Qmax at 6 and 12 months and for reintervention. Comments are provided on statistically significant differences, together with information on nonsignificant results.

IPSS at 6 months

- For 15 of the 21 technologies considered in this report, IPSS at 6 months was assessed using TURP as the comparator. B-TUEP, ThuLEP, B-TUVP and B-TUERP showed significantly better results than TURP, although the estimates and CIs are below the MCID threshold. The quality of the related evidence is low to very low.
- Conversely, TUMT and PAE showed significantly worse results for this outcome in comparison to TURP, although the estimates and CIs are below the MCID threshold. The quality of the related evidence is moderate.
- No differences in IPSS at 6 months were observed for the remaining ten comparisons versus TURP; the quality of the related evidence is low to very low, except for one comparison (DioLEP vs. TURP: moderate).
- Among seven comparisons between newer technologies, no significant differences were observed for this outcome. The quality of the evidence is low to very low.

Table 5-1: IPSS at 6 months: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | VL | | L | | | L | VL | |
| HoLEP | L | | | VL | | | L | | |
| DioLEP | M | | L | | L | | | | L |
| B-TUVP | L | VL | | | VL | VL | | | |
| PVP | | | | | | | | VL | |
| ThuLEP | L | | VL | | L | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | VL | | | | | | | | |
| Aquablation | L | | | | | | | | |
| TUMT | M | | | | | | | | |
| PUL | VL | | | | | | | | |
| TmLRP | L | | | | | | | | |
| B-TUERP | L | | | | | | L | | |
| PAE | VL | | | | | | | | |
| B-VEP | L | | | | | | | | |
| TURP + TUIP | L | | | | | | | | |

Key to quantitative differences

| | |
|--|---|
| | Intervention statistically significantly better than control (CI crossing MCID) |
| | Intervention statistically significantly better than control (CI below MCID) |
| | No difference |
| | Intervention statistically significantly worse than control (CI below MCID) |
| | Intervention statistically significantly worse than control (CI crossing MCID) |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|---|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | RoB, indirectness, imprecision |
| B-TUEP | OP | RoB, indirectness, imprecision |
| B-TUEP | ThuLEP | Single RCT (imprecision) |
| B-TUEP | DioLEP | Indirectness, RoB |
| B-TUEP | B-TUVP | Single RCT (imprecision), RoB |
| B-TUERP | TURP | Single RCT (imprecision) |
| B-TUVP | TURP | Inconsistency, indirectness |
| B-TUVP | OP | Single RCT (imprecision), RoB |
| B-TUVP | PVP | Single RCT (imprecision), RoB |
| B-VEP | TURP | Single RCT (imprecision) |
| DioLEP | TURP | Imprecision |
| DioLEP | B-TUERP | Single RCT (imprecision) |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | ThuLEP | Indirectness, inconsistency, rob |
| HoLEP | TURP | Inconsistency, indirectness |
| HoLEP | DioLEP | Single RCT (imprecision) |
| PAE | TURP | Single RCT (imprecision), RoB |
| PUL | TURP | Single RCT (imprecision), RoB |
| ThuLEP | TURP | Indirectness, RoB |
| TmLRP | TURP | Single RCT (imprecision) |
| TUMT | TURP | RoB |
| TURP + TUIP | TURP | Imprecision (pooling not possible); RoB |
| TUVRP | TURP | Imprecision, RoB, inconsistency |

IPSS at 12 months

- For 14 of the 21 technologies in this report, IPSS at 12 months was assessed using TURP as the comparator. Only HoLEP showed a statistically significant better result for IPSS at 12 months, although its estimate and CI are below the MCID threshold. The quality of the related evidence is very low.
- PVP, DioLVP, TUMT and PUL showed statistically significant worse results for this outcome compared to TURP, although this result could be clinically relevant only for PUL (CI crossing the MCID). The quality of the related evidence is low to very low.
- No differences were shown for the remaining eight comparisons; the quality of the related evidence is low to very low, except for one comparison (B-TUVP vs. TURP: moderate)
- Among nine comparisons between newer technologies, a statistically significant difference was evident in favour of HoLEP versus PVP, a result that could be clinically relevant (CI crossing the MCID). The quality of the related evidence is low to very low, except for one comparison (B-TUEP vs. DioLEP: moderate).

Table 5-2: IPSS at 12 months: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | VL | L | L | | | M | VL | |
| HoLEP | VL | | | VL | L | L | VL | | |
| DioLEP | | | VL | | M | | | | L |
| B-TUVP | M | VL | | | VL | L | | | |
| PVP | VL | | L | | | | | L | |
| ThuLEP | L | | VL | | L | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | L | | | | | | | | |
| ThuVARP | VL | | | | | | | | |
| Aquablation | L | | | | | | | | |
| TUMT | L | | | | | | | | |
| TUIP | L | | | | | | | | |
| PUL | VL | | | | | | | | |
| TmLRP | L | | | | | | | | |
| B-TUERP | | | | | | | L | | |

Key to quantitative differences

| | |
|--|---|
| | Intervention statistically significantly better than control (CI crossing MCID) |
| | Intervention statistically significantly better than control (CI below MCID) |
| | No difference |
| | Intervention statistically significantly worse than control (CI below MCID) |
| | Intervention statistically significantly worse than control (CI crossing MCID) |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|----------------------------------|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | RoB, indirectness, imprecision |
| B-TUEP | DioLEP | Indirectness |
| B-TUEP | ThuLEP | Single RCT (imprecision) |
| B-TUEP | B-TUVP | Single RCT (imprecision), RoB |
| B-TUERP | DioLEP | Single RCT (imprecision) |
| B-TUVP | TURP | Imprecision |
| B-TUVP | OP | Single RCT (imprecision), RoB |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | ThuLEP | Indirectness, inconsistency, RoB |
| HoLEP | PVP | Imprecision, indirectness |
| HoLEP | TURP | Inconsistency, indirectness, RoB |
| HoLEP | B-TUEP | Indirectness, RoB |

| Intervention | Control | Reason |
|--------------|---------|--------------------------------|
| HoLEP | DioLEP | Single RCT (imprecision) |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | Imprecision, indirectness, RoB |
| PVP | B-TUVP | Single RCT (imprecision) |
| ThuLEP | TURP | Indirectness, RoB |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Single RCT (imprecision) |
| TUIP | TURP | RoB, imprecision |
| TUMT | TURP | RoB, inconsistency |
| TUVRP | TURP | Imprecision, RoB |

Qmax at 6 months

- Fifteen of the 21 technologies in this report assessed Qmax at 6 months using TURP as the comparator. B-TUVP and the combination of TUIP plus TURP showed statistically significant better results for this outcome versus TURP, with CIs crossing the MCID threshold. The quality of the related evidence is low to very low.
- TUMT, PUL and PAE showed statistically significant worse results for this outcome compared to TURP, with CIs crossing the MCID threshold. The quality of the related evidence is very low.
- No differences were shown for the remaining eleven comparisons versus TURP; the quality of the related evidence is low to very low, except for one comparison (DioLEP vs. TURP: moderate)
- Among seven comparisons between newer technologies, one statistically significant difference was shown in favour of B-TUEP versus B-TUVP; the quality of evidence for this comparison is very low and the CI crosses the MCID threshold. The quality of evidence for the other comparisons is low to very low.

Table 5-3: Qmax at 6 months: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | VL | | L | | | L | VL | |
| HoLEP | L | | | VL | | | L | | |
| DioLEP | M | | L | | L | | | | L |
| B-TUVP | L | VL | | | VL | VL | | | |
| PVP | | | | | | | | VL | |
| ThuLEP | L | | VL | | L | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | VL | | | | | | | | |
| Aquablation | L | | | | | | | | |
| TUMT | VL | | | | | | | | |
| TUIP + TURP | VL | | | | | | | | |

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| PUL | VL | | | | | | | | |
| TmLRP | L | | | | | | | | |
| B-TUERP | L | | | | | | L | | |
| PAE | VL | | | | | | | | |
| B-VEP | L | | | | | | | | |

Key to quantitative differences

| | |
|--|---|
| | Intervention statistically significantly better than control (CI crossing MCID) |
| | Intervention statistically significantly better than control (CI below MCID) |
| | No difference |
| | Intervention statistically significantly worse than control (CI below MCID) |
| | Intervention statistically significantly worse than control (CI crossing MCID) |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|----------------------------------|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | RoB, indirectness, imprecision |
| B-TUEP | DioLEP | Indirectness, imprecision |
| B-TUEP | ThuLEP | Single RCT (imprecision) |
| B-TUEP | B-TUVP | Single RCT (imprecision), RoB |
| B-TUERP | TURP | Single RCT (imprecision) |
| B-TUERP | DioLEP | Single RCT (imprecision) |
| B-TUVP | TURP | Indirectness, inconsistency |
| B-TUVP | OP | Single RCT (imprecision), RoB |
| B-VEP | TURP | Single RCT (imprecision) |
| DioLEP | TURP | Imprecision |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | ThuLEP | Indirectness, inconsistency, rob |
| HoLEP | TURP | Inconsistency, indirectness |
| HoLEP | DioLEP | Single RCT (imprecision) |
| PAE | TURP | Single RCT (imprecision), RoB |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | B-TUVP | Single RCT (imprecision), RoB |
| ThuLEP | TURP | Indirectness, RoB |
| TmLRP | TURP | Single RCT (imprecision) |
| TUMT | TURP | RoB, inconsistency, imprecision |
| TUVRP | TURP | Imprecision, RoB, inconsistency |






Qmax at 12 months

- Thirteen of the 21 technologies in this report assessed Qmax at 6 months using TURP as the comparator. Only HoLEP showed a statistically significant better result versus TURP, although the estimate and its CI are below the MCID threshold. The quality of the related evidence is low.
- DioLVP, ThuVARP, TUMT, TUIP and PUL showed statistically significant worse results for this outcome compared to TURP, with CIs crossing the MCID threshold (except for DioLVP). The quality of the related evidence is low to very low.
- No differences were shown for the remaining seven comparisons versus TURP; the quality of the related evidence is low to very low, except for one comparison (B-TUVP vs. TURP: moderate).
- Among nine comparisons between newer technologies, statistically significant differences were shown in favour of B-TUEP versus HoLEP and versus B-TUVP (with estimate and CI below the MCID threshold) and in favour of HoLEP versus PVP (with estimate and CI crossing the MCID threshold). The quality of evidence for these and for the other comparisons is low to very low.

Table 5-4: Qmax at 12 months: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | VL | L | L | | | L | VL | |
| HoLEP | L | | | VL | L | L | L | | |
| DioLEP | | | L | | L | | | | L |
| B-TUVP | M | VL | | | VL | L | | | |
| PVP | VL | | L | | | | | L | |
| ThuLEP | L | | VL | | L | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | L | | | | | | | | |
| ThuVARP | VL | | | | | | | | |
| Aquablation | L | | | | | | | | |
| TUMT | L | | | | | | | | |
| TUIP | L | | | | | | | | |
| PUL | VL | | | | | | | | |
| TmLRP | L | | | | | | | | |
| B-TUERP | | | | | | | L | | |

Key to quantitative differences

| | |
|---|---|
|  | Intervention statistically significantly better than control (CI crossing MCID) |
|  | Intervention statistically significantly better than control (CI below MCID) |
|  | No difference |
|  | Intervention statistically significantly worse than control (CI below MCID) |
|  | Intervention statistically significantly worse than control (CI crossing MCID) |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|---------------------|----------------|----------------------------------|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | RoB, indirectness, imprecision |
| B-TUEP | DioLEP | Indirectness, imprecision |
| B-TUEP | ThuLEP | Single RCT (imprecision) |
| B-TUEP | B-TUVP | Single RCT (imprecision), RoB |
| B-TUERP | DioLEP | Single RCT (imprecision) |
| B-TUVP | TURP | Imprecision |
| B-TUVP | OP | Single RCT (imprecision), RoB |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | TURP | Indirectness, RoB |
| HoLEP | ThuLEP | Indirectness, inconsistency, RoB |
| HoLEP | PVP | Inconsistency, indirectness |
| HoLEP | B-TUEP | Indirectness, RoB |
| HoLEP | DioLEP | Single RCT (imprecision) |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | Imprecision, indirectness, RoB |
| PVP | B-TUVP | Single RCT (imprecision) |
| ThuLEP | TURP | Indirectness, RoB |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Single RCT (imprecision) |
| TUIP | TURP | RoB, imprecision |
| TUMT | TURP | RoB, inconsistency |
| TUVRP | TURP | Imprecision, RoB |

Reintervention

- Seven of the 21 technologies in this report assessed reintervention using TURP as the comparator. Only HoLEP showed a statistically significant better result for this outcome, although the quality of the related evidence is very low.
- Conversely, TUIP showed a statistically significant worse result for this outcome compared to TURP, although the quality of the related evidence is low. No differences were shown for the remaining five comparisons; the quality of the related evidence is low to very low
- There is only one comparison between newer technologies, showing a statistically significant difference in favour of HoLEP versus PVP. The quality of the related evidence is low.

Table 5-5: Reintervention: comparisons available, results and quality of evidence

| Intervention | Control | | |
|--------------|---------|-------|-----|
| | TURP | HoLEP | PVP |
| HoLEP | VL | | L |
| B-TUVP | VL | | |
| PVP | L | L | |
| DioLVP | VL | | |
| TUMT | L | | |
| TUIP | L | | |
| TmLRP | L | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

H=high
M=moderate
L=low
VL=very low

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|--|
| B-TUVP | TURP | Inconsistency, imprecision, RoB |
| DioLVP | TURP | Imprecision, indirectness, RoB |
| HoLEP | TURP | Inconsistency, indirectness, imprecision |
| HoLEP | PVP | Imprecision, indirectness |
| PVP | TURP | Indirectness, RoB |
| TmLRP | TURP | Single RCT |
| TUIP | TURP | RoB, imprecision |
| TUMT | TURP | RoB, imprecision |

6 OVERVIEW OF SAFETY OUTCOMES

This section presents results for some of the critical safety outcomes by technology. A synthesis of results for erectile dysfunction, retrograde ejaculation, transfusion requirement, UTI, urethral stricture and urinary incontinence is provided. Comments are provided regarding statistically significant differences, together with information on nonsignificant results.

Erectile dysfunction

- Fifteen of the 21 technologies in this report assessed erectile dysfunction using TURP as the comparator. Only ThuLEP showed a statistically significant better result versus TURP for this outcome; the quality of the related evidence is low.
- No differences were shown for the remaining 14 comparisons versus TURP; the quality of the related evidence is low to very low, except for HoLEP versus TURP (moderate).
- Three comparisons between newer technologies are available and showed no statistically significant differences with low to very low quality of evidence.

Table 6-1: Erectile dysfunction: comparisons available, results and quality of evidence

| Intervention | Control | | | | | |
|--------------|---------|-------|--------|-----|--------|--------|
| | TURP | HoLEP | B-TUEP | PVP | DioLEP | B-TUVP |
| B-TUEP | VL | | | | VL | |
| HoLEP | M | | | L | | |
| DioLEP | | | VL | | | |
| B-TUVP | VL | | | VL | | |
| PVP | VL | L | | | | VL |
| ThuLEP | L | | | | | |
| DioLVP | VL | | | | | |
| ThuVARP | VL | | | | | |
| TUMT | L | | | | | |
| PAE | VL | | | | | |
| Aquablation | L | | | | | |
| TUIP | L | | | | | |
| TUIP + TURP | L | | | | | |
| PUL | VL | | | | | |
| TmLRP | L | | | | | |
| B-VEP | L | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|---|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | Imprecision, RoB, indirectness |
| B-TUEP | DioLEP | Indirectness, RoB, imprecision |
| B-TUVP | TURP | Wide imprecision (pooling not possible; 1 trial with 0 events), RoB |
| B-VEP | TURP | Single RCT (imprecision) |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | TURP | Imprecision |
| HoLEP | PVP | Imprecision, two studies, pooling not possible |
| PAE | TURP | Single RCT (imprecision), RoB |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | RoB, indirectness, imprecision |
| PVP | B-TUVP | Single RCT (imprecision), RoB |
| ThuLEP | TURP | Single RCT (imprecision) |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Single RCT (imprecision) |
| TUIP | TURP | RoB, imprecision |
| TUIP + TURP | TURP | Single RCT (imprecision) |
| TUMT | TURP | Wide imprecision (pooling not possible; 1 trial with 0 events) |

Retrograde ejaculation

- Twelve of the 21 technologies in this report assessed retrograde ejaculation using TURP as the comparator. TUIP, Aquablation and PUL showed statistically significant better results versus TURP for this outcome. The quality of evidence is moderate (TUIP vs. TURP) to very low (PUL vs. TURP).
- Conversely, HoLEP showed a statistically significant worse result for this outcome compared to TURP. The quality of the related evidence is low.
- No differences were shown for the remaining eight comparisons; the quality of the related evidence is low to very low, except for B-TURP versus TURP, and TmLRP versus TURP (moderate).
- Four comparisons between newer technologies are available. PVP showed a statistically significant better result versus HoLEP, with low quality of evidence. The quality of evidence is low to very low for the other three comparisons.

Table 6-2: Retrograde ejaculation: comparisons available, results and quality of evidence

| Intervention | Control | | | | | |
|--------------|---------|-------|--------|-----|--------|--------|
| | TURP | HoLEP | B-TUEP | PVP | DioLEP | B-TUVP |
| B-TUEP | VL | | | | VL | |
| HoLEP | L | | | L | L | |
| DioLEP | | L | VL | | | |
| B-TUVP | M | | | VL | | |

| Intervention | Control | | | | | |
|--------------|---------|-------|--------|-----|--------|--------|
| | TURP | HoLEP | B-TUEP | PVP | DioLEP | B-TUVP |
| PVP | L | L | | | | VL |
| ThuLEP | L | | | | | |
| ThuVARP | VL | | | | | |
| Aquablation | L | | | | | |
| TUIP | M | | | | | |
| TUIP + TURP | L | | | | | |
| PAE | VL | | | | | |
| PUL | VL | | | | | |
| TmLRP | M | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

H=high
M=moderate
L=low
VL=very low

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|--|
| Aquablation | TURP | Single RCT, wide difference but no confidence interval (imprecision) |
| B-TUEP | TURP | Single RCT (imprecision), RoB |
| B-TUEP | DioLEP | Indirectness, RoB, inconsistency |
| B-TUVP | TURP | RoB |
| HoLEP | TURP | Imprecision (pooling not possible) |
| HoLEP | DioLEP | Single RCT (imprecision) |
| HoLEP | PVP | Single RCT (imprecision) |
| PAE | TURP | Two RCTs, statistical assessment not available |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | Imprecision (pooling not possible) |
| PVP | B-TUVP | Limited data from two RCTs that could not be pooled |
| ThuLEP | TURP | RoB, imprecision |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Imprecision |
| TUIP | TURP | RoB |
| TUIP + TURP | TURP | Single RCT (imprecision) |

Transfusion requirement

- Sixteen of the 21 technologies in this report assessed transfusion requirement using TURP as the comparator. HoLEP, B-TUVP, ThuLEP, PVP and M-TUERP showed statistically significant better results versus TURP for this outcome. The quality of evidence is moderate for HoLEP, B-TUVP and ThuLEP versus TURP, low for PVP versus TURP, and very low for M-TUERP versus TURP.
- No differences were shown for the remaining eleven comparisons; the quality of the related evidence is low to very low (very low in most cases).
- Eight comparisons between newer technologies are available. ThuLEP showed statistically significant better results versus HoLEP, with very low quality of evidence. Other comparisons did not show statistically significant differences, with low to very low quality of evidence (very low in most cases).

Table 6-3: Transfusion requirement: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|----|-------|--------|--------|-----|--------|--------|---------|
| | TURP | OP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | VL | | VL | | | VL | VL | |
| HoLEP | M | | | VL | | VL | L | | |
| DioLEP | VL | | L | | VL | | | | VL |
| B-TUVP | M | VL | | | VL | VL | | | |
| PVP | L | | VL | | | | | VL | |
| ThuLEP | M | | VL | | VL | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | L | | | | | | | | |
| ThuVARP | VL | | | | | | | | |
| Aquablation | VL | | | | | | | | |
| TUIP | L | | | | | | | | |
| TUIP + TURP | VL | | | | | | | | |
| TmLRP | VL | | | | | | | | |
| B-TUERP | L | | | | | | VL | | |
| M-TUERP | VL | | | | | | | | |
| B-VEP | VL | | | | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

H=high
M=moderate
L=low
VL=very low

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|--|
| Aquablation | TURP | Wide imprecision (1 trial with 1 event) |
| B-TUEP | TURP | Imprecision, RoB, rare events |
| B-TUEP | DioLEP | Wide imprecision (1 RCT with 1 event) |
| B-TUEP | ThuLEP | Single RCT (imprecision), RoB |
| B-TUEP | B-TUVP | Single RCT (imprecision), RoB |
| B-TUEP | OP | Single RCT (imprecision), RoB |
| B-TUERP | DioLEP | Single RCT with zero events |
| B-TUERP | TURP | Single RCT (imprecision) |
| B-TUVP | TURP | Imprecision |
| B-TUVP | OP | Single RCT (imprecision), RoB |
| B-VEP | TURP | Wide imprecision (1 RCT with 3 events) |
| DioLEP | TURP | Zero events |
| DioLVP | TURP | RoB, inconsistency, imprecision |
| HoLEP | TURP | RoB |
| HoLEP | DioLEP | Single RCT (imprecision) |
| HoLEP | ThuLEP | Imprecision (pooling not possible; 1 trial with 0 events, another one with just 2 events) |
| HoLEP | PVP | Wide imprecision (pooling not possible; 1 trial with 0 events, 1 trial with just 1 event) |
| M-TUERP | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | RoB, indirectness |
| PVP | B-TUVP | Wide imprecision (1 RCT with 1 event) |
| ThuLEP | TURP | Imprecision |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Wide imprecision (pooling not possible; 1 trial with 0 events, 1 trial with just 2 events) |
| TUIP | TURP | RoB, imprecision |
| TUIP + TURP | TURP | Single RCT, zero events |
| TUVRP | TURP | Imprecision, RoB |

Urinary tract infection

- Sixteen of the 21 technologies in this report assessed UTI using TURP as the comparator. HoLEP and PAE showed statistically significant better results versus TURP for this outcome. The quality of evidence is moderate for HoLEP versus TURP and low for PAE versus TURP.
- Conversely, PVP showed a statistically significant worse result for this outcome in comparison to TURP. The quality of the related evidence is low.
- No differences were shown for the remaining 13 comparisons; the quality of the related evidence is low to very low, except for B-TUVP versus TURP (moderate).
- Seven comparisons between newer technologies are available and did not show any statistically significant differences, with low to very low quality of evidence.

Table 6-4: Urinary tract infection: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | |
|--------------|---------|-------|--------|--------|-----|--------|--------|
| | TURP | HoLEP | ThuLEP | B-TUEP | PVP | ThuVEP | DioLEP |
| B-TUEP | VL | L | VL | | | | VL |
| HoLEP | M | | L | L | VL | VL | L |
| DioLEP | VL | L | | VL | | | |
| B-TUVP | M | | | | | | |
| PVP | L | VL | | | | | |
| ThuVEP | VL | VL | | | | | |
| ThuLEP | L | L | | VL | | | |
| DioLVP | VL | | | | | | |
| TUVRP | L | | | | | | |
| ThuVARP | VL | | | | | | |
| Aquablation | L | | | | | | |
| TUMT | L | | | | | | |
| TUIP + TURP | VL | | | | | | |
| PUL | VL | | | | | | |
| TmLRP | L | | | | | | |
| PAE | L | | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

H=high
M=moderate
L=low
VL=very low

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|--|
| Aquablation | TURP | Single RCT (imprecision) |
| B-TUEP | TURP | Imprecision, RoB, indirectness |
| B-TUEP | DioLEP | Single RCT (imprecision), RoB |
| B-TUEP | ThuLEP | Single RCT (imprecision), RoB |
| B-TUVP | TURP | Imprecision |
| DioLEP | TURP | Single RCT, rare event |
| DioLVP | TURP | Data from a single RCT (pooling not possible), RoB |
| HoLEP | TURP | Imprecision |
| HoLEP | B-TUEP | RoB, imprecision |
| HoLEP | DioLEP | Single RCT (imprecision) |
| HoLEP | ThuLEP | Single RCT (imprecision) |
| HoLEP | ThuVEP | Single RCT, just two events (imprecision) |
| HoLEP | PVP | Imprecision, very rare events |

| Intervention | Control | Reason |
|--------------|---------|-------------------------------|
| PAE | TURP | RoB, imprecision |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | RoB, indirectness |
| ThuLEP | TURP | RoB, imprecision |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| ThuVEP | TURP | Single RCT, no cases |
| TmLRP | TURP | Single RCT (imprecision) |
| TUIP + TURP | TURP | Single RCT (imprecision), RoB |
| TUMT | TURP | Imprecision, RoB |
| TUVRP | TURP | Imprecision, RoB |

Urethral stricture

- Nineteen of the 21 technologies in this report assessed urethral stricture using TURP as the comparator. No statistically significant differences were shown. The quality of evidence is low to very low.
- Eight comparisons between newer technologies are available and showed no statistically significant differences, with very low quality of evidence (except for HoLEP vs. ThuLEP: low).

Table 6-5: Urethral stricture: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|-------|--------|--------|-----|--------|--------|--------|---------|
| | TURP | HoLEP | ThuLEP | B-TUEP | PVP | DioLEP | B-TUVP | DioLVP | B-TUERP |
| B-TUEP | VL | VL | VL | | | VL | | | |
| HoLEP | L | | L | VL | | VL | | | |
| DioLEP | VL | VL | | VL | | | | | VL |
| B-TUVP | L | | | | VL | | | VL | |
| PVP | VL | | | | | | VL | | |
| ThuLEP | L | L | | VL | | | | | |
| DioLVP | VL | | | | | | VL | | |
| TUVRP | VL | | | | | | | | |
| ThuVARP | VL | | | | | | | | |
| Aquablation | VL | | | | | | | | |
| TUMT | L | | | | | | | | |
| TUIP | VL | | | | | | | | |
| TUIP + TURP | VL | | | | | | | | |
| PUL | VL | | | | | | | | |
| TmLRP | L | | | | | | | | |
| B-TUERP | VL | | | | | VL | | | |
| M-TUERP | VL | | | | | | | | |
| B-VEP | L | | | | | | | | |
| PAE | VL | | | | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

H=high
M=moderate
L=low
VL=very low

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|--------------|---------|---|
| Aquablation | TURP | Single RCT, rare event |
| B-TUEP | TURP | Imprecision, RoB, indirectness |
| B-TUEP | DioLEP | Single RCT, rare event |
| B-TUEP | ThuLEP | Single RCT (imprecision), RoB |
| B-TUERP | DioLEP | Single RCT, zero events |
| B-TUERP | TURP | Single RCT, rare event |
| B-TUVP | TURP | Imprecision, RoB |
| B-TUVP | DioLVP | Single RCT (imprecision), RoB |
| B-VEP | TURP | Single RCT (imprecision) |
| DioLEP | TURP | Imprecision, two studies not possible to pool, rare event |
| DioLVP | TURP | Data from a single RCT |
| HoLEP | TURP | RoB, imprecision |
| HoLEP | B-TUEP | Single RCT, zero events |
| HoLEP | DioLEP | Single RCT, rare event |
| HoLEP | ThuLEP | RoB, imprecision |
| M-TUERP | TURP | Single RCT (imprecision), RoB |
| PAE | TURP | RoB, imprecision, rare event |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | Single RCT, rare event |
| PVP | B-TUVP | Single RCT, rare event |
| ThuLEP | TURP | RoB, imprecision |
| ThuVARP | TURP | Single RCT (imprecision), RoB |
| TmLRP | TURP | Imprecision |
| TUIP | TURP | RoB, imprecision, rare event |
| TUIP + TURP | TURP | Single RCT, rare event |
| TUMT | TURP | Imprecision, RoB |
| TUVRP | TURP | Single RCT, rare event |

Urinary incontinence

- Fifteen of the 21 technologies in this report assessed incontinence using TURP as the comparator. Only PUL showed significantly better results for this outcome versus TURP, with very low quality of evidence.
- Conversely, B-TUEP, HoLEP and PVP showed significantly worse results for this outcome versus TURP. The quality of the related evidence is low for HoLEP and PVP versus TURP to very low for B-TUEP versus TURP.
- No differences were found for the remaining eleven comparisons; the quality of the related evidence is low to very low, except for TmLRP versus TURP (moderate).
- There are nine comparisons between newer technologies. ThuLEP showed significantly better results for this outcome versus HoLEP, with low quality of evidence. Other comparisons do not show any statistically significant differences, with low to very low quality of evidence.

Table 6-6: Urinary incontinence: comparisons available, results and quality of evidence

| Intervention | Control | | | | | | | | |
|--------------|---------|-------|--------|--------|-----|--------|--------|--------|---------|
| | TURP | HoLEP | ThuLEP | B-TUEP | PVP | ThuVEP | DioLEP | B-TUVP | B-TUERP |
| B-TUEP | VL | L | VL | | | | L | | |
| HoLEP | L | | L | L | VL | L | L | | |
| DioLEP | L | L | | L | | | | | L |
| B-TUVP | L | | | | VL | | | | |
| PVP | L | VL | | | | | | VL | |
| ThuVEP | | L | | | | | | | |
| ThuLEP | L | L | | VL | | | | | |
| DioLVP | VL | | | | | | | | |
| TUVRP | VL | | | | | | | | |
| TUMT | L | | | | | | | | |
| PAE | L | | | | | | | | |
| PUL | VL | | | | | | | | |
| TmLRP | M | | | | | | | | |
| B-TUERP | L | | | | | | L | | |
| M-TUERP | VL | | | | | | | | |
| B-VEP | L | | | | | | | | |

Key to quantitative differences

| | |
|--|--|
| | Intervention statistically significantly better than control |
| | No difference |
| | Intervention statistically significantly worse than control |

Abbreviations:

| |
|-------------|
| H=high |
| M=moderate |
| L=low |
| VL=very low |

Note: Comparison of each technology (intervention, left column) by row to the other technologies (control, other columns). The colours denote the quantitative difference for each comparison, as shown in the key. Letters denote the quality of the evidence.

Reasons for downgrading of evidence

| Intervention | Control | Reason |
|---------------------|----------------|---|
| B-TUEP | TURP | Imprecision, RoB, indirectness |
| B-TUEP | DioLEP | Indirectness, RoB |
| B-TUEP | ThuLEP | Single RCT (imprecision), RoB |
| B-TUERP | DioLEP | Single RCT (imprecision) |
| B-TUERP | TURP | Single RCT (imprecision) |
| B-TUVP | TURP | Imprecision, rare event |
| B-VEP | TURP | Single RCT (imprecision) |
| DioLEP | TURP | Imprecision, two studies not possible to pool |
| DioLVP | TURP | Single RCT (imprecision), RoB |
| HoLEP | TURP | RoB, imprecision |
| HoLEP | B-TUEP | RoB, imprecision |
| HoLEP | DioLEP | Single RCT (imprecision) |
| HoLEP | ThuLEP | RoB, imprecision |
| HoLEP | ThuVEP | Single RCT (imprecision) |
| HoLEP | PVP | Imprecision, two studies not possible to pool |
| M-TUERP | TURP | Single RCT (imprecision), RoB |
| PAE | TURP | RoB, imprecision |
| PUL | TURP | Single RCT (imprecision), RoB |
| PVP | TURP | RoB, indirectness |
| PVP | B-TUVP | Single RCT, rare event |
| ThuLEP | TURP | RoB, imprecision |
| TmLRP | TURP | Imprecision |
| TUMT | TURP | Single RCT (imprecision) |
| TUVRP | TURP | Two RCTs, not possible to pool |

7 DISCUSSION

BPH is a common nonmalignant urological condition that involves progressive proliferation of glandular epithelium, smooth muscle and connective tissue in the transition zone of the prostate. In a large proportion of BPH patients, prostate enlargement causes BOO, which has an adverse impact on urinary tract function, resulting in LUTS. On average, approximately one in four men are likely to develop BPH over their lifetime. Bothersome LUTS occur in up to 30% of men older than 65 years, of whom one-quarter will develop severe LUTS. As many as 30% of those who develop BPH receive treatment for the condition.

BPH is associated with high personal and societal burdens, both directly through increased medical costs and indirectly because of losses in daily functioning, in addition to a negative impact on QoL for patients and their partners. According to the latest World Health Organization estimates for the European region, BPH was responsible for 0.25% of the total DALYs caused by all conditions.

The most common indication for surgical intervention is moderate to severe voiding symptoms attributed to BPH that are refractory to conservative or medical therapy (relative indications for surgery). Surgical treatment is also required when patients have experienced recurrent or refractory urinary retention, overflow incontinence, recurrent UTIs, bladder stones or diverticula, treatment-resistant macroscopic haematuria because of BPH and/or BPE, or dilatation of the upper urinary tract because of BPO, with or without renal insufficiency (absolute indications for surgery).

The choice of surgical technique depends on prostate size, patient comorbidities, ability to undergo anaesthesia, patient preferences, willingness to accept surgery-associated specific side effects, the availability of surgical techniques in a specific centre and the experience of the surgeon with these techniques. The experience and preference of the treating surgeon often have an important role in the choice of surgical treatment for BPH. TURP has remained the cornerstone of LUTS/BPO surgical treatment for decades. Despite its high rate of success, TURP has a perioperative morbidity rate of approximately 20% and has long-term complications that include ejaculatory dysfunction (65%), erectile dysfunction (10%), urethral stricture (7%), UTI (4%), urinary incontinence (2%) and bleeding requiring transfusion (2%) [60]. The development of different minimally invasive technologies has provided alternatives that are expected to have similar effectiveness but a better safety profile in comparison to TURP.

- Different ablative technologies have been developed. These remove excess prostatic tissue in different ways, as follows:
- Resection with holmium or thulium lasers (e.g., TmLRP) as an alternative to classical TURP;
- Enucleation using either holmium (HoLEP), thulium (ThuLEP) or diode (DioLEP) laser or different electrodes delivering bipolar energy (B-TUEP) to peel the enlarged prostate from the prostate capsule without cutting into it or dissecting it;
- Vaporisation with a bipolar electrode (B-TUVP) or a laser system (e.g., KTP or LBO PVP or DioLVP) to remove excess prostate tissue by heating and evaporating it;
- Hybrid techniques such as vapoenucleation (e.g., with a thulium laser [ThuVEP] or with bipolar energy [B-VEP]), vaporessection (using resection with the help of electric current or laser and vaporisation with the use of a vaporisation electrode [TUVRP and ThuVARP]) or enucleoresection (using monopolar M-TUERP - or bipolar energy – B-TUERP);
- Aquablation using a high-speed jet of saline (waterjet) to remove excess prostate tissue;
- TUMT using electromagnetic waves to thermoablate prostatic tissue; and
- WAVE using convective water vapour generated via radiofrequency current and injected into the prostate to destroy excess tissue.

Nonablative techniques have also been developed. These include the following:

- Incision (TUIP) into the bladder neck reduces the pressure of the prostate on the urethra, which is an option especially suitable for men with smaller prostates, with a trade-off between minor efficacy and higher safety or a lesser impact on sexual function.
- PAE uses PVA and other newer synthetic biocompatible materials to reduce the blood flow in the prostate, causing it to undergo ischaemic necrosis.
- PUL uses small adjustable permanent implants to create an open channel to increase urine flow.
- TIND creates new channels in the urethra to increase urine flow.

According to the American Urological Association, some techniques (such as HoLEP and ThuLEP) are size-independent, while others (such as PVP, Aquablation, WAVE, TUMT, TUVP and PUL) are especially suitable for small to medium prostates and TUIP is only suitable for small prostates.

In this REA we assessed the effectiveness and safety of 21 of these technologies in comparison to TURP. Eighty-four RCTs (in 94 publications) were eventually selected; all but three of these RCTs were two-arm trials. Sixty-six RCTs (3 multiarm trials) compared newer technologies to TURP, 18 RCTs (3 multiarm trials) compared two newer technologies to each other, one RCT (multiarm) compared newer technologies to OP and one RCT compared newer technologies to sham. All trials were relatively small: the highest number of patients per study arm was 205, with an average size of 63. Among the newer technologies, HoLEP was the one most frequently assessed in the RCTs (in 25), followed by B-TUVP (in 13), B-TUEP (in 12), ThuLEP (in 9), DioLEP and PVP (in 6), TUIP (in 5), TUMT and TUVRP (in 4), DioLVP and PAE (in 5), B-TUERP, ThuVEP, TmLRP and TUIP + TURP (in 2), and Aquablation, B-VEP, M-TUERP, PUL, ThuVARP and WAVE (in 1). WAVE was only assessed in an RCT versus sham and no comparative data versus alternative technologies were available. No head-to-head RCTs assessing TIND were found.

Regarding potential conflicts of interest, there was disclosure of sponsorship or receipt of equipment from manufacturers in eight RCTs, while the authors' personal conflicts of interest were disclosed in six additional RCTs.

Only 20 RCTs provided power calculations for detection of defined differences for primary outcomes of interest for this REA; in five of these trials, two co-primary outcomes were declared. Among these RCTs, IPSS was the outcome most frequently declared as the primary endpoint (in 10), followed by Qmax (in 6), catheterisation time (in 5) and hospitalisation time (in 3). A noninferiority hypothesis was declared in eight RCTs, in which primary outcomes were IPSS in five of them, IPSS and Qmax (as a co-primary outcomes) in one, Qmax in one and reintervention rate in one.

The vast majority of the studies included populations that were heterogeneous in terms of prostate size and it was not possible to assess the effectiveness and safety of the different technologies in our predefined prostate size subgroups. Studies including relatively homogeneous populations were available for TUIP and its combination with TURP, targeted at patients with smaller prostates (<30-40 ml); DioLEP (in two RCTs); for WAVE and Aquablation (in one RCT), with studies including patients with prostate size between 30 and 80 ml; and for HoLEP, B-VEP (each in 2 RCTs), PVP, B-TUEP and M-TUERP (each in 1 RCT), with studies including patients with prostate size >80 ml.

Clinical effectiveness: direct comparisons

New technologies versus TURP: IPSS and Qmax (with follow-up >6 months)

Some of the available RCTs and pooled data showed the following.

- There were statistically significant better IPSS results versus TURP for HoLEP, B-TUEP, B-TUVP and ThuLEP from pooled data, and for B-TUERP from single RCTs.
- There were statistically significant better results for IPSS for TURP versus TUMT, PVP and PAE from pooled data, and versus PUL and DioLVP from single RCTs.
- There were statistically significant better results for Qmax versus TURP for HoLEP, B-TUEP and B-TUVP from pooled data, and for TUIP + TURP and B-TUERP from single RCTs.
- There were statistically significant better results for Qmax for TURP versus TUMT and TUIP from pooled data, and versus PAE, PUL, DioLVP and ThuVARP from single RCTs.

Nevertheless, the clinical relevance of the differences observed is either low or difficult to establish. Mean pooled estimates of the MD are in most cases below the MCID values reported in the literature (3 points for IPSS, 2 ml/sec for Qmax, the latter based on consensus among a panel of experts from the UK National Institute for Health and Care Excellence) and their CIs only infrequently cross the MCID (in particular for ThuVARP, TUMT, TUIP, PUL and PAE compared to TURP). In cases for which only data from single RCTs were available, even when the MDs cross the MCID threshold, CIs are either lacking or imply wide imprecision, so that the relevance is quite uncertain. Nevertheless, it is not possible to exclude the possibility that choosing one of these technologies instead of others may provide some patients with a clinically relevant benefit (depending on how wide the CI for the MD is). It should be noted that in five of the eight RCTs comparing newer technologies versus TURP with either IPSS or Qmax as the primary outcome and a rigorous sample size calculation, the aim was to demonstrate noninferiority of the newer technology. This could imply that the proposed techniques are intended to offer patients less invasive alternatives while accepting the lack of better functional outcomes over TURP. If this is the case, it should be noted that the trial investigators did not try to establish sufficient statistical power to demonstrate improvements in outcomes that may benefit from lower invasiveness.

New technologies versus TURP: PVR and QoL

A few RCTs showed statistically significant better PVR and QoL results in favour of HoLEP and B-TUERP versus TURP from pooled data, and in favour of TURP versus PVP and TUMT (for PVR), versus ThuLEP (for QoL), and versus PAE and PUL (the latter from single RCTs). However, it was not possible to establish the clinical relevance of the differences observed, since no MCID has been established for PVR or QoL (in terms of IPSS QoL, the scale that was probably used in most of the trials). In addition, these differences were numerically small and thus, even though the range for the scores is unknown, it seems unlikely that these differences were clinically relevant.

New technologies versus TURP: reintervention

Limited information is available on reintervention. Only HoLEP showed a lower incidence for this outcome compared to TURP and to PVP, although the quality of evidence is low to very low. Conversely, TUIP, an option for patients with smaller prostates, showed higher odds of reintervention, with low quality of evidence.

New technologies versus TURP: hospitalisation and operative times

Newer technologies showed a shorter hospitalisation time versus TURP that ranged from <1 day to 1–2 days less. Regarding operative time, more time is generally required for newer technologies compared to TURP (except for TUIP, which had a shorter surgery time than TURP). However, the differences are generally in the order of minutes and this outcome was not identified as critical for decision-making. For both outcomes, statistical heterogeneity was often observed, probably because of different policies in different centres (and surgeon experience). In light of these considerations, we decided that pooling of data for these outcomes would generally not be appropriate.

New technologies versus OP

OP was used as the comparator in only one RCT, and had a longer hospitalisation time (>4 days longer) compared to B-TUEP and B-TUVP.

Comparisons between new technologies

For comparisons among newer technologies, a few studies showed statistically significant differences in favour of the following:

- B-TUEP versus HoLEP and versus B-TUVP for Qmax;
- ThuLEP versus HoLEP for IPSS, PVR and QoL;
- ThuVEP versus HoLEP for QoL (from a single RCT);
- PVP versus HoLEP for QoL;
- HoLEP versus PVP for IPSS, Qmax, PVR and the reintervention rate;
- PVP versus B-TUVP for PVR; and
- DioLEP versus B-TUEP and versus B-TUERP for irritative symptoms (the latter from a single RCT).

Safety: direct comparisons

The available comparisons did not show any differences for bladder perforation, bladder or ureteral injury, erectile dysfunction, TUR syndrome, urethral stricture or bladder neck contracture.

Comparisons of new technologies versus TURP

Some of the RCTs and pooled data showed statistically significant benefits in favour of newer technologies compared to TURP for some of the critical and important outcomes considered in this REA, specifically:

- A rate ratio of 0.4 for retrograde ejaculation for TUIP, an absolute reduction of 16% for Aquablation and an absolute reduction (from 34% to 0%) for anejaculation for PUL (the latter two from single RCTs);
- A lower incidence (–27%) of erectile dysfunction for ThuLEP in a single RCT;
- A rate ratio for transfusion requirement of the order of 0.1–0.3 for HoLEP, ThuLEP, B-TUVP and PVP and a reduction of 9% for M-TUERP (the latter from a single RCT);
- A rate ratio for UTI between 0.2 and 0.5 for HoLEP and PAE;

- A rate ratio for urinary incontinence of 0.1 for PAE and a reduction of 15% for PUL (the latter from a single RCT); and
- A 7% reduction in recatheterisation and an 11% reduction in retention for M-TUERP (from a single RCT).

Outcomes that were worse for some technologies in comparison to TURP are as follows:

- Incontinence for HoLEP, B-TUEP (rate ratio 1.9) and PVP (rate ratio 2.6); and
- UTI for PVP (rate ratio 1.8).

RCTs generally showed a shorter catheterisation time for newer technologies, but large statistical heterogeneity, probably explained by different policies in different centres, precluded data pooling.

Comparisons among newer technologies

A few data from single RCTs are available, showing statistically significant differences in favour of ThuLEP versus HoLEP for incontinence (rate ratio 3.4) and in favour of ThuVEP versus HoLEP for urinary retention (13% absolute difference in a single RCT).

Since the claimed benefits of newer technologies mainly fall in the safety domain and are often centred on patient preferences and expectations, typically in relation to preserving sexual function and avoiding adverse effects such as incontinence, it is surprising that no RCTs were powered for any of these outcomes; only five trials were powered for catheterisation time, which is only indirectly related to safety.

Quality of the evidence

The quality of the evidence for all of these outcomes has been judged as moderate to very low, considering internal and external validity. Regarding internal validity, most studies provided limited information in terms of random allocation, allocation concealment and losses to follow-up; study protocols or trial registrations were rarely available to check for selective reporting. In addition, since surgery trials could be blinded to patients and to assessors (although rarely declared) but not to surgeons (although their optimal performance cannot be in doubt), biases in assessment of outcomes cannot be ruled out, especially in assessing subjective outcomes. Some inconsistency in results and relevant uncertainties (owing to low precision of estimates) also contributed to lower-quality judgements, as well as statistical heterogeneity and the uncertain external validity because of limited information about prostate size for the patients included or the inclusion of heterogeneous populations in this regard.

8 CONCLUDING SUMMARY

Minimally invasive technologies are expected to reduce short- and long-term side effects of standard surgical treatments for BPH (in particular TURP) even if this may result in lower effectiveness for functional outcomes. Using a systematic analysis of the available RCTs, we assessed parallel comparisons of 21 of these technologies versus TURP or OP (defined as standard interventions) or cross-comparisons. Eighty-four RCTs were eventually selected.

Most of the trials selected provide information on functional outcomes. Few comparisons show statistically significant differences in either direction and the results in most cases are below the MCID threshold. The quality of the related evidence has been graded as low to very low, suggesting limited confidence in the estimates and that further research is likely to change these estimates.

Limited information is available on reintervention. Only HoLEP showed a lower incidence for this outcome compared to TURP and to PVP, although the quality of the evidence is low to very low. Conversely, TUIP, an option for patients with smaller prostates, showed higher odds of reintervention compared to TURP, with low quality of evidence.

Regarding impact on sexual activity, ThuLEP, TUIP, Aquablation and PUL may provide some advantage over TURP, with the quality of evidence ranging from moderate (lower incidence of retrograde ejaculation among patients with small prostates undergoing TUIP) to low or very low.

Regarding other possible safety concerns and side effects, some newer technologies may offer some advantage over TURP in reducing the requirement for transfusion; mixed results (improvement or worsening), limited to very few technologies, are available for UTI and incontinence.

Small sample sizes, biases in study design, heterogeneous populations and (in most cases) an undefined primary hypothesis indicate the need for more and better research so that the advantages and disadvantages of all these technologies can be more clearly defined. In particular, adequately powered studies may help to identify preferred technologies according to prostate size.

Considering its wide scope in terms of the number of technologies, comparisons and outcomes that have been assessed, this HTA may help in providing a comprehensive and updated overview of the available evidence on technologies for BPH surgery. It should be noted that this report did not assess the organisational and economic impact of different technologies or their possible impact on equity of access; these issues were beyond the scope of the assessment but can be critical for decision-makers.

9 REFERENCES

- [1] McVary KT. Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnostic-evaluation-of-benign-prostatic-hyperplasia?search=benign%20prostate%20hyperplasia&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2.
- [2] Lim KB. Epidemiology of clinical benign prostatic hyperplasia. *Asian J Urol.* 2017;4(3):148-51.
- [3] Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. *BJU Int.* 2008;102(8):981-6.
- [4] McVary KT. Epidemiology and pathophysiology of benign prostatic hyperplasia. Available from: https://www.uptodate.com/contents/epidemiology-and-pathophysiology-of-benign-prostatic-hyperplasia?search=Benign%20Prostatic%20Hyperplasia&topicRef=6889&source=see_link.
- [5] Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. *N Engl J Med.* 2012;367(3):248-57.
- [6] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. *The Journal of urology.* 1984;132(3):474-9.
- [7] Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). *Med Clin North Am.* 2011;95(1):87-100.
- [8] World Health Organization. Health statistics and information systems. Disease burden and mortality estimate. Global Health Estimates 2016. 2018; Available from: https://www.who.int/healthinfo/global_burden_disease/estimates/en/.
- [9] Errando-Smet C, Muller-Arteaga C, Hernandez M, Lenero E, Roset M. Healthcare resource utilization and cost among males with lower urinary tract symptoms with a predominant storage component in Spain: The epidemiological, cross-sectional MERCURY study. *Neurourol Urodyn.* 2018;37(1):307-15.
- [10] Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. *Sci Rep.* 2017;7(1):7984.
- [11] The National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management. 2010; [Clinical guideline]. Available from: <https://www.nice.org.uk/guidance/cg97>.
- [12] European Association of Urology (EAU). EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018; Available from: <https://uroweb.org/guidelines/>.
- [13] Lukacs B, Cornu JN, Aout M, *et al.* Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. *Eur Urol.* 2013;64(3):493-501.
- [14] Peyronnet B, Cornu JN, Roupret M, Bruyere F, Misrai V. Trends in the use of the GreenLight laser in the surgical management of benign prostatic obstruction in France over the past 10 years. *Eur Urol.* 2015;67(6):1193-5.

- [15] Kang JY, Min GE, Son H, Kim HT, Lee HL. National-wide data on the treatment of BPH in Korea. *Prostate Cancer Prostatic Dis.* 2011;14(3):243-7.
- [16] Schroeck FR, Hollingsworth JM, Kaufman SR, Hollenbeck BK, Wei JT. Population based trends in the surgical treatment of benign prostatic hyperplasia. *The Journal of urology.* 2012;188(5):1837-41.
- [17] Takamori H, Masumori N, Kamoto T. Surgical procedures for benign prostatic hyperplasia: A nationwide survey in Japan, 2014 update. *Int J Urol.* 2017;24(6):476-7.
- [18] Morton A, Williams M, Perera M, *et al.* Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. *BJU Int.* 2020;126 Suppl 1:18-26.
- [19] McVary KT, Roehrborn CG, Avins AL, *et al.* Update on AUA guideline on the management of benign prostatic hyperplasia. *The Journal of urology.* 2011;185(5):1793-803.
- [20] McVary K. Surgical treatment of benign prostatic hyperplasia (BPH). In: O'Leary M, editor. UpToDate. Waltham, MA. (cited 01.12.2020): UpToDate; 2020.
- [21] Huang SW, Tsai CY, Tseng CS, *et al.* Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. *BMJ.* 2019;367:l5919.
- [22] Holmium:YAG surgical lasers. *Health Devices.* 1995;24(3):92-122.
- [23] American Urological Association (AUA). Benign prostatic hyperplasia: surgical management of benign prostatic hyperplasia/lower urinary tract symptoms (2018, amended 2019, 2020). 2020.
- [24] European Association of Urology (EAU). Guidelines on lasers and technologies. 2014.
- [25] Pillai RG, Al Naieb Z, Angamuthu S, Mundackal T. Diode laser vaporisation of the prostate vs. diode laser under cold irrigation: A randomised control trial. *Arab J Urol.* 2014;12(4):245-50.
- [26] Patel A. Transurethral bipolar electrosurgery in the lower urinary tract. In: Baba S, Ono Y, editors. *Interventional management of urological diseases.* Japan: The Japanese Society of Endourology and ESWL 2006. p. 157-78.
- [27] Li S, Kwong JSW, Zeng X-T, *et al.* Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis. *Sci Rep.* 2015;5(1):12002.
- [28] Montorsi F, Saitta G, Suardi N. Chapter 13 - Surgical treatment for LUTS/BPH: laser devices. In: Morgia G, Russo GI, editors. *Lower urinary tract symptoms and benign prostatic hyperplasia:* Academic Press; 2018. p. 257-88.
- [29] The National Institute for Health and Care Excellence (NICE). Holmium laser prostatectomy. *Interventional procedures guidance [IPG17].* 2003 [cited 2020 21 Sept 2020]; Available from: <https://www.nice.org.uk/guidance/ipg17>.
- [30] El Din AG, Abd-Al Baky TM, El-Sherif EAR, Ghonaimy AS. Role of bipolar plasma enucleation of the prostate in the treatment of benign prostatic hyperplasia. *Menoufia Med J.* 2020;33(2):523-7.

- [31] Wang Z, Li H, Chong T. A prospective, randomised trial comparing transurethral enucleation with bipolar system (TUEB) to monopolar resectoscope enucleation of the prostate for symptomatic benign prostatic hyperplasia. *Biomed Res J.* 2017;28(12).
- [32] Hruby S, Sieberer M, Schätz T, *et al.* Eraser laser enucleation of the prostate: technique and results. *Eur Urol.* 2013;63(2):341-6.
- [33] Erol A, Keskin S, Başok E, Dönmezer S. Diode 980 nm laser vaporesction of the prostate: a comparison of 150 to 250 watt. *J Urol Surg.* 2018;5:83-7.
- [34] U.S. Food and Drug Administration (FDA). 510(k) summary. K100275. 2010; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100275.pdf.
- [35] The National Institute for Health and Care Excellence (NICE). Transurethral electrovaporisation of the prostate. 2003 [10.10.2020]; Available from: <https://www.nice.org.uk/guidance/ipg14>.
- [36] Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). *European Urology.* 2006;49(6):961-9.
- [37] The National Institute for Health and Care Excellence (NICE). GreenLight XPS for treating benign prostatic hyperplasia. 2016 [cited 2020 15.09.2020]; Available from: <https://www.nice.org.uk/guidance/mtg29/chapter/2-the-technology>.
- [38] Peng B, Huang J, Wang G, Zhang H, Liu M. Transurethral enucleation of prostate with button electrode plasmakinetic vaporization for the treatment of benign prostatic hyperplasia. *Sci Rep* 2016;6:39583.
- [39] Gomez Sancha F, Rivera VC, Georgiev G, Botsevski A, Kotsev J, Herrmann T. Common trend: move to enucleation—Is there a case for GreenLight enucleation? Development and description of the technique. *World J Urol.* 2015;33(4):539-47.
- [40] Li S, Kwong JSW, Zeng X-T, *et al.* Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis. *Sci Rep.* 2015;5:12002.
- [41] Geavlete B, Multescu R, Dragutescu M, Jecu M, Georgescu D, Geavlete P. Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: 'the better choice' in benign prostatic hyperplasia? *BJU International.* 2010;106(11):1695-9.
- [42] High power holmium laser for BPH treatments. Holmium laser vaporesction of the prostate (HoLVRP) procedure. Clarion Medical Technologies; [11.09.2020]; Available from: <https://www.clarionmedical.com/en-CA/Divisions/Urology/Lasers/Holmium-Laser-VapoResection-of-the-Prostate>.
- [43] Hashim H, Worthington J, Abrams P, *et al.* Thulium laser transurethral vaporesction of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. *Lancet.* 2020;396(10243):50-61. Epub July 04, 2020.
- [44] Ajib K, Zgheib J, Salibi N, *et al.* Monopolar transurethral enucleo-resection of the prostate versus holmium laser enucleation of the prostate: a Canadian novel experience. *Journal of Endourology.* 2018;32(6):509-15.

- [45] Wei Y, Xu N, Chen S-H, *et al.* Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate for prostates larger than 60gr: A retrospective study at a single academic tertiary care center. *International braz j urol.* 2016;42:747-56.
- [46] TURiS – Transurethral resection in saline. Review of clinical evidence for bipolar resection and plasma vaporization. Olympus; [10.10.2020]; Available from: https://www.olympus-europa.com/medical/rmt/media/en/Content/Content-MSD/Documents/Brochures/TURis_clinical_brochure_EN_20140303.pdf.
- [47] The National Institute for Health and Care Excellence (NICE). Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. 2018 [10.10.2020]; Available from: <https://www.nice.org.uk/guidance/ipg629>.
- [48] McVary KT, Gange SN, Gittelman MC, *et al.* Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. *J Sex Med.* 2016;13(6):924-33.
- [49] McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology.* 2019;126:171-9.
- [50] The National Institute for Health and Care Excellence (NICE). Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2020 [15.11.2020]; Available from: <https://www.nice.org.uk/guidance/mtg49>.
- [51] Roehrborn CG, Gange SN, Gittelman MC, *et al.* Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *The Journal of urology.* 2017;197(6):1507-16.
- [52] McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology.* 2018;111:1-9.
- [53] the National Institute for Health and Care Excellence (NICE). Laparoscopic prostatectomy for benign prostatic obstruction. 2008 [14.10.2020]; Available from: <https://www.nice.org.uk/guidance/ipg275>.
- [54] Healthwise. Transurethral microwave therapy (TUMT) for benign prostatic hyperplasia. 2019 [20.20.2020]; Available from: <https://www.uofmhealth.org/health-library/ug1939>.
- [55] Garcia C, Chin P, Rashid P, Woo HH. Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia. *Prostate International.* 2015;3(1):1-5.
- [56] NeoTract I. UroLift® System UL400 instructions for use. 2020 [20.03.2021]; Available from: https://f.hubspotusercontent30.net/hubfs/2618738/Brochures_Forms/L00181-01_RevA_UroLift%20_System_UL400_IFU_US.pdf.
- [57] the National Institute for Health and Care Excellence (NICE). Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. 2018 [13.10.2020]; Available from: <https://www.nice.org.uk/guidance/ipg611>.

- [58] The National Institute for Health and Care Excellence (NICE). Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. 2019 [15.11.2020]; Available from: <https://www.nice.org.uk/guidance/ipg641>.
- [59] Sountoulides P, Karatzas A, Gravas S. Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. *Therapeutic Advances in Urology*. 2019;11:1756287219828971.
- [60] Magistro G, Stief CG. Surgery for benign prostatic obstruction. *The Lancet*. 2020;396(10243):5-7.
- [61] Parsons K, Barry M, Dahm P, *et al*. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. May 2020; Available from: [https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(bph\)-guideline#:~:text=Clinicians%20should%20consider%20holmium%20laser,%3B%20Evidence%20Level%3A%20Grade%20B](https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline#:~:text=Clinicians%20should%20consider%20holmium%20laser,%3B%20Evidence%20Level%3A%20Grade%20B).
- [62] The Cochrane Collaboration. Chapter 16: Special topics in statistics. In: Higgins J, editor. *Cochrane Handbook for Systematic Reviews of Interventions (Version 510)*2011.
- [63] McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. *Statistical Methods in Medical Research*. 2020;29(9):2520-37.
- [64] Barry MJ, Williford WO, Chang Y, *et al*. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? *The Journal of urology*. 1995;154(5):1770-4. Epub 1995/11/01.
- [65] Higgins JPT, Altman DG, Gøtzsche PC, *et al*. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
- [66] Henderson AR. Evidence-based medicine—How to practice and teach EBM. . In: D. L. Sackett WSR, W. Rosenberg, and R. B. Haynes. , editor. *Clinical Chemistry*. New York: Churchill Livingstone1997. p. 2014-.
- [67] The Cochrane Collaboration. 9.5.2 Identifying and measuring heterogeneity. In: Higgins J, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions (Version 510)*: The Cochrane Collaboration; 2011.
- [68] Montori VM, Guyatt GH. Intention-to-treat principle. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2001;165(10):1339-41. Epub 2002/01/05.
- [69] The Cochrane Collaboration. Part 3: Special topics. 16.2 Intention-to-treat issues. In: Higgins J, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions (Version 510)*2011.
- [70] Schünemann H, Brozek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. [Updated October 2013]. 2009; Available from: <https://gdt.gradepr.org/app/handbook/handbook.html>.

- [71] Abt D, Hechelhammer L, Mullhaupt G, *et al.* Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. *BMJ.* 2018;361:k2338.
- [72] Cetinkaya M, Onem K, Rifaioglu MM, Yalcin V. 980-nm diode laser vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: randomized controlled study. *Urol J.* 2015;12(5):2355-61.
- [73] Chen YB, Chen Q, Wang Z, *et al.* A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. *The Journal of urology.* 2013;189(1):217-22.
- [74] Elshal AM, Elkoushy MA, El-Nahas AR, *et al.* GreenLight laser (XPS) photoselective vapo-enucleation versus holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic hyperplasia: a randomized controlled study. *The Journal of urology.* 2015;193(3):927-34.
- [75] Elshal AM, Soltan M, El-Tabey NA, Laymon M, Nabeeh A. Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. *BJU International.* 2020;126(6):731-8.
- [76] Ghobrial FK, Shoma A, Elshal AM, *et al.* A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years. *BJU Int.* 2020;125(1):144-52.
- [77] Bachmann A, Tubaro A, Barber N, *et al.* 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study. *Eur Urol.* 2014;65(5):931-42.
- [78] Bachmann A, Tubaro A, Barber N, *et al.* A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. *The Journal of urology.* 2015;193(2):570-8.
- [79] Thomas JA, Tubaro A, Barber N, *et al.* A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. *Eur Urol.* 2016;69(1):94-102.
- [80] Hashim H, Worthington J, Abrams P, *et al.* Thulium laser transurethral vaporessection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. *Lancet.* 2020;396(10243):50-61.
- [81] Insausti I, Saez de Ocariz A, Galbete A, *et al.* Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. *J Vasc Interv Radiol.* 2020;31(6):882-90.
- [82] Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. *The Journal of urology.* 2004;172(3):1012-6.

- [83] Lusuardi L, Myatt A, Sieberer M, Jeschke S, Zimmermann R, Janetschek G. Safety and efficacy of Eraser laser enucleation of the prostate: preliminary report. *The Journal of urology*. 2011;186(5):1967-71.
- [84] Neill MG, Gilling PJ, Kennett KM, *et al*. Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. *Urology*. 2006;68(5):1020-4.
- [85] Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). *The Journal of urology*. 2003;170(4 Pt 1):1270-4.
- [86] Gilling P, Barber N, Bidair M, *et al*. WATER: a double-blind, randomized, controlled trial of Aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. *The Journal of urology*. 2018;199(5):1252-61.
- [87] Gilling PJ, Barber N, Bidair M, *et al*. Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. *Urology*. 2019;125:169-73.
- [88] Gilling P, Barber N, Bidair M, *et al*. Two-year outcomes after auablation cmpared to TURP: efficacy and ejaculatory improvements sustained. *Adv Ther*. 2019;36(6):1326-36.
- [89] Kasivisvanathan V, Hussain M. Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. *Can J Urol*. 2018;25(3):9317-22.
- [90] Gilling P, Barber N, Bidair M, *et al*. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. *Can J Urol*. 2020;27(1):10072-9.
- [91] McVary KT, Gange SN, Gittelman MC, *et al*. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *The Journal of urology*. 2016;195(5):1529-38.
- [92] Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. *Eur Urol*. 2008;53(2):382-89.
- [93] Yee CH, Wong JH, Chiu PK, *et al*. Short-stay transurethral prostate surgery: a randomized controlled trial comparing transurethral resection in saline bipolar transurethral vaporization of the prostate with monopolar transurethral resection. *Asian J Endosc Surg*. 2015;8(3):316-22.
- [94] Yip SK, Chan NH, Chiu P, Lee KW, Ng CF. A randomized controlled trial comparing the efficacy of hybrid bipolar transurethral vaporization and resection of the prostate with bipolar transurethral resection of the prostate. *J Endourol*. 2011;25(12):1889-94.
- [95] Zhang J, Ou Z, Zhang X, *et al*. Holmium laser enucleation of the prostate versus thulium laser enucleation of the prostate for the treatment of large-volume prostates > 80 ml: 18-month follow-up results. *World J Urol*. 2020;38(6):1555-62.
- [96] Zhu L, Chen S, Yang S, *et al*. Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. *The Journal of urology*. 2013;189(4):1427-31.

- [97] Zou Z, Xu A, Zheng S, *et al.* Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results. *World J Urol.* 2018;36(7):1117-26.
- [98] Abd-El Kader O, Mohy El Den K, El Nashar A, Hussein A, Yehya E. Transurethral incision versus transurethral resection of the prostate in small prostatic adenoma: long-term follow-up. *African Journal of Urology.* 2012;18(1):29-33.
- [99] Bai F, Feng S, Xu C, Xu Z, Chen J, Zheng Y. Transurethral resection versus holmium laser enucleation of the prostate: a prospective randomized trial comparing perioperative thrombin generation and fibrinolysis. *Medicine (Baltimore).* 2019;98(15):e15223.
- [100] Basic D, Stankovic J, Potic M, Ignjatovic I, Stojkovic I. Holmium laser enucleation versus transurethral resection of the prostate: a comparison of clinical results. *Acta Chir Iugosl.* 2013;60(1):15-20.
- [101] Bozzini G, Seveso M, Melegari S, *et al.* Thulium laser enucleation (ThuLEP) versus transurethral resection of the prostate in saline (TURis): a randomized prospective trial to compare intra and early postoperative outcomes. *Actas Urol Esp.* 2017;41(5):309-15. Enucleacion con laser de tulio (ThuLEP) frente a reseccion transuretral de la prostata en solucion salina (TURis): un ensayo prospectivo aleatorizado para comparar resultados intra y postoperatorios tempranos.
- [102] Bozzini G, Berti L, Maltagliati M, *et al.* Ejaculation-sparing thulium laser enucleation of the prostate (ES-ThuLEP): outcomes on a large cohort. *World Journal of Urology.* 2020.
- [103] Gratzke C, Barber N, Speakman MJ, *et al.* Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int.* 2017;119(5):767-75.
- [104] Sonksen J, Barber NJ, Speakman MJ, *et al.* Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol.* 2015;68(4):643-52.
- [105] Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. *Cardiovascular and interventional radiology.* 2016;39(1):44-52. Epub 2015/10/29.
- [106] Chang CH, Lin TP, Chang YH, Huang WJ, Lin AT, Chen KK. Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study. *BMC Urol.* 2015;15:40.
- [107] D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, De La Rosette JJ. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. *Br J Urol.* 1998;81(2):259-64.
- [108] Dahlstrand C, Walden M, Geirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. *Br J Urol.* 1995;76(5):614-8.

- [109] Dorflinger T, Jensen FS, Krarup T, Walter S. Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. *Scand J Urol Nephrol*. 1992;26(4):333-8.
- [110] Dunsmuir WD, McFarlane JP, Tan A, *et al*. Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. *Prostate Cancer Prostatic Dis*. 2003;6(2):182-6.
- [111] Elsakka AM, Eltatawy HH, Almekaty KH, Ramadan AR, Gameel TA, Farahat Y. A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate. *Arab J Urol*. 2016;14(4):280-6.
- [112] Eltabey MA, Sherif H, Hussein AA. Holmium laser enucleation versus transurethral resection of the prostate. *Can J Urol*. 2010;17(6):5447-52.
- [113] Enikeev D, Netsch C, Rapoport L, *et al*. Novel thulium fiber laser for endoscopic enucleation of the prostate: a prospective comparison with conventional transurethral resection of the prostate. *Int J Urol*. 2019;26(12):1138-43.
- [114] Fayad AS, Elsheikh MG, Zakaria T, *et al*. Holmium laser enucleation of the prostate versus bipolar resection of the prostate: a prospective randomized study. "Pros and cons". *Urology*. 2015;86(5):1037-41.
- [115] Feng L, Zhang D, Tian Y, Song J. Thulium laser enucleation versus plasmakinetic enucleation of the prostate: a randomized trial of a single center. *J Endourol*. 2016;30(6):665-70.
- [116] Floratos DL, Kiemeny LA, Rossi C, Kortmann BB, Debruyne FM, de La Rosette JJ. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. *The Journal of urology*. 2001;165(5):1533-8.
- [117] Gao Y-a, Huang Y, Zhang R, *et al*. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate—a prospective, randomized, and controlled clinical trial. *Radiology*. 2014;270(3):920-8.
- [118] Geavlete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. *Urology*. 2011;78(4):930-5.
- [119] Geavlete B, Stanescu F, Moldoveanu C, Geavlete P. Continuous vs conventional bipolar plasma vaporisation of the prostate and standard monopolar resection: a prospective, randomised comparison of a new technological advance. *BJU Int*. 2014;113(2):288-95.
- [120] Geavlete B, Bulai C, Ene C, Checherita I, Geavlete P. Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases? *J Endourol*. 2015;29(3):323-31.
- [121] Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. *BJU Int*. 2006;97(1):85-9.
- [122] Habib E, Ayman LM, ElSheemy MS, *et al*. Holmium laser enucleation vs bipolar plasmakinetic enucleation of a large volume benign prostatic hyperplasia: a randomized controlled trial. *J Endourol*. 2020;34(3):330-8.

- [123] Hamouda A, Morsi G, Habib E, Hamouda H, Emam AB, Etafy M. A comparative study between holmium laser enucleation of the prostate and transurethral resection of the prostate: 12-month follow-up. *Journal of Clinical Urology*. 2014;7(2):99-104.
- [124] He G, Shu Y, Wang B, Du C, Chen J, Wen J. Comparison of diode laser (980 nm) enucleation vs holmium laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized controlled trial with 12-month follow-up. *J Endourol*. 2019;33(10):843-9.
- [125] Higazy A, Tawfeek AM, Abdalla HM, Shorbagy AA, Mousa W, Radwan AI. Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial. *Int J Urol*. 2020.
- [126] Hon NHY, Brathwaite D, Hussain Z, *et al*. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. *Journal of Urology*. 2006;176(1):205-9.
- [127] Jahnsen S, Dalen M, Gustavsson G, Pedersen J. Transurethral incision versus resection of the prostate for small to medium benign prostatic hyperplasia. *Br J Urol*. 1998;81(2):276-81.
- [128] Jhanwar A, Sinha RJ, Bansal A, Prakash G, Singh K, Singh V. Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized study. *Urol Ann*. 2017;9(1):45-50.
- [129] Jovanovic M, Dzamic Z, Acimovic M, Kajmakovic B, Pejicic T. Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia. *Acta Chir Jugosl*. 2014;61(1):57-61.
- [130] Karadag MA, Cecen K, Demir A, Kocaaslan R, Altunrende F. Plasmakinetic vaporization versus plasmakinetic resection to treat benign prostatic hyperplasia: A prospective randomized trial with 1 year follow-up. *Can Urol Assoc J*. 2014;8(9-10):E595-9.
- [131] Kaya C, Ilktac A, Gokmen E, Ozturk M, Karaman IM. The long-term results of transurethral vaporization of the prostate using plasmakinetic energy. *BJU Int*. 2007;99(4):845-8.
- [132] Kini M, Te AE, Kashanian JA, Kaplan S, Chughtai B. Ejaculatory hood-sparing photoselective vaporization of the prostate vs bipolar button plasma vaporization of the prostate in the surgical management of benign prostatic hyperplasia. *J Endourol*. 2020;34(3):322-9.
- [133] Li X, Pan JH, Liu QG, *et al*. Selective transurethral resection of the prostate combined with transurethral incision of the bladder neck for bladder outlet obstruction in patients with small volume benign prostate hyperplasia (BPH): a prospective randomized study. *PLoS One*. 2013;8(5):e63227.
- [134] Li K, Wang D, Hu C, *et al*. A novel modification of transurethral enucleation and resection of the prostate in patients with prostate glands larger than 80 mL: surgical procedures and clinical outcomes. *Urology*. 2018;113:153-9.
- [135] Luo YH, Shen JH, Guan RY, Li H, Wang J. Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients. *Urology*. 2014;84(4):904-10.

- [136] Mavuduru RM, Mandal AK, Singh SK, *et al.* Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. *Urol Int.* 2009;82(2):130-5.
- [137] Montorsi F, Naspro R, Salonia A, *et al.* Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. *The Journal of urology.* 2004;172(5 Pt 1):1926-9.
- [138] Netsch C, Becker B, Tiburtius C, *et al.* A prospective, randomized trial comparing thulium vapoenucleation with holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic obstruction: perioperative safety and efficacy. *World J Urol.* 2017;35(12):1913-21.
- [139] Nuhoglu B, Balci MB, Aydin M, *et al.* The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. *Urol Int.* 2011;87(4):400-4.
- [140] Radwan A, Farouk A, Higazy A, Samir YR, Tawfeek AM, Gamal MA. Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia. *Prostate Int.* 2020;8(3):130-3.
- [141] Ran L, He W, Zhu X, Zhou Q, Gou X. Comparison of fluid absorption between transurethral enucleation and transurethral resection for benign prostate hyperplasia. *Urol Int.* 2013;91(1):26-30.
- [142] Razzaghi MR, Mazloomfard MM, Mokhtarpour H, Moeini A. Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: randomized clinical trial with 2-year follow-up. *Urology.* 2014;84(3):526-32.
- [143] Riehmman M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC. Transurethral resection versus incision of the prostate: a randomized, prospective study. *Urology.* 1995;45(5):768-75.
- [144] Samir M, Tawfick A, Mahmoud MA, *et al.* Two-year follow-up in bipolar transurethral enucleation and resection of the prostate in comparison with bipolar transurethral resection of the prostate in treatment of large prostates. Randomized controlled trial. *Urology.* 2019;133:192-8.
- [145] Shoji S, Hanada I, Otaki T, *et al.* Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study. *Int J Urol.* 2020;27(11):974-80.
- [146] Skinner TAA, Leslie RJ, Steele SS, Nickel JC. Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia. *Can Urol Assoc J.* 2017;11(6):194-8.
- [147] Sun N, Fu Y, Tian T, *et al.* Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. *Int Urol Nephrol.* 2014;46(7):1277-82.
- [148] Swiniarski PP, Stepien S, Dudzic W, Kesy S, Blewniewski M, Rozanski W. Thulium laser enucleation of the prostate (TmLEP) vs. transurethral resection of the prostate (TURP): evaluation of early results. *Cent European J Urol.* 2012;65(3):130-4.
- [149] Tefekli A, Muslumanoglu AY, Baykal M, Binbay M, Tas A, Altunrende F. A hybrid technique using bipolar energy in transurethral prostate surgery: a prospective, randomized comparison. *The Journal of urology.* 2005;174(4 Pt 1):1339-43.

- [150] Tkocz M, Prajsner A. Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. *Neurourol Urodyn*. 2002;21(2):112-6.
- [151] Wagrell L, Schelin S, Nordling J, *et al*. Feedback microwave thermotherapy versus TURP for clinical BPH--a randomized controlled multicenter study. *Urology*. 2002;60(2):292-9. Epub 2002/07/26.
- [152] Wang Z, Zhang J, Zhang H, *et al*. Impact on sexual function of plasma button transurethral vapour enucleation versus plasmakinetic resection of the large prostate >90 ml: Results of a prospective, randomized trial. *Andrologia*. 2020;52(1):e13390.
- [153] Wu G, Hong Z, Li C, Bian C, Huang S, Wu D. A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up. *Lasers Med Sci*. 2016;31(4):599-604.
- [154] Xu A, Zou Y, Li B, *et al*. A randomized trial comparing diode laser enucleation of the prostate with plasmakinetic enucleation and resection of the prostate for the treatment of benign prostatic hyperplasia. *J Endourol*. 2013;27(10):1254-60.
- [155] Yan H, Ou TW, Chen L, *et al*. Thulium laser vaporessection versus standard transurethral resection of the prostate: a randomized trial with transpulmonary thermodilution hemodynamic monitoring. *Int J Urol*. 2013;20(5):507-12.
- [156] Yang Z, Wang X, Liu T. Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. *Urology*. 2013;81(2):396-400.
- [157] Yeni E, Unal D, Verit A, Gulum M. Minimal transurethral prostatectomy plus bladder neck incision versus standard transurethral prostatectomy in patients with benign prostatic hyperplasia: a randomised prospective study. *Urol Int*. 2002;69(4):283-6.
- [158] Zhang K, Sun D, Zhang H, Cao Q, Fu Q. Plasmakinetic vapor enucleation of the prostate with button electrode versus plasmakinetic resection of the prostate for benign prostatic enlargement >90 ml: perioperative and 3-month follow-up results of a prospective, randomized clinical trial. *Urol Int*. 2015;95(3):260-4.
- [159] Zhang J, Wang X, Zhang Y, Shi C, Tu M, Shi G. 1470 nm diode laser enucleation vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: a randomized study. *J Endourol*. 2019;33(3):211-7.
- [160] Zhang F, Shao Q, Herrmann TR, Tian Y, Zhang Y. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. *Urology*. 2012;79(4):869-74.
- [161] Zhang SY, Hu H, Zhang XP, *et al*. Efficacy and safety of bipolar plasma vaporization of the prostate with "button-type" electrode compared with transurethral resection of prostate for benign prostatic hyperplasia. *Chin Med J (Engl)*. 2012;125(21):3811-4. Epub 2012/10/31.
- [162] Zhao Z, Zeng G, Zhong W, Mai Z, Zeng S, Tao X. A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. *Eur Urol*. 2010;58(5):752-8.

- [163] EUnetHTA OTCA17 Assessment Team. Lithium triborate (LBO) laser for photoselective vapori-sation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH). Collaborative Assessment. Diemen (The Netherlands): EUnetHTA, 2019 Contract No.: Report No. OTCA17.
- [164] UroLift® System FAQ. NeoTract, Inc.; 2019 [04.11.2020]; Available from: <https://urolift.co.uk/urolift-system/faqs/>.
- [165] U.S. Food and Drug Administration (FDA). 510(k) Summary K133281. 2013 [04.11.2020]; Available from: <https://www.accessdata.fda.gov/CDRH510K/K133281.pdf>.
- [166] U.S. Food and Drug Administration (FDA). 510(k) Summary K150786. 2015 [16.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/K150786.pdf.
- [167] U.S. Food and Drug Administration (FDA). 510(k) Summary K180237. 2018 [14.11.2020]; Available from: <https://fda.report/PMN/K180237/18/K180237.pdf>.
- [168] Medi-Tate Ltd. Medi-Tate iTind System Instructions for Use. 2020 [20.11.2020]; Available from: https://www.itind.com/wp-content/uploads/ENGLISH-iTind_Website_IFU-1.pdf.
- [169] U.S. Food and Drug Administration (FDA). De Novo request for classification DEN190020. 2020 [11.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf19/DEN190020.pdf.
- [170] National Institute for Health Research (NIHR) Horizon Scanning Research & Intelligence Centre. AQUABEAM® aquablation system for benign prostate hyperplasia. 2017.
- [171] U.S. Food and Drug Administration (FDA). De Novo request for classification DEN170024. 2017 [11.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170024.pdf.
- [172] Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic hyperplasia. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment, 2017 Contract No.: 105.
- [173] U.S. Food and Drug Administration (FDA). 510(k) Summary K180102. 2018 [16.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180102.pdf.
- [174] U.S. Food and Drug Administration (FDA). De Novo request for classification DEN160040 2016 [11.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160040.pdf.
- [175] U.S. Food and Drug Administration (FDA). 510(k) Summary K092735. 2009 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf9/K092735.pdf.
- [176] Lumenis. VersaPulse®PowerSuite™. 2017. [01.12.2020]; Available from: <https://information.lumenis.com/versapulse-kit>.
- [177] U.S. Food and Drug Administration (FDA). 510(k) Summary K011703. 2001 [28.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/K011703.pdf.
- [178] Lumenis. Lumenis®Pulse™ 120 H. 2017 [28.12.2020]; Available from: <http://www.mikronmed.se/dokument/lumenis-pulse-120h-3.pdf>.

- [179] U.S. Food and Drug Administration (FDA). 510(k) Summary K140388. 2014 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf14/K140388.pdf.
- [180] Lumenis. Moses 2.0 Technology. 2020 [28.12.2020]; Available from: <https://information.lumenis.com/hubfs/Surgical/Moses/PB-00018250DE-A,%20Rev%20B%20Moses%20brochure%20web.pdf>.
- [181] LISA Laser Products. Sphinx. Holmium laser. Versatile holmium laser for minimally invasive surgery in urology, spine, arthroscopy and ENT. 2008 [22.12.2020]; Available from: <https://docplayer.net/23563245-Sphinx-holmium-laser-versatile-holmium-laser-for-minimally-invasive-surgery-in-urology-spine-arthroscopy-and-ent.html>.
- [182] U.S. Food and Drug Administration (FDA). 510(k) Summary K033437. 2004 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf3/K033437.pdf.
- [183] Dornier Medilas H Solvo product brochure. [21.12.2020]; Available from: <https://www.olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/Dornier-Medilas-H-Solvo.html>.
- [184] U.S. Food and Drug Administration (FDA). 510(k) Summary K192600. 2019 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192600.pdf.
- [185] U.S. Food and Drug Administration (FDA). 510(k) Summary K131987. 2014 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf13/K131987.pdf.
- [186] Boston Scientific. Auriga XL. [11.12.2020]; Available from: <https://www.bostonscientific.com/en-EU/products/lithotripsy/auriga-xl.html>.
- [187] U.S. Food and Drug Administration (FDA). 510(k) Summary K111475. 2011 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf11/K111475.pdf.
- [188] U.S. Food and Drug Administration (FDA). Premarket Approval P000043B. 2001 [03.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/P000043B.pdf.
- [189] Urologix Inc. Targis[®] System CoolWave[®] control unit user manual. 2015 [03.12.2020]; Available from: https://www.urologix.com/wp-content/uploads/2017/09/250023-001revL_CW-User-Manual-1.pdf.
- [190] FDA approves new Urologix CoolWave(TM) control unit. 2006 [29.12.2020]; Available from: <https://www.biospace.com/article/releases/fda-approves-new-urologix-coolwave-tm-control-unit/>.
- [191] ProstaLund. Inbjudan till teckning av units iProstaLund AB (publ). 2020 [03.12.2020]; Available from: <https://aqurat.se/wp-content/uploads/2020/06/prostalund-teaser-2020.pdf>.
- [192] U.S. Food and Drug Administration (FDA). Premarket Notification P010055A. 2002 [02.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/P010055A.pdf.
- [193] The National Institute for Health and Care Excellence (NICE). The TURis system for transurethral resection of the prostate 2015 [10.11.2020]; Available from: <https://www.nice.org.uk/guidance/mtg23>.
- [194] U.S. Food and Drug Administration (FDA). 510(k) Summary K102781. 2011 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K102781.pdf.

- [195] LISA Laser Products. Revolix. 2013 [09.11.2020]; Available from: <https://www.medicalexpo.de/prod/lisa-laser-products/product-69126-465698.html>.
- [196] U.S. Food and Drug Administration (FDA). 510(k) Summary K051167. 2005 [22.11.2020]; Available from: <https://fda.report/PMN/K051167/5/K051167.pdf>.
- [197] U.S. Food and Drug Administration (FDA). 510(k) Summary K131081. 2013 [22.11.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf13/K131081.pdf.
- [198] Jena Surgical. MultiPulse Tm+1470. 2018 [18.12.2020]; Available from: https://www.jenasurgical.com/wordpress/wp-content/uploads/2018/10/JS_MultiPulse-TM+1470_EN_REV_02_WEB.pdf.
- [199] U.S. Food and Drug Administration (FDA). 510(k) Summary K133891. 2015 [10.12.2020]; Available from: <https://fda.report/PMN/K133891/13/K133891.pdf>.
- [200] U.S. Food and Drug Administration (FDA). 510(k) Summary K103654. 2011 [10.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103654.pdf.
- [201] U.S. Food and Drug Administration (FDA). 510(k) Summary K091323. 2009 [10.12.2020]; Available from: <https://fda.report/PMN/K091323/9/K091323.pdf>.
- [202] biolitec. LEONARDO[®] Universal and ingenious. 2018 [02.12.2020]; Available from: https://www.biolitec.com/fileadmin/user_upload/pdf/AErzte/Leonardo/20181108_LEONARDO_Broschuere_EN_web.pdf.
- [203] biolitec. TWISTER XCAVATOR[®]. 2019 [02.12.2020]; Available from: https://www.biolitec.com/fileadmin/user_upload/pdf/AErzte/Urologie/20191210_Urologie_EN_web.pdf.
- [204] Gyrus ACMI. PlasmaKinetic SuperPulse generator user manual. 2011 [30.12.2020]; Available from: <https://akinglobal.com.tr/uploads/subdir-421-4/PK%20Superpulse%20User%20Manual%201.pdf>.
- [205] U.S. Food and Drug Administration (FDA). 510(k) Summary K031085. 2003 [09.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf3/K031085.pdf.
- [206] Storz. Highlights 2020 units. 2020 [29.12.2020]; Available from: https://www.karlstorz.com/cps/rde/xbcr/karlstorz_assets/ASSETS/3617413.pdf.
- [207] U.S. Food and Drug Administration (FDA). 510(k) Summary K171717. 2017 [10.12.2020]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171717.pdf.

APPENDIX 1

Documentation of the Search Strategies

The search strategy developed for all the three databases was the following:

("Prostatic Hyperplasia"[Mesh] OR "Lower Urinary Tract Symptoms"[Mesh]) OR "Prostatism"[Mesh] OR benign prostatic hyperplasia OR BPH OR lower urinary tract symptom* OR luts OR prostatism)

AND

((thulium OR holmium OR diode OR eraser OR ktp OR greenlight) AND laser) OR KTP LVP OR Bipolar EP OR Bipolar VP OR bipolar transurethral resection OR Bipolar TURP OR plasmakinetic OR water vapour OR steam OR water vaporization OR rezum OR rezumTM OR nxthera OR (nx and thera) OR urolift OR prostatic urethral lift OR "Embolization, Therapeutic"[Mesh] OR embolization OR embolisation OR TUIP OR transurethral incision prostate OR TUMT OR transurethral microwave therapy OR aquablation OR TIND OR iTIND OR Nitinol OR robotic assisted prostatectomy OR "Transurethral Resection of Prostate"[Mesh] OR Transurethral Resection of Prostate OR TURP)

Language limitations: articles in English, German and Italian were included.

Scientific literature was monitored to check the availability of newly published RCTs that could be included.

APPENDIX 2**List of excluded Studies****Table A1: List of excluded studies (full text level) with reasons for exclusion)****Clinical effectiveness and safety**

| Reference | Main reason for exclusion (full text level) |
|----------------------|---|
| Ahmed 1997 | Selection of participants was partly outcome-based, and excluded patients were substituted out of a randomization process. |
| Norby 2002 | Three-arm RCT with a control group considering patients who undertook either TURP or TUIP (mixed population), and with one of the other assessed technologies (ILC) outside the remit of this report. |
| Pimentel 2019 | Reporting of the outcomes of interest is scarce, i.e. data available only in figures. This data is reported in other included publications on the trial (Gilling et.al publications). |
| Plante 2019 | Post hoc exploratory subgroup analysis. |
| Peng 2016 | 2 PVP 80 W was used |
| Kasivisvanathan 2018 | 3 Assessed only the subgroup of patients of US centres |
| Enikeev 2020 | 4 Intervention (monopolar enucleation) out of scope. |
| Fuschi 2020 | 5 Intervention (robotic and laparoscopic prostatectomy) not our comparator. |

APPENDIX 3

Guidelines for diagnosis and management

Table A2: Overview of guidelines

| Name of society / organisation issuing guidance | Date of issue | Country/ies to which applicable | Summary of recommendation | Level of evidence (A,B,C)* / class of recommendation (I, IIa, IIb, III) # |
|---|---------------|---------------------------------|---|---|
| American Urological Association (AUA) | May 2020 | U.S. | Surgery is recommended for patients who have renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections, recurrent bladder stones or gross hematuria due to BPH, and/or with LUTS attributed to BPH refractory to and/or unwilling to use other therapies. | Clinical principle |
| | | | TURP should be offered as a treatment option for men with LUTS attributed to BPH | Moderate recommendation, LE: B |
| | | | Clinicians may use a monopolar or bipolar approach to TURP, depending on their expertise with these techniques. | Expert opinion |
| | | | Clinicians should consider open, laparoscopic or robotic assisted prostatectomy, depending on their expertise with these techniques, for patients with large prostates. | Moderate recommendation; LE: C |
| | | | TUIP should be offered as an option for patients with prostates ≤30g for the surgical treatment of LUTS attributed to BPH | Moderate recommendation; LE: B |
| | | | Bipolar TUVP may be offered to patients for the treatment of LUTS attributed to BPH | Conditional Recommendation; LE: B |
| | | | Clinicians should consider PVP as an option using 120W or 180W platforms for patients for the treatment of LUTS attributed to BPH | Moderate recommendation; LE: B |
| | | | PUL may be offered as an option for patients with LUTS attributed to BPH provided prostate volume <80g and verified absence of an obstructive middle lobe. | Moderate recommendation; LE: C |

| Name of society / organisation issuing guidance | Date of issue | Country/ies to which applicable | Summary of recommendation | Level of evidence (A,B,C)*/ class of recommendation (I, IIa, IIb, III) # |
|---|---------------|---------------------------------|---|--|
| | | | PUL may be offered to eligible patients who desire preservation of erectile and ejaculatory function. | Conditional recommendation; LE: C |
| | | | TUMT may be offered to patients with LUTS attributed to BPH. | Conditional recommendation; LE: C |
| | | | Water vapor thermal therapy may be offered to patients with LUTS attributed to BPH provided prostate volume <80g; however. | Moderate recommendation; LE: C |
| | | | Water vapor thermal therapy may be offered to eligible patients who desire preservation of erectile and ejaculatory function. | Conditional recommendation; LE: C |
| | | | Clinicians should consider HoLEP or ThuLEP, depending on their expertise with either technique, as prostate size-independent options for the treatment of LUTS attributed to BPH. | Moderate recommendation; LE: B |
| | | | Aquablation may be offered to patients with LUTS attributed to BPH provided prostate volume >30/<80g. | Conditional recommendation; LE: C |
| | | | PAE for the treatment of LUTS secondary to BPH is not supported by current data and trial designs, and benefit over risk remains unclear; therefore, PAE is not recommended outside the context of clinical trials. | Expert opinion |
| | | | HoLEP, PVP, and ThuLEP should be considered in patients who are at higher risk of bleeding, such as those on anti-coagulation drugs. | Expert opinion |
| European Association of Urology (EAU) | 2018 | Europe | TUIP should be offered to men with moderate-to-severe LUTS and prostate size < 30 mL, without a middle lobe. | Strong recommendation, LE:1 |
| | | | M-TURP or B-TURP should be offered to men with moderate-to-severe LUTS and prostate size 30-80 mL. | Strong recommendation, LE:1 |
| | | | B-TUVP should be offered as an alternative to M-TURP for men with moderate to severe LUTS and a prostate size of 30-80 mL. | Weak recommendation, LE:1 |
| | | | Open prostatectomy should be offered in the absence of endoscopic enucleation to treat moderate-to-severe LUTS in men with prostate | Strong recommendation, LE:1 |

| Name of society / organisation issuing guidance | Date of issue | Country/ies to which applicable | Summary of recommendation | Level of evidence (A,B,C)* / class of recommendation (I, IIa, IIb, III) # |
|---|---------------|---------------------------------|---|---|
| | | | size > 80 mL. | |
| | | | HoLEP should be offered to men with moderate-to-severe LUTS as an alternative to TURP or open prostatectomy. | Strong recommendation, LE:1a |
| | | | 80-W 532-nm KTP laser vaporisation of the prostate should be offered to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to TURP. | Strong recommendation, LE: 1a |
| | | | 120-W 532-nm LBO laser vaporisation of the prostate should be offered to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to TURP. | Strong recommendation, LE: 1a |
| | | | 180-W 532-nm LBO laser vaporisation of the prostate should be offered to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to TURP. | Strong recommendation, LE: 1b |
| | | | Laser vaporisation of the prostate using 80-W KTP, 120- or 180-W LBO lasers for the treatment of patients receiving antiplatelet or anticoagulant therapy with a prostate volume < 80 mL should be offered. | Weak recommendation, LE: 3 |
| | | | 120-W 980 nm DioVAP should be offered to men with moderate-to-severe LUTS as a comparable alternative to TURP. | Weak recommendation, LE: 1b, 3 |
| | | | 120-W 980 nm or 1,318 nm DioLEP should be offered to men with moderate-to-severe LUTS as a comparable alternative to TURP or bipolar enucleation. | Weak recommendation, LE: 1b |
| | | | ThuVEP and ThuLEP should be offered to men with moderate-to-severe LUTS as alternatives to TURP and HoLEP. | Weak recommendation, LE: 1b |
| | | | ThuVEP should be offered to patients receiving anticoagulant or antiplatelet therapy. | Weak recommendation, LE: 2b |
| | | | ThuVAP should be offered as an alternative to TURP. | Strong recommendation, LE: 1a |

| Name of society / organisation issuing guidance | Date of issue | Country/ies to which applicable | Summary of recommendation | Level of evidence (A,B,C)*/ class of recommendation (I, IIa, IIb, III) # |
|--|---------------|---------------------------------|--|--|
| | | | ThuVARP should be offered to patients receiving anticoagulant or antiplatelet therapy. | Weak recommendation, LE: 1a |
| | | | PUL should be offered to men with LUTS interested in preserving ejaculatory function, with prostates < 70 mL and no middle lobe. | Strong recommendation, LE: 1b |
| | | | Aquablation should be offered to patients with moderate-to-severe LUTS and prostates between 30-80 mL as an alternative to TURP. | Weak recommendation, LE: 1b |
| | | | In Aquablation, patients should be informed about the risk of bleeding and the lack of long-term follow up data. | Strong recommendation, LE: 1b |
| | | | PAE should be offered to men with moderate-to-severe LUTS who wish to consider minimally invasive treatment options and accept less optimal objective outcomes compared with TURP. | Weak recommendation, LE: 1 |
| | | | Perform PAE only in units where the work up and follow up is performed by urologists working collaboratively with trained interventional radiologists for the identification of PAE suitable patients. | Strong recommendation, LE: 1 |
| <p>* The AUA categorizes body of evidence strength as Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data)</p> | | | | |
| <p># see https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009</p> | | | | |
| <p>Abbreviations: BPH <i>benign prostatic hyperplasia</i>, B-TURP <i>bipolar transurethral resection of the prostate</i>, DioLEP <i>diode laser enucleation of the prostate</i>, DioVAP <i>diode laser vaporisation of the prostate</i>, HoLEP <i>holmium laser enucleation of the prostate</i>, KTP <i>Potassium-Titanyl-Phosphate</i>, LBO <i>Lithium Borat</i>, LE <i>level of evidence</i>, LUTS <i>lower urinary symptoms</i>, M-TURP <i>monopolar transurethral resection of the prostate</i>, PAE <i>prostate artery embolization</i>, PUL <i>prostatic urethral lift</i>, PVP <i>photoselective vaporisation of the prostate</i>, ThuLEP <i>thulium laser enucleation of the prostate</i>, ThuVARP <i>thulium laser vaporesction of the prostate</i>, ThuVEP <i>thulium laser enucleation of the prostate</i>, TUIP <i>transurethral incision of the prostate</i>, TUMT <i>transurethral microwave therapy</i></p> | | | | |

APPENDIX 4

Table A3: Studies included in the assessment: data extraction and risk of bias assessment

| Study ID | Abd-El Kader 2012 |
|--|---|
| Authors: | O. Abd-El Kader, K. Mohy El Den, A. El Nashar, A. Hussein, E. Yehya |
| Title: | Transurethral incision versus transurethral resection of the prostate in small prostatic adenoma: Long-term follow-up |
| Journal/Book/Source: | African Journal of Urology |
| Date of Publication: | 2012 |
| Volume: | 18 |
| Issue: | / |
| Pages: | 29-33 |
| METHODS (study design; length of follow up) | RCT 48 months follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 86 |
| Country of participants | Egypt |
| Data collection period | Between January 2005 and December 2010 |
| Inclusion criteria | being on the waiting list for surgical treatment of BPH, total prostatic weight \leq 30 g as measured with transrectal ultrasound, and the ability to give informed consent |
| Exclusion criteria | suspected prostate cancer (abnormal digital rectal examination, or elevated prostate specific antigen, bladder pathology (including mass, stones or chronic cystitis), prominent median lobe of the prostate or inability to comply with the follow-up schedule |
| Average age | TURP: 63.6 \pm 4.2 years TUIP: 66.2 \pm 6.1 years |
| INTERVENTIONS (technology 1) | Transurethral resection of the prostate (TURP) |
| INTERVENTIONS (technology 2) | Transurethral incision of the prostate (TUIP) |
| Number of patients in TURP | 40 |
| Number of patients in TUIP | 40 |
| OUTCOMES | IPSS, Qmed, Qmax, PVR, operative time, blood transfusion, duration of catheterization, length of hospital stay, retrograde ejaculation, erectile dysfunction, bladder neck contracture, urethral stricture, reoperation |

| | | |
|---|---|--|
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Funding source: not mentioned in the article. Conflicts of Interest: not mentioned in the article. Trial registration number: not mentioned in the article. | |
| Risk of bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | No information reported. |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Of the 86 patients enrolled, 80 completed the study: 40 patients in each group. Total loss to f-up: 7,0%. Difference in attrition between the two groups: no information, no flow chart; unknown the number of patients initially assigned to each of the two groups. For none of the outcomes, attrition varies for different follow-up times (in fact, there are no different follow-up times). |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | uncertain risk of bias | No information about possible conflicts of interest |

| | |
|--|---|
| Study ID | Abt 2018 |
| Authors: | Abt D, Hechelhammer L, Müllhaupt G, Markart S, Güsewell S, Kessler TM, Schmid HP, Engeler DS, Mordasini L. |
| Title: | Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial |
| Journal/Book/Source: | BMJ |
| Date of Publication: | 2018 |
| Volume: | 361 |
| Issue: | k2338 |
| Pages: | 1-10 |
| METHODS (study design; length of follow up) | investigator initiated, open label, single centre, randomised controlled trial; non-inferiority trial 12 weeks follow-up |

| | | |
|---|--|---|
| PARTICIPANTS | | |
| Total Number of Participants randomized | 103 | |
| Country of participants | Switzerland | |
| Data collection period | 11 February 2014 - 24 May 2017 | |
| Inclusion criteria | men aged at least 40 years, TURP indicated, refractory to medical treatment or not willing to undergo or continue medical treatment, with a prostate size 25-80 mL as measured by trans-abdominal ultrasound, with an international prostate symptoms score (IPSS) of at least 8, with an IPSS related quality of life of at least 3 points, with a maximum urinary flow rate of less than 12 mL/s or urinary retention, and who provided written informed consent | |
| Exclusion criteria | severe atherosclerosis, aneurysmatic changes or severe tortuosity in the aortic bifurcation or internal iliac arteries, acontractile detrusor, neurogenic lower urinary tract dysfunction, urethral stenosis, bladder diverticulum, bladder stone, allergy to intravenous contrast media, contraindication for magnetic resonance imaging, pre-interventionally proven carcinoma of the prostate, and renal failure (glomerular filtration rate <60 mL/min) | |
| Average age | PAE: 65.7 ± 9.3 years TURP: 66.1 ± 9.8 years | |
| INTERVENTIONS (technology 1) | Prostate artery embolization (PAE) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PAE | 48 | |
| Number of patients in TURP | 51 | |
| OUTCOMES | IPSS, Qmax, PVR, haematoma, ejaculatory dysfunction, procedure time, bladder catheter indwelling time, duration of hospital stay, IIEF, persistent irritative symptoms (irritation, pain, discomfort), urinary retention, urinary incontinence, urinary tract infection, strictures (meatal) | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Funding: The trial was supported by a grant from the research committee of St Gallen Cantonal Hospital (14/08). The funder had no role in the conduct or analysis of the trial. Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from St Gallen Cantonal Hospital for the submitted work; no financial relationship with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Trial registration number: Clinicaltrials.gov NCT02054013. | |
| Risk of bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | We performed randomisation using the data management software SecuTrial, stratifying for patient age (<70 or ≥ 70 years) and prostate volume (<50 or ≥ 50 mL) through minimisation. SecuTrial |

| | | |
|---|------------------------|--|
| | | was programmed by the clinical trials unit's data manager. |
| Allocation concealment (selection bias) | low risk of bias | Automatic treatment allocation by SecuTrial was determined for individual patients without a predefined sequence after inclusion and entry of baseline characteristics by the investigators. |
| Blinding of participants and personnel (performance bias) | high risk of bias | Blinding of patients and physicians was not feasible in the framework of our trial. Therefore, both patients and physicians might have been biased in favour of or against a new treatment. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | Blinding of patients and physicians was not feasible. No information about blinding of assessors. |
| Incomplete outcome data (attrition bias) | low risk of bias | Total lost to f-up: 0%. Difference in attrition between the two groups: 0%. For none of the outcomes, attrition varies for different follow-up times (in fact, there are no different follow-up times). |
| Selective reporting (reporting bias) | low risk of bias | Trial registration: Clinicaltrials.gov NCT02054013 No difference between reported outcomes and protocol neither methods section. |
| Other bias | Low risk of bias | The trial was supported by a grant from the research committee of St Gallen Cantonal Hospital (14/08). The funder had no role in the conduct or analysis of the trial. Competing interests: authors declare no financial relationship with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work |

| | |
|----------------------|--|
| Study ID | Bai 2019 |
| Authors: | Bai F, Feng S, Xu C, Xu Z, Chen J, Zheng Y. |
| Title: | Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis. |
| Journal/Book/Source | Medicine |
| Date of Publication: | 2019 |
| Volume: | 98 |
| Issue: | 15 |
| Pages: | 1-5 (open access article) |

| | | |
|---|--|---|
| METHODS (study design; length of follow up) | prospective RCT Follow up: just baseline and perioperative data. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 70 | |
| Country of participants | China | |
| Data collection period | June 2015 - March 2017 | |
| Inclusion criteria | severe lower urinary tract symptoms (LUTS), refractory to medical therapy with alpha-blockers and/or 5-alpha reductase inhibitors, post void residual urine (PVR)>100ml, and acute urinary retention | |
| Exclusion criteria | neurogenic bladder, cardiovascular and/or cerebrovascular thromboembolic diseases, DVT, PE, malignancy, coagulopathy, and on antiplatelet or anticoagulant therapy | |
| Average age | TURP: 69.3 ± 4.3 years HoLEP: 71.2 ± 6.0 years | |
| INTERVENTIONS (technology 1) | Transurethral resection of the prostate (TURP) | |
| INTERVENTIONS (technology 2) | Holmium laser enucleation of the prostate (HoLEP) | |
| Number of patients in TURP | 32 | |
| Number of patients in HoLEP | 33 | |
| OUTCOMES | Qmax, PVR, IPSS, QoL, operative time, catheterization, hospitalization | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | This study was funded by Zhejiang Provincial Natural Science Foundation of China (LY16H160028). The authors have no conflicts of interest to disclose. Trial registration: ChiCTR1800019005 | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | Patients were assigned into two groups by computer-generated randomization in 1:1 ratio. |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Total lost to f-up: 7,1%. Difference in attrition between the two groups: 2,9%. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | low risk of bias | Registered trial. No difference between reported outcomes and protocol (in Chinese and in English) in the trial repository. No difference between reported outcomes and methods section. |

| | | |
|------------|------------------|--|
| | | No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Low risk of bias | This study was funded by Zhejiang Provincial Natural Science Foundation of China. The authors had no conflicts of interest to disclose |

| | |
|--|--|
| Study ID | Basic 2013 |
| Authors: | Basić D, Stanković J, Potić M, Ignjatović I, Stojković I. |
| Title: | Holmium laser enucleation versus transurethral resection of the prostate: a comparison of clinical results. |
| Journal/Book/Source: | Acta Chir Jugosl. |
| Date of Publication: | 2013 |
| Volume: | 60 |
| Issue: | 1 |
| Pages: | 15-20 |
| METHODS (study design; length of follow up) | RCT Follow up: 12 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 40 |
| Country of participants | Serbia |
| Data collection period | October 2011 - December 2012 |
| Inclusion criteria | postvoid residue > 50ml, prostate volume up to 50g, repeated episodes of acute urinary retention, indwelling urinary catheter, recurrent urinary tract infection, recurrent haematuria due to BPH and IPSS score >19 |
| Exclusion criteria | voiding disorders out of BPH origin, previous urethral, bladder neck or prostatic surgery, and history of prostate cancer |
| Average age | HoLEP: 63.3 ± 7.4 years TURP: 65.1 ± 6.9 years |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP) |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) |
| Number of patients in HoLEP | 20 |
| Number of patients in TURP | 20 |

| | | |
|---|---|--|
| OUTCOMES | IPSS, QoL, PVR, drop in serum sodium (addressed in Methods, but not reported in the results o in a table), operative time, transfusion, catheterization time, hospitalization time, bladder mucosal injury, urinary incontinence, acute urinary retention, persistent irritative symptoms (Urge incontinence + Dysuria), bladder neck stricture, reintervention | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | This work has been supported by the Serbian Ministry of Education and Science, grant No 175092. Conflicts of interest: no information. Trial registration number: no information | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | No information reported |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | low risk of bias | No lost to follow-up. (Pag. 16 b) All patients reached the 12-month follow-up. No difference in attrition between the two groups. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. Only one outcome is addressed in Methods, but not reported in the results in a table: drop in serum sodium etc. All data were collected in a database. Serum biochemistry (etc) were evaluated after the 1st month postoperatively, and reevaluated if it was indicated. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Low risk of bias | Supported by the Serbian Ministry of Education and Science |

| | |
|-----------------|---------------------|
| Study ID | Bozzini 2017 |
|-----------------|---------------------|

| | |
|--|---|
| Authors: | Bozzini G, Seveso M, Melegari S, de Francesco O, Buffi NM, Guazzoni G, Provenzano M, Mandressi A, Taverna G. |
| Title: | Thulium laser enucleation (ThuLEP) versus transurethral resection of the prostate in saline (TURis): A randomized prospective trial to compare intra and early postoperative outcomes. |
| Journal/Book/Source: | Actas Urol Esp. |
| Date of Publication: | 2017 Jun |
| Volume: | 41 |
| Issue: | 5 |
| Pages: | 309-315 |
| METHODS (study design; length of follow up) | RCT Follow up: 3 months after surgery. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 208 |
| Country of participants | Italy |
| Data collection period | between September 2014 and September 2015 |
| Inclusion criteria | All male patients with bothersome lower urinary tract symptoms due to BPH with indications for surgical intervention regardless of the patient age, International Prostate Symptom Score (IPSS), and prostatic size. |
| Exclusion criteria | Patients with mild symptoms (IPSS <8 and/or maximum urinary flow rate ≥ 15 ml/s and postvoid residual urine <50 ml), small adenomas <20 g measured by transrectal ultrasound, presence of urethral stricture, neurogenic bladder, vesicoureteric reflux, huge retentive bladder diverticulum, previous prostatic surgeries, previous or subsequent diagnosis of prostatic adenocarcinoma, patients receiving anticoagulant drugs due to the fact that holmium can be used safely in patients receiving anticoagulant drugs unlike TURis. |
| Average age | ThuLEP: 72.5 \pm 17.5 years B-TURP: 70.7 \pm 16.1 years |
| INTERVENTIONS (technology 1) | Thulium laser transurethral enucleation of the prostate (ThuLEP) |
| INTERVENTIONS (technology 2) | Bipolar transurethral resection of the prostate in saline (TURis) (B-TURP) |
| Number of patients in ThuLEP | 102 |
| Number of patients in B-TURP (TURis) | 106 |
| OUTCOMES | IPSS, Qmax, PVR, operative time, catheterization time, hospital stay, blood transfusion, postvoid urinary retention (in our as- |

| | | |
|---|--|--|
| | assessment: acute urinary retention), stress incontinence (in our assessment: urinary incontinence), urge incontinence (in our assessment: persistent irritative symptoms), urethral strictures, bladder injury, QoL | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Funding source: not mentioned in the article. Authors declare no conflicts of interest. Trial registration number: not mentioned in the article. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | No information reported |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Authors do not address loss to follow-up. Not declared any difference in attrition between the two groups. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Low risk of bias | Authors declare no conflicts of interest. |

| | |
|----------------------|--|
| Study ID | Bozzini 2020 |
| Authors: | Bozzini G, Berti L, Aydoğan TB, Maltagliati M, Roche JB, Bove PL, Besana U, Calori A, Pastore AL, Müller A, Micali S, Sighinolfi MC, Rocco B, Buizza C |
| Title: | A prospective multicenter randomized comparison between Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP) |
| Journal/Book/Source: | World Journal of Urology |
| Date of Publication: | 2020 |

| | | |
|---|---|---|
| Volume: | https://doi.org/10.1007/s00345-020-03468-6 | |
| Issue: | - | |
| Pages: | - | |
| METHODS (study design; length of follow up) | RCT Follow-up at 3 and 12 months | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 236 | |
| Country of participants | Italy and France | |
| Data collection period | 2015-2018 | |
| Inclusion criteria | IPSS \geq 8; weak or no response to previous medical treatments; Qmax<15 ml/sec; acute urinary retention | |
| Exclusion criteria | History of prostatic surgery; prostate or bladder cancer suspicion/history; documented/suspected neurogenic bladder; urethral stricture; anticoagulant/antiaggregant therapy; concurrent bladder stones; patients unfit for surgery | |
| Average age | HoLEP: 69.5 \pm 15.54 ThuLEP: 67.1 \pm 17.83 | |
| INTERVENTIONS (technology 1) | Thulium laser enucleation of the prostate (ThuLEP) | |
| INTERVENTIONS (technology 2) | Holmium laser enucleation of the prostate (HoLEP) | |
| Number of patients in ThuLEP | 115 | |
| Number of patients in HoLEP | 121 | |
| OUTCOMES | Hospital stay, operative time, catheterization time, IPSS, Qmax, PVR, QoL, urinary retention, blood transfusion, bladder injury, stress incontinence, urge incontinence, urethral stricture | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | The authors declared that they had no conflict of interest or any known competing financial interests | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Used adaptive randomization software |
| Allocation concealment (selection bias) | Low risk | Allocation concealment facilitated by the adaptive randomization software |
| Blinding of participants and personnel (performance bias) | Low risk | Participants were blinded |
| Blinding of outcome assessment | Low risk | Assessors were blinded |

| | | |
|---|-----------|---|
| OBJECTIVE OUTCOMES (detection bias) | | |
| Blinding of outcome assessment SUBJECTIVE OUTCOMES (detection bias) | Low risk | Assessors were blinded |
| Incomplete outcome data (attrition bias) | High risk | 50 patients excluded from the analysis either because lost to follow-up, or due to discontinued intervention, because of equipment malfunction |
| Selective reporting (reporting bias) | High risk | Among excluded patients, some are reported to have discontinued intervention because of equipment malfunction |
| Other bias | Low risk | The authors declare that they have no conflict of interest or any known competing financial interests and that that no extra institutional funding was received |

| | |
|---|--|
| Study ID (surname first author and year – add a, b if same author same year) | Carnevale2016 |
| Authors: | Francisco C. Carnevale, Alexandre Iscaife, Eduardo M. Yoshinaga, Airtton Mota Moreira, Alberto A. Antunes, Miguel Srougi |
| Title: | Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis |
| Journal/Book/Source: | Cardiovasc Intervent Radiol |
| Date of Publication: | 27 October 2015 |
| Volume: | 2016 |
| Issue: | 39 |
| Pages: | 44-52 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow up: 1 year |
| PARTICIPANTS | |
| Total Number of Participants randomized | 30 |
| Country of participants | Brazil |

| | | |
|---|--|--|
| Data collection period | November 2010 - December 2012 | |
| Inclusion criteria | Age >45 years; International Prostate Symptom Score (IPSS) >19; symptoms refractory to medical treatment for at least 6 months; negative screening for prostate cancer; prostate volume between 30 and 90 cm ³ on magnetic resonance imaging (MRI); and bladder outlet obstruction (BOO) confirmed by urodynamic examination. | |
| Exclusion criteria | Patients with renal failure, bladder calculi or diverticula, suspected prostate cancer, urethral stenosis, or neurogenic bladder disorders. | |
| Average age | TURP: 66.4 ± 5.6 (range 55–78) PAE: 63.5 ± 8.7 (range 46–75) | |
| INTERVENTIONS (technology 1) | Transurethral resection of the prostate (TURP) | |
| INTERVENTIONS (technology 2) | Prostate artery embolization (PAE) | |
| Number of patients in TURP | 15 | |
| Number of patients in PAE | 15 | |
| Number of patients in technology 3 | | |
| OUTCOMES | IPSS, QoL, International Index of Erectile Function (IIEF-5), PVR, Qmax, procedure time, hospital stay, blood transfusion requirements, capsular perforation, retrograde ejaculation, urinary incontinence, postoperative LUTS, recatheterisation, radiodermatitis. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Uncertain risk | No information about random sequence generation |
| Allocation concealment (selection bias) | Uncertain risk | No information about allocation concealment |
| Blinding of participants and personnel (performance bias) | Uncertain risk | No information whether blinding was performed |
| Blinding of outcome assessment (detection bias) | Uncertain risk | No information whether blinding was performed |
| Incomplete outcome data (attrition bias) | Uncertain risk | There is no number of patients at each follow up visit provided. |
| Selective reporting (reporting bias) | Uncertain risk | There is no study protocol registered |

| | | |
|------------|----------|--|
| bias) | | in order to check selective reporting. |
| Other bias | Low risk | Authors declare they have no financial disclosure. |

| | | |
|--|--|--|
| Study ID | Cetinkaya 2015 | |
| Authors: | Cetinkaya M, Onem K, Rifaioglu MM, Yalcin V. | |
| Title: | 980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study | |
| Journal/Book/Source: | Urol J. | |
| Date of Publication: | 2015 | |
| Volume: | 12 | |
| Issue: | 5 | |
| Pages: | 2355-61 | |
| METHODS (study design; length of follow up) | two-arm, prospective, randomized controlled study Three months follow up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 72 | |
| Country of participants | Turkey | |
| Data collection period | From June 2010 to July 2011 | |
| Inclusion criteria | The inclusion criteria were BPH refractory to medical treatment, recurrent urinary retention, prostate volume of < 80 mL , Qmax of ≤ 15 mL/s (under medical treatment), an IPSS of ≥ 15, and an IPSS-QoL of ≥ 3. | |
| Exclusion criteria | Patients with prostate or bladder cancer histories, neurogenic bladder dysfunction, bladder stones, urethral strictures, or previous bladder, urethral, or prostate surgery were excluded. | |
| Average age | PVP: 63.1 ± 9.1 years TURP: 64.7 ± 10.2 years | |
| INTERVENTIONS (technology 1) | Photoselective vaporization of the prostate (PVP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PVP | 36 | |
| Number of patients in TURP | 36 | |
| OUTCOMES | IPSS, Qmax, operative duration, catheterization time, hospital stay, urinary retention, re-treatment (reintervention), bleeding | |

| | | |
|---|---|---|
| | and need of blood transfusion, capsule perforation, TUR syndrome, urinary tract infection, urethral stricture | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Funding source: not mentioned. Conflicts of interest: none declared. Trial registration: not mentioned. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | Patients were allocated randomly to the diode laser vaporization or TURP group with a schedule balanced in blocks of three. (Comment: they do not explain how they generated the randomization sequence) |
| Allocation concealment (selection bias) | uncertain risk of bias | The allocation was performed by a nurse and biostatistician. (Comment: they do not explain which methods they used to mask the allocation) |
| Blinding of participants and personnel (performance bias) | high risk of bias | Patients were informed about the operation and were not blinded for ethical reasons. |
| Blinding of outcome assessment SUBJECTIVE OUTCOMES (detection bias) | high risk of bias | Patients were not blinded. Three months after the surgical procedure, follow-up assessments were performed by research staff blinded to the patient's procedure. |
| Blinding of outcome assessment OBJECTIVE OUTCOMES (detection bias) | low risk of bias | Patients were not blinded. Three months after the surgical procedure, follow-up assessments were performed by research staff blinded to the patient's procedure. |
| Incomplete outcome data (attrition bias) | low risk of bias | Total lost to f-up: 1,4%. Difference in attrition between the two groups: 2,7%. In total, 36 patients underwent PVP with the diode laser and 36 patients underwent standard TURP. One patient in the laser group was excluded from the study because of bleeding and conversion to TURP. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND |

| | | |
|------------|------------------------|---|
| | | without statistical comparison between groups). |
| Other bias | uncertain risk of bias | No information available about possible conflicts of interest |

| | |
|--|--|
| Study ID | Chang 2015 |
| Authors: | Chang CH, Lin TP, Chang YH, Huang WJ, Lin AT, Chen KK. |
| Title: | Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study |
| Journal/Book/Source: | BMC Urology |
| Date of Publication: | 2015 |
| Volume: | 15 |
| Issue: | 40 |
| Pages: | 1-7 |
| METHODS (study design; length of follow up) | Prospectively nonblind randomized trial 1 year follow up. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 59 |
| Country of participants | Taiwan |
| Data collection period | August 2010 - May 2012 |
| Inclusion criteria | The inclusion criteria were an international prostate symptom score (IPSS) >7, maximum urinary flow rate (Qmax) <15 mL/s, and normal level of age-specific prostate-specific antigen (PSA). |
| Exclusion criteria | Not mentioned in the article |
| Average age | 76.1 ± 9.4 years in the ThuVEP group; 72.6 ± 7.4 years in the TURP group |
| INTERVENTIONS (technology 1) | Th:YAG laser vapoenucleation (ThuVEP) |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) |
| Number of patients in ThuVEP | 29 |
| Number of patients in TURP | 30 |
| OUTCOMES | Qmed, QoL, IIEF-5, IPSS, Qmax, PVR, decrease in serum sodium level, duration of catheterization, total duration of hospitalization, acute urinary retention, recatheterization, urinary tract infection, hemorrhage/hematuria requiring transfusion, TUR syndrome, death |

| | | |
|---|---|---|
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Funding source. Not mentioned in the article. Conflicts of Interest. The authors declare that they have no competing interests. Trial registration number. ISRCTN registry with study ID ISRCTN52339705. Date assigned: 06/03/2015. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | No information reported. |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | high risk of bias | Non-blind randomized trial. |
| Blinding of outcome assessment (detection bias) | high risk of bias | Non-blind randomized trial. |
| Incomplete outcome data (attrition bias) | low risk of bias | Total lost to f-up: 5%. In all, 96.3% patients in the ThuVEP group and 93.3% in the TURP group completed the 1-year follow-up study. (Difference in attrition between the two groups: 3%). For none of the outcomes, attrition varies for different follow-up times (no information, but it does not seem so; the f-up is just 12 months and the lost to f-up in both groups is low) |
| Selective reporting (reporting bias) | low risk of bias | Retrospectively registered in the ISRCTN registry; (abstract) date assigned: 06/03/2015. No difference between reported outcomes and methods section. Two outcomes: QoL and IIEF -5 have incomplete data: their values at baseline and at follow-up are not in the text nor in figures, nor in tables. However, for all outcomes there is a statistical comparison between groups: (pag 3 b) All measurement data for the two groups were statistically analyzed using a two-tailed Student's t test. The scoring and questionnaire results were analyzed using analysis of variance (ANOVA). |
| Other bias | Low risk of bias | The authors declared that they had no competing interests |

| | |
|---|--|
| Study ID | Chen 2013 |
| Authors: | Chen YB, Chen Q, Wang Z, Peng YB, Ma LM, Zheng DC, Cai ZK, Li WJ, Ma LH. |
| Title: | A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. |
| Journal/Book/Source: | J Urol. |
| Date of Publication: | 2013 |
| Volume: | 189 |
| Issue: | 1 |
| Pages: | 217-22 |
| METHODS (study design; length of follow up) | prospective randomized clinical trial 2-year follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 280 |
| Country of participants | China |
| Data collection period | from August 2008 to February 2010 |
| Inclusion criteria | Indications for the surgical treatment of BPH. |
| Exclusion criteria | Patients with severe pulmonary disease or heart disease, bladder calculus, neurogenic bladder dysfunction, bladder cancer, previous prostate surgery, prostate cancer, urethral stricture or coagulopathy were excluded from study |
| Average age | PKRP: 73.5 ± 8.8 years HoLEP: 72.1 ± 7.8 years |
| INTERVENTIONS (technology 1) | Plasmakinetic resection of the prostate (PKRP) |
| INTERVENTIONS (technology 2) | Holmium laser enucleation of the prostate (HoLEP) |
| Number of patients in PKRP | 140 |
| Number of patients in HoLEP | 140 |
| OUTCOMES | Operative duration, serum sodium decrease, catheter time, hospital stay, IPSS, QoL, Qmax, PVR, IIEF-5, TUR syndrome), re-catheterization, blood transfusion due to postoperative blood loss, urinary incontinence, reoperation, retrograde ejaculation, urethral stricture, bladder neck contracture |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Supported by grants from the Natural Science Foundation of China (No. 81070544 and No. 81172450). Conflicts of interest: not mentioned Trial registration: not mentioned. |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | low risk of bias | Each patient was assigned with an envelope through the computerized random number generator. |
| Allocation concealment (selection bias) | low risk of bias | Allocation concealment was done using sequentially numbered and sealed envelopes. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | The study was a single blinded trial in which only the patients were blinded to the treatments while the surgeons and supervisors were not. |
| Blinding of outcome assessment SUBJECTIVE OUTCOMES (detection bias) | low risk of bias | Patients were blinded. No information reported about blinding of assessors (Comment: probably they are not blinded) |
| Blinding of outcome assessment OBJECTIVE OUTCOMES (detection bias) | high risk of bias | Patients were blinded. No information reported about blinding of assessors (Comment: probably they are not blinded) |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Authors do not address loss to follow-up. Not declared any difference in attrition between the two groups. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Low risk of bias | Supported by grants from the Natural Science Foundation of China |

| | |
|----------------------|---|
| Study ID | Dahlstrandt 1995 |
| Authors: | DAHLSTRAND C, WALDEN M, GEIRSSON G, PETERSSON S |
| Title: | Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up |
| Journal/Book/Source: | Br J Urol |

| | | |
|---|--|--|
| Date of Publication: | 1995 | |
| Volume: | 76 | |
| Issue: | | |
| Pages: | 614-618 | |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 3, 6, 12 and 24 months | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 72 | |
| Country of participants | Sweden | |
| Data collection period | | |
| Inclusion criteria | Prostate length of 35-50mm, symptom score of 28 according to the Madsen and Iversen system | |
| Exclusion criteria | Patients with an indwelling catheter or a residual urine volume of > 350 mL, with malignancy of the prostate or bladder, urethral stricture, a large median lobe, prior treatment for BPH, a neurogenic bladder disorder, a metallic hip implant, previous surgery for pelvic malignancy or regional arterial insufficiency, | |
| Average age | 68 | |
| INTERVENTIONS (technology 1) | TUMT | |
| INTERVENTIONS (technology 2) | TURP | |
| Number of patients in TUMT | 37 | |
| Number of patients in TURP | 32 | |
| OUTCOMES | Qmax, PVR, reintervention, urinary retention, urethral stricture, UTI, erectile dysfunction, blood loss, operation time, hospital stay | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |

| | | |
|---|--------------|--|
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | Incomplete follow-up mostly at 24 months (for 10 patients) |
| Selective reporting (reporting bias) | Unclear risk | No study protocol available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|---|
| Study ID | D'Ancona 1998 |
| Authors: | D'ANCONA FCH, FRANCISCA EAE, WITJES WPJ, WELLING L, DEBRUYNE FMJ, De La ROSETTE JJM |
| Title: | Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results |
| Journal/Book/Source: | British Journal of Urology |
| Date of Publication: | 1998 |
| Volume: | 81 |
| Issue: | |
| Pages: | 259–264 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 1, 3, 6, 12 and 30 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 52 |
| Country of participants | The Netherlands |
| Data collection period | January 1994 - August 1995 |
| Inclusion criteria | Age \geq 45, prostate length 25-50 mm, prostate volume 30-100 ml, |

| | | |
|---|--|--|
| | symptoms since > 3 months, Madsen symptom score ≥ 8 , Qmax ≤ 15 ml/s with a minimum voided volume of 100 ml, PVR ≤ 350 ml | |
| Exclusion criteria | Neurogenic disorders affecting bladder function, prostatic carcinoma, prior prostate surgery, microwave sensitive implants (pacemaker or hip prosthesis), diabetic neuropathy, urinary retention requiring indwelling catheter, renal impairment, obstructed bladder neck due to an enlarged median lobe of the prostate, drug therapies for BPH | |
| Average age | 69 | |
| INTERVENTIONS (technology 1) | TUMT | |
| INTERVENTIONS (technology 2) | TURP | |
| Number of patients in TUMT | 31 | |
| Number of patients in TURP | 21 | |
| OUTCOMES | IPSS, Qmax, PVR, catheterization time, UTI, hospitalization time, irritative symptoms, repeat treatment | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data | High risk | >20% of patients were lost to follow-up |

| | | |
|--------------------------------------|--------------|---|
| (attrition bias) | | after 2.5 years |
| Selective reporting (reporting bias) | Unclear risk | No protocol available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | | |
|--|---|--|
| Study ID | Dørflinger 1992 | |
| Authors: | Dørflinger T, Svendsen Jensen F, Krarup T, Walter S. | |
| Title: | Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. | |
| Journal/Book/Source: | Scand J Urol Nephrol | |
| Date of Publication: | 1992 | |
| Volume: | 26 | |
| Issue: | 4 | |
| Pages: | 333-338 | |
| METHODS (study design; length of follow up) | prospective randomized controlled study 12-months follow up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 60 | |
| Country of participants | Denmark | |
| Data collection period | Not declared | |
| Inclusion criteria | The study comprised unselected patients who had not had any prostatic surgery. This included patients with prostatism and urinary retention as a result of benign prostatic hypertrophy, estimated prostatic weight of less than 20 g and a bladder neck to seminal crest distance of less than 2 cm. | |
| Exclusion criteria | Patients with prostatic cancer, urethral stricture , those who had had previous pelvic operations, and those with obvious neurological or psychiatric diseases, or who were at poor surgical risk were excluded. | |
| Average age | median values TURP: 71 years TUIP: 69 years | |
| INTERVENTIONS (technology 1) | Transurethral resection of the prostate (TURP) | |
| INTERVENTIONS (technology 2) | transurethral incision of the prostate (TUIP) | |

| | | |
|---|---|--|
| Number of patients in TURP | 31 | |
| Number of patients in TUIP | 29 | |
| OUTCOMES | persistent irritative symptoms, obstructive symptoms (LUTS), maximum flow rate (ml/sec), length of operation, blood transfusion due to blood loss, urethral stricture, bladder neck contraction, catheterization time, reoperation, recatheterization, retrograde ejaculation | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Fund: not mentioned. Conflicts of interest: not mentioned. Trial registration: not mentioned. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | no information about sequence generation |
| Allocation concealment (selection bias) | uncertain risk of bias | patients were randomly allocated (no other information) |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported about blinding of assessors. |
| Incomplete outcome data (attrition bias) | high risk | Overall lost to follow-up: 21.7% |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Uncertain risk of bias | No information about possible conflicts of interest |

| | |
|----------------------|---|
| Study ID | Dunsmuir 2003 |
| Authors: | Dunsmuir WD, McFarlane JP, Tan A, Dowling C, Downie J, Kourambas J, Donnellan S, Redgrave N, Fletcher R, Frydenberg M, Love C. |
| Title: | Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. |
| Journal/Book/Source: | Prostate Cancer Prostatic Dis. |
| Date of Publication: | 2003 |

| | | |
|---|--|--|
| Volume: | 6 | |
| Issue: | 2 | |
| Pages: | 182-6 | |
| METHODS (study design; length of follow up) | Randomized prospective single-blind trial Follow up: 1 year. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 51 | |
| Country of participants | Australia | |
| Data collection period | No information | |
| Inclusion criteria | men less than 80 y of age, presenting to the outpatient clinic with LUTS considered to be secondary to BPH and considered to be appropriate for TURP | |
| Exclusion criteria | men presenting with acute urinary retention, anticoagulant therapy, prostate volume greater than 80 cm ³ , previous prostatic surgery, or suspicion of prostate cancer. The latter included men with a PSA 4.4 ng/ml (unless biopsies were negative for cancer) | |
| Average age | B-TUVP: 63 ± 7.1 years TURP: 60 ± 6.5 years | |
| INTERVENTIONS (technology 1) | Bipolar electrovaporization (B-TUVP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in B-TUVP | 30 | |
| Number of patients in TURP | 21 | |
| OUTCOMES | Qmax, PVR, AUA symptom score (analogue to IPSS or American Urological Association-Symptom Index (AUA-SI), operation time, catheter removal, time to discharge, recatheterization, serum sodium, procedural blood loss and transfusion requirements | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Funding source: not mentioned in the article. Conflicts of interest: not mentioned in the article. Trial registration number: not mentioned in the article. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | Randomization was made by drawing a chit from a previously sealed box containing an equal number of tickets for the two surgical modalities. |
| Allocation concealment | uncertain risk of bias | No information reported. |

| | | |
|---|------------------------|--|
| (selection bias) | | |
| Blinding of participants and personnel (performance bias) | high risk of bias | Single-blind trial: Ward-nursing staff was blind to the surgical modality used. (Patients and clinicians are not blind) |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported about blinding of assessors. Patients are not blinded. |
| Incomplete outcome data (attrition bias) | high risk of bias | Missing overall: 22% |
| Selective reporting (reporting bias) | high risk of bias | Not registered trial. No difference between reported outcomes and methods section. These outcomes: AUA (analogue to IPSS), Qmax, PVR are reported at the baseline only; their values during follow-up are only in figures, not in tables nor in the text. For these outcomes, the statistical comparison between groups is only in Fig.3. |
| Other bias | Uncertain risk of bias | No information about possible conflicts of interest |

| | |
|--|---|
| Study ID | Elsakka 2016 |
| Authors: | Elsakka AM, Eltatawy HH, Almekaty KH, Ramadan AR, Gameel TA, Farahat Y. |
| Title: | A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate. |
| Journal/Book/Source: (abbreviated name) | Arab J Urol. |
| Date of Publication: | 2016 |
| Volume: | 14 |
| Issue: | 4 |
| Pages: | 280-286 |
| METHODS (study design; length of follow up) | prospective RCT follow up: 3 and 6 months postoperatively |
| PARTICIPANTS | |
| Total Number of Participants randomized | 84. However, two patients in group I were lost during follow-up and excluded from the study. |
| Country of participants | Egypt |

| | | |
|---|---|--|
| Data collection period | 1 April 2010 - 1 January 2012 | |
| Inclusion criteria | patients with LUTS secondary to BOO with an IPSS of ≥ 8 , low maximum urinary flow rate (Qmax) < 15 mL/s, not responding to medical treatment, and/or BPH complications such as refractory retention or recurrent haematuria, and prostate size <80 mL | |
| Exclusion criteria | Patients unfit for surgery and those suspected of prostatic carcinoma were excluded from the study | |
| Average age | B-TUVP: 56.9 years M-TURP: 55.6 years | |
| INTERVENTIONS (technology 1) | Bipolar transurethral plasma vaporisation (B-TUVP) | |
| INTERVENTIONS (technology 2) | Monopolar transurethral resection of the prostate (M-TURP) | |
| Number of patients in in B-TUVP | 40 | |
| Number of patients in M-TURP | 42 | |
| OUTCOMES | IPSS, Qmax, PVR, Na ⁺ , perioperative mortality, operative time, catheterization time, bladder perforation, re-catheterisation, urinary tract infection, stress urinary incontinence, bladder neck obstruction, bleeding necessitating transfusion, TUR syndrome, stricture urethra, secondary intervention (reintervention) | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Source of funding: none. Conflicts of interest. Trial registration number: not mentioned in the article. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | uncertain risk of bias | No information reported. |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | low risk of bias | -Total lost to f-up: 2,4%. -Difference in attrition between the two groups: 4,8%. -For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported |

| | | |
|------------|------------------------|--|
| | | outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Uncertain risk of bias | No information about possible conflicts of interest |

| | |
|--|---|
| Study ID | Elshal 2015 |
| Authors: | Elshal AM, Elkoushy MA, El-Nahas AR, Shoma AM, Nabeeh A, Carrier S, Elhilali MM. |
| Title: | GreenLight™ laser (XPS) photoselective vapo-enucleation versus holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic hyperplasia: a randomized controlled study. |
| Journal/Book/Source: | J Urol |
| Date of Publication: | 2015 |
| Volume: | 193 |
| Issue: | 3 |
| Pages: | 927-34 |
| METHODS (study design; length of follow up) | randomized controlled noninferiority trial follow up: 1 year |
| PARTICIPANTS | |
| Total Number of Participants randomized | 108 randomized, 103 included in the final analysis. |
| Country of participants | Canada |
| Data collection period | January 2012 - March 2013 |
| Inclusion criteria | patient age greater than 50 years, refractory LUTS secondary to BPH, I-PSS greater than 15, QOL score 3 or greater, Qmax less than 15 ml per second or patients with acute urinary retention secondary to BPH in whom trial of voiding failed, and prostate size on preoperative TRUS of 40 to 150 ml |
| Exclusion criteria | Patients with neurological disorder, active urinary tract infection, active bladder or prostate cancer were excluded. |
| Average age | PVEP: 74,1 years HoLEP: 71 years |
| INTERVENTIONS (technology 1) | Photoselective vapo-enucleation of the prostate-XPS 180 W (PVEP) |
| INTERVENTIONS (technology 2) | Holmium laser enucleation of prostate (HoLEP) |

| | | |
|---|--|--|
| Number of patients in PVEP | 53 | |
| Number of patients in HoLEP | 50 | |
| OUTCOMES | Reintervention, Qmax, PVR, IPSS, QOL, IIEF-15, operative time, blood sodium deficit catheterization time, hospital stay, dysuria, urge urinary incontinence, prostate capsule violation, bladder injury, recatheterisation, anemia requiring transfusion, urinary tract infection, stress urinary incontinence, bladder neck contracture, urethral stricture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Financial interest and/or other relationship with Lumenis and AMS. Conflicts of interest: no information. Trial registration: ClinicalTrials.gov ID: NCT01494337 | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | Computer generated random tables in a 1:1 ratio were used. Patients were randomly assigned to one of the treatment groups by stratified-blocked randomization. |
| Allocation concealment (selection bias) | uncertain risk of bias | No information reported. |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported. |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported. |
| Incomplete outcome data (attrition bias) | low risk of bias | Total lost to f-up: 4,6%. Difference in attrition between the two groups: 9,1%. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | Uncertain risk of bias | Trial registration: ClinicalTrials.gov ID: NCT01494337. No difference between reported outcomes and methods section. These outcomes: PVR, I-PSS, QOL, IIEF are reported at the baseline only; their values during follow-up are only in figures, not in tables nor in the text. IIEF is not even in figure. However, for these outcomes there is a statistical comparison between groups. Mean QOL at 1, 4 and 12 months were comparable in the HoLEP and PVEP groups. No significant changes were noted in |

| | | |
|------------|-------------------|--|
| | | <p>IIEF-15 score or its subdomains in both groups.</p> <p>Noninferiority of I-PSS at 1 year was evaluated using a 1-sided test at 5% level of significance. The statistical significance of other comparators was assessed at the (2-sided) 5% level.</p> <p>There was significant, comparable improvement in I-PSS and post-void residual urine volume (PVR) at 1, 4 and 12 months.</p> |
| Other bias | High risk of bias | Corresponding author had financial interest and/or other relationship with manufacturers |

| | |
|--|--|
| Study ID | Elshal 2020 |
| Authors: | Elshal AM, Soltan M, El-Tabey NA, Laymon M, Nabeeh A |
| Title: | Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes |
| Journal/Book/Source: | BJU Int |
| Date of Publication: | 2020 |
| Volume: | 126 |
| Issue: | |
| Pages: | 731-8 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1, 2 and 3 years |
| PARTICIPANTS | |
| Total Number of Participants randomized | 184 |
| Country of participants | Egypt |
| Data collection period | 2014-16 |
| Inclusion criteria | Patients with estimated prostate volumes of 80–150 mL with refractory LUTS or with acute urine retention secondary to benign prostatic obstruction who failed medical treatment |
| Exclusion criteria | Neurological disorder, bleeding tendency, ongoing anticoagulants or antiplatelet medications, history of previous prostate surgery or diagnosis of prostate cancer |
| Average age | 66 |
| INTERVENTIONS (technology 1) | PVP (Greenlight) |

| | | |
|---|--|---|
| INTERVENTIONS (technology 2) | HoLEP | |
| INTERVENTIONS (technology 3) | Bipolar transurethral resection (TURis system) (B-TURP) | |
| Number of patients in PVP | 60 | |
| Number of patients in HoLEP | 60 | |
| Number of patients in B-TURP | 62 | |
| OUTCOMES | Retreatment (primary); hospital stay, operative time, time to catheter removal, dysuria, IIEF, IPSS, Qmax, PVR, QoL, capsular perforation, blood transfusion, bladder wall injury, UTI | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Conflict of interest: none declared | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low | Computer generated random tables |
| Allocation concealment (selection bias) | Uncertain | No information available |
| Blinding of participants and personnel (performance bias) | Uncertain | No information about blinding of patients and post-surgery attending clinicians |
| Blinding of outcome assessment | Uncertain | No information about blinding of assessors |
| Incomplete outcome data (attrition bias) | Uncertain | No information available |
| Selective reporting (reporting bias) | Uncertain | 10% were lost to follow-up at 3 years |
| Other bias | Low | No conflict of interest was declared |

| | |
|----------------------|--|
| Study ID | Eltabey 2010 |
| Authors: | Eltabey MA, Sherif H, Hussein AA. |
| Title: | Holmium laser enucleation versus transurethral resection of the prostate |
| Journal/Book/Source: | Can J Urol |
| Date of Publication: | 2010 |
| Volume: | 17 |
| Issue: | 6 |
| Pages: | 5345-5350 |

| | | |
|---|--|--|
| METHODS (study design; length of follow up) | Prospective RCT follow up: 1 year | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 80 | |
| Country of participants | Saudi Arabia | |
| Data collection period | April 2008 - December 2009 | |
| Inclusion criteria | patients who presented to the Urology Department at King Fahd Specialist Hospital in Al Qassin, Saudi Arabia, with bladder outlet obstruction caused by BPH, with related voiding symptoms, and prostate volume greater than 30 g but less than 100 g (as determined by TRUS), who had not responded to pharmacologic therapy, and who were eligible for surgical treatment were enrolled in this randomized, prospective study. Other inclusion criteria were an AUA symptom score of 12 or higher and a peak urinary flow rate of 15 mL/sec or lower | |
| Exclusion criteria | neurogenic bladder; previous urethral, bladder neck, or prostate surgery; suspected prostatic cancer by abnormal digital rectal examination (DRE), total serum PSA > 4 ng/mL or abnormal TRUS; and TRUS-guided prostate biopsy | |
| Average age | HoLEP: 67.5 ± 8.1 years TURP: 68.3 ± 9.2 years | |
| INTERVENTIONS (technology 1) | holmium laser enucleation of the prostate (HoLEP) | |
| INTERVENTIONS (technology 2) | transurethral resection of the prostate (TURP) | |
| Number of patients in HoLEP | 40 | |
| Number of patients in TURP | 40 | |
| OUTCOMES | Qmax, PVR, AUA symptom score (analogue to IPSS or American Urological Association-Symptom Index (AUA-SI)), total operating time, blood transfusion, catheterization time, hospital stay, irritative voiding symptoms, urge urinary incontinence, mixed urinary incontinence, stress urinary incontinence, urethral stricture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Source of funding: no information reported. Conflicts of interest: no information reported Trial registration number: no information reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | The patients were randomized using a computer-generated table. |
| Allocation concealment | uncertain risk of bias | No information reported. |

| | | |
|---|------------------------|--|
| (selection bias) | | |
| Blinding of participants and personnel (performance bias) | uncertain risk of bias | No information reported |
| Blinding of outcome assessment (detection bias) | uncertain risk of bias | No information reported |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Authors do not address loss to follow-up. Postoperative improvement in symptoms and micturition parameters were significantly better with HoLEP than with TURP; these occurred within the first month and lasted up to 12 months of follow up. For none of the outcomes, attrition varies for different follow-up times. |
| Selective reporting (reporting bias) | uncertain risk of bias | Not registered trial. No difference between reported outcomes and methods section. No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | Uncertain risk of bias | No information about possible conflicts of interest |

| | |
|--|--|
| Study ID | Enikeev 2019 |
| Authors: | Enikeev D, Netsch C, Rapoport L, Gazimiev M, Laukhtina E, Snurnitsyna O, Alekseeva T, Becker B, Taratkin M, Glybochko P |
| Title: | Novel thulium fiber laser for endoscopic enucleation of the prostate: A prospective comparison with conventional transurethral resection of the prostate |
| Journal/Book/Source: | Int J Urol |
| Date of Publication: | 2019 |
| Volume: | 26 |
| Issue: | |
| Pages: | 1138--1143 |
| METHODS (study design; length of follow up) | RCT Follow-up of 3, 6 and 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 119 (data on 103) |
| Country of participants | Russia |

| | | |
|---|--|--|
| Data collection period | Not reported. | |
| Inclusion criteria | Prostate volume <80 cc, IPSS >20 and Qmax <10 mL/s | |
| Exclusion criteria | Prostate cancer, bladder stones, acute urinary retention (indwelling suprapubic or transurethral catheter), urethral strictures, neurogenic bladder and anticoagulant therapy | |
| Average age | 67 | |
| INTERVENTIONS (technology 1) | Thulium fiber laser enucleation (ThuLEP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in ThuLEP | 51 | |
| Number of patients in TURP | 52 | |
| OUTCOMES | PVR, IPSS, Qmax, QoL, surgery time, catheterization time, hospital stay, reduction of serum sodium, urinary incontinence, UTI, acute urinary retention, urethral stricture, bladder neck contracture, retrograde ejaculation | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Conflict of interest: none declared | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Randomization list, not specified how it was generated. Judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs. |
| Allocation concealment (selection bias) | High risk | Non blind assignment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified. |
| Incomplete outcome data (attrition bias) | Unclear risk | 8.5% of patients were lost to follow-up. |
| Selective reporting (reporting bias) | Unclear risk | Protocol not available. |
| Other bias | Unclear risk | No information available about possible conflicts of interest. |

| | |
|--|---|
| Study ID | Fayad 2015 |
| Authors: | Fayad AS, Elsheikh MG, Zakaria T, Elfotouh HA, Alsergany R, Elshenoufy A, Elghamarawy H |
| Title: | Holmium Laser Enucleation of the Prostate Versus Bipolar Resection of the Prostate: A Prospective Randomized Study. "Pros and Cons" |
| Journal/Book/Source: | Urology |
| Date of Publication: | 2015 |
| Volume: | 86 |
| Issue: | |
| Pages: | 1037-1041 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1 week, 1 month and 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 120 |
| Country of participants | Egypt |
| Data collection period | 2008-2013 |
| Inclusion criteria | Bothersome lower urinary tract symptoms due to BPH with indications for surgical intervention regardless of the patient age, International Prostate Symptom Score (IPSS), and prostatic size |
| Exclusion criteria | Patients with mild symptoms (IPSS <8 and/or maximum urinary flow rate 15 mL/s and minimal postvoiding residual urine), small adenomas <20 g measured by transrectal ultrasound, urethral stricture, neurogenic bladder, vesicoureteric reflux, huge retentive bladder diverticulum, previous prostatic surgeries, prostatic adenocarcinoma, patients receiving anticoagulant drugs (for the fact that holmium can be used safely in patients receiving anticoagulant drugs unlike bipolar TURP) |
| Average age | 61 |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP) |
| INTERVENTIONS (technology 2) | Bipolar transurethral resection of the prostate (B-TURP) |
| Number of patients in HoLEP | 60 |
| Number of patients in B-TURP | 60 |
| OUTCOMES | IPSS, Qmax, PVR, prostate size, operative time, blood loss, |

| | | |
|---|---|--|
| | intraoperative and postoperative complications, catheterization time, hospital stay, costs | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The authors declared that they had no relevant financial interests. No trial registration available | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | A sequence of consecutive numbers |
| Allocation concealment (selection bias) | High risk | A secretary allocated consecutive patients (giving each of them a consecutive number) to each of the two groups according to timing of inclusion |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | Limited loss to follow-up (< 5%) up to one month. 12 months data suffer for a more pronounced loss to follow-up (>10%) |
| Selective reporting (reporting bias) | Unclear risk | No protocol or trial registration available |
| Other bias | Low risk | The authors declare that they have no relevant financial interests |

| | |
|--|---|
| Study ID | Feng 2016 |
| Authors: | Feng L, Zhang D, Tian Y, Song J |
| Title: | Thulium Laser Enucleation Versus Plasmakinetic Enucleation of the Prostate: A Randomized Trial of a Single Center |
| Journal/Book/Source: | JOURNAL OF ENDOUROLOGY |
| Date of Publication: | 2016 |
| Volume: | 30 |
| Issue: | 6 |
| Pages: | 665-670 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 3, 6 and 12 months |
| PARTICIPANTS | |

| | | |
|---|---|---|
| Total Number of Participants randomized | 127 | |
| Country of participants | China | |
| Data collection period | 2011-2013 | |
| Inclusion criteria | Age \geq 50 years but $<$ 85 years, IPSS \geq 7, Qmax $<$ 15 mL/seconds, and medical therapy failure | |
| Exclusion criteria | Neurogenic bladder, documented or suspected prostate cancer, a history of prostatic or urethral surgery, and a poor tolerance for surgery | |
| Average age | 69 | |
| INTERVENTIONS (technology 1) | Thulium laser enucleation of the prostate (ThuLEP) | |
| INTERVENTIONS (technology 2) | Plasmakinetic enucleation of the prostate (PKEP) | |
| Number of patients in ThuLEP | 61 | |
| Number of patients in PKEP | 66 | |
| OUTCOMES | IPSS, QoL score, Qmax, PVR, catheterization time, operation time, changes in serum sodium and hemoglobin levels, hospital stay, complications | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The authors declare that no competing financial interests exist | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs. |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs. |
| Blinding of participants and personnel (performance bias) | High risk | Open trial |
| Blinding of outcome assessment (detection bias) | High risk | Blinding of assessors was not mentioned. |
| Incomplete outcome data | Low risk | No patients lost to follow-up. |

| | | |
|--------------------------------------|--------------|--|
| (attrition bias) | | |
| Selective reporting (reporting bias) | Unclear risk | No protocol or trial registration available. |
| Other bias | Low risk | The authors declare that no competing financial interests exist. |

| | |
|--|---|
| Study ID | Floratos 2001 |
| Authors: | FLORATOS DL, KIEMENEY LAL, ROSSI C, KORTMANN BBM, DEBRUYNE FMJ, DE LA ROSETTE JJM |
| Title: | Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study |
| Journal/Book/Source: | The Journal of Urology |
| Date of Publication: | 2001 |
| Volume: | 165 |
| Issue: | |
| Pages: | 1533-1538 |
| METHODS (study design; length of follow up) | RCT Follow-up of 3, 6, 12, 18, 24 and 36 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 155 |
| Country of participants | The Netherlands |
| Data collection period | Jan 1996-Mar 1997 |
| Inclusion criteria | Age \geq 45 years, lower urinary tract symptoms persisting longer than 3 months, prostate volume \geq 30 ml, prostatic urethral length \geq 25 mm, a Madsen symptom score \geq 8, Qmax \geq 15 ml per second, PVR \leq 350 ml |
| Exclusion criteria | Acute prostatitis or urinary tract infection, evidence of prostatic carcinoma, an isolated prostatic middle lobe protruding in the bladder, urethral stricture, neurological disorders affecting lower urinary tract function, previous prostatic surgery and severe comorbidity not allowing surgery |
| Average age | 67 |
| INTERVENTIONS (technology 1) | Transurethral microwave thermotherapy (TUMT) |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) |
| Number of patients in TUMT | 78 |

| | | |
|---|---|--|
| Number of patients in TURP | 66 | |
| OUTCOMES | PVR, IPSS, Qmax, QoL, re-treatment rate, urethral stricture, bladder neck contracture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | - | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | Less than 20% of loss to follow-up |
| Selective reporting (reporting bias) | High risk | For some critical outcomes: data only presented as figures and lack of statistical comparisons in parallel (only before-after comparisons for each group) |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|---|---|
| Study ID (surname first author and year – add a, b if same author same year) | Gao2014 |
| Authors: | Yuan-an Gao, Yan Huang, Rui Zhang, Yu-dong Yang, Qing Zhang, Min Hou, Yi Wang |

| | |
|--|---|
| Title: | Prostatic Arterial Embolization versus Transurethral Resection of the Prostate—A Prospective, Randomized, and Controlled Clinical Trial |
| Journal/Book/Source: | Radiology |
| Date of Publication: | 2014 |
| Volume: | 270 |
| Issue: | 3 |
| Pages: | 920-8 |
| METHODS (study design; length of follow up) | Randomised controlled trial (RCT) Follow up: 1, 3, 6, 12, and 24 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 114 |
| Country of participants | China |
| Data collection period | January 2007 - January 2012 |
| Inclusion criteria | International Prostate Symptom Score (IPSS) greater than 7 after failed medical therapy with a washout period of 2 or more weeks, prostate volume of 20–100 mL on transrectal ultrasonographic (US) or magnetic resonance (MR) images, peak urinary flow of less than 15 mL/sec, and patient understanding and written informed consent. |
| Exclusion criteria | Detrusor hyperactivity or hypocontractility at urodynamic study, urethral stricture, prostate cancer, diabetes mellitus, and previous prostate, bladder neck, or urethral surgery. Patients who had a prostate-specific antigen (PSA) value greater than 4 ng/mL or an abnormal finding at digital rectal examination and who had positive US guided prostate biopsy. |
| Average age | PAE: 67.7 ± 6 8.7 TURP: 66.4 ± 6 7.8 |
| INTERVENTIONS (technology 1) | Prostatic arterial embolization (PAE) |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) |
| Number of patients in PAE | 57 |
| Number of patients in TURP | 57 |
| OUTCOMES | IPSS, QoL, PVR, Qmax, operative time, decrease in serum sodium levels within 24 hours after the procedure, transfusion requirements, hospital stay, catheter requirements, reintervention, TUR syndrome, acute urinary retention, UTI, urethral stricture, bladder neck contracture. |

| | | |
|---|---------------------------|--|
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Randomization was performed by using computer-generated simple random tables in a 1:1 ratio. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information whether blinding was performed. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information whether blinding was performed. |
| Incomplete outcome data (attrition bias) | Unclear risk | loss to follow up in both arms between 5 and 20% |
| Selective reporting (reporting bias) | Unclear risk | There is no pre-registered protocol available. |
| Other bias | Unclear risk | There is no funding statement. |

| | |
|--|---|
| Study ID | Geavlete 2010 |
| Authors: | Geavlete B, Multescu R, Dragutescu M, Jecu M, Georgescu D, Geavlete P |
| Title: | Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: 'the better choice' in benign prostatic hyperplasia? |
| Journal/Book/Source: | BJU INTERNATIONAL |
| Date of Publication: | 2010 |
| Volume: | 106 |
| Issue: | |
| Pages: | 1695–1699 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1, 3 and 6 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 155 |

| | | |
|---|---|---|
| Country of participants | Romania | |
| Data collection period | | |
| Inclusion criteria | Qmax <10 mL/ s, IPSS >19, prostate volume 30–80 mL | |
| Exclusion criteria | Severe comorbidities, previous prostate surgery, history of prostate cancer, abnormal DRE and/ or increased PSA level | |
| Average age | 66 | |
| INTERVENTIONS (technology 1) | Transurethral resection in saline plasma vaporization (TUVRP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in TUVRP | 75 | |
| Number of patients in TURP | 80 | |
| OUTCOMES | IPSS, HRQL, Qmax, PVR, catheterization time, operation time, capsular perforation, intraoperative bleeding, blood transfusion, haematuria, hemoglobin decrease, urinary tract infection, acute urinary retention, dysuria, urgency, | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | No conflict of interest was declared | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | Consecutive numbers |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes |
| Blinding of participants and personnel (performance bias) | Low risk | Blinding of patients and of urologists is declared. Surgeons could not be blinded, but we assume that their professional performance is as high as possible |
| Blinding of outcome assessment (detection bias) | Low risk | Blinding of urologists and patients was specified |
| Incomplete outcome data (attrition bias) | Unclear risk | No information provided |
| Selective reporting (reporting bias) | Unclear risk | No protocol or trial registration available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|-----------------|----------------------|
| Study ID | Geavlete 2011 |
|-----------------|----------------------|

| | |
|---|--|
| Authors: | Geavlete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P |
| Title: | Bipolar Plasma Vaporization vs Monopolar and Bipolar TURP–A Prospective, Randomized, Long-term Comparison |
| Journal/Book/Source: | Urology |
| Date of Publication: | 2011 |
| Volume: | 78 |
| Issue: | 4 |
| Pages: | 930-935 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1, 3 and 6, 12 and 18 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 510 |
| Country of participants | Romania |
| Data collection period | |
| Inclusion criteria | BPH and severe LUTS |
| Exclusion criteria | Severe comorbidities, previous prostate surgery, history of prostate cancer, abnormal DRE, and/or increased PSA |
| Average age | 67 |
| INTERVENTIONS (technology 1) | Bipolar plasma vaporization (B-PVP) |
| INTERVENTIONS (technology 2) | Transurethral resection in saline (TURis) (B-TURP) |
| INTERVENTIONS (technology 3) | M-TURP |
| Number of patients in B-PVP | 170 |
| Number of patients in B-TURP | 170 |
| Number of patients in M-TURP | 170 |
| OUTCOMES | IPSS, QoL, Qmax, PVR, operation time, catheterization time, hospital stay, Intraoperative bleeding, blood transfusion, capsular perforation, TUR syndrome, re-catheterization, early irritative symptoms, dysuria, bladder neck sclerosis, urinary stricture, urinary incontinence, urinary tract infections, retreatment rate |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | No information provided |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes |
| Blinding of participants and personnel (performance bias) | Low risk | Blinding of patients and of urologists is declared. Surgeons could not be blinded, but we assume that their professional performance is as high as possible |
| Blinding of outcome Assessment (detection bias) | Low risk | Blinding of urologists and patients was specified |
| Incomplete outcome data (attrition bias) | Unclear risk | No information provided |
| Selective reporting (reporting bias) | Unclear risk | No protocol or trial registration available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|--|
| Study ID | Geavlete 2014 |
| Authors: | Geavlete B, Stanescu F, Moldoveanu C, Geavlete P |
| Title: | Continuous vs conventional bipolar plasma vaporisation of the prostate and standard monopolar resection: a prospective, randomised comparison of a new technological advance |
| Journal/Book/Source: | BJU Int |
| Date of Publication: | 2014 |
| Volume: | 113 |
| Issue: | |
| Pages: | 288-295 |
| METHODS (study design; length of follow up) | Randomised controlled trial Follow-up at 1, 3, 6 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 180 |
| Country of participants | Romania |
| Data collection period | |

| | | |
|---|---|--|
| Inclusion criteria | Qmax<10 mL/s and IPSS >19 | |
| Exclusion criteria | Severe associated co-morbidities, previous prostate surgery or history of prostate cancer | |
| Average age | 69 | |
| INTERVENTIONS (technology 1) | Continuous bipolar plasma vaporisation of the prostate (C-BPVP) | |
| INTERVENTIONS (technology 2) | Standard bipolar plasma vaporisation of the prostate (S-BPVP) | |
| INTERVENTIONS (technology 3) | Transurethral resection of the prostate (TURP) | |
| Number of patients in C-BPVP | 60 | |
| Number of patients in S-BPVP | 60 | |
| Number of patients in TURP | 60 | |
| OUTCOMES | IPSS, QoL, Qmax, PVR, operation time, capsular perforation, catheterization time, hospital stay, re-catheterization | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | One of the authors received honoraria from Olympus when he spoke at company sponsored symposia | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), postoperative team blinded, no information on patient blinding |
| Blinding of outcome assessment (detection bias) subjective outcomes | Unclear risk | Patient blinding is not mentioned |
| Blinding of outcome assessment (detection bias) objective outcomes | Low risk | Postoperative team blinded (we can assume assessors were blinded) |
| Incomplete outcome data (attrition bias) | Unclear risk | No information available |
| Selective reporting | Unclear risk | No protocol or trial registration available |

| | | |
|------------------|-----------|--|
| (reporting bias) | | |
| Other bias | High risk | The main author received honoraria from the manufacturer |

| | |
|--|---|
| Study ID | Geavlete 2015 |
| Authors: | Geavlete B, Bulai C, Ene C, Checherita I, Geavlete P |
| Title: | Bipolar Vaporization, Resection, and Enucleation Versus Open Prostatectomy: Optimal Treatment Alternatives in Large Prostate Cases? |
| Journal/Book/Source: | JOURNAL OF ENDOUROLOGY |
| Date of Publication: | 2015 |
| Volume: | 29 |
| Issue: | 3 |
| Pages: | 323-331 |
| METHODS (study design; length of follow up) | Randomised controlled trial follow-up at 1, 3, 6, 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 320 |
| Country of participants | Romania |
| Data collection period | Between January 2009 and May 2013 |
| Inclusion criteria | Prostate volume \geq 80 mL, Qmax < 10 mL/second, IPSS > 19, or urinary retention imposing catheter indwelling |
| Exclusion criteria | Associated comorbidities preventing BPH surgery, previous prostate surgery, urethral strictures, and not BPH-related voiding disorders, prostate cancer |
| Average age | 68 |
| INTERVENTIONS (technology 1) | Transurethral enucleation with bipolar energy (B-TUEB) |
| INTERVENTIONS (technology 2) | Transurethral vaporization with bipolar energy (B-TUVP) |
| INTERVENTIONS (technology 3) | Transurethral resection of the prostate (TURP) |
| INTERVENTIONS (technology 4) | Open prostatectomy (OP) |
| Number of patients in B-TUEB | 80 |
| Number of patients in B-TUVP | 80 |
| Number of patients in TURP | 80 |

| | | |
|---|--|---|
| Number of patients in OP | 80 | |
| OUTCOMES | IPSS, QoL, Qmax, PVR, operation time, catheterization time, hospital stay, change in haemoglobin level, blood transfusion, re-catheterization, urinary stricture, urinary incontinence, urinary tract infections | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | One author declared having been a lecturer for the manufacturer | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | The authors mention sealed envelopes but not how the sequence has been randomised |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome Assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | 9% lost to follow-up |
| Selective reporting (reporting bias) | Unclear risk | No protocol or trial registration available |
| Other bias | High risk | The main author received honoraria from the manufacturer |

| | |
|-------------------------------|---|
| Study ID | Ghobrial 2020 |
| Authors: | Ghobrial FK, Shoma A, Elshal AM, Laymon M, El-Tabey N, Nabeeh A, Shokeir AA |
| Title: | A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years |
| Journal/Book/Source: | BJU International |
| Date of Publication: | 2020 |
| Volume: | 125 |
| Issue: | |
| Pages: | 144–152 |
| METHODS (study design; | RCT |

| | | |
|---|---|--|
| length of follow up) | Follow-up at 1, 4, 12, 24 months | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 120 | |
| Country of participants | Egypt | |
| Data collection period | October 2014 - November 2015 (surgery) | |
| Inclusion criteria | Age >50 years; LUTSsecondary to BOO attributable to BPH for which medical treatment has failed; IPSS >15; maximum urinary flow rate (Qmax) <15 mL/s with at least 125 mL voided volume or acute urinary retention secondary to BPH with failed trial of voiding after medical treatment; and TRUS-estimated prostate size 30–80 mL | |
| Exclusion criteria | Patients with neurological disorders or diagnosed prostate cancer | |
| Average age | 64 | |
| INTERVENTIONS (technology 1) | PVP (GreenLight laser xps-180watt) | |
| INTERVENTIONS (technology 2) | Bipolar transurethral vaporization (B-TUVP) | |
| Number of patients in PVP | 58 | |
| Number of patients in B-TUVP | 59 | |
| OUTCOMES | Qmax, PVR, IPSS, QoL, IIEF-15, operating time, catheterization time, hospital stay, blood sodium change, UTI, postoperative LUTS, bladder neck contracture, urethral stricture, urinary incontinence, urinary retention, anaemia necessitating blood transfusion, retention/re-catheterization, bladder wall injury, capsular violation, retrograde ejaculation-anejaculation | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | All authors declared they had nothing to disclose. Trial registration number: NCT02283684 | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer-generated random tables |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and | Unclear risk | Open trial (surgeons cannot be blind), but |

| | | |
|---|--------------|--|
| personnel (performance bias) | | no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | 18% of patients were lost to follow-up |
| Selective reporting (reporting bias) | Low risk | No substantial differences emerge from (limited) information available in the trial register (NCT02283684) |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|---|
| Study ID | WATER Study: Gilling2018 |
| Authors: | Peter Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan, Ronald P. Kaufman, Jr., Andrew Trainer, Andrew Arther, Gopal Badlani, Mark Plante, Mihir Desai, Leo Doumanian, Alexis E. Te, Mark DeGuenther and Claus Roehrborn |
| Title: | WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia |
| Journal/Book/Source | The journal of urology |
| Date of Publication | May 2018 |
| Volume: | 199 |
| Issue: | - |
| Pages: | 1252-1261 |
| METHODS (study design; length of follow up) | Double-blind, multicentre, prospective RCT |
| PARTICIPANTS | |
| Total Number of Participants randomized | 184 |
| Country of participants | United States, United Kingdom, Australia, New Zealand |
| Data collection period | October 2015 – December 2016 |
| Inclusion criteria | Age between 45-80 years old, prostate size between 30 and 80 gm, IPSS of 12 or greater, maximum urinary flow rate less than 15 ml per second. |
| Exclusion criteria | History of prostate or bladder cancer, neurogenic bladder, bladder calculus or clinically significant bladder diverticulum, active infection, treatment for chronic prostatitis, diagnosis of urethral stricture, meatal stenosis or bladder neck contracture, a damaged external urinary sphincter, stress urinary incontinence, post-void residual urine greater than 300 ml or urinary retention, self-catheterization or prior prostate surgery, men receiving anticoagulants or bladder anticholinergics, men with severe cardiovascular disease |
| Average age | Aquablation: 66.0±7.3 |

| | | |
|---|---|---|
| | TURP: 65.8 ±7.2 | |
| INTERVENTIONS (technology 1) | Aquablation | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients Aquablation | 116 | |
| Number of patients in TURP | 65 | |
| OUTCOMES | <p>Primary outcomes: IPSS, adverse events classified as Clavien-Dindo</p> <p>Secondary outcomes: resection time and total operative time, hospital stay, reoperation or repeat intervention rate, proportion of sexually active subjects who reported worsening sexual function through 6 months on IIEF-5 (6-point decrease) or MSHQ-EjD (2-point decrease) and proportion of subjects with a serious device or procedure related adverse event. (The reoperation or repeat intervention rate was defined as any invasive procedure, eg cystoscopy, of the lower urinary tract to treat problems potentially related to BPH. The definition excluded required study evaluations and bladder catheterization only without a surgical intervention).</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | <p>ClinicalTrials.gov Identifier NCT02505919</p> <p>No direct or indirect commercial incentive associated with publishing this article.</p> <p>Supported by PROCEPT BioRobotics (manuscript preparation).</p> <p>Gilling, Anderson, Desai, Te, DeGuenther: Financial interest and/or other relationship with PROCEPT BioRobotics.</p> | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | "Subjects were assigned at random in a 2:1 ratio to Aquablation or TURP. Randomization was done through a web based system and stratified by study site and baseline I-PSS score category with random block sizes." |
| Allocation concealment (selection bias) | Unclear risk | No mention to allocation mode |
| Blinding of participants and personnel (performance bias) | Unclear risk | Patients are blinded |
| Blinding of outcome assessment (detection bias) | Low risk | Patients are blinded and a separate blinded team (coordinator and physician) performed the follow up visits and will do so out to the completion of the trial |
| Incomplete outcome data (attrition bias) | Low risk | Compliance with study visits was high. Of the patients 178 (98%) completed the 3-month follow up and 175 (97%) completed the 6-month follow up. |

| | | |
|---|-----------|--|
| Selective reporting (re-reporting bias) | Low risk | The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way |
| Other bias | High risk | Financial interest, manufacturer financed the study. |

| | | |
|---|--|---|
| Study ID | WATER Study: Gilling2019a | |
| Authors: | Peter J. Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan and Claus Roehrborn | |
| Title: | Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes | |
| Journal/Book/Source (abbreviation): | Urology | |
| Date of Publication (year): | 2019 | |
| Volume: | 125 | |
| Issue: | | |
| Pages: | 169-173 | |
| PARTICIPANTS | Same as Gilling 2018 | |
| OUTCOMES | IPSS, quality of life, Qmax, PVR Complications | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | ClinicalTrials.gov Identifier NCT02505919 Conflict of Interest: Mohamed Bidair and Eugene Kramolowsky are consultants for PROCEPT BioRobotics. No other author has a conflict of interest with PROCEPT BioRobotics. Financial Disclosure: The study was funded by PROCEPT BioRobotics. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | "Subjects were assigned at random (2:1 ratio) to Aquablation or TURP. Assignments, stratified by study site and baseline IPSS score category with random block sizes, were obtained prior to treatment using a web-based system." |
| Allocation concealment (selection bias) | Unclear risk | No mention to allocation mode |
| Blinding of participants and personnel (performance bias) | Unclear risk | Patients are blinded |
| Blinding of outcome assessment (detection bias) | Low risk | All follow-up assessments were administered by a blinded research team (physician and coordinator). Visits included IPSS, uroflow meas- |

| | | |
|--|-----------|--|
| | | urements, quality of life, adverse events, and blinding assessment. |
| Incomplete outcome data (attrition bias) | Low risk | Overall lost to follow-up lower than 5% (2.8%) |
| Selective reporting (reporting bias) | Low risk | The protocol is available. 4 main outcomes are reported in figures but are appropriately commented in the results section. Not clear the complications report. |
| Other bias | High risk | Financial interest, manufacturer financed the study. |

| | | |
|---|--|--|
| Study ID | WATER Study: Gilling2019b | |
| Authors: | Peter J. Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan, Ronald P. Kaufman Jr., Andrew Trainer, Andrew Arther, Gopal Badlani, Mark Plante, Mihir Desai, Leo Doumanian, Alexis E. Te , Mark DeGuenther, Claus Roehrborn | |
| Title: | Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained | |
| Journal/Book/Source: | Adv Ther | |
| Date of Publication: | April 2019 | |
| Volume: | 36 | |
| Issue: | | |
| Pages: | 1326-1336 | |
| PARTICIPANTS | Same as Gilling 2018 | |
| OUTCOMES | 2-year efficacy outcomes Procedure-related complications occurring between months 12 and 24 | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | ClinicalTrials.gov Identifier NCT02505919 Funding: PROCEPT BioRobotic Funding. WATER, the article processing fees and the Open Access fee were funded by PROCEPT BioRobotics. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Disclosures. Mihir Desai is a consultant for PROCEPT BioRobotics and Auris Surgical. Mo Bidair is a consultant for PROCEPT BioRobotics and has performed commercial Aquablation procedures. Eugene Kramalowsky is a consultant for PROCEPT BioRobotics. Peter Gilling has performed commercial Aquablation procedures. Neil Barber has performed commercial Aquablation procedures. Paul Anderson has performed commercial Aquablation procedures. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | "Subjects were assigned at random (2:1 ratio) to Aquablation or TURP. Assignments, stratified by study site and baseline IPSS score category with random block sizes, were ob- |

| | | |
|---|--------------|---|
| | | tained prior to treatment using a web-based system.” |
| Allocation concealment (selection bias) | Unclear risk | No mention to allocation mode |
| Blinding of participants and personnel (performance bias) | Unclear risk | Patients are blinded |
| Blinding of outcome assessment (detection bias) | Low risk | A blinded research team performed all follow-up assessments |
| Incomplete outcome data (attrition bias) | Low risk | Overall lost to follow-up lower than 5% (4.4%) |
| Selective reporting (reporting bias) | Low risk | The protocol is available. The efficacy outcomes are reported in graphs but results are commented in the text and a supplementary material with precise numbers concerning IPSS, IPSS QOL, Qmax and complications is provided |
| Other bias | High risk | Financial interest, manufacturer financed the study |

| | |
|--|---|
| Study ID | WATER Study: Gilling2020 |
| Authors: | Peter Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan, Ronald P Kaufman Jr, Andrew Trainer, Andrew Arther, Gopal Badlani, Mark Plante, Mihir Desai, Leo Doumanian, Alexis E Te, Mark DeGuenther, Claus Roehrborn |
| Title: | Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial |
| Journal/Book/Source: | Can J Urol. |
| Date of Publication: | 2020 |
| Volume: | 27 |
| Issue: | 1 |
| Pages: | 10072-10079 |
| METHODS (study design; length of follow up) | Prospective double-blinded multicenter international randomized controlled trial (RCT). Follow up: 3 years. |
| PARTICIPANTS | Same as Gilling 2018. |
| OUTCOMES | International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), PVR, QoL, bladder neck contracture, dysuria, retrograde ejaculation, urethral stricture, urinary retention, urinary tract infection, urinary urgency/frequency/difficulty/leakage, dysuria, erectile dysfunction, reintervention. |

| | | |
|---|--|---|
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The study was funded by PROCEPT BioRobotics. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Subjects were assigned at random (2:1 ratio) to Aquablation or TURP. Assignments, stratified by study site and baseline IPSS score category with random block sizes, were obtained prior to treatment using a web-based system. |
| Allocation concealment (selection bias) | Unclear risk | No information available about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Personnel was not blinded. |
| Blinding of outcome assessment (detection bias) | Low risk | Assessors and participants were blinded for treatment. |
| Incomplete outcome data (attrition bias) | Unclear risk | Slightly higher percent of lost to follow up in TURP group (16.4%) than in Aquablation group (15.4%). |
| Selective reporting (reporting bias) | Low risk | This is a three year follow up and postoperative complications were not reported. Other outcomes (functional and safety) are reported in line with research protocol. |
| Other bias | High | Financial interest, the manufacturer financed the study. |

Note: the three articles Bachmann 2014, Bachmann 2015 and Thomas 2016 are part of the GOLIATH Study, analysed in the EUnetHTA Report OTCA17 [163].

| | |
|-----------------|---|
| Study ID | GOLIATH study: Thomas 2016, Bachmann 2014, Bachmann 2015 |
|-----------------|---|

| | |
|------------|---|
| 6 Authors: | Thomas JA, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Bachmann A. |
|------------|---|

| | |
|--|--|
| 7 Title: | A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GO-LIATH Study |
| Journal/Book/Source: | 8 Eur Urol. |
| Date of Publication: | 9 2016 |
| Volume: | 10 69 |
| Issue: | 11 1 |
| Pages: | 12 94-102 |
| METHODS (study design; length of follow up) | open-label, multicenter, prospective, randomized, and controlled noninferiority trial (29 centres in nine European countries); 24 months follow up. |

| | |
|---|--|
| 13 PARTICIPANTS | |
| Total Number of Participants randomized | 281 |
| Country of participants | nine European countries |
| Data collection period | Between April 2011 and September 2012 |
| Inclusion criteria | <p>The complete list of inclusion/exclusion criteria was previously published (Bachmann 2014, Table 1):</p> <p>Subject has provided informed consent and agrees to attend all study visits, has diagnosis of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction, is willing to be randomised, is able to complete self-administered questionnaires, is a surgical candidate for either the XPS or the TURP procedure and may be randomised into either arm, is 40–80 yr of age, has an IPSS score ≥ 12 measured at the baseline visit, has medical record documentation of Qmax <15 ml/s, has medical record documentation of a prostate volume ≤ 100 ml by TRUS, is classified ASA I, II, or III, has a serum creatinine within the normal range for the study centre.</p> |
| Exclusion criteria | <p>The complete list of inclusion/exclusion criteria was previously published (Bachmann 2014, Table 1)</p> <p>Subject has a life expectancy <2 yrs, is currently enrolled in or plans to enrol in any concurrent drug or device study, has an active infection (eg, urinary tract infection or prostatitis), has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome (eg, nonbacterial chronic prostatitis), has been diagnosed with a urethral stricture or bladder neck contracture within the last 180 d, has been diagnosed with two or more urethral strictures and/or bladder neck contractures within 5 yrs, has a diagnosis of lichen sclerosus, has a neurogenic bladder or other neurologic disorder that affects bladder function, has a diagnosis of polyneuropathy (eg, diabetic), has history of lower urinary tract surgery, has diagnosis of stress urinary incontinence that requires treatment or daily pad or device use. Subject has a history of intermittent self-catheterisation, has been catheterised or has a PVR >400 ml in the 14 d prior to the surgical procedure, has current diagnosis of bladder stones., has diagnosis of prostate cancer, has a history of CIS, TaG2, TaG3, or any T1 stage bladder cancer, has damage to external urinary sphincter, has a medical contraindication for undergoing either TURP or XPS surgery, has a disorder of the coagulation cascade (eg, haemophilia) or disorders that affect platelet count or function (eg, von Willebrand disease) that would put the subject at risk for intraoperative or postoperative bleeding. Subject is unable to discontinue anticoagulant and antiplatelet therapy preoperatively (3–5 d) except for low-dose aspirin (eg, ≤ 100 mg). Subject has had an acute myocardial infarction, open heart sur-</p> |

| | | |
|---|--|---|
| | gery, or cardiac arrest <180 d prior to the date of informed consent. Subject is immunocompromised (eg, organ transplant, leukaemia). | |
| Average age | Bachmann 2014: PVP: 65.9 ± 6.8 years TURP: 65.4 ± 6.6 years | |
| INTERVENTIONS (technology 1) | Greenlight photo-vaporization of the prostate (PVP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PVP | 136 | |
| Number of patients in TURP | 133 | |
| OUTCOMES | IPSS, Qmax, PVR, Erectile dysfunction (measured by the IIEF-5), Urinary tract infection, Irritative symptoms, Stricture (meatal, urethral, bladder neck), Urinary incontinence, Urinary retention, Reoperation | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | <p>Funding/Support and role of the sponsor: American Medical Systems (AMS) helped designed and conduct the study, collect, manage, and analyze the data, and prepare, review, and approve the manuscript. This study was sponsored by an AMS clinical grant (NCT01218672).</p> <p>Financial disclosures: James A. Thomas certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: James A. Thomas and Alexander Bachmann and are the European Joint principal investigators of the Goliath study; both are advisers for AMS and received honoraria for presentations. The other authors have nothing to disclose.</p> <p>Trial registration: The trial was registered at www.clinicaltrials.gov (NCT01218672).</p> | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | low risk of bias | Patients were assigned to treatments following a computer generated 1:1 randomization schedule with varying block sizes of two and four, stratified by center. |
| Allocation concealment (selection bias) | low risk of bias | The treatment assignments were prepared centrally by the study sponsor, sealed in opaque, sequentially numbered envelopes, and opened by trained center staff at the time of randomization. |

| | | |
|---|------------------------|---|
| Blinding of participants and personnel (performance bias) | high risk of bias | patients and treating physicians were not blinded to the therapy |
| Blinding of outcome assessment SUBJECTIVE OUTCOMES (detection bias) | high risk of bias | See the articles Bachmann 2014 and Bachmann 2015 that are part of the GOLIATH Study with Thomas 2016. |
| Blinding of outcome assessment OBJECTIVE OUTCOMES (detection bias) | low risk of bias | See the articles Bachmann 2014 and Bachmann 2015 that are part of the GOLIATH Study with Thomas 2016. |
| Incomplete outcome data (attrition bias) | uncertain risk of bias | Total lost to f-up: 7,4%. Difference in attrition between the two groups =3,1% (lost in PVP group 5,9%; lost in TURP group 9,0%). (Bachmann 2015) For some of the outcomes, attrition varies for different follow-up times; at 12 months lost in TURP group, for IPSS, 5,3%; at 12 months lost in TURP group, for Qmax, 10,4%. In Thomas 2016, few outcomes are reported with their attrition, and it is no more than 7%. |
| Selective reporting (reporting bias) | uncertain risk of bias | Registered trial. No difference between reported outcomes and protocol in the trial repository. No difference between reported outcomes and methods section, with the following exception: Secondary outcomes included assessments of BPH Impact Index (assessed up to Mo 3). Note that subsequently this outcome is not treated. It's not even in the other two articles of the Goliath Study. (Comment: Unclear risk can be assigned; it is a compromise solution because "only" one outcome is mentioned in the methods and is not reported in the results. This is a single, non-main outcome, so it can be assigned not high risk, but unclear risk.) No outcomes have incomplete data (e.g. data shown as a figure AND without statistical comparison between groups). |
| Other bias | High risk of bias | Funded by the manufacturer |

| | |
|-----------------|---------------------------------|
| Study ID | BPH6 Study: Gratzke 2017 |
|-----------------|---------------------------------|

| | |
|---|--|
| Authors: | Gratzke et al |
| Title: | Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomised study |
| Journal/Book/Source: | BJUI |
| Date of Publication: | 2017 |
| Volume: | 119 |
| Issue: | - |
| Pages: | 767-775 |
| METHODS (study design; length of follow up) | Prospective RCT, 2 years FU (BPH6 study) |
| PARTICIPANTS | |
| Total Number of Participants randomized | 80 |
| Country of participants | 10 centres in Germany, Denmark and UK |
| Data collection period | February 2012 – October 2013 |
| Inclusion criteria | Men >50 years old and candidate for TURP, IPSS>12, Qmax≤15 mL/s, and prostate volume ≤60 cc on ultrasonography |
| Exclusion criteria | Other medical condition or co-morbidity contraindicative for TURP or UroLift |
| Average age yrs (SD) | PUL: 63 (6.8) TURP: 65 (6.4) |
| INTERVENTIONS PUL | UroLift System. Investigator experience ranged from 0 to 20 PUL procedures |
| INTERVENTIONS TURP | Each investigator had xtensive previous experience with TURP and conducted TURP procedures in accordance with their own standards and practices. |
| Number of patients in PUL | 44 (1 patient was excluded due to violation of protocol) |
| Number of patients in TURP | 35 |
| OUTCOMES | IPSS, Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD), Incontinence Severity Index (ISI), Quality of Recovery visual analogue score (QoR VAS), Clavien–Dindo classification of adverse events, QoL, patient satisfaction |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Sponsor NeoTract, Inc. Study authors reported grants from NeoTract, Inc., Astellas, Lilly, Janssen, Amgen, Olympus, Boston Scientific, Intuitive Surgical, Medtronic, Pfizer, Recordati, Allergan. This is a follow-up study of Sonksen 2015. |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Low risk | Randomisation using permuted blocks of various sizes chosen randomly. |
| Allocation concealment (selection bias) | Low risk | Consealed through password protected computer. |
| Blinding of participants and personnel (performance bias) | High risk | Nonblinded study. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information available |
| Incomplete outcome data (attrition bias) | High risk | Over 20% of patients were lost to follow-up in the TURP arm and less than 5% in the PUL arm. |
| Selective reporting (reporting bias) | Low risk | Outcomes reported in the study protocol are reported in the study. |
| Other bias | High risk | Funding of the study from the manufacturer of PUL and majority of the study investigators received grants from the the PUL manufacturer, as well as other manufacturers of other products. |

| | |
|--|---|
| Study ID | Gupta 2006 |
| Authors: | GUPTA N, KRISHNA S, KUMAR R, DOGRA PN, SETH A |
| Title: | Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g |
| Journal/Book/Source: | BJU International |
| Date of Publication: | 2006 |
| Volume: | 97 |
| Issue: | |
| Pages: | 85-89 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 6 and 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 150 |
| Country of participants | India |
| Data collection period | 2002-2003 |
| Inclusion criteria | Patients with BPH who were candidates for TURP and with glands of >40 g |

| | | |
|---|--|--|
| Exclusion criteria | Patients with a previous history of prostatic and urethral surgery, neurovesical dysfunction, and carcinoma of the prostate | |
| Average age | 66 | |
| INTERVENTIONS (technology 1) | HoLEP | |
| INTERVENTIONS (technology 2) | Transurethral vapour resection (TUVRP) | |
| INTERVENTIONS (technology 3) | Transurethral resection of the prostate (TURP) | |
| Number of patients in HoLEP | 50 | |
| Number of patients in TUVRP | 50 | |
| Number of patients in TURP | 50 | |
| OUTCOMES | IPSS, Qmax, PVR, operative duration, catheterization time, reduction of serum sodium, recatheterization, fever (UTI), blood transfusion, capsular perforation, bladder mucosal injury, transient dysuria, urethral stricture, incontinence | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Conflict of interest: none declared | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | Just the n. of randomised patients is stated, there is no mention of n. of patients followed up to 1 year |

| | | |
|--------------------------------------|--------------|---|
| Selective reporting (reporting bias) | Unclear risk | No protocol is available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | | |
|--|---|--|
| Study ID | Habib 2020 | |
| Authors: | Habib E, Ayman LM, ElSheemy MS, El-Feel AS, Elkhoully A, Nour HH, Badawy MH, Elbaz AG, Roshdy MA | |
| Title: | Holmium Laser Enucleation vs Bipolar Plasmakinetic Enucleation of a Large Volume Benign Prostatic Hyperplasia: A Randomized Controlled Trial | |
| Journal/Book/Source: | Journal of endourology | |
| Date of Publication: | 2020 | |
| Volume: | 34 | |
| Issue: | 3 | |
| Pages: | 330-338 | |
| METHODS (study design; length of follow up) | RCT Follow-up of 12 months | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 64 | |
| Country of participants | Egypt | |
| Data collection period | November 2016 to February 2018 | |
| Inclusion criteria | IPSS >13, Qmax <15 mL/s, prostate size \geq 80 g | |
| Exclusion criteria | Presence of a urethral stricture, neurological disorder affecting bladder function, bladder cancer, prostate cancer, or a previous history of TURP or bladder neck surgery | |
| Average age | 67 | |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP) | |
| INTERVENTIONS (technology 2) | Bipolar plasmakinetic enucleation of prostate (B-PEP) | |
| Number of patients in HoLEP | 33 | |
| Number of patients in B-PEP | 31 | |
| OUTCOMES | PVR, IPSS, Qmax, QoL, IIEF, operative time, catheterization time, hospital stay, pre-post serum sodium, capsule perforation, urinary retention, transient urinary incontinence, irritative symptoms, UTI, blood transfusion, bladder neck contracture | |
| Notes (e.g. funding source; | ClinicalTrials.gov Identifier: NCT03998150. The authors declare | |

| | | |
|---|--|--|
| conflicts of Interest; trial registration number, etc) | that no competing financial interests exist and that no funding have been received | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information provided. Judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Low risk | Opaque and sealed envelopes |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) subjective outcomes | Unclear risk | Not clear if patients were blinded |
| Blinding of outcome assessment (detection bias) objective outcomes | Low risk | Blinded evaluation |
| Incomplete outcome data (attrition bias) | Low risk | No loss to follow-up |
| Selective reporting (reporting bias) | Low risk | No discrepancies with information registered in clinicaltrials.gov |
| Other bias | Low risk | The authors declared that no competing financial interests exist |

| | |
|--|---|
| Study ID | Hamouda 2014 |
| Authors: | Hamouda A, Morsi G, Habib E, Hamouda H, Emam AB, Etafy M |
| Title: | A comparative study between holmium laser enucleation of the prostate and transurethral resection of the prostate: 12-month follow-up |
| Journal/Book/Source: | J Clin Urol |
| Date of Publication: | 2014 |
| Volume: | 7 |
| Issue: | 2 |
| Pages: | 99-104 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1, 3, 6, 12 months |
| PARTICIPANTS | |

| | | |
|---|---|--|
| Total Number of Participants randomized | 60 | |
| Country of participants | Egypt | |
| Data collection period | 2009-2010 | |
| Inclusion criteria | Prostate weight 20-80 g; AUA symptom score ≥ 12 ; peak urinary flow rate ≤ 15 ml/sec | |
| Exclusion criteria | Neurogenic bladder, previous urethral, bladder neck or prostate surgery, suspected prostatic cancer by abnormal digital rectal examination (DRE), total serum prostate-specific antigen (SPSA) > 4 ng/ml | |
| Average age | 67 | |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in HoLEP | 30 | |
| Number of patients in TURP | 30 | |
| OUTCOMES | AUA symptom score (corresponding 7/8 to IPSS); Qmax, PVR, urinary tract infection, blood transfusion, urethral stricture, irritative voiding symptom, incontinence, operative time, catheterization time, hospital stay | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |

| | | |
|---|--------------|--|
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Low risk | The authors stated that the 60 randomised patients were followed up to 12 months |
| Selective reporting (reporting bias) | Unclear risk | No protocol available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|--|
| Study ID | Hashim2020 |
| Authors: | Hashim Hashim, Jo Worthington, Paul Abrams, Grace Young, Hilary Taylor, Sian M Noble, Sara T Brookes, Nikki Cotterill, Tobias Page, K Satchi Swami, J Athene Lane, on behalf of the UNBLOCS Trial Group |
| Title: | Thulium laser transurethral vaporesction of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial |
| Journal/Book/Source: | Lancet |
| Date of Publication: | July, 2020 |
| Volume: | 359 |
| Issue: | |
| Pages: | 50-61 |
| METHODS (study design; length of follow up) | Randomized, blinded, parallel-group, pragmatic equivalence trial. 12 months follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 410 |
| Country of participants | UK |
| Data collection period | July 23, 2014 - December 30,2016 |
| Inclusion criteria | Men presenting in secondary care with either bothersome lower urinary tract symptoms or urinary retention, secondary to benign prostatic obstruction, and suitable for TURP surgery (having failed conservative and medical therapy) |
| Exclusion criteria | Men were excluded if they had neurogenic lower urinary tract symptoms, prostate cancer, previous prostate or urethral surgery, a prostate specific antigen level outside the normal age-related range without prostate cancer excluded, or were unable to give informed consent or complete trial documentation. |
| Average age | ThuVERP: 70.85 (7.85) TURP: 69.22 (7.91) |
| INTERVENTIONS (technology 1) | Thalium laser transurethral vaporesction (ThuVERP) |
| INTERVENTIONS | Transurethral resection (TURP) |

| | | |
|---|--|--|
| (technology 2) | | |
| Number of patients in Thu- VERP | 203 (allocated) | |
| Number of patients in TURP | 204 (allocated) | |
| OUTCOMES | <p>Co-primary outcome: Qmax, IPSS</p> <p>Surgical secondary outcome: complications occurring after leaving recovery until completion of 12-month follow up, length of hospital stay, perioperative complications, postoperative catheterisation time, urinary post-void residual, blood loss during surgery (change in haemoglobin and blood transfusion rate), absorption of irrigation fluid.</p> <p>Low urinary tract symptoms (IPSS, ICIQ-MLUTS)</p> <p>Sexual function (ICIQ-MLUTSsex, IIEF)</p> <p>Quality of life (IPSS QoL subscore, ICIQ-LUTSqol)</p> <p>Patient satisfaction (ICIQ Satisfaction questionnaire)</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | <p>PA reports grants and personal fees from Astellas Pharma and personal fees from Pfizer, Ipsen, Pierre Fabre, Coloplast UK, and Sun Pharmaceuticals Industries, outside the submitted work. All other authors declare no competing interests.</p> <p>The trial is registered with the ISRCTN Registry, ISRCTN00788389.</p> <p>Role of the funding source: The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p> | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Patients were randomly assigned (1:1) to TURP or ThuVARP through an automated, computer-generated web or telephone randomisation system. |
| Allocation concealment (selection bias) | Unclear risk | No mention in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | Patients remained masked to their allocation while surgeons clearly were not masked |
| Blinding of outcome assessment (detection bias) SUBJECTIVE OUTCOMES | Low risk | Outcome assessors were not masked |
| Blinding of outcome assessment (detection bias) OBJECTIVE OUTCOMES | High risk | Outcome assessors were not masked |
| Incomplete outcome data (attrition bias) | Low risk | |
| Selective reporting (reporting bias) | Low risk | |
| Other bias | Low risk | One author reports grants and personal fees from pharmaceutical industry, |

| | | |
|--|--|---|
| | | but not from other companies producing technologies for BPH. Other authors have nothing to declare. |
|--|--|---|

| | |
|--|--|
| Study ID | He 2019 |
| Authors: | Gaofei He, Yuanyuan Shu, Bohan Wang, Chuanjun Du, Jimin Chen, Jiaming Wen |
| Title: | Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up |
| Journal/Book/Source: | J Endurol. |
| Date of Publication: | 2019 |
| Volume: | 33 |
| Issue: | 10 |
| Pages: | 843-849 |
| METHODS (study design; length of follow up) | RCT Follow up: 3, 6, and 12 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 126 |
| Country of participants | China |
| Data collection period | December 2016 - December 2017 |
| Inclusion criteria | The BPH patients who required surgical treatment. Additional criteria were: (1) maximum flow rate (Qmax) ≤ 15 mL/s, (2) quality of life (QoL) score ≥ 3 , and (3) international prostate symptom score (IPSS) ≥ 8 . |
| Exclusion criteria | (1) confirmed prostate cancer or history of prostate surgery, (2) acute prostatitis or urethritis, and (3) neurogenic bladder and urethral injury. |
| Average age | DiLEP: 71.7 ± 8.7 years HoLEP: 71.6 ± 9.8 years |
| INTERVENTIONS (technology 1) | DiLEP |
| INTERVENTIONS (technology 2) | HoLEP |
| Number of patients in DiLEP | 63 |
| Number of patients in HoLEP | 63 |
| OUTCOMES | Qmax, postvoid residual (PVR), IPSS, QoL, decrease in serum sodium, bladder injury, blood transfusion, capsule perforation, |

| | | |
|---|---|---|
| | TUR syndrome, urinary retention, re-catheterization, retrograde ejaculation, urinary incontinence, UTI, urethral stricture, bladder neck contracture, operative time, catheter duration, hospital stay. | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | This randomized controlled trial (RCT) was registered in the Chinese Clinical Trials Register (ChiCTR 190002207). This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LY18H040007 to J.W.) and the National Natural Science Foundation of China (No. 81871153 to J.W. and 81500532 to B.W.). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | The computer-generated allocation sequence was used for randomization of the patients. |
| Allocation concealment (selection bias) | Unclear risk | No information about concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information about blinding. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information whether outcome assessment was blinded. |
| Incomplete outcome data (attrition bias) | Low risk | No lost to follow up occurred in neither of two groups. |
| Selective reporting (reporting bias) | Low risk | The study protocol is available and all of the pre-specified functional outcomes are reported in the study. |
| Other bias | Low risk | No funding was received for this article and authors have no conflict of interest to declare. |

Study ID**Higazy 2020**

Authors:

Higazy A, Tawfeek AM, Abdalla HM, Shorbagy AA, Mousa W, Radwan AI

Title:

Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial

Journal/Book/Source:

International Journal of Urology

Date of Publication:

2020

Volume:

-

Issue:

online before inclusion in an issue

Pages:

-

METHODS (study design; RCT
length of follow up) Follow-up: 12 months

PARTICIPANTS

Total Number of Participants 120
randomized

Country of participants Egypt

Data collection period April – December 2018

Inclusion criteria LUTS secondary to BPH with prostatic volume >80 mL, failed medical treatment, refractory hematuria, recurrent attacks of urine retention, upper urinary tract affected or high IPSS ≥ 20 that affects QoL.

Exclusion criteria Patients using anticoagulant or antiplatelet medications, or those with neurogenic bladder, urethral stricture, bladder stones, prostate cancer, previous prostate or urethral surgery were excluded.

Average age HoLEP: 66.1 (7.22)
B-PEP: 67.7 (6.48)

INTERVENTIONS
(technology 1) HoLEP

INTERVENTIONS
(technology 2) B-PEP

Number of patients in HoLEP 54

Number of patients in B-PEP 53

OUTCOMES mean operative time (from the initiation of the endoscopic procedure to catheter insertion), enucleation and morcellation time, the volume of resected tissue, perioperative complications according to the Clavien–Dindo classification, catheter removal time, hospital stay, PSA, Qmax, PVR, IPSS, QoL (1, 3 and 12-month follow-up). For patients who started to develop a recurrence of symptoms with a drop in their Qmax, the incidence of urethral stricture or bladder neck contracture was evaluated.

Notes (e.g. funding source; NCT04275076
conflicts of Interest; trial registration number, etc) Conflicts of interest: none declared.

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|---|
| Random sequence generation (selection bias) | Uncertain risk | It is not described in the publication. |
| Allocation concealment (selection bias) | Low risk | Patients were randomized into two groups with a 1:1 ratio using sealed envelopes that were prepared by the department's ethics committee. |
| Blinding of participants and personnel (performance bias) | Low risk | Patients were blinded to the type of intervention, as were the data collector |

| | | |
|---|----------|---|
| Blinding of outcome assessment (detection bias) | Low risk | and the statistician. Patients were blinded to the type of intervention, as were the data collector and the statistician. |
| Incomplete outcome data (attrition bias) | Low risk | In one treatment arm 10% loss-to-follow-up, in the other treatment arm even less than 10%. |
| Selective reporting (reporting bias) | Low risk | The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way. |
| Other bias | Low risk | Authors declared no conflicts of interest. |

| | |
|--|---|
| Study ID | Hon 2006 |
| Authors | Hon NHY, Brathwaite D, Hussain Z, Ghiblawi S, Brace H, Hayne D, Coppinger SWV |
| Title: | A Prospective, Randomized Trial Comparing Conventional Transurethral Prostate Resection With PlasmaKinetic [®] Vaporization of the Prostate: Physiological Changes, Early Complications and Long-Term Followup |
| Journal/Book/Source: | THE JOURNAL OF UROLOGY |
| Date of Publication: | 2006 |
| Volume: | 176 |
| Issue: | |
| Pages: | 205-209 |
| METHODS (study design; length of follow up) | RCT Mean follow-up: 247-265 days |
| PARTICIPANTS | |
| Total Number of Participants randomized | 160 |
| Country of participants | United Kingdom |
| Data collection period | Not stated |
| Inclusion criteria | Bladder outflow obstruction undergoing elective transurethral prostatectomy |
| Exclusion criteria | Previous myocardial infarction within the 6 months preceding surgery, previous TURP, confirmed or suspected prostate cancer, serum creatinine more than 200 mmol/l and prostate volume greater than 80 cc |
| Average age | 67 |

| | | |
|---|---|---|
| INTERVENTIONS (technology 1) | Plasmakinetic prostate vaporization (PKVP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PKVP | 81 | |
| Number of patients in TURP | 79 | |
| OUTCOMES | Resection time, intraoperative blood loss, serum sodium change, postoperative stay, transfusion, urethral stricture, reintervention, IPSS, Qmax, Qmed, PVR, QoL | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer generated numbers |
| Allocation concealment (selection bias) | Low risk | Opaque envelopes |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | 6 to 7,5% of patients were lost to follow-up (similar numbers between the two groups). |
| Selective reporting (reporting bias) | Unclear risk | No protocol available |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

Study ID**Insausti 2020**

Authors:

Insausti I, Ocariz AS, Galbete A, Capdevila F, Solchaga S, Giral P, Bilhim T, Isaacson A, Urtasun F, Napal S

Title:

Randomized Comparison of Prostatic Artery Embolization versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia

Journal/Book/Source:

J Vasc Interv Radiol

Date of Publication:

2020

| | |
|---|--|
| Volume: | 31 |
| Issue: | - |
| Pages: | 882-890 |
| METHODS (study design; length of follow up) | RCT Follow-up: 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 61 |
| Country of participants | Spain |
| Data collection period | November 2014 - January 2017 |
| Inclusion criteria | age>60 years; BPH-related LUTS refractory to medical treatment for at least 6 months or the patient could not tolerate medical treatment; IPSS \geq 8; QoL related to LUTS \geq 3; Qmax \leq 10 mL/s or urinary retention |
| Exclusion criteria | advanced atherosclerosis and tortuosity of the iliacarteries, non-visualization of the prostatic artery or other accessory arteries supplying the prostate on computed tomography angiography, urethral stenosis, detrusorfailure or neurogenic bladder, glomerularfiltration rate of less than 30 mL/min, and the presence of prostate cancer |
| Average age | PAE: 72.4 (6.2) TURP: 71.8 (5.5) |
| INTERVENTIONS (technology 1) | PAE |
| INTERVENTIONS (technology 2) | TURP |
| Number of patients in PAE | 31 |
| Number of patients in TURP | 30 |
| OUTCOMES | Qmax, IPSS, QoL, prostate volume, PVR, IIEF-6, PSA, adverse events according to Clavien-Dindo classification, patient satisfaction, pain |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | NCT01963312 Manufacturer funded study. |

| | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Low risk | A simple, unreplaced 1:1 randomization was performed in balanced blocks of 6. The principal investigator randomly selected a number from a table of random numbers determining the |

| | | |
|---|--------------|--|
| Allocation concealment (selection bias) | Unclear risk | sequence of 10 blocks. It is described in the study that the random sequence was known only by the study data manager, and the individual enrolling participants were unaware of the allocation of the next participants. This is unclear if the participants were aware of their own allocation. |
| Blinding of participants and personnel (performance bias) | High risk | There was no blinding of clinicians or patients due to the nature of the trial. |
| Blinding of outcome assessment (detection bias) | Unclear risk | It was not described in the study. |
| Incomplete outcome data (attrition bias) | High risk | 74 resp. 73% of randomised patients were analysed and this number was below the pre-specified 80% of power required for the non-inferiority hypothesis. |
| Selective reporting (reporting bias) | Low risk | The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way. |
| Other bias | High risk | Manufacturer sponsored study. The authors did not include a statement on conflicts of interest. |

| | |
|--|--|
| Study ID | Jahnsen 1998 |
| Authors: | JAHNSON S, DALEN M, GUSTAVSSON G, PEDERSEN J |
| Title: | Transurethral incision versus resection of the prostate for small to medium benign prostatic hyperplasia |
| Journal/Book/Source: | Br J Urol |
| Date of Publication: | 1998 |
| Volume: | 81 |
| Issue: | |
| Pages: | 276–281 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 2–3, 6, 12, 24, 60 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 85 |

| | | |
|---|--|--|
| Country of participants | Sweden | |
| Data collection period | 1991 | |
| Inclusion criteria | No previous treatment for BPH; estimated prostate weight 20–40 g; distance from verumontanum to bladder neck <4.0 cm | |
| Exclusion criteria | Bladder stone; bladder cancer; prostatitis; prostatic cancer; prominent median lobe | |
| Average age | 71 | |
| INTERVENTIONS (technology 1) | Transurethral incision of the prostate (TUIP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in TUIP | 43 | |
| Number of patients in TURP | 42 | |
| OUTCOMES | Qmax, PVR, blood loss, transfusion, catheterisation time, operative duration, reinterventions | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | High risk | Up to 25% patients with missing data at 24 months |
| Selective reporting (reporting bias) | High risk | For some critical outcomes: data only presented as figures and lack of statistical |

| | | |
|------------|--------------|--|
| | | comparisons in parallel (only before-after comparisons for each group) |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|---|
| Study ID | Jahnwar 2017 |
| Authors: | Jhanwar A, Sinha RJ, Bansal A, Prakash G, Singh K, Singh V |
| Title: | Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized study |
| Journal/Book/Source: | Urology Annals |
| Date of Publication: | 2017 |
| Volume: | 9 |
| Issue: | |
| Pages: | 45-50 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow up at 1, 3, 6, 12, 24 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 164 |
| Country of participants | India |
| Data collection period | 2012-2015 |
| Inclusion criteria | Age < 75, Qmax <15 ml/s, prostate size >60 g, gross hematuria secondary to BPH, recurrent urinary tract infection (UTI), acute urinary retention, PVR > 150 ml, Schafer Grade II or more in pressure flow study |
| Exclusion criteria | BPH with associated neurogenic bladder, stricture urethra, prostatic carcinoma, or previous history of intervention |
| Average age | 67 |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP) |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) |
| Number of patients in HoLEP | 72 |
| Number of patients in TURP | 72 |
| OUTCOMES | IPSS, PVR, Qmax, blood transfusion, TUR syndrome, reduction of serum sodium, urinary tract infection, urinary incontinence, urethral stricture, recatheterization, IIEF, hospital stay, catheterization time |

| | | |
|---|--|--|
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | The authors declared the absence of any financial support and of conflicts of interest | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | 6% of randomised patients were lost to follow-up. 11 patients were excluded before randomization for lack of consent |
| Selective reporting (reporting bias) | Unclear risk | No study protocol available |
| Other bias | Low risk | The authors declared that there were no conflicts of interest. |

| | |
|--|--|
| Study ID | Jovanovic 2014 |
| Authors: | Jovanović M, Džamić Z, Aćimović M, Kajmaković B, Pejčić T |
| Title: | Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia |
| Journal/Book/Source: | Acta Chir Iugosl |
| Date of Publication: | 2014 |
| Volume: | 61 |
| Issue: | 1 |
| Pages: | 57-61 |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 1, 3, 6, 12 months |

| | | |
|---|---|--|
| PARTICIPANTS | | |
| Total Number of Participants randomized | 62 | |
| Country of participants | Serbia | |
| Data collection period | 2011-2013 | |
| Inclusion criteria | Patients with moderate or severe LUTS (IPSS >16), failure of previous medical treatment with a washout period of at least 2 weeks, Qmax <15 ml/s, PVR urine >100 ml, prostate volume (TRUS) <100 ml | |
| Exclusion criteria | Patients on anticoagulants, those with urethral strictures, bladder stone or neurogenic bladder or diagnosed or suspected of having prostate cancer | |
| Average age | 67 | |
| INTERVENTIONS (technology 1) | Photovaporization of the prostate (PVP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PVP | 31 | |
| Number of patients in TURP | 31 | |
| OUTCOMES | IPSS, Qmax (ml/s) , PVR, operative time, catheterisation time, hospital stay, blood transfusion, capsule perforation, TURP syndrome, dysuria/urge, bladder neck contracture, urethral stricture, urinary incontinence | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |

| | | |
|---|--------------|---|
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | No information on loss to follow-up was reported |
| Selective reporting (reporting bias) | High risk | Point estimates at different time follow-up were not reported |
| Other bias | Unclear risk | No information available about possible conflicts of interest |

| | |
|--|---|
| Study ID | Karadag 2014 |
| Authors: | Karadag MA, Cecen K, Demir A, Kocaaslan R, Altunrende F |
| Title: | Plasmakinetic vaporization versus plasmakinetic resection to treat benign prostatic hyperplasia: A prospective randomized trial with 1 year follow-up |
| Journal/Book/Source: | Can Urol Assoc J |
| Date of Publication: | 2014 |
| Volume: | 8 |
| Issue: | |
| Pages: | e595-9 |
| METHODS (study design; length of follow up) | RCT Follow-up at 1 and 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 183 |
| Country of participants | Turkey |
| Data collection period | 2008-2012 |
| Inclusion criteria | Moderate to severe LUTS, based on IPSS, requiring surgery, recurrent urinary retention, failed medical therapy (at least 21 days) and obstructive pressure flow study or Qmax less than 10 mL/s |
| Exclusion criteria | Suspicion of prostatic adenocarcinoma, abnormal DRE or elevated PSA, known urethral stricture or neurogenic bladder and a history of prostate surgery |
| Average age | 67 |
| INTERVENTIONS | Plasmakinetic vaporization of the prostate (PKVP) |

| | | |
|---|---|--|
| (technology 1) | | |
| INTERVENTIONS (technology 2) | Plasmakinetic resection of the prostate (PKRP) | |
| Number of patients in PKVP | 96 | |
| Number of patients in PKRP | 87 | |
| OUTCOMES | Qmax, PVR, IPSS, blood loss, catheterization time, operation time, infravesical obstruction, incontinence, recatheterization, UTI | |
| Notes (e.g. funding source; conflicts of interest; trial registration number, etc) | Authors declared no competing financial or personal interests. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Allocation concealment (selection bias) | Unclear risk | Not mentioned by the authors and judged according to rating criteria indicated in the Cochrane handbook, although we strongly believe that information on randomization procedures should not be missing in RCTs |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Unclear risk | No indication of any type is available on n. of patients at follow-up |
| Selective reporting (reporting bias) | Unclear risk | No protocol available |
| Other bias | Low risk | All authors declared no competing financial interests |

| | |
|-----------------|--|
| Study ID | Kaya 2007 |
| Authors: | Kaya, Ilktac, Gokmen, Ozturk, Kraman |
| Title: | The long-term results of transurethral vaporization of the |

| | | |
|---|--|--|
| | prostate using plasmakinetic energy | |
| Journal/Book/Source: | BJU International | |
| Date of Publication: | 2006 | |
| Volume: | 99 | |
| Issue: | - | |
| Pages: | 845-848 | |
| METHODS (study design; length of follow up) | RCT | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 40 | |
| Country of participants | Turkey | |
| Data collection period | 2001-2003 | |
| Inclusion criteria | Qmax < 10 mL/s or obstructive pressure-flow study, severe LUTS requiring surgical treatment, based on the IPSS and a prostate volumen of <60 mL | |
| Exclusion criteria | Neurogenic bladder, prostate cancer, urethral stricture and previous prostate surgery | |
| Average age | PKVP: 67.2 (58-78) TURP: 66 (53-74) | |
| INTERVENTIONS (technology 1) | PKVP: with plasmakinetic 27 F resectoscope with a plasmakinetic loop electrode of the Plasma Kinetic Management System (Gyrus Medical Ltd), including a bipolar electro-surgical device used endoscopically to instantly remove the obstructing prostate tissue by vaporisation. | |
| INTERVENTIONS (technology 2) | TURP: with 26 F continuous flow resectoscope | |
| Number of patients in PKVP | 25 | |
| Number of patients in TURP | 15 | |
| OUTCOMES | IPSS, Qmax, urethral stricture, erectile dysfunction, retrograde ejaculation, overall satisfaction | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Non declared. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | It is reported that from 75 admitted patients 40 were randomised. It is not clear why the rest were not randomised |

| | | |
|---|--------------|--|
| | | and how the 40 were selected for randomisation. |
| Allocation concealment (selection bias) | High risk | It is reported that those were included in the study who returned for follow-up. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported. |
| Incomplete outcome data (attrition bias) | Low risk | No loss to follow-up. |
| Selective reporting (reporting bias) | Low risk | Outcomes specified in the methods are reported on in the results. |
| Other bias | Unclear risk | Trial registration number and funding source were not reported. |

| | |
|--|---|
| Study ID | Kini 2020 |
| Authors: | Kini et al. |
| Title: | Ejaculatory hood-sparing photoselective vaporization of the prostate vs bipolar button plasma vaporization of the prostate in the surgical management of benign prostatic hyperplasia |
| Journal/Book/Source: | Journal of Endourology |
| Date of Publication: | 2020 |
| Volume: | 34 |
| Issue: | - |
| Pages: | 322-329 |
| METHODS (study design; length of follow up) | RCT 6 month follow-up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 27 |
| Country of participants | USA |
| Data collection period | August 2016 – March 2018 |
| Inclusion criteria | Sexually active, antegrade ejaculation before the intervention, LUTS secondary to BPH, IPSS >12, Qmax <15 mL/s, prostate volume <80 mL |
| Exclusion criteria | Chronic prostatitis, chronic pelvic pain syndrome, urethral stricture, bladder neck contracture within 5 years, pre-existing erectile or ejaculatory dysfunction |
| Average age | PVP: 66.1 (7.5) BPVP: 65.1 (9.5) |
| INTERVENTIONS (technology 1) | Photovaporisation of the prostate with Greenlight Laser 180 W (PVP) |
| INTERVENTIONS (technology 2) | Plasma vaporization with bipolar energy (B-PVP) |

| | | |
|---|--|---|
| Number of patients in PVP | 13 | |
| Number of patients in B-PVP | 14 | |
| OUTCOMES | Ejaculation preservation (measured by Male Sexual Health Questionnaire), IPSS, QoL (measured by SF-12 and overactive bladder questionnaire form), PVR, PSA | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Boston Scientific supported the study with a grant. One of the study authors who was one of the two surgeons performing the interventions was a consultant for Boston Scientific, Olympus, Meditate. The other authors did not report financial interests. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Fix block size of 2, order of treatment within the block was randomly permuted, random number sequence was used to choose a particular block |
| Allocation concealment (selection bias) | Low risk | After enrollment the patients were randomly allocated with a fixed block size of 2. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information provided. |
| Blinding of outcome assessment (detection bias) | Low risk | Objective outcomes: Analysis was performed by an independent statistician and the specific study results were not shared with the study authors, site personnel and patients. |
| | High risk | Subjective outcomes: these are self-assessed by patients, therefore blinding of assessors will not influence the risk of bias. |
| Incomplete outcome data (attrition bias) | High risk | Based on the interim analysis the study was terminated. |
| Selective reporting (reporting bias) | High risk | The authors state that the study was not intended as a registration trial. |
| Other bias | High risk | Financial interest, manufacturer financed the study. |

| | |
|----------------------|---|
| Study ID | Kuntz 2004 |
| Authors: | Kuntz, Ahyai, Lehrich, Fayad |
| Title: | Transurethral Holmium Laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomised prospective trial in 200 patients |
| Journal/Book/Source: | The Journal of Urology |
| Date of Publication: | 2004 |

| | | |
|---|---|--|
| Volume: | 172 | |
| Issue: | - | |
| Pages: | 1012-1016 | |
| METHODS (study design; length of follow up) | RCT 12 month follow-up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 200 | |
| Country of participants | | |
| Data collection period | June 1999 - December 2001 | |
| Inclusion criteria | AUA symptom score ≥ 12 , Qmax ≤ 12 ml/s (voided volume ≥ 150 ml), PVR > 50 ml, urodynamic obstruction in pressure flow (Schäfer grade) ≥ 2 , prostate volume < 100 cc | |
| Exclusion criteria | Carcinoma of the prostate (evaluated by TRUS guided biopsies in patients with abnormal digital rectal examination, elevated serum prostate specific antigen and/or suspicious lesions on TRUS). Patients who had undergone previous urethral or prostatic surgery were also excluded. | |
| Average age | HoLEP: 68.0 ± 7.3 TURP: 68.7 ± 8.2 | |
| INTERVENTIONS (technology 1) | HoLEP was performed with a maximum average power of 80 W (2.0 J at 40 Hz) or 100 W (2.0 J at 50 Hz). The prostatic lobes were enucleated subtotally. | |
| INTERVENTIONS (technology 2) | A standard tungsten wire loop with a cutting current of 80 W and a coagulating current of 160 was used. | |
| Number of patients in HoLEP | 100 | |
| Number of patients in TURP | 100 | |
| OUTCOMES | AUA symptom score, Qmax, postoperative catheter time, total postoperative hospital stay, haemoglobin loss, resected tissue weight, total operative time (time that the resectoscope sheath was within the urethra), decrease in serum sodium, total laser energy (in the holmium group), PVR, sexual function, continence, intraoperative and postoperative complications | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Financial interest and/or other relationship with Lumenis, Inc. and Karl Storz, Inc. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Randomised with a schedule balanced in blocks of 4 |
| Allocation concealment | Unclear risk | Not described |

| | | |
|---|--------------|--|
| (selection bias) | | |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not described |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not described |
| Incomplete outcome data (attrition bias) | Low risk | Loss-to-follow-up is explained by the exclusion of patients with prostate cancer at 1 month. At 6 and 12 months, loss-to-follow-up was under 5%. |
| Selective reporting (reporting bias) | Low risk | |
| Other bias | High risk | Financial interest from manufacturer of product under assessment |

| | |
|--|--|
| Study ID | Li 2013 |
| Authors: | Li, Pan, Liu, He, Song, Jlang, Zhou |
| Title: | Selective Transurethral Resection of the Prostate Combined with Transurethral Incision of the Bladder Neck for Bladder Outlet Obstruction in Patients with Small Volume Benign Prostate Hyperplasia (BPH): a Prospective Randomized Study |
| Journal/Book/Source: | Plos One |
| Date of Publication: | 2013 |
| Volume: | 8 |
| Issue: | 5 |
| Pages: | e63227 |
| METHODS (study design; length of follow up) | RCT |
| PARTICIPANTS | |
| Total Number of Participants randomized | 124 |
| Country of participants | China |
| Data collection period | July 2009 – June 2010 |
| Inclusion criteria | ≥ 50 years; diagnosis of BPH; capable of reading, understanding and completing a symptom and Quality of Life questionnaire; prostate grand volume 20 to 40 cm ³ ; IPSS≥ 20, failed conservative medical therapy; BOO on urodynamic study; normal urinary bladder function |
| Exclusion criteria | History or evidence of prostate cancer or bladder cancer; PSA level > 4.0 ng/mL; previous prostate surgery or other invasive procedures to treat BPH; diabetes mellitus, cerebrovascular events, and/or neurogenic diseases; was expected to move out |

| | | |
|---|--|---|
| | of the are during study period; currently participating in a clinical trial or other research study | |
| Average age | TURP: 68.66 (7.52) STURP+TUIP: 66.83 (4.91) | |
| INTERVENTIONS (technology 1) | TURP | |
| INTERVENTIONS (technology 2) | Selective transurethral resection combined with transurethral incision of the bladder neck performed using Olympus resectoscope (STURP+TUIP) | |
| Number of patients in TURP | 61 | |
| Number of patients in STURP+TUIP | 63 | |
| OUTCOMES | Operation time, intraoperative blood loss, hospital stay, changes in hemoglobin and serum sodium, catheterization time, TURP syndrome, perioperative complications, IPSS, Qmax, PVR, major adverse events (acute urinary retention, need for prostate biopsy, gross hematuria, acute urinary tract infection, urinary stricture, bladder contracture, prostate cancer), QoL, PSA level | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | It is not reported how the patients were randomized, only that they were randomized. |
| Allocation concealment (selection bias) | Unclear risk | It is not reported if and how allocation concealment happened. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported. |
| Blinding of outcome assessment (detection bias) | High risk | Same personnel designed the study, analyzed data and collected the data. |
| Incomplete outcome data (attrition bias) | Low risk | Study outcomes specified in the methods are reported in the results section. |
| Selective reporting (reporting bias) | High risk | The methods section states that 1,3,6 and 12 month follow-up data for the primary endpoints (QoL and IPSS) are recorded, however, the baseline QoL score, the 1,3 and 12 months follow-up data for QoL and IPSS are not reported. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial numbers are not reported. |

| | |
|--|--|
| Study ID | Li 2017 |
| Authors: | K.Li, Wang, Hu, Mao, M.Li, Si-Tu, Huang, W.Qiu, J.Qiu |
| Title: | A Novel Modification of Transurethral Enucleation and Resection of the Prostate in Patients With Prostate Glands Larger than 80 mL: Surgical Procedures and Clinical Outcomes |
| Journal/Book/Source: | Urology |
| Date of Publication: | 2018 |
| Volume: | 113 |
| Issue: | - |
| Pages: | 153-159 |
| METHODS (study design; length of follow up) | RCT |
| PARTICIPANTS | |
| Total Number of Participants randomized | 86 |
| Country of participants | China |
| Data collection period | April 2012 – May 2014 |
| Inclusion criteria | Prostate volume > 80 mL; IPSS> 13, Qmax < 10 mL/s, recurrent or persistent gross hematuria caused by an enlargement of the prostate or the bladder calculi. 5 α -reductase inhibitors or α -blockers had to be stopped before surgery. |
| Exclusion criteria | Prostate or bladder cancer, neurogenic bladder, permanent anticoagulation therapy, previous urethral or prostate surgery |
| Average age | B-TURP: 69.89 (8.1) M-TUERP: 73.33 (5.9) |
| INTERVENTIONS (technology 1) | Bipolar transurethral resection of the prostate (B-TURP) (Olympus plasmakinetic bipolar system with 140 W cutting and 60 W coagulating power) |
| INTERVENTIONS (technology 2) | Modified transurethral enucleation and resection (M-TUERP) (Olympus plasmakinetic bipolar system) |
| Number of patients in B-TURP | 44 |
| Number of patients in M-TUERP | 42 |
| OUTCOMES | PVR, QoL, IPSS, Qmax, PSA level, prostate volume, change in serum sodium level and hemoglobin, duration of surgery, weight of resected tissue, intraoperative IP, bladder irrigation fluid drainage, catheterization time, immediate or late postoperative complications, TUR syndrome, micturition parameters |
| Notes (e.g. funding source; | Authors reported that they had no relevant financial interestst. |

| | | |
|---|---|--|
| conflicts of Interest; trial registration number, etc) | The study was supported by the National Natural Science Foundation of China, National Natural Science Foundation of Guangdong Province, Science and Technology Program of Guangzhou, Basic Service Charge Young Teachers Cultivation Project of Sun Yat-sen University, Medical Scientific Research Foundation of Guangdong Province. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | It is reported that a sealed envelope sequence was used and that patients were randomized. It is not detailed how the randomization took place. |
| Allocation concealment (selection bias) | Low risk | Sealed envelope sequence was used. |
| Blinding of participants and personnel (performance bias) | High risk | Neither patients, nor surgeons were blinded. |
| Blinding of outcome assessment (detection bias) | High risk | Subjective outcomes: As patients and surgeons were not blinded, for the subjective outcomes, the blinding of outcome assessment has no influence on potential bias. |
| | Low risk | Objective outcomes: 2 independent investigators carried out the follow-up management. |
| Incomplete outcome data (attrition bias) | Unclear risk | Loss-to follow-up is not reported. |
| Selective reporting (reporting bias) | Unclear risk | IPSS, QoL, Qmax and PVR follow-up data are reported only in figures/graphs and not tabular view (exact numbers are not known), but the authors presented a between group statistical analysis as well. |
| Other bias | Unclear risk | Study registration number was not reported. There are no financial interests though. |

| | |
|----------------------|--|
| Study ID | Luo 2014 |
| Authors: | Luo, Shen, Guan, Li, Wang |
| Title: | Plasmakinetic Enucleation of the Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: Comparison of Outcomes According to Prostate Size in 310 Patients |
| Journal/Book/Source: | Urology |

| | | |
|---|---|---|
| Date of Publication: | 2014 | |
| Volume: | 84 | |
| Issue: | - | |
| Pages: | 904-910 | |
| METHODS (study design; length of follow up) | RCT | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 310 | |
| Country of participants | China | |
| Data collection period | October 2009 – October 2011 | |
| Inclusion criteria | Qmax<15 mL/s, IPSS> 12, medical therapy failure, TRUS volume >20 ml with no upper limit | |
| Exclusion criteria | Abnormal digital rectal examination, increased serum PSA level, known neurogenic bladder, history of prostatic or urethral surgery | |
| Average age | PKEP: 70 (5.7) PKRP: 69.8 (5.9) | |
| INTERVENTIONS (technology 1) | Plasmakinetic enucleation (PKEP): 27F Storz resectoscope (Karl Storz) with Gyrus Plasmakinetic SuperPulse System with a cutting power of 160 W and coagulating power of 80 W | |
| INTERVENTIONS (technology 2) | Plasmakinetic resection (PKRP): 27F Storz resectoscope (Karl Storz) with Gyrus Plasmakinetic SuperPulse System with a cutting power of 160 W and coagulating power of 80 W | |
| Number of patients in PKEP | 155 | |
| Number of patients in PKRP | 155 | |
| OUTCOMES | IPSS, Qmax, QoL, PVR, TURS, UTI, incontinence, recatheterization, bladder neck contracture, urethral stricture, blood transfusion, hospital stay, catheter time, blood loss, operation time, resected tissue weight | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | It is not reported how the randomization happened but randomization to 1:1 is mentioned only. |
| Allocation concealment (selection bias) | Unclear risk | Not reported. |

| | | |
|---|--------------|---|
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported. |
| Incomplete outcome data (attrition bias) | Unclear risk | 10% loss to follow-up at the 24 month follow-up visit. |
| Selective reporting (reporting bias) | Low risk | In the methods section listed outcomes were reported on. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|--|---|
| Study ID | Lusuardi 2011 |
| Authors: | Lusuardi, Myatt, Sieberer, Jeschke, Zimmermann, Janetschek |
| Title: | Safety and Efficacy of Eraser Laser Enucleation of the Prostate: Preliminary Report |
| Journal/Book/Source: | The Journal of Urology |
| Date of Publication: | 2011 |
| Volume: | 186 |
| Issue: | - |
| Pages: | 1967-1971 |
| METHODS (study design; length of follow up) | RCT |
| PARTICIPANTS | |
| Total Number of Participants randomized | 60 |
| Country of participants | Austria |
| Data collection period | Febr 2010 – Sept 2010 |
| Inclusion criteria | Symptomatic bladder outflow obstruction |
| Exclusion criteria | Suspicion of prostate cancer, patients on oral anticoagulation and 5 α -reductase inhibitor |
| Average age | ELEP: 66.5 (5.96) B-TURP: 65.7 (6.2) |
| INTERVENTIONS (technology 1) | Eraser laser enucleation (ELEP) with Storz laser resectoscope, 120 W output power, tissue morcellation with the Piranha Laser Enucleations-System |
| INTERVENTIONS (technology 2) | Bipolar TURP using Plasmakinetic™ system (B-TURP) |
| Number of patients in ELEP | 30 |

| | | |
|---|---|--|
| Number of patients in B-TURP | 30 | |
| OUTCOMES | Blood loss, operative time, catheter time, hospital time, intraop irrigation, morcellation time, resected wt, retrieval rate, bleeding velocity, Hb loss, postop Hb, Qmax, IPSS, QoL, PVR | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Balanced, blocked randomization with a block size of 6 patients. |
| Allocation concealment (selection bias) | Unclear risk | Not reported. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported if patients were blinded or not. Surgeon was not blinded. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported. |
| Incomplete outcome data (attrition bias) | Unclear risk | The number of participants in the follow-up visits is not reported. |
| Selective reporting (reporting bias) | Low risk | Study registration number is not reported, outcomes listed in the methods section are reported on. |
| Other bias | Unclear risk | Funding source, conflicts of interests are not reported. |

| | |
|--|---|
| Study ID | Mavuduru 2009 |
| Authors: | Mavuduru, Mandal, Singh, Acharya, Agarwal, Garg, Kumar |
| Title: | Comparison of HoLEP and TURP in Terms of Efficacy in the Early Postoperative Period and Perioperative Morbidity |
| Journal/Book/Source: | Urol Int |
| Date of Publication: | 2009 |
| Volume: | 82 |
| Issue: | - |
| Pages: | 130-135 |
| METHODS (study design; length of follow up) | RCT |
| PARTICIPANTS | |
| Total Number of Participants randomized | 30 |

| | | |
|---|--|---|
| Country of participants | India | |
| Data collection period | Not reported | |
| Inclusion criteria | Patients who underwent BPH surgery. | |
| Exclusion criteria | History of previous prostatic or urethral surgery, and documented cases of prostate carcinoma | |
| Average age | TURP: 66.46 (5.79) HoLEP: 69.86 (9.6) | |
| INTERVENTIONS (technology 1) | TURP with 26-Fr resectoscope (Karl Storz) with 100-120 W cutting current, 50-60 W coagulating current | |
| INTERVENTIONS (technology 2) | HoLEP (550 nm end-firing flexible quartz, 27-Fr resectoscope, Versapulse Holmium laser) | |
| Number of patients in TURP | 15 | |
| Number of patients in HoLEP | 15 | |
| OUTCOMES | Total operative time, total amount of prostate excised, any intraoperative adverse events, blood transfusions, incidence of TUR syndrome, total volume of irrigation fluid required, total traction time, irrigation time, catheter time, post-catheter removal stream and complications, median time of discharge, histopathology, IPSS, uroflowmetry, PVR, adverse events, urethral stricture, urine culture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | Patients who underwent surgery were randomized into the TURP or HoLEP group. 30 operated patients to 15 group each. This does not mean randomization if the patients were allocated to a group after surgery. |
| Allocation concealment (selection bias) | High risk | Patients were allocated to a group after the surgery, based on which surgery they had. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported. |
| Incomplete outcome data (attrition bias) | Unclear risk | For the 9 month follow-up, 10% of the patients were lost to follow-up |
| Selective reporting (reporting bias) | High risk | A total of 2 intraoperative complications |

| | | |
|------------|--------------|---|
| bias) | | are reported but in the HoLEP group only one is detailed and it is unknown what was the other complication. |
| Other bias | Unclear risk | No funding, conflict of interest or study registration number was reported. |

| | | |
|--|---|--|
| Study ID | Montorsi 2004 | |
| Authors: | Montorsi, Naspro, Salonia, Suardi, Briganti, Zanoni, Valenti, Vavassori, Rigatti | |
| Title: | Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective randomized trial in patients with obstructive benign prostatic hyperplasia | |
| Journal/Book/Source: | The Journal of Urology | |
| Date of Publication: | 2004 | |
| Volume: | 172 | |
| Issue: | - | |
| Pages: | 1926-1929 | |
| METHODS (study design; length of follow up) | RCT | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 100 | |
| Country of participants | Italy | |
| Data collection period | January 2002 – October 2002 | |
| Inclusion criteria | <75 years, Qmax < 15 ml/s, PVR < 100 cc, medical therapy failure, transrectal ultrasound adenoma volume < 100 gm, urodynamic obstruction | |
| Exclusion criteria | Neurogenic bladder, diagnosis of prostate cancer, any previous prostatic, bladder neck or urethral surgery | |
| Average age | HoLEP: 65.14 TURP: 64.5 | |
| INTERVENTIONS (technology 1) | Holmium laser enucleation of the prostate (HoLEP): 360 μ fiber delivered the holmium laser energy, placed in a 24Fr resectoscope. Enucleation was performed at 2.0 J and 35 Hz. | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP): Standard tungsten wire loop with a cutting current of 80 W and a coagulating current of 160 W | |
| Number of patients in HoLEP | 52 | |
| Number of patients in TURP | 48 | |

| | | |
|---|---|---|
| OUTCOMES | Operative time, resected tissue weight, retrieval rate per minute, hemoglobin level, blood loss, catheterization time, hospital stay, Qmax, Qmed, IPSS, QoL, urodynamic findings, IIEF, early and late adverse events (1, 6, 12 months) | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Not reported. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | 100 consecutive patients were considered and included in the study. The method of randomization is not described. |
| Allocation concealment (selection bias) | Unclear risk | No information provided. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information provided. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information provided. |
| Incomplete outcome data (attrition bias) | Low risk | No patient lost to follow-up. |
| Selective reporting (reporting bias) | Low risk | No difference between reported outcomes and methods section. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|--|--|
| Study ID | Neill 2006 |
| Authors: | Mischel g. Neill, Peter j. Gilling, Katie m. Kennett, Christopher m. Frampton, Andre m. Westenberg, Mark r. Fraundorfer, and Liam c. Wilson |
| Title: | Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. |
| Journal/Book/Source: | Urology |
| Date of Publication: | 2006 |
| Volume: | 68 |
| Issue: | 5 |
| Pages: | 1020-1024 |
| METHODS (study design; length of follow up) | Prospective randomized controlled trial, 12 months follow-up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 40 |
| Country of participants | New Zealand |
| Data collection period | May 2001-November 2003 |

| | | |
|---|--|---|
| Inclusion criteria | clinical diagnosis of BPH, desired and agreed to surgical treatment, older than 45 years of age, prostate volume on TRUS measurement was required to be 20 to 200 cm ³ , the Q _{max} to be less than 15 mL/s, the IPSS to be greater than 12, urodynamically proven obstruction (Schäfer linearized passive urethral resistance relation grade 2 or greater) had to be present. | |
| Exclusion criteria | previous prostatic or urethral surgery, patients with prostate cancer, neurogenic bladder dysfunction, urinary retention (or postvoid residual urine volume greater than 399 mL), coagulopathy, anticoagulant medication, or urinary tract infection at enrollment | |
| Average age | HoLEP: 68.9 ± 2.0 (52–83) PKEP: 67.0 ± 1.7 (56–83) | |
| INTERVENTIONS (technology 1) | Holmium laser enucleation (HoLEP) | |
| INTERVENTIONS (technology 2) | Plasmakinetic enucleation (with Gyrus) (PKEP) | |
| Number of patients in HoLEP | 20 | |
| Number of patients in PKEP | 20 | |
| OUTCOMES | <p><u>Perioperative outcome</u>: operation time (assessed as the time the resectoscope sheath was in place), pathologic specimen weight, energy requirement (in kilojoules), amount of intraoperative and postoperative irrigant used, duration of indwelling catheter, time spent in the postoperative recovery room, time spent in the hospital, adverse events.</p> <p><u>Preoperative outcome measures were reassessed at 1, 3, 6, and 12 month</u>: IPSS, Sexual function questionnaire, continence and dysuria questionnaire, adverse events (<i>only 12 months: bladder irrigation required - %, urinary tract infection, urethral stricture, urinary incontinence, reoperation, transfusion</i>), Q_{max} at the 6-month assessment, urodynamic pressure flow studies, digital rectal examination, TRUS measurement of prostate volume</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | P. J. Gilling is a study investigator funded by Gyrus Limited. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information in the text |
| Allocation concealment (selection bias) | Unclear risk | A sealed envelope sequence was used but it is not clear whether envelopes are opaque. |
| Blinding of participants and personnel (performance bias) | High risk | No blinding was used |
| Blinding of outcome | High risk | No blinding was used |

| | | |
|--|--------------|---|
| assessment (detection bias) | | |
| Incomplete outcome data (attrition bias) | Unclear risk | No information in the text, no mention to lost at FU |
| Selective reporting (reporting bias) | Unclear risk | A protocol is not available, adverse events are not pre-specified. Data on some outcome are not reported (e.g.: sexual function questionnaire) |
| Other bias | High risk | Financial interest, principal investigator funded by the manufacturer |

| | |
|--|---|
| Study ID | Netsch 2017 |
| Authors: | Christopher Netsch, B. Becker, C. Tiburtius, C. Moritz, A. Venneri Becci, T. R. W. Herrmann, A. J. Gross |
| Title: | A prospective, randomized trial comparing thulium vapoenucleation with holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic obstruction: perioperative safety and efficacy |
| Journal/Book/Source: | World J Urol (2017) 35:1913–1921 |
| Date of Publication: | 11 July 2017 |
| Volume: | 35 |
| Issue: | |
| Pages: | 1913-1921 |
| METHODS (study design; length of follow up) | Prospective randomized trial, 4 weeks follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 107 |
| Country of participants | Germany |
| Data collection period | January 2015 – February 2016 |
| Inclusion criteria | Qmax) ≤15 ml/s, IPSS) ≥12, male patients ≥18 years, and/or failed medical therapy of BPO, recurrent urinary tract infections (UTI), and/or recurrent episodes of urinary retention |
| Exclusion criteria | previous urethral/prostatic surgery, known prostate cancer (PCa) or urethral strictures, urodynamically diagnosed neurogenic bladder |
| Average age | ThuVEP: median age: 74 (68-76.75) HoLEP: median age: 71.5 (67-75) |
| INTERVENTIONS (technology 1) | Thulium vapoenucleation (ThuVEP) |
| INTERVENTIONS (technology 2) | Holmium laser enucleation (HoLEP) |
| Number of patients in ThuVEP | 48 |
| Number of patients in HoLEP | 46 |
| OUTCOMES | IPSS, QoL, Q _{max} , PVR, Operation time, Catheterization time, Hospitalization time, Complication Rate (CR) |
| Notes (e.g. funding source; conflicts of Interest; trial regis- | None This RCT was registered in the German Clinical Trials Regis- |

| | | |
|---|-----------------------------|--|
| tration number, etc) | ter (DRKS-ID: DRKS00008206) | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer generated block randomization |
| Allocation concealment (selection bias) | Unclear risk | No information in the article |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information in the article |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the article |
| Incomplete outcome data (attrition bias) | Unclear risk | Overall lost to follow-up=13% |
| Selective reporting (reporting bias) | Unclear risk | This RCT was registered in the German Clinical Trials Register (DRKS-ID: DRKS00008206). https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008206 But outcome are not reported in detail |
| Other bias | | The authors have nothing to disclose. |

| | |
|--|---|
| Study ID | Nuhoglu 2011 |
| Authors: | Bariş Nuhoglu, Mustafa Bahadir, Can Balci Memduh, Aydin Ismet Hazar, Ozkan Onuk, Tuncay Tas, Onur Fikri |
| Title: | The Role of Bipolar Transurethral Vaporization in the Management of Benign Prostatic Hyperplasia |
| Journal/Book/Source: | Urologia Internationalis |
| Date of Publication: | November 11,2011 |
| Volume: | 87 |
| Issue: | |
| Pages: | 400-404 |
| METHODS (study design; length of follow up) | Prospective randomized trial, 1 year follow-up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 90 |
| Country of participants | Turkey |
| Data collection period | February 2009-February 2010 |
| Inclusion criteria | Patients with established surgical indications with lower urinary tract symptoms secondary to BPH, BPH patients with a Qmax of <15 ml/s and a total IPSS scores of >=8 points were included in the study. |
| Exclusion criteria | Patients with prostate carcinoma or neurogenic urinary dysfunction, and those with a history of prostatic and/or urethral surgery |

| | | |
|---|--|--|
| Average age | TURP: 64.7 ±7.3 TUVV: 65.4±8.9 | |
| INTERVENTIONS (technology 1) | Transurethral resection (TURP) | |
| INTERVENTIONS (technology 2) | Transurethral vaporization (TUVV) | |
| Number of patients in TURP | 47 | |
| Number of patients in TUVV | 43 | |
| OUTCOMES | IPSS, PVRU, Qmax, Prostate volume, Operative time, Amount of bleeding, Post-operative hyponatremia, Catheter tetention time, Blood transfusion, Urethral stricture, Recatjeterization, Urinary retention, Re-TURP, Bladder neck incision, Urethral stricture, Reoperation , TUR syndrome, Urinary incontinence | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information in the article |
| Allocation concealment (selection bias) | Unclear risk | No information in the article |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information in the article |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the article |
| Incomplete outcome data (attrition bias) | Unclear risk | 5 patients are lost to follow-up but it is not clear if they are excluded or not. If they are excluded the initial numbers of patients was 95 not 90 |
| Selective reporting (reporting bias) | Unclear risk | No protocol and outcome not pre-specified |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|-------------------------------------|--|
| Study ID | Peng 2016 |
| Authors: | Mou Peng, Lu Yi, and Yinhuai Wang |
| Title: | Photoselective Vaporization of the Prostate vs Plasmakinetic Resection of the Prostate: A Randomized Prospective Trial With 12-Month Follow-up in Mainland China |
| Journal/Book/Source (abbreviation): | Urology |
| Date of Publication (year): | 2016 |
| Volume: | 87 |
| Issue: | |
| Pages: | 161-165 |

| | | |
|---|--|---|
| METHODS (study design; length of follow up) | Randomized prospective trial, 12 months follow-up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 120 | |
| Country of participants | China | |
| Data collection period | January 2011-June 2012 | |
| Inclusion criteria | patients with BPH-related LUTS, exclusive age range from 50 to 80 years, IPSS >7, Qmax <15 mL/s, transrectal ultrasound volume >30 and <150 cc | |
| Exclusion criteria | diagnosis of or suspected prostate cancer, neurogenic bladder, urethral stricture, bladder stone, postvoid residual (PVR) urine volume of >300 mL | |
| Average age | PVP: 69.3 ± 6.4 PKRP: 68.7 ± 5.8 | |
| INTERVENTIONS (technology 1) | Photoselective vaporization of the prostate (PVP) | |
| INTERVENTIONS (technology 2) | Plasmakinetic Resection of Prostate (PKRP) | |
| Number of patients in PVP | 61 | |
| Number of patients in PKRP | 59 | |
| OUTCOMES | <p>Perioperative outcome: Prostate volume, Total PSA level, IPSS, Qmax, QoL score, PVR volume, Operation time, Length of catheterization, Hospital stay</p> <p>Postoperative outcomes evaluated at 1,3,6,12 months: IPSS, Qmax, QoL</p> <p>Complications evaluated at 12 months: Clot retention, Incontinence, Retrograde ejaculation, Urethral stricture, Transfusion, Reoperation</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Randomization was performed using a computer-generated list |
| Allocation concealment (selection bias) | Unclear risk | No information |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information |
| Incomplete outcome data (attrition bias) | Low risk | No missing outcome data |
| Selective reporting (reporting bias) | Unclear risk | No protocol. All pre-specified outcome (in the method section) are evaluated but |

| | | |
|------------|----------|--|
| | | not all expected outcomes have been reported. |
| Other bias | Low risk | The authors declare that they have no relevant financial interest. |

| | |
|--|---|
| Study ID | Radwan 2020 |
| Authors: | Ahmed Radwan, Ahmed Farouk, Ahmed Higazy, Younan R. Samir, Ahmed M. Tawfeek, Mohamed A. Gamal |
| Title: | Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia |
| Journal/Book/Source: | Prostate International |
| Date of Publication: | 2020 |
| Volume: | 8 |
| Issue: | 3 |
| Pages: | 130-133 |
| METHODS (study design; length of follow up) | Randomized trial. Follow up: 1 and 6 months postoperatively. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 60 |
| Country of participants | Egypt |
| Data collection period | January 2016 to January 2018 |
| Inclusion criteria | Patients complained of LUTSs with an IPSS score of 8e35 (8 being moderate and 35 being severe), uroflowmetry with an average flow of ≤ 10 ml/sec, and a prostate volume less than 100 ml by transrectal ultrasound. |
| Exclusion criteria | Patients with elevated kidney functions (≥ 1.5 mg/dl), with allergy to intravenous (IV) contrast media, unfit for surgery, with prostatic adenocarcinoma, with previous history of prostatic or urethral operations, with signs of the decompensated bladder (e.g., bladder diverticulum), with signs of upper urinary tract infection revealed by pelvic abdominal ultrasound. |
| Average age | The demographic data for patients in the 3 groups were nearly the same, with a mean age of 63 years. |
| INTERVENTIONS (technology 1) | Prostatic artery embolization (PAE) |
| INTERVENTIONS (technology 2) | Monopolar transurethral resection of prostate (M-TURP) |
| INTERVENTIONS (technology 3) | Bipolar transurethral resection of prostate (B-TURP) |
| Number of patients in PAE | 20 |
| Number of patients in | 20 |

| | | |
|---|--|--|
| M-TURP | | |
| Number of patients in B-TURP | B-TURP n = 20 | |
| OUTCOMES | International prostate symptom score (IPSS) score, postvoid residual urine, Qmed, AUR, catheter time, operative time, TUR syndrome | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Participants were randomly allocated into 3 equal groups using the sealed envelope method. |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes were used. |
| Blinding of participants and personnel (performance bias) | Unclear | No information whether they were blinded. |
| Blinding of outcome assessment (detection bias) | Unclear | No information whether they were blinded. |
| Incomplete outcome data (attrition bias) | Unclear | Numbers of patients at follow up not presented |
| Selective reporting (reporting bias) | Unclear | Study protocol not registered. |
| Other bias | Low risk | The authors have no conflict of interest to declare. |

| | |
|--|--|
| Study ID | Ran 2013 |
| Authors: | Longfei Ran, Weiyang He, Xin Zhu, Qingsong Zhou, Xin Gou |
| Title: | Comparison of Fluid Absorption between Transurethral Enucleation and Transurethral Resection for Benign Prostate Hyperplasia |
| Journal/Book/Source | Urol Int |
| Date of Publication | April 2013 |
| Volume: | 91 |
| Issue: | |
| Pages: | 26-30 |
| METHODS (study design; length of follow up) | Prospective RCT, no follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 60 |
| Country of participants | China |
| Data collection period | From April 2011 to December 2011 |
| Inclusion criteria | Postvoid residual urine between 60 and 250 ml, acute urinary retention, Q max less than 15 ml/s |

| | | |
|---|--|---|
| Exclusion criteria | prostate cancer, urethrostenosis, neurogenic bladder, significantly reduced lung function, suspected bladder tumor, being addicted or allergic to alcohol. | |
| Average age | PKRP: 72.3±8.3 PKEP: 70.9±5.7 | |
| INTERVENTIONS (technology 1) | Transurethral plasma kinetic resection (PKRP) | |
| INTERVENTIONS (technology 2) | Transurethral plasma kinetic enucleation (PKEP) | |
| Number of patients in PKRP | 30 | |
| Number of patients in PKEP | 30 | |
| OUTCOMES | Weight of prostate tissue removed Absorption of irrigation fluid Operation time Hospital stay Catheterization time Intra-operative complications (capsular perforation, obturator nerve reflection, transfusion, NO OTHER COMPLICATIONS SPECIFIED) Reduction in Hb Reduction in Sodium Reduction in Hematocrit Severe complication (TUR syndrome, myocardial arrhythmia NO OTHER COMPLICATIONS SPECIFIED) | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No mention in the text |
| Allocation concealment (selection bias) | Unclear risk | No mention in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | No mention in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No mention in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | No mention of missing data |
| Selective reporting (reporting bias) | Unclear risk | No protocol available. No clear outcome reporting, especially for complications. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|-----------------|--|
| Study ID | Razzaghi 2014 |
| Authors: | Mohammad Reza Razzaghi, Mohammad Mohsen Mazloom- |

| | |
|---|--|
| | fard, Hooman Mokhtarpour and Aida Moeini |
| Title: | Diode Laser (980 nm) Vaporization in Comparison With Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Clinical Trial With 2-year Follow-up |
| Journal/Book/Source | UROLOGY |
| Date of Publication | May 2014 |
| Volume: | 84 |
| Issue: | 3 |
| Pages: | 526-532 |
| METHODS (study design; length of follow up) | RCT with 2 years follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 115 |
| Country of participants | Iran |
| Data collection period | October 2010 – February 2012 |
| Inclusion criteria | Surgical treatment was indicated according to the international BPH guidelines of the European Association of Urology including: lower urinary tract symptoms despite maximal medical therapy, frequent urinary tract infections, hematuria unresponsive to medical therapy, high serum creatinine that decreased with urethral catheter placement, urinary retention despite medical therapy. |
| Exclusion criteria | history of neurogenic bladder, previous prostate surgery, anti-coagulant medication, urethral stricture, bladder stone, diagnosis of prostate cancer, prostate volume >100 mL on transrectal ultrasonography (TRUS) disability, refusal to give a fully informed consent |
| Average age | TURP: 68.2±7.8 Diode Laser: 68.5±8.8 |
| INTERVENTIONS (technology 1) | Transurethral resection of the prostate (TURP) |
| INTERVENTIONS (technology 2) | Diode laser vaporisation (980 nm) (DioLVP) |
| Number of patients in TURP | 58 |
| Number of patients in DioLVP | 57 |
| OUTCOMES | IPSS, PVR, Qmax assessed at baseline, 1,6,12, 24 months. Prostate volume, PSA level assessed at baseline, 6, 12 months. Duration of operation, changes in haemoglobin, serum sodium, perioperative and postoperative complications, hospitalization period, duration of indwelling catheter |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The authors declare that they have no relevant financial interests. The trial is registered at Iranian Registry of Clinical Trials, number: IRCT201202138146N3 |
| | |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Low risk | Randomization was carried out using computerized random numbers |
| Allocation concealment (selection bias) | Unclear risk | No mention in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | No mention in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No mention in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | Missing data declared and balanced between the two groups. However, overall lost to follow-up are 11%. |
| Selective reporting (reporting bias) | High risk | Not clear which complications have been considered. Trial registered in the Iranian Registry but outcome not clearly pre-specified. |
| Other bias | Low risk | The authors declare that they have no relevant financial interest. |

| | |
|----------------------|---|
| Study ID | Rezum II study: McVary2016a, McVary2016b, Roehrborn2017, McVary2018, McVary2019 |
| Authors: | Roehrborn, Gange, Gittelman, Goldberg, Patel, Shore, Levin, Rousseau, Beahrs, Kaminetsky, Cowan, Cantrill, Mynderse, Ulchaker, Larson, Dixon, McVary |
| Title: | <p><u>McVary2016a</u>: Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study</p> <p><u>McVary2016b</u>: Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia</p> <p><u>Roehrborn2017</u>: Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia</p> <p><u>McVary2018</u>: Three-Year Outcomes of the Prospective, Randomized Controlled Rezum System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia</p> <p><u>McVary2019</u>: McVary2019: Rezum Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study</p> |
| Journal/Book/Source: | McVary2016a: J Sex Med McVary2016b: The Journal of Urology |

| | |
|--|--|
| | Roehrborn2017: The Journal of Urology McVary2018: Urology McVary2019: Urology |
| Date of Publication: | McVary2016a: 2016 June McVary2016b: 2016 May Roehrborn2017: 2017 June McVary2018: 2017 November McVary2019: 2019 January |
| Volume: | McVary2016a: 13 McVary2016b: 195 Roehrborn2017: 197 McVary2018: 111 McVary2019: 126 |
| Issue: | - |
| Pages: | McVary2016a: 924-933 McVary2016b: 1529-1538 Roehrborn2017: 1507-1516 McVary2018: 1-9 McVary2019: 171-179 |
| METHODS (study design; length of follow up) | RCT with crossover option after 3 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 197 |
| Country of participants | U.S. |
| Data collection period | September 2013 – August 2014 |
| Inclusion criteria | ≥ 50 yrs old, no prior invasive prostate procedures, 30 – 80 cm ³ prostate size, IPSS ≥ 13, ≥5 Qmax ≤ 15 mL/s with a voided volume of at least 125 mL |
| Exclusion criteria | Postvoid residual volume > 250 mL, PSA > 2.5 ng/mL with free PSA < 25%, active urinary infections, 2 separate infections within 6 months |
| Average age | WAVE: 63.0 ± 7.1 Sham: 62.9 ± 7.0 |
| INTERVENTION 1 (technology 1) | Water vapor thermal therapy with the Rezum System |
| INTERVENTION 2 (technology 2) | Sham procedure using a rigid cystoscopy with simulated active treatment sounds |
| Number of patients in WAVE | 136 |
| Number of patients in sham | 61 |
| OUTCOMES | IPSS, QoL, Qmax, BPHII, IIEF-15 (erectile function), MSHQ-EjD |

| | | |
|---|---|---|
| | (ejaculatory function) | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | NCT01912339 Study was funded by the manufacturer of the Rezum System (NxThera Inc.). Two authors consulted NxThera for trial design, Roehrborn, McVary and Rogers have a financial interest with the manufacturer and competitor devices, the other authors reported no financial interests. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Electronic programming using permuted blocks of random sizes stratified by investigational site |
| Allocation concealment (selection bias) | Unclear risk | Not reported. |
| Blinding of participants and personnel (performance bias) | Low risk | Double blind was maintained for personnel administering and patients until 3 months FU. |
| Blinding of outcome assessment (detection bias) | Low risk | Independent data monitoring and clinical events committees reviewed adverse events and safety. |
| Incomplete outcome data (attrition bias) | Low risk | Considering the first 3 months, until the possibility for the cross-over, across the various outcomes, assessments were missing for at most three subjects in the active treatment arm (2.2%) and none in the sham arm. |
| | High risk | For cross over and the follow-up of the WAVE arm, (12 month, 2, 3 and 4 years) attrition rate was higher, and PP analysis was performed. At 4 years only 66% of patients (90/136) could be followed-up. |
| Selective reporting (reporting bias) | Low risk | The endpoints pre-specified in the trial registration were reported, along with the maximum urinary flow rate, post-void residual urine volume, and BPHII. |
| Other bias | Unclear risk | Study sponsored by the manufacturer. |

| | | |
|---|--|------------------------------|
| Study ID | Riehmann 1995 | |
| Authors: | Morten Riehmann, Jane M. Knes, Dennis Heisey, Paul O. Madsen, Reginald C. Bruskewitz | |
| Title: | Transurethral resection versus incision of the prostate: a randomized, prospective study | |
| Journal/Book/Source | UROLOGY | |
| Date of Publication | 1995 | |
| Volume: | 45 | |
| Issue: | 5 | |
| Pages: | 768-775 | |
| METHODS (study design; length of follow up) | Randomized Prospective study 82 months follow up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 120 | |
| Country of participants | Wisconsin, USA | |
| Data collection period | January 31, 1985 / August 28, 1990 | |
| Inclusion criteria | Patients with symptoms of bladder outlet obstruction caused by smaller benign prostates (estimated resectable weight less than 20g) | |
| Exclusion criteria | Patients were excluded if estimated resectable weight of the prostate by simultaneous cystoscopy and rectal examination exceeded 20 g, the prostatic urethra was longer than 3 cm, the median lobe exceeded 2 g, or cancer of the prostate was suspected. Patients with previous prostatic or major pelvic surgery, high operative risk, or overt neurologic or psychiatric disease were also excluded. Written consent for participation was obtained from all the patients in the project. | |
| Average age | TURP: 64 (42-78) TUIP: 65 (51-77) | |
| INTERVENTIONS (technology 1) | Transurethral Resection (TURP) | |
| INTERVENTIONS (technology 2) | Transurethral Incision (TUIP) | |
| Number of patients in TURP | 56 | |
| Number of patients in TUIP | 61 | |
| OUTCOMES | Preoperative, postoperative and at follow up visits: URINARY SYMPTOMS (total, obstructive and irritative symptom scores) SEXUAL FUNCTION UROFLOWMETRY (peak flow rate) | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No mention in the text |

| | | |
|---|--------------|---|
| Allocation concealment (selection bias) | Unclear risk | No mention in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | No mention in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No mention in the text |
| Incomplete outcome data (attrition bias) | High risk | Overall lost to follow up <5% (4.3%) but the flow chart of the study is not clear. Among lost to follow-up or excluded: 1 bladder perforation and 1 TURP after TUIP!!! |
| Selective reporting (reporting bias) | High risk | No protocol or trial registration available. Some complications are mentioned but it is not specified in which group accrued. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|--|---|
| Study ID | Samir 2019 |
| Authors: | Mohamed Samir, Ahmed Tawfick, Mahmoud a Mahmoud, Hossam Elawady, Mohamed Abuelnaga, Mohamed Shabayek, Abd el hamed Youssef, and Ahmed M. Tawfeek |
| Title: | Two-year Follow-up in Bipolar Transurethral Enucleation and Resection of the Prostate in Comparison with Bipolar Transurethral Resection of the Prostate in Treatment of Large Prostates. Randomized Controlled Trial |
| Journal/Book/Source | UROLOGY |
| Date of Publication | 209 |
| Volume: | 133 |
| Issue: | |
| Pages: | 192-198 |
| METHODS (study design; length of follow up) | RCT with 2 year follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 240 |
| Country of participants | Egypt |
| Data collection period | June 2015 – March 2019 |
| Inclusion criteria | patients aged between 50 and 80 years old prostate sizes of more than 80 gm by transrectal ultrasound severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score [IPSS] >20 and maximal flow rate [Qmax] < 10 mL/sec) refractory to medical treatment with alpha blockers |
| Exclusion criteria | Patients known to have neurogenic bladder, prostate cancer, |

| | | |
|---|--|---|
| | urethral stricture, or who have had previous prostate surgery | |
| Average age | B-TUERP: 66.41±6.38 B-TURP: 64.81±5.73 | |
| INTERVENTIONS (technology 1) | Bipolar Transurethral Enucleation and Resection of the Prostate (B-TUERP) | |
| INTERVENTIONS (technology 2) | Bipolar Transurethral Resection of the Prostate (B-TURP) | |
| Number of patients in B-TUERP | 120 | |
| Number of patients in B-TURP | 120 | |
| OUTCOMES | <p>Efficacy: Operative time, resected prostatic tissue weight, catheterization time and hospital stay, IPSS, Qol assessment, residual prostate volume, uroflowmetry (Qmax), and post-voiding residual urine volume (PVRU).</p> <p>Safety: TUR syndrome, haemoglobin decrease, and transfusion rate, urethral stricture and urinary incontinence.</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The authors declare no conflict of interest | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information in the text |
| Allocation concealment (selection bias) | Low risk | "patients were randomly divided using the closed envelope method" |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | Numbers of subjects analysed are not clear for each follow-up. I consider n=106 (B-TUERP) and n=113 (B_TURP) in each follow-up visit. I consider n=120 pre and post operation. Overall lost to follow-up=8.7% |
| Selective reporting (reporting bias) | Unclear risk | A protocol is not available but all the pre-specified outcomes are presented. However for complications it is not clear the time of follow-up. |
| Other bias | Low risk | The authors declare that they have no relevant financial interest. |

| | |
|-----------------|---|
| Study ID | Shoji 2020 |
| Authors: | Sunao Shoji, Izumi Hanada, Tatsuya Otaki, Takahiro Ogawa, |

| | | |
|---|--|------------------------------|
| | Koichiro Yamada, Takato Uchida, Taro Higure, Masayoshi Kawakami, Hakushi Kim, Masahiro Nitta, Masanori Hasegawa, Yoshiaki Kawamura and Akira Miyajima | |
| Title: | Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study | |
| Journal/Book/Source: | Int J Urol | |
| Date of Publication: | 2020 | |
| Volume: | 27 | |
| Issue: | 11 | |
| Pages: | 974--980 | |
| METHODS (study design; length of follow up) | Randomized trial. Follow up: 1, 3, 6, 9 and 12 months after treatment | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 140 | |
| Country of participants | Japan | |
| Data collection period | April 2017 to February 2019 | |
| Inclusion criteria | (i) aged 50–90 years; (ii) diagnosis of mild or severe BPH based on the IPSS, IPSS QOL, maximum flow rate, residual urine and prostate volume; (iii) symptoms were not improved by medication; and (iv) patients provided informed consent. | |
| Exclusion criteria | (i) patients who had other diseases that affected urinary function; and (ii) patients who had preoperative treatment. | |
| Average age | ThuLEP: median (range) = 72 (57–83) B-TURP: median (range) = 73 (55–86) | |
| INTERVENTIONS (technology 1) | Thulium laser enucleation of the prostate (ThuLEP) | |
| INTERVENTIONS (technology 2) | Bipolar transurethral resection of the prostate (B-TURP) | |
| Number of patients in ThuLEP | 70 | |
| Number of patients in B-TURP | 70 | |
| OUTCOMES | The International Prostate Symptom Score, International Prostate Symptom Score quality of life, Qmax, PVR, International Index of Erectile Function-5, urinary incontinence, operation time, hospitalisation time, catheterisation time, UTI, capsule perforation, blood transfusion, recatheterisation, urethral stricture, bladder neck contracture, erectile dysfunction. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |

| | | |
|---|--------------|---|
| Random sequence generation (selection bias) | Low risk | A randomization list was used for non-blind assignment to treatment groups. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear | No information provided about blinding of participants and personnel. |
| Blinding of outcome assessment (detection bias) | Unclear | No information provided about blinding of outcome assessors. |
| Incomplete outcome data (attrition bias) | Unclear | Number of patients at follow up measurements not provided. |
| Selective reporting (reporting bias) | Unclear | There is no study protocol registered. |
| Other bias | Low risk | Authors declared none competing interest. |

| | |
|--|---|
| Study ID | Skinner 2017 |
| Authors: | Thomas A.A. Skinner; Robert J. Leslie; Stephen S. Steele; J. Curtis Nickel |
| Title: | Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia |
| Journal/Book/Source | CUAJ |
| Date of Publication | 2017 |
| Volume: | 11 |
| Issue: | 6 |
| Pages: | 194-8 |
| METHODS (study design; length of follow up) | RCT, 12 weeks follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 55 |
| Country of participants | Canada |
| Data collection period | June 2014 - June 2016 |
| Inclusion criteria | Age over 45, IPSS \geq 12, estimated prostate volume on digital rectal exam (DRE) \geq 30 cc (as this is a real-life clinical practice study, prostate size and post-void residual were not mandatory). |
| Exclusion criteria | prior invasive intervention for BPH, prostate-specific antigen (PSA) level $>$ 10 ng/ml, urinary retention, medical condition unfit for surgery, history of prostate cancer, documented prostatitis within the past three months, known bleeding disorder, inability to follow directions or sign informed consent due to organic brain or psychiatric disease, history of substance abuse, which would affect compliance |
| Average age | DioVAP: 69.4 B-TUVP: 71.8 |

| | | |
|---|--|---|
| INTERVENTIONS (technology 1) | Diode laser vaporization (DioLVP) | |
| INTERVENTIONS (technology 2) | Bipolar plasma vaporization with the Olympus plasma button (B-TUVP) | |
| Number of patients in DioLVP | 25 | |
| Number of patients in B-TUVP | 30 | |
| OUTCOMES | IPSS, QoL, Surgical team satisfaction, Side effect and complications, Cost analysis | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Dr. Steele has been an advisor for Allergan and Astellas; a speaker for Abbott and Astellas; has received grants from Astellas and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. The remaining authors report no competing personal or financial interests. This study was supported by the Ontario Academic Health Centres – Alternate Funding Plan Innovation Fund. The equipment was provided by Olympus and Biolitec. We thank Dr. Amir Rumman, who assisted the research team in developing the analytical models. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Patients were randomized into two groups using GraphPad QuickCalcs, random number generator software |
| Allocation concealment (selection bias) | Unclear risk | No information in the article |
| Blinding of participants and personnel (performance bias) | Unclear risk | The study is declared as "single-blinded" but it is not clear who is blinded. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the article |
| Incomplete outcome data (attrition bias) | Unclear risk | No mention to missing data!?!? |
| Selective reporting (reporting bias) | High risk | It is not clear to me which complications has been taken into account, standard deviation are missing |
| Other bias | High risk | The equipment was provided by the manufacturer |

| | |
|----------------------|--|
| Study ID | BPH6 Study: Sonksen 2015 |
| Authors: | Sonksen et al |
| Title: | Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study |
| Journal/Book/Source: | European Urology |
| Date of Publication: | 2015 |

| | |
|--|--|
| Volume: | 68 |
| Issue: | - |
| Pages: | 643-652 |
| METHODS (study design; length of follow up) | Prospective RCT, 1 year FU |
| PARTICIPANTS | |
| Total Number of Participants randomized | 91 |
| Country of participants | 10 centres in Germany, Denmark and UK |
| Data collection period | February 2012 – October 2013 |
| Inclusion criteria | Men >50 years old and candidate for TURP, IPSS>12, Qmax≤15 mL/s, PVR < 350 ml, prostate volume ≤60 cc on ultrasonography, sexually active within 6 mo before the index procedure, SHIM score >6, positive response to MSHQ-EjD, ISI score ≤4 |
| Exclusion criteria | active urinary tract infection at the time of treatment, bacterial prostatitis within 1 year of index procedure, obstructive median lobe, urinary retention, urethral conditions that may prevent insertion of a rigid 20F cystoscope, previous TURP, unwilling to report sexual function, anticoagulants within 3 d of the index procedure, severe cardiac comorbidities, PSA ≥10ng/l, history of prostate or bladder cancer, other medical condition or comorbidity contraindicative for TURP or UroLift |
| Average age yrs (SD) | PUL: 63 (6.8) TURP: 65 (6.4) |
| INTERVENTIONS (technology 1) | Prostatic urethral lift (PUL) with the UroLift System |
| INTERVENTIONS (technology 2) | TURP |
| Number of patients in PUL | 44 (1 patient was excluded due to violation of protocol) |
| Number of patients in TURP | 35 |
| OUTCOMES | IPSS, Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD), Incontinence Severity Index (ISI), Quality of Recovery visual analogue score (QoR VAS), Clavien–Dindo classification of adverse events, QoL, patient satisfaction, BPH II, Qmax, PVR, Quality of Recovery visual analogue score (QoR VAS), reintervention at ≤30 d and >30 – 365 d (due to bleeding, urethral stricture, return of LUTS) |
| Notes (e.g. funding source; conflicts of Interest; trial regis- | Sponsor NeoTract, Inc. Study authors reported grants from NeoTract, Inc. |

| | | |
|---|---------------------------|--|
| tration number, etc) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Randomisation using permuted blocks of various sizes chosen randomly. |
| Allocation concealment (selection bias) | Low risk | Consealed through password protected computer. |
| Blinding of participants and personnel (performance bias) | High risk | Nonblinded trial. |
| Blinding of outcome assessment (detection bias) | High risk | Same study authors aquired and analysed the data. |
| Incomplete outcome data (attrition bias) | High risk | Over 20% of patients were lost to follow-up in the TURP arm and less than 5% in the PUL arm. |
| Selective reporting (reporting bias) | Low risk | Outcomes reported in the study protocol are reported in the study. |
| Other bias | High risk | Funding of the study from the manufacturer of PUL. It is reported that the sponsor played a role in the study design and conduct of the study, data mangement and analysis, manuscript preparation and review. |

| | |
|--|---|
| Study ID | Sun 2014 |
| Authors: | Nao Sun, Yaowen Fu, Tengzheng Tian, Jialin Gao, Yuantao Wang, Song Wang, Wei An |
| Title: | Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial |
| Journal/Book/Source: | Int Urol Nephrol |
| Date of Publication: | February 2014 |
| Volume: | 46 |
| Issue: | |
| Pages: | 1277-1282 |
| METHODS (study design; length of follow up) | RCT 12 months FU |
| PARTICIPANTS | |
| Total Number of Participants randomized | 164 |
| Country of participants | Jilin, China |
| Data collection period | January 2010-December 2011 |
| Inclusion criteria | age of less than 90 years old with no contraindication to surgery; Qmax B 10 ml/s; PVR C 50 ml; IPSS C 8; prostate weight\100 g as determined by transrectal ultrasonography. |
| Exclusion criteria | treatment with transurethral prostate surgery previously; neurogenic bladder; suspected prostate cancer. |

| | | |
|---|---|--|
| Average age | HoLEP: 72.16 ± 7.53 TURP: 71.91 ± 7.53 | |
| INTERVENTIONS (technology 1) | Holmium laser enucleation (HoLEP) | |
| INTERVENTIONS (technology 2) | Transurethral resection (TURP) | |
| Number of patients in HoLEP | 82 | |
| Number of patients in TURP | 82 | |
| OUTCOMES | In the method section outcomes are not indicated. From results: Qmax, PVR, IPSS, QOL, (1 month and 12 months after survey) operative time, bladder irrigation time, time of indwelling catheter, hospitalization time, weight of resected prostate, haemoglobin level 1 day after surgery, blood sodium level 1 day after surgery, hyponatremia, blood transfusion, urethral stricture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | The authors declare they have no outside financial interests that would affect the design or outcomes of this study. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information on the generation process of the unique identification numbers used in the group assignment |
| Allocation concealment (selection bias) | Unclear risk | "The information of enrollment for all patients was done by another doctor" |
| Blinding of participants and personnel (performance bias) | Unclear risk | "Patients were blinded to their method of treatment...and the surgeon didn't know whether the patient who under surgery included in the group" |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | A flow chart is not present and there is no mention of missing data in the text |
| Selective reporting (reporting bias) | Unclear risk | It is not present a protocol and outcomes are not pre-specified |
| Other bias | Low risk | The authors declare that they have no conflict of interest. |

| | |
|-----------------|---|
| Study ID | Swiniarski 2012 |
| Authors: | Piotr Paweł Świniarski, Stanisław Stępień, Waldemar Dudzic, Stanisław Kęsy, Mariusz Błewniewski, Waldemar Różański |
| Title: | Thulium laser enucleation of the prostate (TmLEP) vs. transurethral resection of the prostate (TURP): evaluation of early results |

| | | |
|---|--|--|
| Journal/Book/Source: | Central European Journal of urology | |
| Date of Publication: | 2012 | |
| Volume: | 65 | |
| Issue: | 3 | |
| Pages: | 130-134 | |
| METHODS (study design; length of follow up) | Prospective, non-consecutive randomized controlled trial, 3 months fu | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 106 | |
| Country of participants | Poland | |
| Data collection period | February 2007-September 2009 | |
| Inclusion criteria | IPPS >7, Qmax <5 ml/s, and the clinically confirmed BPH. | |
| Exclusion criteria | previous surgical treatment for BPH, prostate cancer, and LUTS resulting from conditions other than BPH | |
| Average age | TmLEP: 68.3±6.8 TURP: 69.3±7.2 | |
| INTERVENTIONS (technology 1) | Thulium laser enucleation (TmLEP) | |
| INTERVENTIONS (technology 2) | Transurethral resection (TURP) | |
| Number of patients in TmLEP | 54 | |
| Number of patients in TURP | 52 | |
| OUTCOMES | Time of surgery, use of laser, morcellation, catheterization, hospitalization, used energy, Hgb loss, removed tissue weight. IPSS, QoL, Qmax and PVR (one and three months after surgery), Perioperative and postoperative complications | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | Financial disclosure: The research was funded from science funds of the Research Department of the Ministry of Science and Higher Education in years 2007-2010 as a research project. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Randomization consisted in preparing a computer-generated list of patients that was well balanced |
| Allocation concealment (selection bias) | Unclear risk | No information in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | No mention of missing data in the text and no flow chart |
| Selective reporting (reporting bias) | Unclear risk | No protocol available but all pre-specified outcomes are presented, however a primary outcome is not pre-specified |

| | | |
|------------|---------|---|
| Other bias | Unclear | There is no information about conflict of interest. |
|------------|---------|---|

| | |
|--|---|
| Study ID | Tan 2003 |
| Authors: | A. H. H. Tan, P. J. Gilling, K. M. Kennett, C. Frampton, A. M. Westenberg and M. R. Fraundorfer |
| Title: | A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams) |
| Journal/Book/Source: | The Journal of urology |
| Date of Publication | 2003 |
| Volume: | 170 |
| Issue: | |
| Pages: | 1270-1274 |
| METHODS (study design; length of follow up) | RCT 12 months follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 61 |
| Country of participants | New Zealand |
| Data collection period | June 1997 – December 2000 |
| Inclusion criteria | prostate volume, as calculated by a TRUS volume of 40 to 200 ml, Qmax 15 ml per second or less, AUA symptom score 8 or greater, post-void residual less than 400 ml and Scha fer grade (linearized passive urethral resistance relation) 2 or greater |
| Exclusion criteria | Cases of carcinoma, Catheterized patients. Patients with a history of urethral or prostatic surgery |
| Average age | HoLEP: 71.7±1.1 (54-84) TURP: 70.3±1.0 (59-83) |
| INTERVENTIONS (technology 1) | Holmium Laser Enucleation (HoLEP) |
| INTERVENTIONS (technology 2) | Transurethral Resection (TURP) |
| Number of patients in HoLEP | 31 |
| Number of patients in TURP | 30 |
| OUTCOMES | <u>Perioperatively</u> the primary outcomes measured included duration of catheterization and hospital stay, and blood transfusion rate. <u>Postoperatively</u> the primary outcome measures were single question quality of life scores, International Prostate Symptom Score and peak flow rate at 1, 3, 6 and 12 months. <u>Perioperatively</u> the secondary outcomes measured included the time that the resectoscope sheath was in place, the time that the laser or electrocautery unit was in action, morcellation time in the HoLEP group, the amount of tissue resected and total irrigation volume (intraoperative and postoperative). <u>Postoperatively</u> the secondary outcomes measured included |

| | | |
|---|---|--|
| | <p>continence and sexual function. A pressure flow urodynamic assessment was performed at the 6-month followup interval, consisting of the measurement of detrusor pressure at Qmax (PdetQmax), Scha"fer grade and post-void residual volume. Transrectal ultrasound volume measurements were made preoperatively and again at 6 months of followup. All adverse events, such as reoperation, re-catheterization and urinary tract infection, were also recorded.</p> | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | <p>PJG and MRF has financial interest/otr other relationship with Lumenis, Inc., Tel Aviv, Israel</p> | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | "Blanced blocked randomization schedule" |
| Allocation concealment (selection bias) | Unclear risk | "sequence of sealed envelope" |
| Blinding of participants and personnel (performance bias) | High risk | "Participant were not blinded" |
| Blinding of outcome assessment (detection bias) SUBJECTIVE OUTCOMES | High risk | "outcome assessments were performed of staff blinded to patient treatment" |
| Blinding of outcome assessment (detection bias) OBJECTIVE OUTCOMES | Low risk | "outcome assessments were performed of staff blinded to patient treatment" |
| Incomplete outcome data (attrition bias) | Unclear risk | Overall lost to follow-up is 15% |
| Selective reporting (reporting bias) | Unclear risk | No protocol available |
| Other bias | High risk | Financial interest, manufacturer financed the study. |

| | |
|--|---|
| Study ID | Tefekli 2005 |
| Authors: | Ahmet Tefekli, Ahmet Yaser Muslumanoglu, Murat Baykal, Murat Binbay, Aytul Tas and Fatih Altunrende |
| Title: | A hybrid technique using bipolar energy in transurethral prostate surgery: a prospective, randomized comparison |
| Journal/Book/Source: | The journal of Urology |
| Date of Publication | 2005 |
| Volume: | 174 |
| Issue: | |
| Pages: | 1339-1343 |
| METHODS (study design; length of follow up) | RCT, 12 months follow up |
| PARTICIPANTS | |
| Total Number of Participants randomized | 101 |
| Country of participants | Turkey |

| | | |
|---|--|--|
| Data collection period | 2001 and 2002 | |
| Inclusion criteria | failed medical therapy in 72 men (71.3%) recurrent urinary retention in 29 (28.7%). | |
| Exclusion criteria | abnormal DRE, increased serum PSA, evidence of neurogenic bladder (ie history of diabetes, cerebrovascular accident, etc), urethral stricture disease, bladder stone, tumor, a history of prostate surgery | |
| Average age | PlasmaKinetic 68.7±6.3 (N=49) TURP 69.4±5.9 (N=47) | |
| INTERVENTIONS (technology 1) | Transurethral vaporessection (TUVRP) with bipolar PlasmaKinetic technique | |
| INTERVENTIONS (technology 2) | Transurethral prostate surgery using monopolar energy (M-TURP) | |
| Number of patients in TUVRP | 51 | |
| Number of patients in M-TURP | 50 | |
| OUTCOMES | IPSS, Uroflowmetry scores, Operative time, Catheterization duration, Hospital stay, Complication rates | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information in the text |
| Allocation concealment (selection bias) | Unclear risk | No information in the text |
| Blinding of participants and personnel (performance bias) | High risk | In the discussion: "... the fact that randomization in this study was not double-blind..." |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Low risk | Overall lost to follow-up is 5% |
| Selective reporting (reporting bias) | Unclear risk | A protocol is not present and outcomes are not clearly pre-specified |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|---------------------|---|
| Study ID | Tkocz 2002 |
| Authors: | Michal Tkocz, Andrzej Praisner |
| Title: | Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy |
| Journal/Book/Source | Neurourology and urodynamics |
| Date of Publication | 2002 |
| Volume: | 21 |

| | | |
|--|---|--|
| Issue: | | |
| Pages: | 112-116 | |
| METHODS (study design; length of follow up) | Randomized study, with 24 months follow up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 100 | |
| Country of participants | Poland | |
| Data collection period | n.a. | |
| Inclusion criteria | Moderate symptoms of bladder outlet obstruction caused by smaller benign prostate. Average prostate weight before operation no more than 30g | |
| Exclusion criteria | Patients with third lobe | |
| Average age | 63 ± 6.7 | |
| INTERVENTIONS (technology 1) | Transurethral incision (TUIP) | |
| INTERVENTIONS (technology 2) | Transurethral resection (TURP) | |
| Number of patients in TUIP | 50 | |
| Number of patients in TURP | 50 | |
| OUTCOMES | mean weight of the resection adenoma, mean weight of the incised adenoma, IPSS, QoL, daily and nocturnal micturition frequency, mean volume of a single urine portion, maximum flow rate during free flowmetry and during pressure-flow study, Voiding volume, urine retention, maximal cystometric capacity, detrusor pressure and detrusor pressure maximal flow rate, compliance of the bladder, opening detrusor pressure, linearized passive urethral resistance relation, detrusor instability, transfusion, retrograde ejaculation, urine incontinence | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | None | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information in the text |
| Allocation concealment (selection bias) | Unclear risk | No information in the text |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information in the text |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | Missing data are not mentioned in the text. |
| Selective reporting (reporting bias) | Unclear risk | No protocol available. Outcomes are not clearly pre-specified. |
| Other bias | Unclear | Funding source, conflicts of interest |

| | | |
|--|--|---|
| | | and trial registration number are not reported. |
|--|--|---|

| | | |
|--|---|--|
| Study ID | Wagrell 2002 | |
| Authors: | Wagrell, Schelin, Nordling, Richthoff, Masgnusson, Schain, Larson, Boyle, Duelund, Kroyer, Ageheim, Mattiasson | |
| Title: | Feedback microwave thermotherapy versus TURP for clinical BPH – a randomized controlled multicenter study | |
| Journal/Book/Source: | Adult Urology | |
| Date of Publication: | 2002 | |
| Volume: | - | |
| Issue: | 2 | |
| Pages: | 292-299 | |
| METHODS (study design; length of follow up) | RCT | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 154 | |
| Country of participants | United States, Scandinavia (Sweden and Denmark) | |
| Data collection period | October 1998 to November 1999 | |
| Inclusion criteria | symptomatic BPH, IPSS of 13 or greater, prostate volume of 30 to 100 mL, Qmax less than 13 mL/s | |
| Exclusion criteria | Not reported. | |
| Average age | TUMT: 67 (8) TURP: 69 (8) | |
| INTERVENTIONS (technology 1) | Transurethral microwave thermotherapy (TUMT) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in TUMT | 100 | |
| Number of patients in TURP | 46 | |
| OUTCOMES | IPSS, Qmax, PVR, QoL, detrusor pressure, prostate volume, all adverse events (serious adverse events defined separately), catheter time | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | Study was sponsored by the manufacturer of the TIMT device (ProstaLund). Wagrell, Schelin, Larson and Matthiasson are paid consultants of the manufacturer. Trial registration number was not provided. | |
| | | |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Unclear risk | Not reported. |
| Allocation concealment (selection bias) | Unclear risk | Not reported. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Not reported. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported. |
| Incomplete outcome data (attrition bias) | Unclear risk | Loss-to-follow-up was higher than 5% but lower than 15% within groups and it had the same proportion between groups. |
| Selective reporting (reporting bias) | Low risk | Outcomes were reported as a priori described in the methods (study protocol). |
| Other bias | High risk | Study sponsored by the manufacturer and 4 authors were paid consultants of the manufacturer. |

| | |
|--|--|
| Study ID | Wang 2019 |
| Authors: | Wang Z, Zhang J, Zhang H, Liu S, Sun D, Hu L, Fu Q, Zhang K |
| Title: | Impact on sexual function of plasma button transurethral vapour enucleation versus plasmakinetic resection of the large prostate >90 ml: Results of a prospective, randomized trial |
| Journal/Book/Source: | Andrologia |
| Date of Publication: | 2019 |
| Volume: | |
| Issue: | |
| Pages: | |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow-up at 3 and 6 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 101 |
| Country of participants | China |
| Data collection period | 2017-2018 |
| Inclusion criteria | Symptomatic BPH |
| Exclusion criteria | Prostate \leq 90 ml, prostatic cancer, severe respiratory or circulatory diseases, coagulopathy, uncontrolled diabetes with HbA1c levels \geq 7 mg/dl, neurogenic bladder disease, major |

| | | |
|--|---|---|
| | psychiatric disorder, receiving a 5 α -reductase inhibitor or phosphodiesterase-5 (PDE5) inhibitor, history of prostatic or urethral surgery | |
| Average age | 67 | |
| INTERVENTIONS (technology 1) | Plasma button transurethral vapour enucleation (B-VEP) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in B-VEP | 50 | |
| Number of patients in TURP | 51 | |
| OUTCOMES | Qmax, IPSS, PVR, QoL, IIEF-5, erectile dysfunction, anejaculation | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information available |
| Allocation concealment (selection bias) | Unclear risk | No information available |
| Blinding of participants and personnel (performance bias) | Unclear risk | Open trial (surgeons cannot be blind), but no information on other clinicians/health personnel in charge and patients |
| Blinding of outcome assessment (detection bias) | Unclear risk | Blinding of assessors and of patients was not specified |
| Incomplete outcome data (attrition bias) | Low risk | No patients lost to follow-up |
| Selective reporting (reporting bias) | Unclear risk | No study protocol available |
| Other bias | | |

| | |
|-----------------------------------|---|
| Study ID | Wu 2016 |
| Authors: | Gang Wu & Zhe Hong & Chao Li & Cuidong Bian & Sheng-song Huang & Denglong Wu |
| Title: | A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up |
| Journal/Book/Source (abbreviated) | Lasers Med Sci |

| | | |
|--|---|--|
| viation): | | |
| Date of Publication (year): | January 2016 | |
| Volume: | 31 | |
| Issue: | | |
| Pages: | 599-604 | |
| METHODS (study design; length of follow up) | RCT with 12-months follow-up | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 80 | |
| Country of participants | Shanghai, China | |
| Data collection period | January 2013 – June 2014 | |
| Inclusion criteria | Patients with indications for the surgical treatment of BPH and a prostate volume ≥ 80 ml | |
| Exclusion criteria | Patients with severe pulmonary disease or heart disease, bladder calculus, neurogenic bladder dysfunction, bladder cancer, prostate cancer, urethral stricture, or coagulopathy | |
| Average age | PKEP: 73.6 ± 6.2 (54-81) DioLEP: 75.4 ± 8.4 (56-85) | |
| INTERVENTIONS (technology 1) | Plasmakinetic enucleation (PKEP) | |
| INTERVENTIONS (technology 2) | Diode laser enucleation (DioLEP) | |
| Number of patients in PKEP | 40 | |
| Number of patients in DioLEP | 40 | |
| OUTCOMES | Perioperative parameters Perioperative or postoperative complications Clinical outcomes assess at 3,6 and 12 months | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This work was supported by Grants from the National Natural Science Foundation of China (81172426) and Shanghai Education Commission Research and Innovation projects (12ZZ034). The authors declare that they have no competing interests. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Grouping strategy was performed by using sequentially numbered and sealed envelopes. Each patient was handed out with an envelope through the computerized random number generator |
| Allocation concealment (selection bias) | Low risk | Grouping strategy was performed by using sequentially numbered and sealed envelopes. Each patient was handed out with an envelope through the computerized random |

| | | |
|---|--------------|--|
| | | number generator |
| Blinding of participants and personnel (performance bias) | Unclear risk | Only the patients were blinded to the treatments |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information in the text |
| Incomplete outcome data (attrition bias) | Unclear risk | In the results: "All 80 patients completed the 12-month assessment." But perioperative data are collected for 35 patients but missing data are not justified |
| Selective reporting (reporting bias) | Unclear risk | No protocol available and outcomes not clearly pre-specified |
| Other bias | Low risk | The authors declare that they have no conflict of interest. |

| | |
|--|--|
| Study ID | Xia 2008 |
| Authors: | Shu-Jie Xia, Jian Zhuo, Xiao-Wen Sun, Bang-Min Han, Yi Shao, Yi-Nan Zhang |
| Title: | Thulium Laser versus Standard Transurethral Resection of the Prostate: A Randomized Prospective Trial |
| Journal/Book/Source: | Eur Urol. |
| Date of Publication: | 2008 |
| Volume: | 53 |
| Issue: | 2 |
| Pages: | 382-389 |
| METHODS (study design; length of follow up) | Randomised controlled trial (RCT) Follow up: 1, 6, and 12 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 100 |
| Country of participants | China |
| Data collection period | November 2004 to December 2005 |
| Inclusion criteria | Age younger than 85 yr, maximum urinary flow rate (Q _{max}) less than 15 ml/s, postvoid residual (PVR) urine volume less than 150 ml, medical therapy failure, transrectal ultrasound (TRUS) adenoma volume less than 100g, and urodynamic obstruction (Schäfer grade 2 or greater). |
| Exclusion criteria | Neurogenic bladder; a diagnosis of prostate cancer and any previous prostatic, bladder-neck, or urethral surgery; and the presence of an indwelling catheter. |
| Average age | TmLRP-TT: 68.9 ± 7.7 (range 57–85) |

| | | |
|--|---|--|
| | TURP: 69.3 ± 7.3 (range 52–82) | |
| INTERVENTIONS (technology 1) | Thulium laser resection of the prostate-tangerine technique (TmLRP-TT) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in TmLRP | TmLRP-TT n = 52 | |
| Number of patients in TURP | TURP n = 48 | |
| OUTCOMES | International Prostate Symptom Score (IPSS), quality of life score (QoLs), 5-item version of the International Index of Erectile Function (IIEF-5) questionnaires, PVR volume, Qmax, operative time, serum sodium decrease, catheterization time, hospital day, blood transfusion, TUR syndrome, UTI, re-catheterization, acute urinary incontinence, retrograde ejaculation, urethral stricture. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | / | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information about randomization. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information whether patients or personnel were blinded. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information whether outcomes assessors were blinded of the procedure. |
| Incomplete outcome data (attrition bias) | Low risk | All patients completed the 12-mo assessment. |
| Selective reporting (reporting bias) | Unclear risk | There is no study protocol available to judge this bias. |
| Other bias | Low risk | The authors have nothing to disclose. |

| | |
|----------------------|---|
| Study ID | Xu 2013 |
| Authors: | Abai Xu, Yong Zou, Bingkun Li, Chunxiao Liu, Shaobo Zheng, Hulin Li, Yawen Xu, Binshen Chen, Kai Xu, Haiyan Shen |
| Title: | A Randomized Trial Comparing Diode Laser Enucleation of the Prostate with Plasmakinetic Enucleation and Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia |
| Journal/Book/Source: | J Endurol. |
| Date of Publication: | 2013 |

| | | |
|--|---|--|
| Volume: | 27 | |
| Issue: | October | |
| Pages: | 1254-1260 | |
| METHODS (study design; length of follow up) | Randomized trial. Follow up at 3, 6, and 12 months. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 80 | |
| Country of participants | China | |
| Data collection period | July 2011 to November 2011 | |
| Inclusion criteria | Age \geq 50 years, IPSS \geq 7, and Qmax \leq 15 mL/s. | |
| Exclusion criteria | Neurogenic bladder, history of prostatic or urethral surgery and prostate cancer. | |
| Average age | | |
| INTERVENTIONS (technology 1) | Transurethral plasma kinetic enucleation and resection of prostate (PKERP) | |
| INTERVENTIONS (technology 2) | Diode Laser Enucleation of the Prostate (DioLEP) | |
| Number of patients in PKERP | 40 | |
| Number of patients in DioLEP | 40 | |
| OUTCOMES | Postvoid residual (PVR) urine volume, Qmax, IPSS, and quality of life (QoL) score, operative time, changes in serum sodium levels, the need for blood transfusion, catheterization time, hospital stay, death, TUR syndrome, bladder injury, transient incontinence, urethral stricture, irritative symptoms. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This work was supported by China Postdoctoral Science Foundation funded project (No. 2012M511830 for Bingkun Li). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Patients were randomly assigned to either DiLEP or PKERP but no information on sequence generation method. |
| Allocation concealment (selection bias) | Unclear risk | Information about concealment not provided. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Information about blinding not provided. |
| Blinding of outcome | Unclear risk | No information whether outcome |

| | | |
|--|--------------|--|
| assessment (detection bias) | | assessment was blinded. |
| Incomplete outcome data (attrition bias) | Low concern | All patients in the two groups completed the follow-up at 3, 6, and 12 months after operation. |
| Selective reporting (reporting bias) | Unclear risk | There is no study protocol registered in order to judge this bias. |
| Other bias | Low risk | Authors declare that they have no competing financial interest. |

| | |
|--|--|
| Study ID | Yan 2013 |
| Authors: | Hao Yan, Tong-Wen Ou, Liang Chen, Qi Wang, Fei Lan, Peng Shen, Jin Li, Jian-Jun Xu. |
| Title: | Thulium laser vaporesction versus standard transurethral resection of the prostate: A randomized trial with transpulmonary thermodilution hemodynamic monitoring |
| Journal/Book/Source: | Int J Urol. |
| Date of Publication: | 2013 |
| Volume: | 20 |
| Issue: | / |
| Pages: | 507-512 |
| METHODS (study design; length of follow up) | Randomised controlled trial (RCT). Follow up: 3 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 80 |
| Country of participants | China |
| Data collection period | August 2010 and October 2011 |
| Inclusion criteria | Indication for the surgical treatment of BPH |
| Exclusion criteria | Patients with prostate cancer, bladder calculus, neurogenic bladder dysfunction, previous prostate surgery, urethral stricture or coagulopathy and any other diseases that interfere with the PiCCO monitoring system, such as severe heart or pulmonary diseases. |
| Average age | Mean value (SD, min-max) TmLRP: 72.5 (7.9, 57–91) Mean value (SD, min-max) TURP: 74.5 (6.5, 58–87) |
| INTERVENTIONS (technology 1) | Thulium laser vaporesction of the prostate (TmLRP) |
| INTERVENTIONS (technology 2) | Transurethral resection of prostate (TURP) |
| Number of patients in | 40 |

| | | |
|--|--|---|
| TmLRP | | |
| Number of patients in TURP | 40 | |
| OUTCOMES | IPSS, Qmax, TUR syndrome, blood transfusion, recatheterisation, urinary incontinence, urethral stricture, retrograde ejaculation, re-operation, decreases in serum sodium, catheter duration, operation duration, mortality. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This study was supported by a grant-in-aid from Beijing Municipal Science & Technology Project and Clinical Characteristics and Application Research of Capital (Surgery for high-risk patients with benign prostatic hyperplasia, No.D101100050010060). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information about generation sequence method. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information about blinding. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information about blinding. |
| Incomplete outcome data (attrition bias) | Low risk | There was no lost to follow up. |
| Selective reporting (reporting bias) | Unclear risk | There is no protocol available in order to judge this bias. |
| Other bias | Low risk | Authors have no conflict of interest to declare. |

| | |
|--|--|
| Study ID | Yang 2013 |
| Authors: | Zhonghua Yang, Xinghuan Wang, and Tongzu Liu |
| Title: | Thulium Laser Enucleation Versus Plasmakinetic Resection of the Prostate: A Randomized Prospective Trial With 18-Month Follow-up |
| Journal/Book/Source: | Urology |
| Date of Publication: | 2013 |
| Volume: | 81 |
| Issue: | 2 |
| Pages: | 396-401 |
| METHODS (study design; length of follow up) | Randomized controlled trial (RCT) Follow up: 1, 3, 6, 12, and 18 months from surgery. |

| | | |
|--|---|--|
| PARTICIPANTS | | |
| Total Number of Participants randomized | 158 | |
| Country of participants | China | |
| Data collection period | From May 2009 to June 2010. | |
| Inclusion criteria | Age <85 years, maximum urinary flow rate (Qmax) of <15 mL/s, postvoid residual (PVR) urine volume of <150 mL, failure of medical therapy, and transrectal ultrasound (TRUS) volume of <100 g. | |
| Exclusion criteria | Prostate volume <30 mL, documented or suspected prostate cancer, neurogenic bladder, bladder stone or diverticula, urethral stricture, and maximal bladder capacity >500 mL. | |
| Average age | ThuLEP: 62.4 ± 7.2 (range: 51-85) PKRP: 61.4 ± 6.9 (range 52-85) | |
| INTERVENTIONS (technology 1) | Thulium laser transurethral enucleation of the prostate (ThuLEP) | |
| INTERVENTIONS (technology 2) | Plasmakinetic bipolar resection of the prostate (PKRP) (Gyrus) | |
| Number of patients in ThuLEP | 79 | |
| Number of patients in PKRP | 79 | |
| OUTCOMES | International Prostate Symptom Score (IPSS), quality of life score (QOLS), maximum flow rate (Qmax), and postvoid residual urine volume (PVR), blood transfusion, operation time, acute urinary retention, postoperative catheterization time, hospital length of stay. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This study was supported by the National Natural Science Foundation of China (No. 81172734) and Independent Research Projects of Wuhan University (No. 111086). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information about randomisation method. |
| Allocation concealment (selection bias) | Unclear risk | No information about concealment method. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information about blinding. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information about blinding. |
| Incomplete outcome data (attrition bias) | Low risk | No patient was lost during the follow-up. |

| | | |
|--------------------------------------|--------------|--|
| Selective reporting (reporting bias) | Unclear risk | Study protocol not available in order to judge this bias. |
| Other bias | Low risk | Authors declare that they have no financial interest to declare. |

| | |
|--|---|
| Study ID | Yee 2015 |
| Authors: | Chi-hang Yee, Joseph Hon-ming Wong, Peter Ka-fung Chiu, Chi-kiwok Chan, Wai-man Lee, James Hok-leung Tsu, Jeremy Yuen-chun Teoh, Chi-fai Ng. |
| Title: | Short-stay transurethral prostate surgery: A randomized controlled trial comparing transurethral resection in saline bipolar transurethral vaporization of the prostate with monopolar transurethral resection |
| Journal/Book/Source: | Asian J Endosc Surg. |
| Date of Publication: | 2015 |
| Volume: | 8 |
| Issue: | 3 |
| Pages: | 316-322 |
| METHODS (study design; length of follow up) | Multicenter, double-blinded, prospective RCT. Follow up: 3 and 6 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 168 |
| Country of participants | China |
| Data collection period | January and December 2013 |
| Inclusion criteria | Men with BPE, 50–75 years old, American Society of Anesthesiologists Class ≤ 2 , Compliant patients, Activities of daily living independent or largely independent, Agreeable to principle of short-stay surgery, Have access to hospital care within 15 min of travel and either of the following conditions: failed medical therapy with alpha-blockers or 5-alpha reductase inhibitors, with IPSS ≥ 18 and/or Qmax ≤ 15 mL/s, urinary retention status. |
| Exclusion criteria | Previous TURP or other forms of surgical intervention for BPE, patient confirmed to have carcinoma of prostate, patients with known neurogenic bladder, bladder stone, or urethral stricture. |
| Average age | TURis-PVP: 64.3 ± 5.7 TURP: 65.7 ± 5.5 |
| INTERVENTIONS (technology 1) | Transurethral resection in saline bipolar vaporization of the prostate (TURis-PVP) |
| INTERVENTIONS | Monopolar transurethral resection of prostate (TURP) |

| | | |
|--|---|---|
| (technology 2) | | |
| Number of patients in TURis-PVP | 84 | |
| Number of patients in TURP | 84 | |
| OUTCOMES | IPSS, QoL, Qmax, PVR, operative time, catheter time, dysuria score, hospital length of stay, TUR syndrome, blood transfusion. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This research project was funded by the Health and Medical Research Fund, Hong Kong Special Administrative Region Government. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Permuted block design with random block size of two, four, and six was used for subject randomization. |
| Allocation concealment (selection bias) | Unclear risk | No information about concealment allocation methods. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Personnel was blinded, but patients were not. |
| Blinding of outcome assessment (detection bias) | Low risk | Both the patients and the assessors (including doctors and nurses) were blinded to the mode of surgery performed throughout the postoperative period until the completion of the 6-month follow-up. |
| Incomplete outcome data (attrition bias) | High risk | Overall attrition rate more than 20% due to high attrition rate in TURis group (23.8%). More people were lost to follow up in TURP (23.8%) group than in TURis bipolar vaporisation group (16.7%). |
| Selective reporting (reporting bias) | Unclear risk | There is no study protocol to judge this bias. |
| Other bias | Low risk | The authors have no conflict of interest or financial ties to disclose. |

| | |
|----------------------|--|
| Study ID | Yeni 2002 |
| Authors: | Ercan Yeni, Doğan Unal, Ayhan Verit, Mehmet Gulum |
| Title: | Minimal Transurethral Prostatectomy plus Bladder Neck Incision versus Standard Transurethral Prostatectomy in Patients with Benign Prostatic Hyperplasia: A Randomised Prospective Study |
| Journal/Book/Source: | Urol. Int. |
| Date of Publication: | 2002 |
| Volume: | 69 |

| | | |
|--|---|---|
| Issue: | 4 | |
| Pages: | 283-286 | |
| METHODS (study design; length of follow up) | RCT Follow up: 6 months. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 40 | |
| Country of participants | Turkey | |
| Data collection period | | |
| Inclusion criteria | Prostates ≤ 25 ml, maximal flow rates < 10 ml/s, International Prostate Symptom Score (IPSS) values > 7 , prostate-specific antigen < 4 ng/ml, and if they had failed treatment or refused medical treatment. | |
| Exclusion criteria | Patients with strictures of the bladder neck and/or the urethra, suspicious prostate or bladder malignancy, bladder stone, severe urinary infection, and additional pathologies such as diabetes mellitus and neurologic disorders. | |
| Average age | TURP+I: 53.2 ± 6.0 TURP: 54.8 ± 5.7 | |
| INTERVENTIONS (technology 1) | TURP and bladder neck incision (TURP+I) | |
| INTERVENTIONS (technology 2) | TURP | |
| Number of patients in TURP + I | 20 | |
| Number of patients in TURP | 20 | |
| OUTCOMES | IPSS, Qmax, operating time, length of hospital stay, bladder neck contracture, procedural blood loss and transfusion requirements, retrograde ejaculation, erectile dysfunction, TUR syndrome. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Randomization method not described. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information whether patients were blinded. |

| | | |
|---|--------------|--|
| Blinding of outcome assessment (detection bias) | Unclear risk | No information whether outcome assessment was blinded. |
| Incomplete outcome data (attrition bias) | Unclear risk | Number of patients analysed after 6 months not stated. |
| Selective reporting (reporting bias) | Unclear risk | No information whether study protocol was registered. |
| Other bias | Unclear | Funding source and conflicts of interest not reported. |

| | |
|--|---|
| Study ID | Yip 2011 |
| Authors: | Sidney K. Yip, Ning Hong Chan, Peter Chiu, Kim W. Lee, Chi Fai Ng |
| Title: | A Randomized Controlled Trial Comparing the Efficacy of Hybrid Bipolar Transurethral Vaporization and Resection of the Prostate with Bipolar Transurethral Resection of the Prostate |
| Journal/Book/Source: | J Endurol. |
| Date of Publication: | 2011 |
| Volume: | 25 |
| Issue: | 12 |
| Pages: | 1889–1894 |
| METHODS (study design; length of follow up) | Double-blinded phase III RCT Follow up: 12 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 86 |
| Country of participants | China |
| Data collection period | |
| Inclusion criteria | The patients recruited for this study had BPH, were aged 50 or above, and were fit for anesthesia, had undertaken a failed course of medical therapy with alpha-blockers/5-alpha reductase inhibitors, had an IPSS of ≥ 18 , and a Qmax of ≤ 15 mL/s, or had urinary retention. |
| Exclusion criteria | Patients who had a history of TURP or other forms of BPH intervention, were confirmed to have carcinoma of the prostate, or had neurogenic bladder, bladder stones, diverticula, or urethral stricture were excluded from the study. |
| Average age | Mean=69.27 years, standard deviation (SD) = 7.67 years. |
| INTERVENTIONS (technology 1) | Bipolar transurethral vaporization and resection of prostate (TUVRP) |
| INTERVENTIONS | Bipolar transurethral resection of prostate (B-TURP) |

| | | |
|--|---|---|
| (technology 2) | | |
| Number of patients in TUVRP | 46 | |
| Number of patients in B-TURP | 40 | |
| OUTCOMES | IPSS, Qmax, catheter time, length of hospital stay, dysuria score, reintervention, blood transfusion | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | It is an interim analysis. The surgical consumables are supported by Olympus Surgical Technologies Europe. The research is partially funded by the Direct Grant, Medicine Panel, the Chinese University of Hong Kong. | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | A computer-generated permuted block design with random block sizes of 2, 4, and 6 was used for subject randomization. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Patients and assessors were blinded to the type of surgery performed, but operating surgeon and the individual involved in randomization were aware of the type of surgery to be performed. |
| Blinding of outcome assessment (detection bias) | Low risk | Both patients and assessors were blinded to the type of surgery performed. Only the operating surgeon and the individual involved in randomization were aware of the type of surgery to be performed, and they did not participate in subsequent postoperative clinical decisions or in collecting data from the patient. |
| Incomplete outcome data (attrition bias) | Low risk | There was no lost to follow up. |
| Selective reporting (reporting bias) | Low risk | Same outcomes stated in the study protocol were assessed in the article. |
| Other bias | High risk | Financial interest, manufacturer financed the study. |

| | |
|-----------------|---|
| Study ID | Zhang 2015 |
| Authors: | Keqin Zhang, Dingqi Sun, Hui Zhang, Qingwei Cao, Qiang Fu |
| Title: | Plasmakinetic Vapor Enucleation of the Prostate with Button |

| | | |
|--|--|--|
| | Electrode versus Plasmakinetic Resection of the Prostate for Benign Prostatic Enlargement >90 ml: Perioperative and 3-Month Follow-Up Results of a Prospective, Randomized Clinical Trial | |
| Journal/Book/Source: | Urol Int. | |
| Date of Publication: | 2015 | |
| Volume: | 95 | |
| Issue: | 3 | |
| Pages: | 260-264 | |
| METHODS (study design; length of follow up) | Randomized controlled trial Follow up: 3 months | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 112 | |
| Country of participants | China | |
| Data collection period | August 2012 to May 2014 | |
| Inclusion criteria | Patients with urinary symptoms due to benign prostatic enlargement (BPE) >90 ml. | |
| Exclusion criteria | Prostate volume <90 ml (transrectal ultrasound measured), severe pulmonary disease or heart disease, coagulopathy, bladder cancer, prostate cancer, neurogenic bladder, and a history of prostatic or urethral surgery. | |
| Average age | PVEP: 68.25 ± 4.60 PKRP: 67.48 ± 4.87 | |
| INTERVENTIONS (technology 1) | Plasmakinetic vapor enucleation of the prostate (PVEP) | |
| INTERVENTIONS (technology 2) | Button electrode and plasmakinetic resection of the prostate (PKRP) | |
| Number of patients in PVEP | 56 | |
| Number of patients in PKRP | 56 | |
| OUTCOMES | International Prostate Symptom Score (IPSS), quality-of-life score (QoL), maximum urinary flow rate (Q max), the postvoid residual urine volume (PVR), operation time, the serum sodium decrease, transfusion, the duration of catheterization, the duration of hospital stay, urinary incontinence and urethral stricture. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| | | |

| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
|---|---------------------------|--|
| Random sequence generation (selection bias) | Low risk | Patients were randomized in a 1: 1 ratio to undergo either PVEP or PKRP by means of a random number table. |
| Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information whether patients were blinded. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information whether outcome assessment was blinded. |
| Incomplete outcome data (attrition bias) | Low risk | There was no loss to follow up. |
| Selective reporting (reporting bias) | Unclear risk | No information whether study protocol was registered. |
| Other bias | Low risk | The authors have nothing to declare |

| | |
|--|--|
| Study ID | Zhang 2019 |
| Authors: | Jun Zhang, Xilong Wang, Yanbin Zhang, Chaoliang Shi, Minqi Tu, and Guowei Shi |
| Title: | 1470nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study |
| Journal/Book/Source: | J Endurol. |
| Date of Publication: | 2019 |
| Volume: | 33 |
| Issue: | 3 |
| Pages: | 211-217 |
| METHODS (study design; length of follow up) | Design: A single-blinded RCT. Follow up: 3, 6, and 12 months postsurgery. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 152 |
| Country of participants | China |
| Data collection period | January 2016 to March 2017 |
| Inclusion criteria | Prostate volume less than or equal to 80 mL. |
| Exclusion criteria | Neurogenic bladder, urethral stricture, prostate carcinoma, and a history of urethral or prostate surgery. |
| Average age | DioLEP: 73.7 ± 8.4 (range 56–92) PKRP 71.5 ± 8.9 (range 55–93) |

| | | |
|--|---|---|
| INTERVENTIONS (technology 1) | Diode laser enucleation of the prostate (DioLEP) | |
| INTERVENTIONS (technology 2) | Plasmakinetic resection of the prostate (PKRP) | |
| Number of patients in DioLEP | 76 | |
| Number of patients in PKRP | 76 | |
| OUTCOMES | Qmax, PVR, IPSS, QoL, serum sodium decrease, operative time, catheterization time, hospitalization duration, blood transfusion requirement, TURS, urinary incontinence, capsular perforation, and urethral stricture | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | The authors acknowledge financial support from the Guiding Medical Project of Shanghai Science and Technology Committee (Grant No. 16411972000) and the Shanghai Key Medical Specialty Program (Grant No. ZK2015B04). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | The patients were assigned envelopes by a computerized random number generator. |
| Allocation concealment (selection bias) | Low risk | Grouping strategy was performed with sequential numbering and sealed envelopes. |
| Blinding of participants and personnel (performance bias) | Unclear risk | It is a single-blinded RCT but it is not stated who was blinded. |
| Blinding of outcome assessment (detection bias) | Unclear risk | It is a single-blinded RCT but it is not stated who was blinded. |
| Incomplete outcome data (attrition bias) | Low risk | All cases underwent follow-up assessment at 3, 6, and 12 months postoperation. |
| Selective reporting (reporting bias) | Unclear risk | There is no study protocol to judge this bias. |
| Other bias | Low risk | The authors declare that they have no competing interest. |

| | |
|----------------------|--|
| Study ID | Zhang+F 2012 |
| Authors: | Fengbo Zhang, Qiang Shao, Thomas R. W. Herrmann, Ye Tian, Yuhai Zhang |
| Title: | Thulium Laser Versus Holmium Laser Transurethral Enucleation of the Prostate: 18-Month Follow-up Data of a Single Center |
| Journal/Book/Source: | J Urology |

| | | |
|--|--|--|
| Date of Publication: | 2012 | |
| Volume: | 79 | |
| Issue: | 4 | |
| Pages: | 869-874 | |
| METHODS (study design; length of follow up) | Prospective randomized trial Follow up: 1, 6, 12 and 18 months. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 133 | |
| Country of participants | China | |
| Data collection period | December 2007 to April 2009 | |
| Inclusion criteria | Age <85 years, a maximal urinary flow rate (Qmax) <15 mL/s, medical therapy failure, transrectal ultrasound-measured adenoma volume <80 g, and urodynamic obstruction without detrusor dysfunction | |
| Exclusion criteria | Neurogenic bladder, findings suspicious for prostate cancer, and a poor tolerance for surgery. | |
| Average age | ThuLEP: 76.2 ± 9.7 (range 63-85) HoLEP: 73.4 ± 10.3 (range 66-84) | |
| INTERVENTIONS (technology 1) | Thulium laser transurethral enucleation of the prostate (ThuLEP) (70W) | |
| INTERVENTIONS (technology 2) | Holmium laser transurethral enucleation of the prostate (HoLEP) (90W) | |
| Number of patients in ThuLEP | 71 | |
| Number of patients in HoLEP | 62 | |
| OUTCOMES | International Prostate Symptom Score (IPSS), Qmax, postvoid residual urine (PVR), bleeding, reoperation, and urethral/bladder neck stricture, operation time, serum sodium decrease, postoperative catheterization time. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | The randomization numbers obtained from table of randomized numbers were allocated to patients by the sequence of hospitalization. |
| Allocation concealment (selection bias) | Unclear risk | No information about concealment method. |

| | | |
|---|--------------|---|
| Blinding of participants and personnel (performance bias) | Unclear risk | No information about blinding. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information about blinding. |
| Incomplete outcome data (attrition bias) | Low risk | No patient was lost to follow up. |
| Selective reporting (reporting bias) | Unclear risk | There is no study protocol available to judge this bias. |
| Other bias | Unclear | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|--|--|
| Study ID | Zhang+S 2012 |
| Authors: | Zhang Shi-ying, Hu Hao, Zhang Xiao-peng, Wang Dong, Xu Ke-xin, Na Yan-qun, Huang Xiao-bo, Wang Xiao-feng |
| Title: | Efficacy and safety of bipolar plasma vaporization of the prostate with “button-type” electrode compared with transurethral resection of prostate for benign prostatic hyperplasia |
| Journal/Book/Source: | Chin Med J. |
| Date of Publication: | 2012 |
| Volume: | 125 |
| Issue: | 21 |
| Pages: | 3811-3814 |
| METHODS (study design; length of follow up) | Randomized controlled trial Follow up: 1, 3, and 6 months |
| PARTICIPANTS | |
| Total Number of Participants randomized | 30 |
| Country of participants | China |
| Data collection period | January 2009 to January 2012 |
| Inclusion criteria | Bladder outlet obstruction secondary to BPH with maximum flow rate <10 ml/s, prostate volume 25–125 ml. |
| Exclusion criteria | Serious comorbidity, previous history of prostate surgery, history of prostate cancer, abnormal digital rectal examination and prostate-specific antigen (PSA) level >4 ng/ml. |
| Average age | B-PVP: 70.9±7.1 TURP: 71.9±6.1 |
| INTERVENTIONS (technology 1) | Bipolar plasma vaporization of the prostate with “button-type” electrode (B-PVP) |
| INTERVENTIONS | Transurethral resection of prostate (TURP) |

| | | |
|--|--|--|
| (technology 2) | | |
| Number of patients in B-PVP | 15 | |
| Number of patients in TURP | 15 | |
| OUTCOMES | International Prostate Symptom Score (IPSS), quality of life (QOL), Qmax, catheter time, blood loss, hospital stays. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | Sealed envelopes which contain the consecutive digits were used for randomization. |
| Allocation concealment (selection bias) | High risk | Sealed envelopes which contain the consecutive digits were used for randomization. |
| Blinding of participants and personnel (performance bias) | Unclear risk | No information about blinding. |
| Blinding of outcome assessment (detection bias) | Unclear risk | No information about blinding. |
| Incomplete outcome data (attrition bias) | High risk | There is no number of patients at each follow up visit provided and results on changes at follow up are only described in writing without providing numbers. |
| Selective reporting (reporting bias) | Uncertain risk | There is no study protocol registered in order to check selective reporting. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|----------------------|--|
| Study ID | Zhao 2010 |
| Authors: | Zhigang Zhao, Guohua Zeng , Wen Zhong, Zanlin Mai, Shaohua Zeng, Xueting Tao |
| Title: | A Prospective, Randomised Trial Comparing Plasmakinetic Enucleation to Standard Transurethral Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Three-year Follow-up Results |
| Journal/Book/Source: | Eur Urol. |
| Date of Publication: | 2010 |

| | | |
|--|---|------------------------------|
| Volume: | 58 | |
| Issue: | 5 | |
| Pages: | 752-758 | |
| METHODS (study design; length of follow up) | Randomised controlled trial. Follow up: 1, 3, 6, 12, 18, 24, and 36 months. | |
| PARTICIPANTS | | |
| Total Number of Participants randomized | 204 | |
| Country of participants | China | |
| Data collection period | January 2004 to December 2006 | |
| Inclusion criteria | Age >45 yr, maximal urinary flow rate (Qmax) <15 ml/s, International Prostate Symptom Score (IPSS) >12, medication failure, prostate volume on TRUS >20 g with no upper limit, and urodynamically proven obstruction (Schäfer grade ≥2). | |
| Exclusion criteria | Patients with neurovesical dysfunction, a diagnosis of prostate carcinoma, and a previous history of prostatic or urethral surgery. | |
| Average age | PKEP: 67.3 ± 6.6 (range 49–86) TURP: 67.8 ± 6.4 (range 51–84) | |
| INTERVENTIONS (technology 1) | Plasmakinetic enucleation of the prostate (PKEP) (Gyrus) | |
| INTERVENTIONS (technology 2) | Transurethral resection of the prostate (TURP) | |
| Number of patients in PKEP | 102 | |
| Number of patients in TURP | 102 | |
| OUTCOMES | IPSS, quality of life (QoL) score, the International Index of Erectile Function (IIEF)-5 questionnaire, Qmax, postvoid residual urine (PVR) volume, sexual function, operation time, changes in serum sodium, the need for blood transfusion, transurethral resection (TUR) syndrome, urinary tract infections, transient incontinence, retrograde ejaculation, urethral stricture, bladder neck contracture, dysuria, the duration of catheterisation and hospitalization, reintervention. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | This work was supported by a grant from the Science & Technology Planning Project of Guangdong Province, China (No. 2008B080701035). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |

| | | |
|--|-----------|--|
| Random sequence generation (selection bias) | High risk | Patients were randomised in a 1:1 ratio to undergo either PKEP or TURP by using a sealed envelope sequence. |
| Allocation concealment (selection bias) | High risk | Patients were randomised in a 1:1 ratio to undergo either PKEP or TURP by using a sealed envelope sequence. |
| Blinding of participants and personnel (performance bias) | High risk | Neither the patient nor the surgeon was blinded as to the type of the procedure performed. |
| Blinding of outcome assessment (detection bias) SUBJECTIVE OUTCOMES | High risk | Patients were not blinded. |
| Blinding of outcome assessment (detection bias) OBJECTIVE OUTCOMES | Low risk | Two independent investigators, who did not know which treatment the patients had undergone, performed the 1-, 3-, 6-, 12-, 18-, 24-, and 36-mo follow-up assessment. |
| Incomplete outcome data (attrition bias) | Low risk | There was no statistically significant difference in the number of dropouts at any of the follow-up assessments between the two groups. |
| Selective reporting (reporting bias) | Low risk | Numerous outcomes are assessed in the study, it is unlikely that study protocol envisioned more outcomes than reported. |
| Other bias | Low risk | The authors declare that they have no financial or competing interest. |

| | |
|--|--|
| Study ID | Zhu 2013 |
| Authors: | Lingfeng Zhu, Shushang Chen, Shunliang Yang, Meijing Wu, Rong Ge, Weizhen Wu, Lianming Liao, Jianming Tan |
| Title: | Electrosurgical Enucleation Versus Bipolar Transurethral Resection for Prostates Larger than 70 ml: A Prospective, Randomized Trial with 5-Year Followup |
| Journal/Book/Source: | J Urol. |
| Date of Publication: | 2013 |
| Volume: | 189 |
| Issue: | 4 |
| Pages: | 1427-1431 |
| METHODS (study design; length of follow up) | Prospective, open label, randomized trial Follow up: 1, 6, 12, 24, 36, 48 and 60 months. |
| PARTICIPANTS | |
| Total Number of Participants | 80 |

| | | |
|--|--|--|
| randomized | | |
| Country of participants | China | |
| Data collection period | June 2004 to December 2006 | |
| Inclusion criteria | Urodynamically proven obstruction, Qmax less than 10 ml per second, I-PSS greater than 19, age between 50 and 70 years, prostate volume between 70 and 200 ml on transrectal ultrasound, PSA less than 4 ng/ml and failure of medical therapy (combined α -adrenoreceptor blocker and 5-reductase inhibitor for at least 6 months). | |
| Exclusion criteria | Patients with neurogenic bladder, urethral stricture, bladder tumor, prostate cancer or previous prostate, bladder neck or urethral surgery, PSA 4 ng/ml or greater, or prostate biopsy within 3 months. | |
| Average age | PKEP: 64.1 \pm 4.8 B-TURP: 64.8 \pm 3.9 | |
| INTERVENTIONS (technology 1) | PlasmaKinetic™ Electrosurgical enucleation (PKEP) | |
| INTERVENTIONS (technology 2) | Bipolar transurethral resection (B-TURP) | |
| Number of patients in PKEP | 40 | |
| Number of patients in B-TURP | 40 | |
| OUTCOMES | IPSS, Qmax, QOL, PVR, IIEF-5, operative time, catheterization time, postoperative hospital stay, urinary retention, transient incontinence, urinary tract infections. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Patients were randomly assigned in 1:1 fashion using computer generated block randomization. |
| Allocation concealment (selection bias) | High risk | Open label RCT. |
| Blinding of participants and personnel (performance bias) | High risk | Open label RCT. |
| Blinding of outcome assessment (detection bias) | High risk | Two experienced urologists were blinded only to the surgical modality determined bladder irrigation, catheter removal and hospital discharge in all cases, for other safety outcomes as well as functional |

| | | |
|---|----------------|---|
| | | outcomes they were not blinded. |
| Incomplete outcome data (attrition bias) | Low risk | 7.5% and 10% patients were lost to follow up only at 3 years of follow up in PkEP and B-TURP, respectively. |
| Selective reporting (reporting bias) | Uncertain risk | There is no study protocol registered in order to judge selective reporting. |
| Other bias | Unclear risk | Funding source, conflicts of interest and trial registration number are not reported. |

| | |
|--|---|
| Study ID | Zou 2018 |
| Authors: | Zhihui Zou, Abai Xu, Shaobo Zheng, Binshen Chen, Yawen Xu, Hulin Li, Chongyang Duan, Junhong Zheng, Jiasheng Chen, Chaoming Li, Yiming Wang, Yubo Gao, Chaozhao Liang, Chunxiao Liu |
| Title: | Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results |
| Journal/Book/Source: | World J Urol. |
| Date of Publication: | 2018 |
| Volume: | 36 |
| Issue: | 7 |
| Pages: | 1117–1126 |
| METHODS (study design; length of follow up) | Dual-centre, open-label, parallel-design non-inferiority RCT Follow up: 1 week, 1, 3, 6, and 12 months. |
| PARTICIPANTS | |
| Total Number of Participants randomized | 114 |
| Country of participants | China |
| Data collection period | May 2015 to October 2015 |
| Inclusion criteria | IPSS > 12 and the QoL > 4, maximum urinary flow rate (Q _{max}) < 15 mL/s, and/or The Schafer grade > 2, and/or failed medical therapy of BPO, and/or recurrent urinary retention. |
| Exclusion criteria | Previous urethral/prostatic surgery, known prostate cancer or urethral strictures, and neurogenic bladder or other neurologic disorder that may affect micturition. |
| Average age | DioLEP: 67.3 ± 7.7 B-EEP: 69.4 ± 7.5 |
| INTERVENTIONS (technology 1) | Modified diode laser enucleation of the prostate (DioLEP) |

| | | |
|--|--|---|
| INTERVENTIONS (technology 2) | Bipolar endoscopic enucleation of the prostate (B-EEP) | |
| Number of patients in DioLEP | 57 | |
| Number of patients in B-EEP | 57 | |
| OUTCOMES | Post-void residual urine (PVR), International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF-5), operative time, the time of enucleation, blood loss during surgery, decrease in serum sodium, catheterization time, hospital stay days, persistent irritative symptoms, transient incontinence, retrograde ejaculation, recatheterization, UTI, bladder-neck contracture. | |
| Notes (e.g. funding source; conflicts of Interest; trial registration number, etc.) | Funded by Guangzhou Science Technology Key Program (201504301009390). | |
| <i>Risk of bias</i> | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | The randomization sequence (1:1 ratio) was developed using the proc plan process of SAS 9.2. |
| Allocation concealment (selection bias) | Low risk | Allocation concealment was conducted using sealed opaque envelopes. |
| Blinding of participants and personnel (performance bias) | High risk | Open label RCT. |
| Blinding of outcome assessment (detection bias) SUBJECTIVE OUTCOMES | High risk | Patients were not blinded to the type of procedure. |
| Blinding of outcome assessment (detection bias) OBJECTIVE OUTCOMES | Low risk | The assessment of outcomes was made by researchers blinded to treatment allocation. |
| Incomplete outcome data (attrition bias) | Unclear risk | 5.2% loss to follow up in DiLEP and 0% in BEEP. |
| Selective reporting (reporting bias) | Low risk | The study protocol is available and all of the study's pre-specified outcomes have been reported. |
| Other bias | Low risk | The authors have nothing to disclose. |

APPENDIX 5

REGULATORY AND REIMBURSEMENT STATUS

Table A4: Regulatory status

| Technology | Proprietary name | Manufacturer | Class | Intended use | CE mark approval | FDA approval |
|-------------|-------------------------|--|---------|--|-----------------------------|-----------------|
| PUL | UroLift® System | NeoTract Inc. | Class 2 | To treat symptoms due to urinary outflow obstruction secondary to BPH in men ≥ 50 years. | 2013 [164] | 2013 [165] |
| WAVE | Rezūm System | Boston Scientific | Class 2 | To relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume ≥ 30cm ³ and ≤ 80cm ³ . It is indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe. | 2013 | 2015 [166, 167] |
| TIND | iTIND® | Medi-Tate Ltd. | Class 2 | To treat male patients who suffer from lower urinary tract symptoms secondary to BPH. | 2011 [168] | 2020 [169] |
| Aquablation | AquaBeam Robotic System | Procept Biorobotics | Class 2 | To resect and remove prostate tissue in males suffering from lower urinary tract symptoms due to BPH. Contraindications: active UTI, known allergy to device materials, inability to safely stop anticoagulants or antiplatelet agents perioperatively, diagnosed or suspected prostate cancer. | 2014 [170] | 2017 [171] |
| PAE | Embozene™ Microspheres | Boston Scientific | Class 2 | To embolize arteriovenous malformations and hypervascular tumors, including uterine fibroids and hepatoma, and to embolize prostatic arteries for symptomatic BPH. This device is not intended for neurovascular use. | 2005, renewed in 2015 [172] | 2018 [173] |
| PAE | Bead Block® | Boston Scientific (formerly BioCompatibl | Class 2 | To embolize arteriovenous malformations and hypervascular tumours including uterine fibroids, and benign prostatic hyperplasia. | 2003, renewed in 2014 [172] | No |

| | | | | | | |
|---|---|---|--|--|--|------------|
| | | es UK) | | | | |
| PAE | Embos- phere [®] Microsp heres | Merit (formerly BioSphere Medical S.A.) | Class 2 | To embolize arteriovenous malformations, hypervascular tumors, including symptomatic uterine fibroids, and prostatic arteries for symptomatic BPH. | 2013 [172] | 2016 [174] |
| PAE | PVA Foam Embolisation Particles | Cook Medical | Class 2 | To treat symptomatic BPH. | 2013 [172] | No |
| PVP | GreenLight XPS [™] Laser Therapy Sys- tem | Boston Scien- tific | Class 2 GreenLight XPS con- sole: class 2b, MoXy disposable laser fibre: class 2a | To incise, vaporize, ablate, and coagulation soft tissue, including photoselective vaporization of the prostate for BPH. The laser system is contraindicated for patients who: are contraindicated for surgery, contraindicated where appropriate anesthesia is contraindicated by patient history, have calcified tissue, require hemostasis in >2mm vessels, have uncontrolled bleeding disorders, have prostate cancer, have acute UTI, or severe urethral stricture. Possible risks and complications include, but are not limited to, irritative symptoms (dysuria, urgency, frequency), retrograde ejaculation, urinary incontinence, erectile dysfunction, hematuria - gross, UTI, bladder neck contracture/outlet obstruct, urinary retention, perforation - prostate, urethral stricture. | 2010 for the XPS System. The predecessor re- ceived CE mark in 2005. | 2009 [175] |
| HoLEP, HoLRP, HoLAP, TUIP, open surgery | Lumenis [®] VersaPulse [™] 20, 60, 80, 100 W Lasers (including the laser genera- tor, fiber and morcellator) | Lumenis | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | Yes [176] | 2001 [177] |
| HoLEP, HoLRP, | Lumenis [®] Pulse [™] 120H | Lumenis | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this | Yes [178] | 2014 [179] |

| | | | | | | |
|---|--|---|----------|---|-----------|------------|
| HoLAP, TUIP, open surgery | | | | includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | | |
| HoLEP | MOSES™ Pulse 120H | Lumenis | Class 2 | Laser enucleation of the prostate. | Yes [180] | No |
| HoLEP, HoLRP, HoLAP, TUIP, open surgery | Sphinx Laser | LISA Laser USA | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | Yes [181] | 2004 [182] |
| HoLEP | Dornier Medilas® H100 and H140 with integrated morcellator | Dornier MedTech | Class 2b | Combination of laser and auxiliary morcellation module for BPH treatment. | Yes [183] | n.a. |
| HoLEP, HoLRP, HoLAP, TUIP, open surgery | Cyber Ho 100 | Quanta System | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | n.a. | 2019 [184] |
| HoLEP, HoLRP, HoLAP, TUIP, open surgery | MultiPulse HoPLUS with integrated morcellator | Jena Surgical/Asclepion Laser Technologies GmbH | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | n.a. | 2014 [185] |

| | | | | | | |
|--|---|----------------------------------|---------|--|--|------------|
| HoLEP, HoLRP, HoLAP, TUIP, open surgery | Auriga® XL | Boston Scientific | Class 2 | For surgical procedures involving open, laparoscopic and endoscopic ablation, vaporization, excision, incision, and coagulation of soft tissue. In urology this includes: TUIP, bladder neck incision, HoLAP, HoLEP, holmium laser resection of the prostate, open and endoscopic urological surgery. | Yes [186] | 2011 [187] |
| TUMT | TMX-2000 THERMATRX Thermo Therapy System | Boston Scientific (formerly AMS) | n.a. | To treat BPH in men who have a minimum prostatic urethra length of 30 mm and a total prostate volume between 30 and 100 cc. | n.a. | 2001 [188] |
| TUMT | CoolWave® control unit Targis system | Urologix | Class 2 | To relieve symptoms and obstruction associated with BPH and is indicated for men with prostatic urethra lengths of 3 to 5 cm or 2.5 to 3.5 cm. | Yes [189] | 2006 [190] |
| TUMT | CoreTherm™ | Prostalund | Class 3 | To treat BPH in men who have a minimum prostatic urethra length of 35 mm and a total prostate volume between 30 and 100 g. | Yes [191] | 2002 [192] |
| TURP, TUVF, TURV, TURV, TURV, TURV, TURV, TURV | PLASMA (TURiS) System (ESG 400 generator, working elements, telescopes, resectoscopes, HF resection electrodes or HF resection electrodes for plasma vapor- | Olympus Medical | Class 2 | HR resection electrode: to resect, ablate or remove soft tissue where hemostasis is required. The specific urological indications include use in the prostate, bladder and bladder neck. The procedures for which the devices can be used are TURis, transurethral prostatectomy, TURP for benign prostatic hyperplasia, TUIP or bladder neck, transurethral resection of bladder tumors and cystodiathermy. These devices are intended to be used in an irrigated environment. These devices are not intended to be used to treating cancer of the prostate. HF resection electrode for plasma vaporisation: intended for use in urological surgical procedures involving the vaporization, ablation, coagulation, cutting, removal of soft tissue and coagulation where hemostasis is required. The specific soft tissue indications include use in the prostate, bladder and bladder neck. The specific treatment indications include BPH, bladder cancer, tumors, | The components of the TURis system are covered by individual CE marks. The most recent issued in 2013 for the TURis working element. [193] | 2011 [194] |

| | | | | | | |
|--|---|--|---------|--|--|------------|
| | isation) | | | lesions and neoplasms. The specific urological indications include transurethral electrovaporization, also known as transurethral vapor resection of the prostate or transurethral vaporization in saline. | | |
| ThuLEP, ThuVEP, ThuVARP, ThuVAP | Revolix 200 Watt Continu- ous Wave Laser | LISA Laser USA (formerly Quanta Sys- tem) | | RevoLix is a multi-disciplinary surgical laser for the application in urology for the treatment of BPH: ThuVAP, vaporesection, ThuLEP and vapoenucleation. RevoLix 200 is only approved for the treatment of BPH when used at power levels greater than 120W. | Yes [195] | 2005 [196] |
| ThuLEP, ThuVEP, ThuVARP, ThuVAP | Cyber TM Family (Cyber TM 150, 180, 200) | Quanta Sys- tem | Class 2 | Intended for use in surgical procedures using open, laparoscopic and endoscopic incision, excision, resection, ablation, vaporization, coagulation and hemostasis of soft tissue in medical specialties including urology. Cyber Tm 180 and Cyber Tm 200 are only approved for the treatment of BPH when used at power levels greater than 150W. | n.a. | 2013 [197] |
| ThuLEP, ThuVEP, ThuVARP, ThuVAP | MultiPulse Tm+1470 | Jena Surgical/ Asclepion Laser Tech- nologies GmbH | Class 2 | Intended for use in surgical procedures using open, laparoscopic and endoscopic incision, excision, resection, ablation, vaporization, coagulation and hemostasis of soft tissue in medical specialties including urology. | Yes [198] | 2015 [199] |
| ThuLEP, ThuVEP, ThuVARP, ThuVAP | Vela® XL | Boston Scien- tific | Class 2 | Intended for use in surgical procedures using open, laparoscopic and endoscopic incision, excision, resection, ablation, vaporization, coagulation and hemostasis of soft tissue in medical specialties including urology. | n.a. | 2011 [200] |
| DioLEP, DioVAP | Multidiode™ SST 200 | InterMedic | Class 2 | For surgical applications requiring the vaporization, incision, excision, ablation, cutting and hemostasis, or coagulation of soft tissue in conjunction with endoscopic equipment for medical specialties including urology. | Yes 2008 (infor- mation from man- ufacturer) | 2009 [201] |

| | | | | | | |
|------------------------|---|---------------|----------|---|---|------------|
| DioLEP, DioVAP | LEONARDO® (with the Leonardo fiber) and XCAVATOR® (with the Twister fiber) | BioLitec | Class 2 | For incision, excision, ablation, cutting, vaporization, hemostasis, and coagulation of soft tissue contact or non-contact, open or closed endoscopic applications where incision, tissue dissection, excision of external tumors and lesions, complete or partial resection of internal organs, tumors and lesions, tissue vaporization, hemostasis and/or coagulation may be indicated. | Yes for both LEONARDO and XCAVATOR [202, 203] | n.a. |
| B-TURP | Gyrus Plasmakinetic SuperPulse System (generator, resectoscope, electrode) | Gyrus Medical | Class 2 | Intended for use with bipolar instruments used in open, endoscopic and laparoscopic surgical procedures involving the coagulation and cutting of soft tissue. The device is intended for use by qualified medical personnel trained in the use of electro-surgical equipment. | Yes [204] | 2003 [205] |
| B-TURP, B-TUEP, B-TUVP | Bipolar high frequency surgery unit AUTOCON® III (separately working elements, electrodes, morcellator) | Karl Storz | Class 2b | Intended for use by qualified surgeons to provide a high frequency electrical current for monopolar and bipolar cutting and coagulation of tissue structures during surgical operations. | Yes [206] | 2017 [207] |

Abbreviations: BPH benign prostatic hyperplasia, B-TUEP bipolar transurethral enucleation of the prostate, B-TURP bipolar transurethral resection of the prostate, B-TUVP bipolar transurethral vaporisation of the prostate, DioLEP diode laser enucleation of the prostate, DioVAP diode laser vaporisation, HF high frequency, HoLEP holmium laser enucleation of the prostate, HoLRP holmium laser resection of the prostate, LUTS lower urinary tract symptoms, n.a. not available, PAE prostate artery embolization, PUL prostatic urethral lift, PVP photoselective vaporization of the prostate, ThuLEP thulium laser enucleation of the prostate, ThuVARP thulium vaporesction of the prostate, ThuVEP thulium vapoenucleation of the prostate, TIND temporary implantable nitinol device, TUIP transurethral incision of the prostate, TUMT transurethral microwave therapy, TURis transurethral resection in saline, TURP transurethral resection of the prostate, TUVRP transurethral vapor resection of the prostate, TUVis transurethral vaporization in saline, TUVP/TUEVP transurethral electrovaporization, UTI urinary tract infection, WAVE water vapour thermal therapy

Table A5: Summary of (reimbursement) recommendations in European countries for the assessed technologies

| issuing organisation (document number) | Summary of (reimbursement) recommendations and restrictions | Summary of reasons for recommendations, rejections and restrictions |
|--|---|--|
| NICE (MTG49) | Evidence supports the case for adopting Rezum for treating LUTS caused by BPH. Rezum relieves LUTS and improves quality of life. Rezum should be considered as a treatment option for people with: moderate to severe LUTS (IPSS typically 13 or over) and a moderately enlarged prostate (typically between 30 cm ³ and 80 cm ³). Cost modelling estimates that Rezum is cost saving compared with standard treatments such as TURP and HoLEP. Savings compared with UroLift are uncertain. | Clinical evidence shows that using the Rezum procedure relieves LUTS caused by BPH in men with moderate to severe symptoms who have a moderately enlarged prostate. Evidence also shows that using Rezum is associated with improved quality of life and a low risk of sexual dysfunction. Cost analyses suggest that when Rezum is used as an alternative to standard treatment, such as TURP or HoLEP, it is likely to lead to cost savings because it is done as day surgery with reduced operating and recovery costs. |
| NICE (MTG26) | The clinical case for adopting the UroLift system for treating LUTS attributed to BPH is supported by the evidence. The UroLift system relieves LUTS while avoiding the risk to sexual function associated with TURP and HoLEP. Using the system reduces the length of a person's stay in hospital. It can also be used in a day-surgery unit. The UroLift system should be considered as an alternative to current surgical procedures for use in a day-case setting in men with LUTS attributed to BPH who are aged 50 years and older and who have a prostate of less than 100 ml without an obstructing middle lobe. | The Committee concluded that the UroLift system is effective in relieving symptoms of BPH. It noted that the degree of symptom relief outcomes is slightly less than that after TURP or HoLEP, but it is sufficient and clinically important. The duration of symptom relief after using the UroLift system is uncertain. It concluded that it is similar in the medium term (up to 3 years) to the comparators but that further evidence on durability and the need for subsequent procedures would be useful. The Committee considered the evidence that the UroLift system does not damage sexual function to be convincing. This contrasts with a substantial risk to erectile and ejaculatory function after TURP or HoLEP and represents a significant advantage for men who wish to preserve their sexual function. The evidence for avoiding catheterisation after the UroLift system was sparse, but based on expert advice the catheterisation time would be reduced and in many cases catheterisation would be avoided, especially as surgeons gain experience with the procedure. It also concluded that it was reasonable and likely that the UroLift system would be used as a day-surgery procedure, often under local anaesthetic. |

| issuing organisation (document number) | Summary of (reimbursement) recommendations and restrictions | Summary of reasons for recommendations, rejections and restrictions |
|---|---|---|
| NICE (MTG29) | <p>The case for adopting GreenLight XPS for treating BPH is supported in non-high-risk patients. GreenLight XPS is at least as effective in these patients as TURP, but can more often be done as a day-case procedure, following appropriate service redesign. There is currently insufficient high-quality, comparative evidence to support the routine adoption of GreenLight XPS in high-risk patients, that is those who: have an increased risk of bleeding or have prostates larger than 100 ml or have urinary retention. NICE recommends that specialists collaborate in collecting and publishing data on the comparative effectiveness of GreenLight XPS for high-risk patients to supplement the currently limited published evidence. NICE recommends that hospitals adopting GreenLight XPS plan for service redesign to ensure that day-case treatment can be delivered appropriately. Cost modelling indicates that in non-high-risk patients, cost savings with GreenLight XPS compared with TURP are determined by the proportion of procedures done as day cases.</p> | <p>The committee concluded that GreenLight XPS is as effective as TURP for treating BPH in non-high-risk patients. The committee considered that the evidence for the use of GreenLight XPS in high-risk patients is limited, but accepted expert advice that the clinical benefits of its use in this population are plausible. It concluded that further comparative clinical evidence of the benefits of GreenLight XPS in high-risk patients is needed before recommending the procedure for routine adoption in this population. The committee considered that the evidence for GreenLight XPS allowing more procedures to be done on a day-case basis than current practice was both convincing and compelling. The committee concluded that adopting the GreenLight XPS system is likely to drive an increase in rates of day-case surgery and that planning for the redesign of urological services would be required to accommodate this. The committee concluded that, in non-high-risk patients, adopting the GreenLight XPS system is likely to be cost saving compared with TURP, only if the current arrangement where consoles are provided at no cost to the hospital based on a contracted commitment to fibre usage is continued, and that high rates of day-case treatment are achieved.</p> |

| issuing organisation (document number) | Summary of (reimbursement) recommendations and restrictions | Summary of reasons for recommendations, rejections and restrictions |
|---|--|---|
| G-BA (BAnz Nr. 107 (S. 2555) vom 20.07.2011) https://www.g-ba.de/beschluesse/1254/ | <p>Holmium laser resection (HoLRP) and HoLEP are considered alternative treatments to TURP for BPH. The indications for the use of HoLRP and HoLEP are based on the indications for TURP. HoLRP and HoLEP can only be provided and billed by specialists in urology at the expense of the statutory health insurance, who have proven knowledge, experience and skills of the methods. As part of the treatment, the doctor must ensure that the patient is informed in particular about the risk of a necessary re-intervention, about undesirable effects, about the therapeutic significance of TURP and about the natural course of the BPH syndromes.</p> | <p>The G-BA sees the benefits, medical necessity and economic viability for the following procedures proven: HoLRP and HoLEP, so that these procedures can be included in the service catalog of statutory health care. For procedures TmLRP and TUMT, the G-BA, after considering the available evidence, the specific characteristics of the procedures and the existing treatment alternatives, determined that these procedures cannot be conclusively assessed. Studies that are suitable to clarify the open questions, in particular on the re-intervention rate and suitability for defined patient groups, can in principle be carried out and can therefore be expected from the G-BA in a reasonable time. The decision on these procedures should therefore be suspended. The evidence on PVP is also not yet sufficient, but results are expected from ongoing studies that are suitable to answer the question about the benefit. The decision on these procedures should therefore also be suspended. For the following procedures, neither a benefit, a necessity nor an efficacy in comparison to non-treatment could be demonstrated: HoLAP, holmium laser incision, water induced thermotherapy, TUNA, transurethral ethanolablation, high-intensity focused ultrasound, interstitial laser coagulation, hybrid laser technology (KTP and Nd:YAG lasers), so these procedures cannot be applied to the treatment of benign prostate syndrome at the expense of the statutory health insurance.</p> |
| G-BA (BAnz AT 29.08.2017 B5), 2017 https://www.g-ba.de/beschluesse/2985/ | <p>TmLRP is another method for the treatment of BPH and, like TURP, adenomectomy, holmium laser resection (HoLRP) and HoLEP is among the specified treatments for BPH. The indications are based on the indications for TURP. The services according to can only be provided and billed by specialists in urology at the expense of the statutory health insurance who have proven knowledge, experience and skills with TmLRP. The provision of services at the expense of the statutory health insurance is tied to the approval of the responsi-</p> | <p>In comparison with the standard treatment, there was no hint of a greater benefit of TmLRP for the outcomes “symptoms”, “health-related quality of life” and “sexual function”. The TmLRP proved to be non-inferior to the standard treatment with regard to irritative and obstructive symptoms. The perioperative endpoints showed an indication of a shorter length of stay in hospital and a shorter catheterization time compared to standard treatment (indication of a greater</p> |

| issuing organisation (document number) | Summary of (reimbursement) recommendations and restrictions | Summary of reasons for recommendations, rejections and restrictions |
|---|--|---|
| | ble Association of Statutory Health Insurance Physicians. As part of the treatment, the doctor must ensure: that the patient is informed in particular about the risk of a necessary re-intervention, about undesirable effects, about the therapeutic significance of TURP and about the natural course of the BPH syndromes. The provision of TmLRP for the treatment of BPH is introduced into statutory health care. | benefit of TmLRP compared to standard treatment). In addition, the adverse events indicated that blood transfusions are required less frequently with TmLRP and that severe bleeding occurs less frequently with treatment than with standard treatment (indication of lesser harm to TmLRP). Furthermore, for the endpoint irritative postoperative micturition symptoms, there was a hint of lesser harm from TmLRP compared to standard treatment. G-BA therefore comes to the conclusion that the benefit of TmLRP for the treatment of BPH has been sufficiently proven. |
| G-BA (BAnz AT 11.05.2018 B6), 2018 https://www.g-ba.de/beschluesse/3237/ | Provision of ThuLEP for the treatment of BPH is introduced into statutory health care. The indications for ThuLEP and the key points for quality assurance are similar to the already introduced laser methods HoLRP, HoLEP and TmLRP. | It was found that the benefits of the TmLEP have been adequately proven and the medical necessity is given. The G-BA comes to the conclusion that the ThuLEP for the treatment of BPH provides sufficient, appropriate and economic care, and thus the statutory health insurance benefits remain within the scope of hospital treatment. |
| G-BA, 2017 https://www.g-ba.de/beschluesse/3066/ | TUMT can be used in the context of inpatient care, service providers can provide it if it is approved by the health insurance companies. | The trend in the number of cases and the lack of study activity indicate a significantly decreasing relevance of the method. In addition, according to the available findings, the method does not show any frequency of serious adverse events relevant to patient safety. |
| G-BA (BAnz AT 11.05.2018 B7), 2018 https://www.g-ba.de/beschluesse/3235/ | PVP is considered alternative treatments to TURP for BPH. The indications for the use of PVP are based on the indication for TURP. PVP can only be provided and billed by specialists in urology at the expense of the statutory health insurance, who have proven knowledge, experience and skills of the methods. As part of the treatment, the doctor must ensure that the patient is informed in particular about the risk of a necessary re-intervention, about undesirable effects, about the therapeutic significance of TURP and about the natural course of the BPH syndromes. The provision of PVP for the treatment of BPH is introduced into statutory health care. | G-BA came to the conclusion that the benefit of PVP for the treatment of BPH is adequately proven. The medical need is given. The G-BA defines the prerequisites for the indication for PVP and the cornerstones for quality assurance analogous to the already introduced laser procedures HoLRP, HoLEP and TmLRP. |

| issuing organisation (document number) | Summary of (reimbursement) recommendations and restrictions | Summary of reasons for recommendations, rejections and restrictions |
|---|--|--|
| <p>Abbreviations: G-BA Gemeinsamer Bundesausschuss, HoLEP holmium laser enucleation of the prostate, HoLRP holmium laser resection of the prostate, IPSS International Prostate Symptom Score, LUTS lower urinary tract symptoms, NICE National Institute for Health and Care Excellence, PVP photoselective vaporization of the prostate, TmLRP thulium laser resection of the prostate, BPH benign prostatic hyperplasia, ThuLEP thulium laser enucleation of the prostate, TUMT transurethral microwave therapy, TURP transurethral resection of the prostate</p> | | |

APPENDIX 6

Table A6: List of planned, ongoing, withdrawn and completed studies without results on the assessed technologies

| Study ID | Estimated completion date | Study type | Number of patients | Intervention | Comparator | Patient population | Endpoints |
|------------------|---|--|--------------------|---|-------------------------------|--|---|
| ChiCTR2000032522 | Not recruiting, registered in May 2020 | Multi-Center, Single-Blind, Non-Inferiority Design RCT | n.a. | DioVAP (450 nm diode laser) | PVP (Greenlight laser 532 nm) | Male, aged 50-85 years, BPH patients who plan to have surgery, IPSS score of 8-35, prostate volume of 30-100ml, Qmax<= 15ml/s, patients who are able to complete the relevant scale scores under the guidance of doctors, voluntarily participate and sign informed consent. | PRIMARY OUTCOMES: IPSS, Qmax, decrease in hemoglobin SECONDARY OUTCOMES: operative time, serum electrolyte changes, time of bladder irrigation, catheterization time, hospital stay, QoL, IIEF-5, prostate volume; PSA |
| ChiCTR2000036273 | Not recruiting, registered in August 2020 | Prospective single-center RCT | n.a. | transurethral high-power green laser vaporization enucleation PVEP | TURP | Signed informed consent, Chinese males aged 50-100, repeated urinary retention, repeated hematuria, 5a-reductase inhibitor treatment is ineffective, repeated urinary tract infection with bladder stones, secondary upper urinary tract hydrops (with or without renal impairment), combined with large diverticulum of bladder, inguinal hernia, severe hemorrhoids or prolapse. | PRIMARY OUTCOMES: IPSS 1 month after surgery, Qmax SECONDARY OUTCOMES: PVR, QoL |
| ChiCTR2000032510 | Recruiting | RCT | n.a. | HoLEP | TURP | Signed informed consent, Chinese male aged 50-100, meet the western medical diagnostic criteria for BPH: IPSS >= 12 points, prostate volume> 25 cm ³ , Qmax <15 ml/s, PSA <= 4ng/ml. | PRIMARY OUTCOMES: Qmax, IPSS, QoL SECONDARY OUTCOMES: Volume of postoperative flushing fluid, complications |

| Study ID | Estimated completion date | Study type | Number of patients | Intervention | Comparator | Patient population | Endpoints |
|----------------------------------|--|--|--------------------|---------------|-------------------------------|---|--|
| | | | | | | Alpha receptor blocker and 5a reductase inhibition after at least 6 months before surgery. Preoperative examination results completed within 30 days before enrolment. | |
| NCT04560907 | 2027 Nov | Prospective, open-label, non-inferiority RCT | 120 | HoLEP | Aquablation | Men ≥45 years of age and candidate for HoLEP: refractory to medical therapy or not willing to consider (further) medical treatment, prostate size ≥ 50 ml and ≤ 150ml, IPSS ≥12, QoL≥3, Qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml or patient in urinary retention, written informed consent. | IPSS at 6 months |
| NCT04338776 (C.L.E.A.R study) | 2023 Jan | RCT | 120 | PUL (UroLift) | WAVE (Rezum) | Male, aged ≥ 50 years, diagnosis of symptomatic BPH, prostate volume 30cm ³ ≤ 80cm ³ , willing to sign informed consent. | Number of subjects who are catheter independent post-operative day 4 and remain catheter independent through 1-week |
| NCT04471155 | 2020 Apr (no study results posted at the time of our search, Jan 2021) | RCT | 110 | HoLEP | Open prostatectomy | AUA Symptom Score 8 or higher, Qmax 10ml/s or less, Post void residual urine volume of 50 ml or more, total prostate volume of 80 ml or more in TRUS | Primary Outcomes: Qmax at 1 year, AUA symptom score at 1 year, post-voiding residual urine volume at 1 year Secondary Outcomes: hemoglobin drop |
| NCT04386941 | 2022 July | RCT | 92 | PVP | HoVARP holmium vaporessection | Males over 50 years of age referred to urology for refractory LUTS secondary to BPH, prostate size on preoperative TRUS | Primary outcomes: IPSS (baseline, 1 month, 3 months, 6 months, 12 months), QoL (baseline, 1 |

| Study ID | Estimated completion date | Study type | Number of patients | Intervention | Comparator | Patient population | Endpoints |
|----------------------|---|------------|--------------------|--------------|------------|---|---|
| | | | | | | of 40-80 ml, IPSS >15, QOL score ≥ 3 and Qmax <15 ml/sec, written informed consent to participate in the study, ability to comply with the requirements of the study procedures | <p>month, 3 months, 6 months, 12 months), Qmax (baseline, post-catheter removal, 1 month, 3 months, 6 months, 12 months), PVR (baseline, post-catheter removal, 1 month, 3 months, 6 months, 12 months), PSA (baseline, 3 months, 12 months)</p> <p>Secondary outcomes: intraoperative adverse events, prostate size change, IIEF-5 (baseline, 3 months, 12 months)</p> |
| NCT04561505 | 2020 Febr (no study results posted at the time of our search, Jan 2021) | RCT | 60 | HoLEP | M-TURP | Prostate volume less than 80 ml, IPSS more than 19 affecting quality of life, recurrent urinary retention with failure of medical treatment, recurrent urinary tract infection, refractory hematuria, bladder stones, bladder diverticula | <p>Primary outcomes: IPSS and Qmax at 1 year</p> <p>Secondary outcomes: operative time, hemoglobin drop, resected prostate volume, serum sodium drop, catheterization time, hospital stay, PVR at 1 year, intraoperative, early postoperative and late postoperative complications, costs</p> |
| NCT04342533 (PRISSA) | 2021 May | RCT | 140 | HoLEP | ThuLEP | LUTS presence, proven by: IPSS >20; OR Qmax <10 ml/s) | Urinary incontinence (change from 1 week after 6 month after surgery), intra- and perioperative adverse events (until 6 months after surgery), surgery duration, haemoglobin drop, |

| Study ID | Estimated completion date | Study type | Number of patients | Intervention | Comparator | Patient population | Endpoints |
|----------------------|--|----------------|--------------------|---|------------|---|--|
| | | | | | | | catheterization time, hospitalization time, IPSS, QoL, IIEF-5 (at 3 months, 6 months) |
| NCT04236687 | 2022 Febr | RCT | 100 | HoLEP | PAE | Age > 45 years, IPSS \geq 10, Qmax < 12 mL/s), PVR < 300m, prostatic volume between 20mL and 250mL, signed informed consent | Primary outcomes: IPSS improvement from baseline to 6 months Secondary outcomes: Qmax, PVR, PSA, IIEF, adverse events, urinary incontinence (from baseline to 6 months) |
| NCT04398420 | 2024 June | Open label RCT | 180 | B-TURP (TURiS), Vapor Enucleation and resection | HoLEP | Male, age older than 22 and younger than 75 years of age, candidate for surgical treatment of bladder outlet obstruction, BPH, surgical indication (refractory to medical treatment, refractory or recurrent urinary retention, recurrent haematuria, bladder stones, recurrent infections, hydronephrosis), prostate volume >30 and \leq 80 ml, PSA <4 ng/ml in patients above 55 years old and a prostate cancer risk less than 35%. IPSS \geq 8 (moderate to severe), indications for TURiS, Qmax <10ml/second, written informed consent signed. | Change of hemoglobin and hematocrit levels at 6 hours and 24 hours after surgery |
| CTRI/2020/05/02 5100 | Not recruiting, registered in May 2020 | RCT | n.a. | B-TUEP | TURP | Age greater than 50 years. Refractory LUTS secondary to BPH. IPSS greater than 7. QOL score 3 or greater. Qmax less | PRIMARY OUTCOME: IPSS; Qmax at 2 weeks, 4 weeks, 12 weeks SECONDARY OUTCOME: |

| Study ID | Estimated completion date | Study type | Number of patients | Intervention | Comparator | Patient population | Endpoints |
|---|---|------------|--------------------|--------------|------------|---|--|
| | | | | | | than 15 ml per second or patients with acute urinary retention secondary to BPH in whom trial of voiding after medical therapy failed. Prostate size 40 gms or more. | Duration of Surgery, Weight of Tissue resected, Necessity for transfusion, Post-operative pain score, IIEF-5 score, Post op SUI |
| CTRI/2020/08/027056 | Not recruiting, registered in August 2020 | RCT | n.a. | TUIP | TURP | Patients having bothersome LUTS with IPSS > 15 after medical treatment or patients who are not willing for medical management. Qmax less than or equal to 8ml/sec. PSA < 4 ng/ml Prostatic urethra length < 2.5cms, Size of prostate gland less than 25cc | <p>PRIMARY OUTCOMES: improvement in IPSS score and flow rates, rate of complications, need of readmission or re-surgery at 3 months</p> <p>SECONDARY OUTCOMES: improvement in IPSS score and flow rates, rate of complications in, the need of readmission or re-surgery at 3 months</p> |
| <p>Abbreviations: BPH benign prostatic hyperplasia, B-TUEP bipolar transurethral enucleation of the prostate, B-TURP bipolar transurethral resection of the prostate, DioVAP diode laser vaporisation, HoLEP holmium laser enucleation of the prostate, HoVAP holmium vaporesction, IIEF International Index of Erectile Function, IPSS International prostate syndrome score, LUTS lower urinary tract syndrome, PSA prostate specific antigen, PVR postvoid residual, PVP photoselective vaporization of the prostate, RCT randomized controlled trial, TUIP transurethral incision of the prostate, TURP transurethral resection of the prostate, TURiS transurethral resection in saline, TRUS transrectal ultrasonography, Qmax maximum flow rate</p> | | | | | | | |